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The type-1 fibrillinopathies are a family of connective tissue disorders of which Marfan 
syndrome is the most common, affecting between 2-3 in 10,000 individuals. Marfan syndrome is 
a multisystem disorder characterised by ocular, skeletal and cardiovascular abnormalities and can 
be caused by any one of over 2800 unique mutations reported across the fibrillin-1 (FBN1) gene. 
FBN1 encodes the large extracellular glycoprotein, fibrillin-1; the fibrillin-1 monomers aggregate 
to form the backbone of microfibrils. Fibrillin-1 has both structural and regulatory roles, including 
the regulation of transforming growth factor-beta. This regulation is critical in maintaining 
extracellular matrix stability and dysregulation of this function is one of the keystones of the 
Marfan syndrome pathogenesis. Mutations in FBN1 can result in reduced fibrillin-1 expression, 
loss-of-function or the production of two different fibrillin-1 proteins that are unable to interact 
to form functional microfibrils. The result in all three cases is a lack of functional microfibrils and 
destabilisation of the extracellular matrix. The current standard of care relies heavily on surgical 
intervention and lifelong use of medications to slow disease progression, thus the need for new 
therapeutic options that target the cause of disease. 
This thesis focused on developing a suite of short synthetic nucleic acid sequences, known as 
antisense oligonucleotides, to selectively manipulate FBN1 pre-mRNA splicing. We hypothesised 
that the removal of an amenable mutation-associated exon would result in one of the following 
scenarios. For missense mutations, removing the mutation-associated exon from affected and 
unaffected transcripts would eliminate the aberrant sequence and restore homogeneity between 
fibrillin-1 monomers. For splice-site and in-frame deletion mutations, excluding the mutation-
associated exon from the remaining healthy transcripts would restore the domain periodicity and 
monomer homogeneity. Lastly, for mutations resulting in a premature termination codon, 
excluding the mutation-associated exon from the affected transcripts would restore the reading 
frame, rescuing transcript functionality. The mutation-associated exon would also need to be 
removed from the unaffected transcripts to maintain monomer homogeneity. For each of these 
scenarios, we hypothesised that the internally truncated proteins produced would be capable of 
forming functional microfibrils, thereby reducing the severity or slowing the progression of the 
Marfan syndrome phenotype. 
As an initial proof-of-concept for this project, antisense oligonucleotide sequences targeting 
FBN1 exon 52 were assessed. A promising sequence induced dose-dependent exon skipping in 
healthy control cells allowing us to observe the formation of healthy fibrillin-1 fibres with 0% 
exon skipping, loss of extruded fibrillin-1 fibres with 50% skipping; mimicking the disease-like 
state, and subsequent re-appearance of extracellular fibrillin-1 fibres with greater than 80% 
skipping indicating that the internally truncated fibrillin-1 monomers are capable of forming 
aggregates. Similarly, we demonstrate that FBN1 exons 47 and 59 can be efficiently excluded, 
 
iii 
and sufficient skipping can result in fibrillin-1 fibre formation. However, many of the FBN1 exons 
targeted were not as readily excised from the mature mRNA.  
Comparison of three antisense oligonucleotide chemistries revealed the promising efficacy of 
the newer thiophosphoramidate morpholino oligomer chemistry. Similar to the commonly used 
phosphorodiamidate morpholino oligomer, the thiophosphoramidate morpholino oligomer 
sequences resulted in efficient and consistent FBN1 exon 52 skipping. Both chemistries also had 
little effect on paraspeckle protein distribution, an indicator of toxicity, unlike the third, 2′OMe-
PS, chemistry that caused gross paraspeckle protein disruption. Therefore, thiophosphoramidate 
morpholino oligomer should be included in the repertoire of chemistries routinely used in studies 
developing antisense therapeutics. 
Lastly, while we demonstrate that >80% exon skipping can lead to fibrillin-1 microfibril-like 
formations in vitro, we could not confirm the functionality of these fibres nor the effect of exon 
skipping on the Marfan syndrome phenotype. Nevertheless, this study demonstrates proof-of-





Marfan syndrome is a rare disease of the connective tissue or ‘glue’ that holds our cells 
together and allows us to move. Those affected by Marfan syndrome are usually extremely tall 
with long arms, legs, fingers and toes. However, this disease also causes the progressive growth 
of the aorta, the largest blood-carrying vessel in the body. If left untreated, the aorta can continue 
to expand, eventually leading to death. Marfan syndrome affects those of all ethnicities and 
genders equally and yet there is no effective therapy targeting the cause of disease and no cure. 
Currently, treatment of Marfan syndrome relies heavily on corrective surgery and lifelong use of 
drugs to slow the aorta's growth. 
Marfan syndrome has no cure; however, it does have a known genetic cause, an error in the 
DNA or building blocks of life that direct the synthesis of an essential protein called fibrillin-1. 
In a healthy individual, these fibrillin-1 proteins form a supportive scaffold between the cells in 
our body. However, for an individual with Marfan syndrome, the error in one copy of the fibrillin-
1 gene makes a protein that prevents normal formation of the scaffold, leading to the symptoms 
associated with Marfan syndrome. Knowing the cause of the disease is essential. It allows for the 
use of synthetic alternatives of these building blocks of life called antisense oligonucleotides 
(AOs) to act like genetic white-out to mask the disease-causing part of the gene message and 
remove it from the final product. 
We hypothesised that by using this genetic white-out, we could force cells to produce fibrillin-
1 proteins that do not have the error and can therefore make a more functional scaffold. We 
anticipate that the ability to form the scaffold would reduce the severity or slow the progression 
of Marfan syndrome symptoms. In this thesis, we successfully identified and optimised several 
AOs that efficiently remove regions containing known fibrillin-1 errors. However, we also found 
that many regions of the fibrillin-1 gene message could not be efficiently removed and require 
further optimisation in genetic white-out design. We also demonstrated that removing the region 
containing the error can lead to the formation of a fibrillin-1 scaffold. However, further 
investigation is needed to assess the functionality of the re-established scaffold and to confirm 
that removing the error is beneficial for individuals with Marfan syndrome. This study lays a 
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PTC Premature termination codon 
RNA Ribonucleic acid 
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siRNA Small interfering ribonucleic acid 
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TB Transforming growth factor beta binding protein-like 
TGF-β Transforming growth factor beta 
UMD Universal mutation database 
WB Western blot 




This thesis is dedicated to my parents 




Introduction and Literature Review 
2 
1.1 A review of the type-1 fibrillinopathies: 
pathophysiology, diagnosis and novel therapeutic 
strategies 
The following is a modified version of the published review: 
Cale, J. M., Fletcher, S. & Wilton, S. D. A Review of the Type-1 Fibrillinopathies: 
Pathophysiology, Diagnosis and Novel Therapeutic Strategies. J Genet Syndr Gene Нer 9, 7 
(2018). doi:10.4172/2157-7412.100032 
Attribution: 
JC developed the concept, reviewed the literature, interpreted the findings, designed figures, 
and wrote the manuscript. SDW and SF developed the concept, edited the manuscript 
and provided supervision. All authors critically reviewed and approved the final version. 
 
3 
 Introduction to the type-1 fibrillinopathies 
The type-1 fibrillinopathies are a family of heritable connective tissue disorders characterised 
by skeletal, ocular and cardiovascular abnormalities. These diseases are caused by mutations in 
the fibrillin-1 gene (FBN1),1 with over 2800 unique mutations, spread throughout the entire FBN1 
sequence, described in the Human Gene Mutation Database to date.2 The majority of reported 
variants are either missense or nonsense single nucleotide variants; however, insertion, deletion, 
duplication and splicing mutations have also been described.2–4  
Fibrillin-1 is one of three distinct genes in the fibrillin family, along with fibrillin-2 and 
fibrillin-3, all of which share extensive sequence similarities; with parallel domain structure and 
complete conservation of all cysteine residues.5 The fibrillins are large genes; FBN1 consists of 
66 exons spanning over 200Kb.6 While exon 1 of FBN1 does not directly contribute to the 
translated product, the exon numbering system used in this thesis is based on the full 66-exon 
transcript (NM_000138.5, LRG_778t1) in which the translation start site located in exon 2. The 
remaining 65 exons encode a 2871 amino acid pre-pro-protein that is cleaved by the protease furin 
into the large glycoprotein fibrillin-1 and the protein hormone asprosin.7,8  
All three fibrillin proteins are expressed during early embryogenesis and development,5,9 
however fibrillin-2 and fibrillin-3 expression declines soon after birth.5,10 Fibrillin-1 and 2, in 
particular, have a diphasic expression pattern with fibrillin-2 appearing first followed by fibrillin-
1, which continues to be expressed throughout life.9 Fibrillin-1 is expressed in the majority of 
connective tissues and has both structural11 and regulatory roles.12 As a major structural element 
of microfibrils, fibrillin-1 acts as a backbone to which other microfibril associated proteins 
bind,11,13 while also being essential for the stability of elastic fibres.14,15 In addition, fibrillin-1, in 
microfibril form, sequesters transforming growth factor-beta (TGF-β) regulating its 
bioavailability and thus activity.12,16 This regulation is critical to maintaining extracellular matrix 
stability.16 
The assembly of fibrillin-1 into microfibrils is initiated immediately after translation and 
secretion when fibrillin-1 monomers aggregate into multimer units, bound by disulphide bonds 
between the first four cysteine residues at the N-terminus.17 Since the expression of fibrillin-1 and 
fibrillin-2 is diphasic, the majority of microfibrils observed are homopolymers containing either 
fibrillin-1 or fibrillin-2.18 However, Charbonneau18 demonstrated that the two fibrillins can form 
heteropolymers. Mutation studies performed in a mouse model have also shown that microfibrils 
can assemble in the absence of either fibrillin-1 or fibrillin-2 suggesting that each can compensate 
for the absence of the other.5,19 
The structure of fibrillin-1 is complex and highly repetitive, consisting of a large number of 
cysteine-rich domains (Figure 1.1). These include 47 epidermal growth factor (EGF)-like 
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domains, seven TGF-β binding protein-like (TB) domains and two hybrid domains20,21 (Figure 
1.1). The hybrid domains share similarities with both the EGF-like and TB domains and have 
been shown to play an integral role in fibrillin-1 folding and microfibril assembly.21,22 Of the 47 
EGF-like domains, 43 contain a consensus sequence for calcium-binding that is essential for 
protein stability and protection from proteolysis.23 These repeats are, therefore, further denoted 
as cbEGF-like domains.21 Each EGF-like, cbEGF-like, TB and hybrid domain has 6-8 highly 
conserved cysteines that form disulphide bonds in specific patterns, assisting in protein folding 
and enhancing protein function.20,24 Mutations that disrupt these bonds are the most common 
cause of the type-1 fibrillinopathy, Marfan syndrome (MFS).25 
 
Figure 1.1: Domain Structure of the fibrillin-1 preproprotein. 
Fibrillin-1 consists of four EGF-like domains and 43 calcium-binding EGF-like (cbEGF-like) domains interspaced with 
seven TGF-β binding protein-like (TB) domains and two hybrid domains. A proline-rich region toward the N-terminus 
has been implicated in the assembly and specificity of fibrillin-1 multimers.20  
 The spectrum of type-1 fibrillinopathies 
Marfan syndrome 
Marfan syndrome (MFS, MIM 154700) is the most common of the type-1 fibrillinopathies,26 
with an estimated prevalence of 2-3 in 10,000 individuals that remains consistent across gender, 
ethnicity and geographical distribution.27,28 MFS is inherited in an autosomal dominant manner, 
with approximately 25% to 30% of mutations arising de novo.29,30 However, despite being 
consistently described as an autosomal dominant condition, twelve cases of homozygous 
mutations have been recorded in the universal mutation database.3 A number of these cases have 
an unequivocal autosomal recessive inheritance pattern, with relatives of the proband being 
asymptomatic heterozygous carriers.31,32 This suggests that the inheritance pattern of selected 
mutations causing MFS is complex and still not fully understood. 
Clinical features 
Marfan syndrome is a multisystem disorder characterised by skeletal, cardiovascular and 
ocular abnormalities.33,34 The most noticeable features include increased height with 
dolichostenomelia and arachnodactyly; the disproportionate overgrowth of long bones and digits 
respectively, as well as joint hypermobility.33 Spinal deformities such as scoliosis and dural 
ectasia, and chest wall deformities are also common features.33,34 
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Ocular manifestations include myopia or near-sightedness, and ectopia lentis, which is the 
displacement of the crystalline lens from its natural location.34 Such features generally present 
early in disease progression and are therefore critical diagnostic indicators, especially in children. 
However, these features are also common to a multitude of other diseases, including several other 
type-1 fibrillinopathies.33 
Cardiovascular abnormalities are the most common cause of death of MFS patients, especially 
in the most severe form, neonatal Marfan syndrome (nMFS), which is characterised by the early 
onset of cardiovascular manifestations.35,36 Death is typically the result of progressive aortic root 
enlargement and aortic aneurysm, that can eventuate into aortic regurgitation, dissection or 
rupture.37 Other cardiovascular features include mitral valve prolapse and mitral regurgitation.34 
Due to their late-onset and progressive nature, key cardiovascular features are often not present 
or noticeable in younger patients. However, with advances in technology, features such as aortic 
enlargement can now be readily detected in suspected MFS patients using echocardiography, 
allowing for much needed early intervention and symptom management.27 
Diagnostic Odyssey 
The diagnosis of MFS and delineation from other type-1 fibrillinopathies is challenging for 
several reasons, including the large size of FBN1, number of unique mutations and the lack of 
defined mutation hotspots.30,38 These characteristics mean that, despite progress in understanding 
the genetic basis of MFS, as well as advances in genetic testing techniques, there is still no 
efficient, time and cost-effective molecular test for MFS.26,39 Molecular diagnosis is most often 
reserved for patients who have either a clinical diagnosis or a relative with a confirmed 
diagnosis.40  
Difficulties in diagnosis also arise from the extensive phenotypic overlap between MFS and 
the other type-1 fibrillinopathies, as well as the phenotypic variability observed both between and 
within affected families.30,38 The progressive nature of MFS, in particular the late onset of 
cardiovascular features also adds to the challenge, especially in the diagnosis of children for 
whom the symptoms have not fully developed.41 
To overcome these limitations, the diagnosis of MFS is based on a well-defined set of criteria, 
known as the Ghent nosology and supplemented with molecular testing when appropriate.27,40 
These criteria were first described by Beighton et al.42 in 1988 under the umbrella term of the 
Berlin nosology that encompassed the diagnosis of several connective tissue disorders. The Berlin 
nosology outlines features considered major or minor in the MFS phenotype, organised according 
to the organ system involved. The requirements of diagnosis varied, depending on the presence 
of an affected relative and were based on the involvement of at least two organ systems with a 
number of major and minor manifestations.42 
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These diagnostic criteria were subsequently updated in 1996 and reworked into the Ghent 
nosology that is more specific to the diagnosis of Marfan syndrome.43 The updated criteria provide 
a more stringent diagnosis for relatives of MFS individuals as well as revised skeletal involvement 
and further delineation of MFS and MFS-like disorders.43 In 2010, the Ghent nosology was 
revised again due to concerns about the sensitivity of diagnosis, especially concerning age-
dependent manifestations and the resulting potential for misdiagnosis of children.34 The revised 
criteria place more emphasis on aortic root aneurysm and ectopia lentis, with less focus on 
features such as flat feet and pulmonary artery dilation that are common to other type-1 
fibrillinopathies.34 Based on the updated Ghent nosology,34 a diagnosis of Marfan syndrome is 
given upon an individual fulfilling one of the seven scenarios described below. The scoring of 
systemic features is summarised in Table 1.1. 
In the absence of family history, a diagnosis of Marfan syndrome is given if; 
1) Aortic Root Dilatation Z score ≥ 2 AND Ectopia Lentis    OR 
2) Aortic Root Dilatation Z score ≥ 2 AND FBN1 mutation    OR 
3) Aortic Root Dilatation Z score ≥ 2 AND Systemic Score ≥ 7pts    OR 
4) Ectopia lentis AND a FBN1 mutation associated with Aortic Root Dilatation 
In the presence of family history, a diagnosis of Marfan syndrome is given if:  
(Family history is defined as a parent, child or sibling diagnosed with Marfan syndrome based 
on scenarios 1-4) 
5) Family history AND Ectopia lentis    OR 
6) Family history AND Systemic Score ≥ 7pts    OR 
7) Family history AND Aortic Root Dilatation Z score of either ≥ 2 (>20 yrs. Old) or ≥ 3 
(<20 yrs. Old) 
Due to the extensive overlap between the many connective tissue disorders, a caveat was added 
to the updated Ghent nosology. This caveat stipulates that in the presence of any features 
suggestive of other connective tissue disorders, such as Shprintzen Goldberg syndrome, Loeys-
Dietz syndrome, or vascular Ehlers Danlos syndrome, these diagnoses must first be excluded; 
including by performing additional genetic testing as appropriate.34  
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Table 1.1: Scoring of the systemic features of Marfan syndrome 
A score of ≥ 7 out of a total of 20 possible points is indicative of systemic involvement. Adapted from Loeys et al. 34 
Feature Description Score 




Positive wrist OR thumb sign 
• Thumb sign is positive if the thumb-tip protrudes past the 
fifth finger when making a fist around the clenched 
thumb44 
• Wrist sign is positive if thumb and fifth finger overlap 








Pectus excavatum OR  
chest asymmetry 
• Protruding breastbone/chest 
 








• Hindfoot deformities in combination with forefoot 
abduction and lowering of midfoot 
 





Pneumothorax • Any spontaneous pneumothorax (collapsed lung) 2 
Dural ectasia • Expansion of the dural sac surrounding the spinal cord 2 
Protrusio acetabuli • Deformity of the acetabulum leading to the progressive 
migration of the femoral head into the pelvic cavity46 
2 
Reduced upper segment/lower 
segment ratio AND increased arm 
span/height ratio AND no severe 
scoliosis 
• The upper segment (Hips to head) of the body is shorter 
than the lower segment (Hips to feet) 
• The arm span exceeds the height 
• No evidence of severe scoliosis 
1 
Scoliosis OR  
thoracolumbar kyphosis 
• Scoliosis is the excessive sideways curvature of the 
spine 
• Kyphosis is the excessive forward curvature of the spine 
1 
Reduced elbow extension • Elbow extension is reduced if the angle between the 
upper and lower arm at full extension is ≤170° 47 
1 
Facial features 
Presence of at least 3 of 5 facial 
features 
• Dolichocephaly; disproportionately narrow and long head 
• Enophthalmos; posterior displacement of the eyeball 
within the eye socket48 
• Down-slanting palpebral fissures; the area between the 
open eyelids is down-slanting 
• malar hypoplasia; underdeveloped or flattened 
cheekbones 
• retrognathia; posterior placement of either of both jaws in 
relation to the forehead 
1 
Skin striae • Stretch marks on the skin not associated with pregnancy 
or weight changes  
1 
Myopia • Near-sightedness 1 
Mitral valve prolapse • Bulge in the mitral valve leading to improper closure 
between the upper and lower-left chambers of the heart 
1 
   
To be considered as a diagnostic criterion, an FBN1 mutation must conform to one of the 
following rules;34 previously reported mutation known to result in Marfan syndrome, or if not yet 
reported, the mutation must be de novo with the proven absence of both the mutation and disease 
phenotype in parents and fall under one of the following mutation categories. A nonsense 
mutation, an insertion or deletion; either in- or out-of-frame, a splice site mutation; either directly 
affecting the donor/acceptor splice sites or confirmed to alter splicing at the mRNA/cDNA level, 
a missense mutation; affecting or creating a cysteine residue or a missense mutation affecting the 
consensus sequence of an EGF-like domain.34 
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In short, the current diagnosis of a suspected Marfan syndrome patient without a diagnosed 
relative depends on the presence of aortic root dilatation AND ectopia lentis, an FBN1 mutation 
or systemic phenotype.34 Individuals with a first-degree relative diagnosed with MFS, are 
diagnosed based on their family history plus the presence of at least one of the following; ectopia 
lentis, systemic involvement or aortic root dilatation.34 For a full description of the revised Ghent 
nosology and possible differential diagnoses, please refer to Loeys et al.34 
Due to the considerable phenotypic variability of the type-1 fibrillinopathies, affected 
individuals are often informally classified according to where they sit on the ‘Marfan spectrum’.4 
At one end are those diagnosed with neonatal Marfan syndrome, the most severe form of MFS, 
characterised by its early onset and life expectancy of less than 24 months.49 At the other end of 
the spectrum are those who do not fully meet the Ghent nosology or have additional features not 
observed in the Marfan phenotype. Such patients are most often diagnosed with other type-1 
fibrillinopathies, as described below. 
Marfan lipodystrophy syndrome 
Marfan lipodystrophy syndrome (MFLS, MIM 616914); also known as the marfanoid-
progeroid-lipodystrophy syndrome, is an extremely rare autosomal dominant disease, with less 
than ten reported cases globally.50 The phenotype of MFLS is characterised by congenital 
lipodystrophy, the severe lack of fat in the subcutaneous tissues, as well as premature birth and 
disproportionate growth in relation to weight gain.51 Affected individuals also have distinctive 
facial features, including protruding eyes, down-slanting palpebral fissures and a posteriorly 
positioned lower jaw resulting in a severe overbite.51 Other features overlap with Marfan 
syndrome including long limbs and digits, hyperextensible joints and myopia.51,52 Due to these 
similarities, there are cases in which individuals fulfil the Ghent nosology but, due to the 
characteristic lack of subcutaneous fat tissue, are more accurately diagnosed with MFLS.52 
MASS Syndrome 
MASS syndrome (MIM 604308) is the diagnosis given to individuals who have a phenotype 
involving the Mitral valve, Aorta, Skeleton and Skin, but do not fulfil the Ghent nosology.53 
Despite not meeting the diagnostic criteria of MFS, the MASS phenotype shares several features 
with MFS, including disproportionately long limbs, chest deformities, mitral valve prolapse and 
aortic root dilation.43,53 Loeys et al.34 suggests caution in the diagnosis of MASS syndrome due to 
its ambiguity, the lack of understanding of the underlying mutations and the potential for disease 
progression into classic MFS. 
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Ectopia lentis syndrome 
Ectopia lentis syndrome (ELS, MIM 129600) is an autosomal dominant disorder characterised 
by dislocation of the lens due to abnormal stretching of the zonular fibres.54 While ectopia lentis 
is a key feature of the MFS phenotype, ELS describes patients who have ectopia lentis but lack 
the cardiovascular involvement typical of MFS.34 Lens dislocation is often severe in ELS patients 
and can result in acute or chronic impaired vision.54 Much like MFS, ELS is caused by numerous 
mutations throughout FBN1, with approximately 38% of mutations that result in ELS also 
identified in MFS patients.55 
Stiff skin syndrome 
Stiff skin syndrome (SSKS, MIM 184900) is another extremely rare autosomal dominant 
disorder, characterised by thick and hardened skin that leads to reduced joint mobility.56 Due to 
its rarity, the exact cause and pathogenesis of SSKS remain unknown. Using pulse-chase analysis, 
Loeys et al.56 determined that while SSKS patients have normal levels of fibrillin-1 secretion, 
they have increased deposition of fibrillin-1 and elastin in the dermis. The group also observed 
that patient microfibrils were noticeably shorter than those seen in control samples.56 
Other type-1 fibrillinopathies 
Weill-Marchesani syndrome 2 (WMS2, MIM 608328), acromicric dysplasia (ACMID, MIM 
102370) and geleophysic dysplasia 2 (GPHYSD2, MIM 614185) are three autosomal dominant 
disorders characterised by short stature, brachydactyly; short digits, and limited joint 
movement.57,58 While all three disorders share skeletal phenotypes, WMS2 patients also present 
with lens abnormalities, including glaucoma and ectopia lentis.58 GPHYSD2 differs from ACMID 
as affected patients have additional cardiovascular abnormalities that lower life expectancy.57 The 
ACMID phenotype is characterised by unique craniofacial features including a rounded face, with 
distinctive well-defined eyebrows and eyelashes, bulbous nose and a small mouth with thick 
lips.57 
 Genotype-phenotype correlations 
Several studies have attempted to correlate mutations in particular regions of FBN1 with 
specific phenotypes. Such studies have proved difficult due to the high frequency of unique 
mutations; approximately 60%3, and the extensive phenotypic variability between and within 
affected families.4,59 Despite these challenges, one trend that is well accepted is the association of 
neonatal MFS (nMFS) with mutations within exons 25-33 (Figure 1.2).25 However, while the 
entire exon 25-33 region is often quoted as associated with nMFS, Booms et al.49 reported that 
evidence supports the presence of two nMFS hotspots. The first encompasses exons 25-28 and 
 
10 
mainly consists of missense mutations and in-frame insertions.49 The second hotspot spans exons 
32 and 33, in which splice site mutations resulting in exon skipping most often lead to nMFS.49 
 
Figure 1.2: The type-1 fibrillinopathies and associated regions in FBN1. 
In particular, the ‘neonatal’ (nMFS) region that spans exons 25-33, is associated with the most severe form of Marfan 
syndrome. cMFS: classic Marfan syndrome. ELS: ectopia lentis syndrome. nMFS: neonatal Marfan syndrome. MASS: 
MASS syndrome. SSKS: stiff skin syndrome. WMS2: Weill-Marchesani syndrome 2. ACMID: acromicric dysplasia. 
GPHYSD2: geleophysic dysplasia 2. MFLS: Marfan lipodystrophy syndrome.  
Several of the studies attempting to unravel genotype-phenotype associations have noted that 
the type of mutation, rather than its location, influences the resulting phenotype.25,49,60,61 A good 
illustration of this trend is that missense mutations within exons 32 and 33 are most often 
associated with the classic MFS phenotype,3 while donor or acceptor splice site mutations within 
the same region lead to the severe and early onset phenotype of nMFS.49 Other examples are the 
association of premature protein truncating mutations with severe skeletal phenotypes and 
cysteine substitutions with ectopia lentis.25,62 
While mutations causing MFS and ELS are found throughout the FBN1 sequence, many of 
the mutations associated with other type-1 fibrillinopathies are clustered within specific regions 
of FBN1 that have different functions (Figure 1.2). For example, MFLS is associated with 
mutations that affect the 3′ most exons of FBN1.51,52,63–65. The C-terminal region of the fibrillin-1 
pre-pro-protein is known to be cleaved by furin to allow for fibrillin-1 secretion and microfibril 
assembly66. However, in 2016 Romere et al.7 reported that this cleaved product is a protein 
hormone involved in glucose homeostasis that they named asprosin. Asprosin is secreted by 
adipose tissue and recruited by the liver where it can activate pathways to rapidly increase 
circulating glucose levels.7 While asprosin was not extensively studied, Romere et al.7 confirmed 
that the mutations associated with MFLS disrupted asprosin function, most likely resulting in the 
observed lipodystrophy phenotype. Mutations causing MFLS, identified to date include 2bp, 8bp 
and 20bp deletions in FBN1 exon 65,51,65 as well as mutations resulting in early fibrillin-1 
truncation and loss of the C-terminus.64 
The majority of mutations that have been associated with WMS2, ACMID and GPHYSD2 are 
within exons 42 and 43 of FBN1 (Figure 1.2).57,67 It is theorised that it is the nature of these 
mutations that results in the phenotypic differences between these diseases. For example, 
mutations leading to GPHYSD2 have been shown to more specifically affect residues with 
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structural roles, such as the cysteines involved in disulphide bond formation. At the same time, 
ACMID mutations are distributed throughout exons 42 and 43.57 Le Goff et al.57 also suggests 
that short stature and digits are associated with the disruption of the 5th TB domain, encoded by 
exons 42 and 43 specifically. In contrast, mutations in the other TB domains lead to different 
phenotypes; mutations within the 4th TB domain are associated with SSKS, which shares 
phenotypic similarity with WMS2, ACMID and GPHYSD2, but lacks the short stature and 
digits.56 
 Models of pathogenesis 
The Marfan phenotype, in particular the cardiovascular manifestations, have been observed to 
worsen progressively with age. The reason for this remains unknown, as the mechanism behind 
the pathogenesis of MFS, and the other type-1 fibrillinopathies is still not fully understood. Based 
on current knowledge, this progression has been attributed to both the compounding weakness of 
microfibrils and the continuing dysregulation of transforming growth factor-beta (TGF-β). 
Four main models of MFS pathogenesis have been proposed to date. The first is the dominant-
negative model that describes mutations resulting in an altered protein that acts antagonistically 
against the wild-type protein.68 In the case of MFS, this model suggests that aberrant fibrillin-1 
monomers bind incorrectly with wild-type monomers, forming semi- or non-functional multimers 
preventing microfibril assembly. The lack of functional microfibrils leads to disorganisation of 
the extracellular matrix and the observed disease phenotype.68 Therefore, according to this model, 
the severity of the phenotype depends on the level of functional fibrillin-1 expression.68 
The dominant-negative model came under question after the identification of homozygous 
mutations and an autosomal recessive form of MFS. In 2007, de Vries et al.31 studied two related 
individuals who harboured homozygous c.1453C>T mutation (p.Arg485Cys) and presented with 
classic MFS. Hilhorst-Hofstee et al.32 similarly identified a homozygous c.7454A>T mutation 
(p.Asp2485Val) in three related individuals diagnosed with MFS. Both groups observed that in 
the heterozygous state, these mutations did not have a dominant-negative effect, conflicting with 
the dominant-negative model.31,32 It was suggested by de Vries et al.31 that in such cases the 
pathogenesis is more in line with a haploinsufficiency model. That is, a lack of microfibrils or 
fibrillin-1 resulting from protein degradation, intermolecular cross-linking, or reduced fibrillin-1 
synthesis.31,69 
The second model suggests that mutations in FBN1 increase the sensitivity of fibrillin-1 to 
proteolysis, resulting in a steady decline in microfibrils, parallel to the progression of disease 
severity.23 This model is particularly relevant to mutations affecting cbEGF-like repeats, as 
calcium is involved in the formation of microfibrils, and specifically in their stabilisation and 
protection from proteolysis.15 
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The third model suggests that the major role of fibrillin-1 is to maintain tissue homeostasis 
and therefore, MFS is the result of a loss of homeostasis.15 This model was based on findings 
from two mouse models showing that MFS, which caused a typical phenotype in the vesicular 
tissue and resulted in death, did not affect elastic fibres in other tissues.15 Therefore, the authors 
concluded that the primary role of fibrillin-1 was not in the assembly of elastic fibres, rather in 
maintaining homeostasis of existing elastic fibres.15 The model also suggests a critical threshold 
of functional microfibrils required for tissue homeostasis.15 Therefore mutations in FBN1 result 
in MFS because they reduce microfibril abundance below the threshold. This hypothesis was 
based on observations of the two mouse models showing that the outcome of both dominant 
negative and loss-of-function mutations is a similar decrease in the abundance of functional 
microfibrils.70 
The fourth model was proposed in the early 2000s, in light of more recent research that linked 
decreased fibrillin-1 deposition with the dysregulation of TGF-β; a multifunctional cytokine with 
a role in cell signalling and survival.71. The study by Neptune et al.71 identified that the 
dysregulation of TGF-β leads to apoptosis in the lung during development, however when TGF-
β activation was neutralised lung apoptosis was reduced, and alveolar development was rescued. 
Several other studies have now supported these finding, providing more evidence that TGF-β 
dysregulation is the leading cause of pathogenesis in Marfan syndrome, favouring the fourth 
model and directing research focus.13,72 
Mutations in FBN1 lead to an increase in active TGF-β by disrupting the interaction between 
latent TGF-β binding protein (LTBP) and fibrillin-1.73 In the absence of organised microfibril 
lattices, the large latent complex (LLC); made up of TGF-β, latency-associated protein and LTBP, 
is unable to anchor to microfibrils and as a result, the components of the LLC remain 
uncomplexed.73 This leaves TGF-β free to bind to its receptor, activating a phosphorylation 
cascade and a number of downstream effects.73,74 One such effect is increased expression of 
matrix metalloproteinases leading to the degradation of elastin and the resulting loss of 




Figure 1.3: Schematic of TGF-β regulation and dysregulation in Marfan syndrome 
a) In a healthy individual, fibrillin-1 monomers aggregate into multimer units that make up the backbone of microfibrils 
that are most often associated with elastic fibres. Functional microfibrils bind to the large latent complex (LLC) 
sequestering TGF-β in the extracellular matrix (ECM) regulating its signalling cascade. b) In an individual with Marfan 
syndrome, the loss of functional microfibrils releases TGF-β that binds to its receptor on the plasma membrane. Bound 
to its receptor TGF-β activates a signalling cascade including the phosphorylation (P) of Smad leading to the activation 
of matrix metalloproteinase expression. Matrix metalloproteinases are then secreted from the cell and lead to 
elastolysis or degradation of elastin further decreasing the stability of the ECM. Figure adapted from Ramachandra et 
al.16 and Benke et al.73 
The initial disruption of the LTBP and fibrillin-1 interaction, could be the result of several 
different factors and is likely dependent on the type and position of a mutation. Aoyama et al.69 
suggests that most FBN1 mutations can be categorised into five groups depending on their effects 
on fibrillin-1 synthesis and deposition. This group69 also suggests that FBN1 mutations alter 
synthesis and deposition in different ways, supporting the dominant-negative, haploinsufficiency 
and protein degradation models,69 all of which are likely to result in the dysregulation of TGF-β. 
This work is summarised in Table 1.2 
Table 1.2: FBN1 Mutation groups according to fibrillin-1 synthesis and deposition.  
The majority of FBN1 mutations can be classified into five groups. These groups describe the relationship between 
pathogenesis and the observed synthesis and deposition of fibrillin-1 protein. Adapted from Aoyama et al.69 
Group Synthesis Deposition Pathogenesis 
Healthy control 100% 100% Healthy 
I <70% ≥35% Haploinsufficiency 
II <70% <35% Dominant negative 
III ≥70% 35-70% 
Loss of function 
or degradation 
IV ≥70% <35% Dominant negative 
V ≥70% ≥70% Loss of function 
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 Life expectancy and current treatments  
In 1972, the mean age of death for Marfan patients was predicted to be 32 years, with 
cardiovascular complications associated with aortic dilation the primary cause.35 A continuation 
of this study in 1995 found that the mean age of death had increased significantly to 41 years; 
more specifically increasing from 30 to 44 years for females and 33 to 39 years for males.35,75 
Additionally the median cumulative probability of survival which Silverman et al.75 define as “the 
age at which 50% of patients are predicted to be still alive”, was found to have increased by 
several decades for both the male and female cohorts; increasing to 74 years for females and 70 
years for males. The increased survival was attributed to an overall increase in life expectancy for 
the general population, an increase in the proportion of individuals diagnosed with milder 
phenotypes due to increased molecular genetic testing, and significant advances in medical 
intervention, specifically cardiovascular surgery.75 While life expectancy has likely further 
increased since the mid-1990s, a considerable burden on the livelihood and quality of life28 
remains for individuals diagnosed with MFS for whom there is currently no cure. 
The management of Marfan syndrome is multidisciplinary, involving geneticists, 
ophthalmologists, orthopaedists and cardiologists.33 The majority of current treatment options are 
designed to treat particular clinical features with a focus on slowing aorta growth.76,77 Current 
standard of care consists of lifelong use of β-adrenergic receptor blockers76,78 or angiotensin II 
receptor type 1 blockers79,80 that slow the progressive aortic dilation and reduce the associated 
complications.27,33 These drugs are coupled with numerous surgical interventions aimed at 
correcting major abnormalities in the chest, eye, spine and cardiovascular system.27,33 
The progressive nature of type-1 fibrillinopathies means that constant re-evaluation is required 
throughout life. For example, ocular features such as lens dislocation are most often managed 
with corrective lenses, however with increasing severity comes additional surgical intervention 
such as aphakia or removal of the lens.81 Similarly, progressive scoliosis is initially managed with 
bracing, however patients are monitored throughout development, and surgical stabilisation is 
often needed.82 
Following the implication of TGF-β dysregulation in the pathogenesis of MFS, research into 
TGF-β antagonism has been the main research focus for potential therapeutics. The most notable 
outcome of which is trials into the repurposing of Losartan, a drug that is currently used to treat 
hypertension.72 Studies in mouse models have shown that treatment with Losartan can prevent 
aortic root aneurysm, as well as partially rescue lung structure.79 However, clinical trials 
comparing Losartan with β-blockers demonstrated that while treatment with Losartan 
significantly reduces aortic dilation, there was no significant difference in the outcome between 
the two treatment groups.83,84  
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Novel therapeutic strategies 
Therapeutics such as cell or gene replacement for MFS are unlikely to be effective for two 
reasons; the dominant inheritance of MFS and the large size of FBN1. Gene therapy can be 
especially useful for recessive diseases where replacing the defective gene in appropriate tissues 
has a significant therapeutic benefit. However, in the case of Marfan syndrome, the presence of 
wild-type fibrillin-1 protein would have little to no impact on the dominant-negative effect of the 
affected protein.85 Allele-specific down-regulation of the mutated fibrillin-1 protein has also been 
proposed as a possible therapy.85 While the dominant-negative pathogenesis model supports the 
validity of this therapeutic approach, Marfan syndrome has also been linked to a lack of fibrillin-
1.31 
The applications of genome editing technologies such as the CRISPR/Cas9 system have 
expanded in recent years to a wide range of diseases.86 Of particular interest is a series of proof-
of-concept experiments by Zeng et al.87 who report some success in creating and correcting FBN1 
mutations using the more recently established Base Editor system. The Base Editor system utilises 
a modified Cas9 protein and is presented as a safer alternative for genome editing, as it edits at 
specific sites without the formation of double-strand breaks. Zeng et al.87 demonstrate that the 
Base Editor system can efficiently correct pathogenic FBN1 mutations with minimal off target 
effects, signalling a possible future in genome editing-based therapies for MFS. However, Zeng 
et al.87 also outlines some of the limitations and cautions of genome editing, including ethical 
issues and varying efficiency, specificity and off-target effects. In particular given that genome 
editing is most effectively achieved at the embryonic stage uncertainty about efficiency or 
possible undesirable outcomes is unacceptable and presents a serious ethical obstacle. 
Despite the many advances in the field of medicine and drug development, the current 
treatment pipeline for the type-1 fibrillinopathies would benefit significantly from the 
development of novel and effective therapies, especially if such therapies could treat the cause of 
disease rather than its symptoms. Considering the current shift towards more personalised 
medicine, we suggest that antisense oligonucleotides may be an appropriate therapeutic approach 
for MFS with the potential to treat many mutation types by targeting the pre-mRNA directly and 
altering the splicing process.  
1.2 Gene expression and the splicing process 
The first step in protein expression is the transcription of DNA to produce a complete sense 
strand transcript called precursor messenger RNA (pre-mRNA). This pre-mRNA contains both 
coding (exonic) and non-coding (intronic) regions and requires processing before the mature 
mRNA can be translated into protein. Processing of pre-mRNA includes 5′ capping, splicing, 
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tagging with exon junction complexes, cleavage and polyadenylation of the 3′-end and finally, 
export to the cytoplasm for translation.88  
Of particular relevance to this work is splicing, a highly complex and coordinated process that 
takes place for all multi-exon human gene transcripts. During the splicing process introns are 
removed, and the exons are re-joined or spliced together to form an uninterrupted coding 
sequence. Ninety-five percent of multi-exon genes undergo an additional process called 
alternative splicing89 that allows for further diversification of gene expression in a highly 
regulated, tissue and/or development-specific manner. 
 Splice sites and exon definition 
The splicing process is tightly regulated and relies on a large number of cis and trans-acting 
elements to remain precise. Within the transcript, six main features; 5′ and 3′ splice-sites, 
polypyrimidine tract, branchpoint and splicing silencer and enhancer-binding sites, determine 
how an exon is defined.90,91 Referred to as the exon definition model, these features determine 
which sequences are defined as exonic and highlight the exon/intron junctions. This definition 
enables the spliceosome to recognise those sequences that should be retained or excluded during 
the splicing process.  
Exon boundaries are defined by the canonical 5′ (donor) and 3′ (acceptor) splice sites GU and 
AG, respectively. The spliceosome recognises these splice sites, along with the branchpoint and 
polypyrimidine tract, and binds to the intron-exon junction, allowing the intron to be removed 
and the exons to be joined seamlessly. Additional sequences with the potential to be used as a 
donor or acceptor site can often be found within the exon or intron. Such sequences are known as 
cryptic splice sites and can be activated or created as the result of mutations, leading to abnormal 
splicing. 
 Regulation of splicing 
The splicing process is mediated by a complex of small nuclear RNAs (snRNA) and 
ribonuclear proteins called the spliceosome of which there are two; the major and minor. The 
majority of introns; those defined by the canonical GU/AG splice sites are spliced by the major 
spliceosome.92 However, a small proportion of introns have different splice site and branchpoint 
sequences and are instead spliced by the minor spliceosome.93 Such introns; referred to as U12 
type introns are estimated to make up only 0.15% to 0.5% of all introns.94–96 
The major spliceosome predominates and is made up of an estimated 170 distinct proteins.92 
The main building blocks of which are the small nuclear ribonucleoproteins (snRNPs) U1, U2, 
U3, U4/U6 and U5. 92 The current consensus of splicing depicts a step-by-step process ultimately 
resulting in the production of an intron lariat and exon-exon ligation (Figure 1.4). 
 
17 
The process begins with the recognition of cis-acting elements on the pre-mRNA by the U1 
snRNP and supporting proteins (Figure 1.4.a). U1 binds to the GU of the 5′ splice site, while 
splicing factor 1 (SF1) and U2 auxiliary factors (U2AF) 1 (35 kDa subunit) and 2 (65 kDa 
subunit), bind to the branch point, 3′ splice site and polypyrimidine tract respectively. These 
interactions form the spliceosome complex-E (Figure 1.4.b). Binding of the U2 snRNP to the 
branch point displaces SF1 and forms spliceosome complex-A (Figure 1.4.c). 
Following the formation of complex-A, a pre-assembled tri-snRNP complex of U4/U6/U5 is 
recruited with U5 binding 5′ and U6 binding to U2 to form spliceosome complex B (Figure 1.4.d). 
Complex-B is inactive and must undergo conformational changes resulting in the displacement 
of U1 and U4 to enter an active state. Following activation, the first cleavage event takes place, 
producing complex-C and releasing the first exon. Release of the first exon allows the 5′ splice 
site to bind to the branch point leading to the second cleavage event that results in the excision of 
an intron lariat and ligation of the exons (Figure 1.4.e). At this point, the remaining spliceosome 
proteins are dissociated and recycled for further rounds of splicing.97 This process is reviewed in 




Figure 1.4: Simplified schematic of major spliceosome assembly and the mRNA splicing process. 
Including; a) the regulatory elements within the pre-mRNA. b) The binding of U1, splicing factor 1(SF1) and U2 auxiliary 
factor 35 kDa (U2AF1) and 65 kDa (U2AF2) subunits to form complex E. c) the binding of U2 resulting in SF1 
displacement and the formation of complex A. d) Recruitment of U4/5/6 to form complex B. e) After activation of 
complex B the formation of complex C results in the cleavage of the first exon. F) The second cleavage results in a 
free intron lariat that is degraded, dissociation of the spliceosome proteins that are recycled and the ligation of the 
exons. Figure adapted from Douglas et al.,99 Becerra et al.98 and Wahl et al.92 
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 Alternative splicing 
One of the main advantages of eukaryotic genomes is the diversity of proteins that are 
produced from the DNA template. The mechanism by which diversity is increased is through 
alternative splicing. A process that can give rise to a plethora of unique RNA transcripts that may 
be translated into a variety of different proteins from a single DNA template (gene). An extreme 
example of alternative splicing and its role in genetic complexity are the Neurexins, a family of 
proteins involved in intercellular signalling and cell adhesion during synaptogenesis.100 There are 
over 1000 unique neurexin proteins produced from three homologous genes through the use of 
different promoters and alternative splicing.100 While not all genes are alternatively spliced to the 
same extent as the neurexins, alternative transcripts can be detected for more than 90% of human 
multi-exon genes.89,101 Some of the possible alternative splicing outcomes are shown in Figure 
1.5, the result of which can be manifold, including changes to expression, isoform selection and 
function. However, this list is not exhaustive and for many genes a combination of alternative 
splicing will occur. 
  
Figure 1.5: Schematic exploring the possible outcomes of alternative splicing. 
Boxes represent exons, interspaced by introns represented by a black line. The solid and dashed lines above and 
below indicate the splice sites being utilised. 
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A critical factor in determining if an exon is retained or excluded from the final transcript is 
the balance between positive and negative splicing factors and their respective binding domains. 
Splicing factors are trans-acting proteins that bind to cis-acting sequences within the pre-
mRNA.102 Enhancer sequences occur within the exons (exonic splicing enhancer, ESE) and 
introns (intronic splicing enhancer, ISE) and recruit positive splicing factors; most commonly 
members of the serine/arginine-rich (SR) protein family.103 Positive splicing factors enhance the 
recognition of the exon by the spliceosome, resulting in the exon being retained in the final 
transcript.104 Silencer sequences can similarly be found in either the exon (exonic splicing 
silencer, ESS) or intron (intronic splicing silencer, ISS), however, recruit negative splicing 
factors; such as heterogeneous ribonucleoprotein particles (hnRNPs), reducing the recognition of 
the exon, resulting in its removal with the flanking introns.104 
The delicate balance between enhancer and silencer sequences can be shifted by 
polymorphisms or disease-causing variants, resulting in the exclusion of an otherwise included 
exon, or vice versa. This precarious balance is explored further in chapter 4 of this thesis in the 
context of a single nucleotide variation in exon 52 of FBN1 that results in the removal of exon 52 
from transcripts and ultimately Marfan syndrome. Mutations can cause aberrant splicing in 
several ways, often resulting in a disease phenotype. Mutations can disrupt the consensus donor 
or acceptor splice sites, the adjacent sequences, create or activate a cryptic splice site or disrupt 
an enhancer or silencer sequence. 
1.3 Altering exon selection as a genetic therapy 
 Antisense oligonucleotides 
Antisense oligonucleotides (AOs) are single-stranded nucleic acid analogues that can be used 
to manipulate gene expression to include105 or exclude106,107 an exon, induce transcript 
degradation,108–110 transcription inhibition111 or inhibit translation.112 Antisense oligonucleotides 
are typically between 15-30 bases long and are designed to be complementary to the “sense” RNA 
transcript of interest, and thus bind specifically to the targeted sequence through Watson-Crick 
base pairing. There are two broad classes of AOs; those that promote the degradation of targeted 
mRNA, such as ribonuclease H (RNase H)-dependent oligonucleotides or siRNAs, and those that 
physically block or inhibit the splicing or translational machinery, commonly referred to as steric-
blocker oligonucleotides.113  
The first reports of the practical applications of antisense oligonucleotides to alter gene 
expression were released in the late 1970s. In 1977 Paterson et al.114 reported their use of single-
stranded DNA-AOs to inhibit translation of complementary RNA in a cell-free system. In 1978 
Zamecnik and Stephenson115 reported that DNA-AOs could inhibit Rous sarcoma virus 
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replication in chicken embryos. Finally in 1979, Donis-Keller116 demonstrated site-specific 
cleavage of RNA by RNase H through the creation of an RNA/DNA heteroduplex. These reports 
are considered the foundation of the antisense oligonucleotide platform from which the many 
currently known applications stem.  
Of particular interest is the report by Zamecnik and Stephenson115 who introduced chemical 
modifications into the AO to improve its biological activity, and concluded that the increased 
activity was a result of decreased nuclease susceptibility that consequently increased the AO half-
life.115 Since the 1970s great strides have been made in the field with a major contributor to this 
success being the many generations of chemical modifications. Such modifications not only alter 
the dependency on RNase H but also aim at increasing specificity, affinity, efficiency and stability 
while decreasing off-target effects, cost of synthesis and toxicity. 
 Chemistries 
Antisense oligonucleotides can be modified in several ways depending on the desired 
outcome. The early AOs were RNase H dependent phosphodiester (PO) DNA nucleotides and 
therefore negatively charged. While PO-AOs effectively demonstrated proof-of-concept, they are 
highly susceptible to nucleases and thus have limited half-lives. To reduce nuclease susceptibility, 
while retaining the negative charge and the ability to recruit RNase-H, the non-bridging oxygen 
was replaced with sulphur to produce a phosphorothioate (PS) linkage.117 The PS modification 
also increases the affinity of the AO for serum proteins such as heparin, allowing the AO to be 
maintained in circulation for longer and delaying removal by the liver.117 These benefits, in 
conjunction with the relatively low cost of synthesis and their efficiency have made the PS 
chemistry one of the more commonly used. However, the affinity of PS-AO to serum proteins, as 
well as several other off-target effects, have also been linked with increased toxicity.113,118  
Modifications of the Ribose sugar moiety can allow the AO to more closely resemble RNA 
than DNA, thus increasing RNA binding affinity.119 Two of the most common 2′-ribose 
modifications are 2′-O-methyl (2′OMe) and 2′-O-methoxyethyl (MOE).117 When bound to RNA, 
the 2ʹOMe-AOs and MOE-AOs do not support RNase H and therefore the RNA strand is not 
cleaved,117 allowing these compounds to be used for steric blockade applications. The increased 
similarity to RNA as a result of 2′-ribose modifications also increases the stability and thus 
strength of AO-RNA hybridisation, allowing for shorter AO sequences without losing 
efficiency.117 The PS and 2ʹOMe modifications are often used in conjunction forming 2ʹOMe-PS 
AOs that are nuclease and RNase-H resistant, as well as relatively efficient and cost-effective to 
synthesise.  
To overcome the undesirable off-target effects of the PS backbone, a series of neutrally 
charged chemistries were developed, the most well-known of which are the phosphorodiamidate 
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morpholino oligomers (PMO) and peptide nucleic acids. Of particular interest is the PMO 
chemistry, in which the deoxyribose sugar and negative charge are replaced with a backbone of 
morpholine rings joined by phosphorodiamidate linkages.120 The neutral charge of the PMO 
chemistry allows the AO to bind to RNA or DNA with higher specificity and affinity, while not 
recruiting RNase H, thereby making these compounds excellent steric blockers.113 The complete 
replacement of the ribose ring with a morpholine ring means that PMOs are not recognised by 
and thus resistant to the majority of natural enzymes121 making them an excellent choice for in 
vivo applications. Also, due to their neutral charge, PMOs are less likely to interact with proteins 
and thus have shown limited off-target effects or non-specific binding.118,122 Due to these 
advantages PMOs have been studied extensively in animal models and clinical trials, and are 
recognised as both safe and effective in a clinical setting.123–125 
 Delivery 
For an AO to induce the desired outcome, it must first enter the target cells and for many 
applications, enter the nucleus. Oligonucleotides are unable to diffuse through the lipid membrane 
alone and are believed to be actively transported into the cell through endocytosis,126,127 however 
the exact mechanism of nuclear delivery remains unresolved. The uptake of an AO has been 
shown to vary depending on temperature, cell type, AO structure and AO concentration.126–128 
Delivery limitations can be overcome more easily in an in vitro system through the use of 
various commercially available transfection reagents. One of the more common delivery 
mechanisms used is the encapsulation of negatively charged AOs such as 2′OMe-PS, with a 
cationic lipid-based reagent. Forming a positively charged liposome that has a high affinity for 
the negatively charged cell membrane allows the AO to be efficiently delivered into the cell. 
While liposome delivery is efficient for negatively charged AOs, e.g. 2′OMe-PS, neutrally 
charged AOs, the uncharged PMOs require different delivery mechanisms. 
In an in vitro model, PMO delivery is commonly achieved through electroporation-based 
devices such as Nucleofector™ Technology (Lonza) or the Neon™ Transfection System (Thermo 
Fisher Scientific). Both systems allow for the efficient delivery of PMOs by subjecting cells to 
short pulses of electricity, altering the permeability of the cell membrane temporarily. Non-
electroporation-based delivery methods are also available. An example of which is Endo-Porter 
(Gene Tool, LLC) a novel peptide that can deliver AOs into a cell through an endocytosis-
mediated process.129 Endo-Porter is designed to allow for efficient delivery without the membrane 
damage associated with electroporation.129 Other delivery methods include gymnosis or ‘naked’ 
delivery, that relies on the natural properties of cells to promote uptake of the AO without the 
addition of a transfection reagent.130 However, PMOs are notorious for having poor cellular and 
nuclear uptake due to their neutral charge.113 Lastly the hybridization of PMOs to sense-strand 
DNA or RNA-like leashes coupled with cationic liposomes can result in robust PMO delivery.131 
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Delivery of AOs in vivo, is much more complex and is one of the major limitations of antisense 
therapies. If not successfully delivered to the target tissue or cells the most therapeutically active 
compounds can become inert. Along with poor cellular uptake rapid renal clearance of PMOs act 
as a significant challenge.132 Therefore PMOs can be conjugated with cell-penetrating peptides 
(CPP) to improve uptake and kinetic behaviours.133 Various CPPs have been developed, one type 
called arginine-rich peptides have been shown to greatly increase cellular uptake.134,135 However, 
some arginine-rich peptides are also associated with toxicity at higher concentrations, with 
increased toxicity with the each additional arginine.133,134 Other arginine-rich CPPs have been 
shown to successfully increase PMO efficiency with no signs of toxicity.136  
 Application of antisense oligonucleotides 
Blocking of transcription and translation 
Steric blockade AOs can be used to physically block the binding of transcription or translation 
machinery, disrupting the initiation of either process. Binding of an AO, to double-stranded DNA 
can prevent the binding of a transcription factor (TF) as well as inhibiting recognition and 
initiation by RNA polymerase II (Pol)113 (Figure 1.6.a). Antisense peptide nucleic acids are 
particularly useful for this application as the polyamide modified backbone increases their 
flexibility, which in turn increases their affinity for double-stranded DNA.113,137 Translation can 
be similarly inhibited by targeting translation initiation sites; physically blocking and competing 
with the binding of translational machinery, or preventing the movement of the ribosome along 
the mRNA (Figure 1.6.d).112,138  
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Figure 1.6: Possible applications of antisense oligonucleotides to modify gene expression. 
a) transcription blocking,111 b) splice-switching; exclusion106,107 or inclusion,105 c) transcript degradation; via RNase-H
activation108,109 or siRNAs110 and d) translation blocking.112
Splice switching 
Manipulation of pre-mRNA splicing is now becoming a common application of AOs. An AO 
can be designed to bind; and therefore mask or activate splice sites, or splicing enhancer/silencer 
sequences, redirecting the spliceosome and ultimately resulting in exclusion or inclusion of the 
target sequence (Figure 1.6.b). The most common splice switching application is exon exclusion. 
Commonly referred to as exon skipping, an AO is designed to target the donor, acceptor or ESE 
sequences to decrease recognition by the spliceosome and lead to exon exclusion. Conversely, by 
targeting splicing silencers, most often those that are intronic (ISS), the exon recognition can be 
enhanced, leading to exon inclusion.139 Retention of an exon is particularly relevant in cases where 
exon exclusion from the mature mRNA is a result of a disease-causing mutation. 
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Notable examples of splice-switching AOs are eteplirsen, golodirsen and nusinersen marketed 
as Exondys51™, Vyondys53™ and SPINRAZA®, respectively. Both eteplirsen and golodirsen 
are PMOs, licenced to Sarepta Therapeutics, that were granted accelerated approval by the United 
States Food and drug authority (FDA) as a treatment for Duchenne muscular dystrophy in 
2016140,141 and 2019142 respectively. Eteplirsen and golodirsen are designed to induce skipping of 
dystrophin exon 51 and 53, respectively, to restore the mRNA reading frame around frame-
shifting deletions that flank the target exons.143,144 Removal of the exons from transcripts with 
these amenable deletions allows translation of internally truncated dystrophin isoforms, similar 
to those characteristic of the milder Becker's muscular dystrophy.123,144 Nusinersen is an FDA 
approved MOE-AO, licenced to Biogen for the treatment of spinal muscular atrophy that targets 
an intronic silencer element, ISS-N1, to induce the inclusion of SMN2 exon seven, resulting in a 
functional full-length transcript.145 
Transcript degradation 
RNase H-dependent AOs function by forming a heteroduplex between the DNA-like AO and 
RNA target, recruiting the endogenous RNase-H enzyme that binds to and cleaves at the RNA 
target (Figure 1.6.c).146,147 The most commonly used chemistry for this application is DNA 
modified with a phosphorothioate backbone that increases nuclease resistance while retaining 
RNase H dependent activity. RNase H-dependent AOs can be extremely efficient, often achieving 
between 80% and 95% mRNA and protein down-regulation.113 Added to this efficiency, RNase 
H-dependent AOs are not limited to targeting the 5′-region or initiation codon to induce
downregulation of protein expression, while steric blockade AOs do have this limitation113,138 
To date the FDA has approved two RNase H-dependent AOs. The first; Vitravene also known 
as fomivirsen, is a 21-mer phosphorothioate oligodeoxynucleotide designed to disrupt the 
replication of cytomegalovirus (CMV) to treat patients with CMV retinitis.148 The second; 
Kynamro also known as mipomersen, is designed to treat familial hypercholesterolemia by 
inhibiting apolipoprotein B.149 Although the FDA had approved both drugs, Vitravene has been 
withdrawn from the market and Kynamro is only prescribed in special cases as there have been 
several reports of adverse side-effects.148–150 
Applications of antisense oligonucleotides for the type-1 fibrillinopathies 
As discussed, FBN1 is translated into the fibrillin-1 preproprotein that is cleaved by furin into 
asprosin and a fibrillin-1 monomer. Fibrillin-1 monomers are secreted from the cell and rapidly 
aggregated into multimer units to form the backbone of fibrillin-1 microfibrils (Figure 1.7.a).17 
Mutations in FBN1 disrupt microfibrils' formation, either through the expression of abnormal 
fibrillin-1 monomers (Figure 1.7.b and d) or decreased fibrillin-1 expression (Figure 1.7.c). This 
disruption ultimately leads to disease, either Marfan syndrome or another type-1 fibrillinopathy. 
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This study aims to induce the exclusion of exons harbouring disease-causing mutations from 
the FBN1 pre-mRNA, along with the corresponding exon from the transcript encoded by the 
healthy allele. We hypothesise that this will have different effects depending on the mutation type 
but ultimately result in an increase, or rescue of fibrillin-1 microfibrils (Figure 1.7.e). Firstly, 
mutations resulting in altered FBN1 splicing often lead to a dominant-negative interaction 
between the wild-type and mutant proteins (Figure 1.7.b).69,151 Therefore, we hypothesise that 
removing the mutation-associated exon from both alleles' transcripts will re-establish transcript 
homogeneity. This should negate the dominant-negative interaction and allow monomers to form 
microfibrils correctly. 
In contrast, nonsense and frameshift mutations, often result in transcript degradation and thus 
a reduction in fibrillin-1 abundance (Figure 1.7.c). We hypothesise that removing exons 
associated with a nonsense or frameshift mutation will bypass the premature termination site, re-
framing the transcript. The result of which should be the expression of a truncated fibrillin-1 
protein.  
As with the other mutation types, the effect of a missense mutation depends on the nucleotide 
and exon affected. Some missense mutations result in a dominant-negative effect, while others 
result in loss of function or the production of abnormal microfibrils (Figure 1.7.d).68,69,152 We 
hypothesise that removing the affected exon from both alleles will remove the aberrant sequence 
and restore transcript homogeneity allowing monomers to form functional microfibrils.  
Lastly, we hypothesise that fibrillin-1 is amenable to the removal of target exons for two main 
reasons. (1) The highly repetitive nature of fibrillin-1 that suggests domain periodicity is vital for 
microfibril formation and function. (2) The in-frame nature of the FBN1 exons means that most 
exons can be removed without altering the reading frame. The exceptions to this are the exons at 
the N- and C- terminals; exons 2, 3, 64, 65 and 66. The removal of any of these exons would 
disrupt the reading-frame and likely result in no functional protein production. 
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Figure 1.7: Schematic of fibrillin-1 from splicing to microfibril formation 
a) a healthy control. b) a Marfan syndrome patient with a splice site mutation resulting in exon skipping and a dominant-negative effect on microfibril formation. c) a Marfan syndrome patient with a
nonsense mutation resulting in nonsense-mediated decay and fibrillin-1 haploinsufficiency. NMD: Nonsense-mediated decay. d) a Marfan syndrome patient with a missense mutation resulting in a
dominant-negative effect on microfibril formation or the formation of abnormal microfibrils. e) the proposed therapeutic strategy to induce exon exclusion from all transcripts using antisense oligonucleotides,
potentially restoring the formation of functional microfibrils.
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1.4 Summary, final remarks, significance, and aims 
In summary, the type-1 fibrillinopathies are a family of connective tissue disorders, of which 
Marfan syndrome is the most common, with a prevalence of 2-3 in 10,000 individuals. These 
diseases are caused by mutations in the fibrillin-1 gene that encodes for the fibrillin-1 protein, a 
major component of the extracellular matrix microfibrils, providing both structural and regulatory 
support. The type-1 fibrillinopathies have variable ages of onset and are progressive, affecting 
multiple body systems with major clinical manifestations in the skeletal, ocular and 
cardiovascular systems. 
The current standard of care relies heavily on surgical intervention and lifelong use of drugs 
to slow disease progression. We propose that antisense oligonucleotides could present a novel 
therapeutic strategy for the type-1 fibrillinopathies, by mediating the alteration of exon selection 
of both the unaffected and disease-causing pre-mRNA transcripts to force the translation of 
identical fibrillin-1 monomers that can form functional microfibrils. This proposed treatment 
alone or in conjunction with currently accepted symptomatic management could facilitate the 
production and maintenance of functional microfibrils, ultimately decreasing phenotypic severity 
and progression.  
Aims of this study: 
The overall focus of this study is to develop therapeutic alternative splicing strategies for the 
type-1 fibrillinopathies using antisense oligonucleotides. To achieve this, the following specific 
aims were addressed and constitute the results chapters of this thesis 
1. To demonstrate proof-of-concept using FBN1 exon 52 as a model.
a. Design, screen and optimise 2ʹOMe-PS AO sequences to induce the exclusion 
of exon 52 from fibrillin-1 mRNA in healthy control fibroblasts.
b. Evaluate the efficacy of lead sequences as the clinically applicable PMO 
chemistry in both healthy control and appropriate patient derived fibroblasts.
c. Determine the effects of exon skipping on the firbillin-1 protein 
using immunofluorescence staining.
2. To evaluate the applicability of AO-mediated skipping to other FBN1 exons.
a. Design, screen and optimise a series of 2ʹOMe-PS AO sequences to induce  
skipping of FBN1 exons; 15, 16, 22, 26, 27, 31, 32, 39, 44, 45, 46, 47, 49 and 
59 in healthy control fibroblasts.
b. Evaluate the efficacy of lead sequences as the clinically applicable PMO 
chemistry in both healthy control and appropriate patient derived fibroblasts.
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c. Determine the effects of efficient exon skipping on the firbillin-1 protein using
immunofluorescence staining.
3. To investigate the feasibility of triple-exon skipping.
a. Optimise cocktails of 2ʹOMe-PS AO sequences to induce exon 45, 46 and 47 
exclusion.
b. Evaluate the efficacy of lead sequences as the clinically applicable PMO 
chemistry in both healthy control and appropriate patient derived fibroblasts.
c. Determine the effects of efficient exon skipping on the firbillin-1 protein 
using immunofluorescence staining.
4. Investigate the effect of AO design and chemistry on AO efficiency
a. Compare the efficacy of the 2ʹOMe-PS, PMO and TMO chemistries using 
exon 52 as a model.
b. Investigate the impact of each chemistry on paraspeckle protein sequestration
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Chapter 2 




Table 2.1: List of reagents used in this study and their suppliers 
Reagent Supplier (Location) 
100 bp molecular size marker Geneworks (SA, Australia) 
Acetic acid, glacial (CH3COOH) BDH Laboratories (Radnor, PA, USA) 
Acetone (C3H6O) 
Honeywell Research Chemicals (SA, 
Australia) 
Agarose powder (molecular biology grade) Scientifix (VIC, Australia) 
Amaxa™ P3 primary cell 4D-Nucleofector™ X Kit S Lonza (VIC, Australia) 
AmpliTaq Gold™ DNA Polymerase with Gold Buffer and MgCl2 Applied Biosystems (VIC, Australia) 
Analar glycerol Sigma Chemicals (NSW, Australia) 
Anti-SFPQ antibody (ab38148) Abcam (Melbourne, Australia) 
Baxter sterile water Baxter Healthcare (NSW, Australia) 
Deoxynucleotide triphosphates (dNTPs) Life Technologies (VIC, Australia) 
Diffinity RapidTip® Sigma-Aldrich (NSW, Australia) 
Dimethyl sulfoxide (DMSO; C2H6OS) Sigma Chemicals (NSW, Australia) 
Dulbecco’s modified Eagle’s Medium (DMEM) Life Technologies (VIC, Australia) 
Endo-Porter Gene Tools (Philomath, OR, USA) 
Ethanol (C2H5OH) Sigma-Aldrich (NSW, Australia) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (NSW, Australia) 
Foetal bovine serum (FBS) Scientifix (VIC, Australia) 
GlutaMAX™ Supplement 
Thermo Fisher Scientific (VIC, 
Australia) 
Hoechst 33342 Sigma-Aldrich (NSW, Australia) 
Horse serum (HS) Life Technologies (VIC, Australia) 
IgG Alexa Fluor 488 goat anti-mouse (A-11001) 
Thermo Fisher Scientific (VIC, 
Australia) 
IgG Alexa Fluor 488 goat anti-rabbit (A-11008) 
Thermo Fisher Scientific (VIC, 
Australia) 
IgG Alexa Fluor 568 goat anti-mouse (A-11004) 
Thermo Fisher Scientific (VIC, 
Australia) 
Isopropanol (C3H8O) Sigma-Aldrich (NSW, Australia) 
Lipofectamine™ 3000 Transfection Reagent Life Technologies (VIC, Australia) 
MagMAX™ -96 Total RNA Isolation Kit Applied Biosystems (VIC, Australia) 
Methanol (CH3OH) Rowe Scientific (WA, Australia) 
Mouse anti-fibrillin-1 monoclonal antibody, clone 26 (mAB2502) 
EMD Millipore Corporation (Temecula, 
CA, USA) 
Neon™ Transfection System 10 μl Kit 
Thermo Fisher Scientific (VIC, 
Australia) 
Opti-MEM® Reduced Serum Medium Life Technologies (VIC, Australia) 
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Reagent Supplier (Location) 
ProLong™ Gold antifade reagent 
Thermo Fisher Scientific (VIC, 
Australia) 
PureLink™ Genomic DNA Mini Kit 
Thermo Fisher Scientific (VIC, 
Australia) 
RedSafe™ Nucleic Acid Staining Solution iNtRON Biotechnologies (South Korea) 
Sterile-filtered Water (tissue culture grade) Sigma-Aldrich (NSW, Australia) 
SuperScript™ III One-Step RT-PCR System with Platinum™ Taq 
DNA Polymerase 
Life Technologies (VIC, Australia) 
SuperScript™ IV First-Strand Synthesis System Life Technologies (VIC, Australia) 
TaKaRa LA Taq® DNA Polymerase (Mg2+ plus buffer) Scientifix (VIC, Australia) 
Triton X-100 Sigma-Aldrich (NSW, Australia) 
Trizma base Sigma-Aldrich (NSW, Australia) 
Trypan Blue Sigma-Aldrich (NSW, Australia) 
Trypsin Life Technologies (VIC, Australia) 
TURBO DNase Ambion (Austin, TX, USA) 
Tween 20 Sigma-Aldrich (NSW, Australia) 
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Buffers and solutions 
Table 2.2: Composition of buffers made in-house 
Buffer pH Composition 
1x PBS 
Autoclaved 
7.4 137 mM NaCl 
2.7 mM KCl 
10 mM Sodium Phosphate dibasic 
2 mM Potassium Phosphate monobasic 
1x TAE 8.2 20 mM Trizma base 
40 mM Acetic Acid 
1 mM EDTA 
2% Agarose 8 g Agarose powder 
Make to 400 ml with 1 x TAE 
Boiled to dissolve and stored at 65°C 
Gel-loading buffer 0.5% Bromophenol blue 
0.25% Xylene cyanol FF 
30% glycerol 
In water 
1% SDS in 1mM EDTA 
1 x PBST 
(Tween-20) 
7.4 137 mM NaCl 
2.7 mM KCl 
10 mM Sodium Phosphate dibasic 
2 mM Potassium Phosphate monobasic 
0.1% Tween-20 
1 x PBST 
(Triton-X) 
7.4 137 mM NaCl 
2.7 mM KCl 
10 mM Sodium Phosphate dibasic 
2 mM Potassium Phosphate monobasic 
0.1% Triton-X 
Post-stain buffer 10 µl RedSafe 
250 ml water 
2.2 Methods 
Antisense oligonucleotide design and synthesis 
Antisense oligonucleotides (AO) were designed to anneal to acceptor and donor splice sites, 
as well as potential splicing factor motifs predicted in silico using SpliceAid.153,154 For initial 
screening AOs with 2′-O-methyl (2ʹOMe) modified bases on a phosphorothioate backbone (PS) 
were used. The 2′OMe-PS AOs were either synthesised in-house on an Expedite 8909 or Akta 
OligoPilot plus10 using the 1 µmol thioate synthesis protocol or purchased from TriLink 
Biotechnologies, LLC (San Diego, CA, USA). After screening, AO sequences found to mediate 
optimal skipping were purchased from Gene Tools (Philomath, OR, USA) as phosphorodiamidate 
morpholino oligomers (PMO). Thiophorphroamidate morpholino oligomers (TMO) were kindly 
provided by Professor Marvin Caruthers and Ondřej Kostov from the University of Colorado 
Boulder, USA. 
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A minimum of one AO sequence, completely unrelated to FBN1, was used per chemistry as a 
sham treatment to observe sequence-independent chemistry-related effects. A full list of all the 
AO sequences used in this study and their details is provided in Table A1.1, as well as in 
respective chapters. AO nomenclature is derived from Mann et al.155 and includes the species (‘H’ 
for homo sapiens), exon number, acceptor (A) or donor (D) splice site and coordinates (xx/yy). 
Exonic coordinates are denoted by ‘+’ while intronic coordinates by ‘-’. Therefore, FBN1 
H52A(+29+53) describes an oligomer annealing to the human FBN1 mRNA between bases 29 
and 53 of exon 52 (Figure 2.1) 
Figure 2.1: Antisense oligonucleotide nomenclature  
An AOs name includes information on the gene, species, exon number, splice site and sequence coordinates. Adapted 
from Mann et al.155 
Cell culture 
Cell lines 
The use of human cells for this research was approved by the Murdoch University Human 
Ethics Committee; approval numbers 2013_156 and 2017_101 and The University of Western 
Australia Human Research Ethics Committee; approval number RA4/1/2295. Healthy control 
fibroblasts were cultured from a dermal biopsy of a healthy volunteer taken after informed 
consent.  
A total of eight patient cell lines were used in this study. The following cell lines were obtained 
from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research 
(Camden, NJ, USA): GM21936, GM21932, GM21940, GM21934, GM21941, GM21952, 
GM21992, GM21937. The mutation profile of each patient cell line was confirmed using Sanger 
sequencing. Mutation nomenclature was determined with respect to the FBN1 gene Locus 
Reference Genomic sequence transcript 1 (LRG_778t1) and NCBI Reference Sequence 
(NM_000138.5) in which the translation start codon is in the second of 66 exons. A full list of the 
Marfan syndrome patient cell lines used in this study and their details is provided in Table A1.2. 
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Cell resurrection, maintenance and freezing conditions 
Cells were resurrected from liquid nitrogen by thawing at 37°C, transferring into 9 ml of pre-
warmed 10%-HS DMEM and centrifuging for 3 minutes at 1,000 g. Cell pellets were gently 
resuspended in growth medium and maintained in T75 cm2 flasks at 37°C and 5% CO2. The 
composition of growth media is described in Table 2.3. Media was replaced every 2-4 days as 
necessary.  
Once at 80% confluence, cells were passaged for further expansion, freezing or use in 
experiments. Passaging involved, washing cells with 1x PBS, incubation with 1x trypsin for 2-4 
minutes followed by inactivation with 10% FCS DMEM and centrifugation at 1,000 g for 3 
minutes. Cell pellets were resuspended in growth media. As required, cells were counted by 
mixing 5 µl of cell suspension with 45 µl of trypan blue before 10 µl of the mixture was loaded 
into a haemocytometer.  
For expansion, 3x105 or 7x105 cells were re-seeded into a T75 or T175 flask respectively with 
growth medium. For freezing, aliquots containing approximately 1x106 cells and 10% DMSO 
were made up to 1 ml with 10% HS DMEM and transferred to cryovials for cryopreservation. 
Vials were kept at -80°C, allowing them to come to temperature before being stored in liquid 
nitrogen vapour phase. When required for 2ʹOMe-PS AOs transfection, fibroblasts were seeded 
into 24 well plates with 15,000 cells per well and incubated for 24 hours at 37 °C and 5% CO2. 
For Nucleofection and Neon transfections, cells were transfected immediately. 
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Table 2.3: Cell culture media and buffers  
Solutions were prepared in a Class II biological safety hood under aseptic conditions. Prepared solutions were stored 
at 4°C and warmed to 37°C when required. 
Reagent (Cell type/purpose) Composition 
10% FCS DMEM 
(growth medium for healthy control fibroblasts) 
High-glucose(4.5 g/L) DMEM 
10% foetal bovine serum 
15% FCS DMEM + GlutaMAX 
(Growth medium for patient fibroblasts) 
High-glucose(4.5 g/L) DMEM 
15% foetal bovine serum 
1% GlutaMAX 
5% FCS DMEM 
(Nucleofection transfection medium) 
High Glucose DMEM 
5% foetal bovine serum 
Opti-MEM 
(Lipofectamine 3000 transfection medium) 
100% Opti-MEM 
10% HS DMEM 
(Temporary and cryo-storage medium) 
High Glucose DMEM 
10% Horse serum 
1x trypsin 
(Detachment of adherent cells) 
1% Trypsin 
1x PBS 
1 × Phosphate buffered saline (PBS) 
(Washing buffer, 
Autoclaved and filter sterilised) 
pH 7.4 
137 mM NaCl 
2.7 mM KCl 
10 mM Sodium Phosphate dibasic 
2 mM Potassium Phosphate monobasic 
Transfection 
Transfection with 2ʹOMe-PS AOs 
The initial screening 2ʹOMe-PS AOs were delivered as cationic lipoplexes using 
Lipofectamine® 3000 transfection reagent in Opti-MEM™ reduced serum. This reagent was used 
according to the manufacturer's instructions. In brief, 3 µl of Lipofectamine 3000 reagent and 
sufficient AO for a final concentration of 400 nM were incubated together in 50 µl of Opti-MEM 
for 10 min to allow for complexes to be formed. The transfection master mix was then diluted in 
Opti-MEM to a volume of 1 ml. The master mix was serially dilution to obtain concentrations of 
200 nM, 100 nM and 50 nM in 1 ml each. These concentrations were used for the majority of 
experiments; however, higher and lower concentrations were obtained in the same manner.  
The final transfection mixture was applied to fibroblasts seeded into 24-well plates 24 hours 
prior. Transfections were performed in duplicate with 500 µl of transfection mixture added to 
each well. Cells were incubated for a further 24 hours at 37°C and 5% CO2 unless stated 
otherwise. 
Transfection with PMOs 
Phosphorodiamidate morpholino oligomers were delivered via Nucleofection using the 
Amaxa 4D-Nucleofector and P3 Primary Cell, 16-well Nucleocuvette™ kit (Lonza). Due to the 
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requirement of hyper-confluence for protein studies and to avoid cell growth post-transfection, 
3x105 fibroblasts were used per treatment group. Cells were pelleted then resuspended in 19 µL 
of P3 solution(82%)-supplement(18%). The cell mixture was added to a Nucleocuvette™ along 
with, 1 µl of pre-warmed stock PMO (5mM) either undiluted (250 µM) or diluted 1:4 in filter 
sterilised water (50 µM). PMOs were pre-warmed for 5 min at 37°C. The Nucleocuvette™ strip 
was subsequently placed into the X unit of the Amaxa 4D-Nucleofector and pulsed with the 
predefined code optimised for dermal fibroblasts; CA-137. After electroporation cells were 
allowed to ‘recover’ for 10 min before the contents of each cuvette were diluted in 5%-FBS 
DMEM. The nucleofected cell mixture was divided between 4 wells in a 24 well plate. Two wells 
were seeded with 5x104 for RNA analysis and two coverslip-lined wells with 1x105 cells for 
immunofluorescence. Each well was made up to 500 µl with 5% FBS DMEM and incubated at 
37°C for between 24 hours and 14 days as indicated. For incubation past three days, media was 
replaced with fresh 5% FBS DMEM as required. 
Endo-Porter® (Gene Tools) was used to deliver select PMOs according to the manufacturer’s 
instruction. Fibroblasts were seeded into a 24 well plate at a density of 8x104 cells per well and 
incubated for 24 hours before transfection. Culture medium was replaced with 500 µl fresh 10% 
FBS DMEM containing 3 μl of Endo-Porter®. One microlitre of stock PMO (5 mM) was added 
either undiluted (10 µM) or diluted 1:4 in filter sterilised water (2.5 µM) and the plate gently 
mixed. Cells were incubated for 72 hours at 37°C and 5% CO2. 
Neon transfection 
To compare the three chemistries particular 2′OMe-PS, PMO and TMO AOs were delivered 
into fibroblasts using the Neon Transfection System and 10 µl Kit following the manufacturer’s 
protocol. In brief, cells were trypsinised, counted and washed with PBS, centrifuging for 2 min at 
1,000 g between each step. Washed cells were resuspended in Resuspension Buffer R, with 
3.15x105 cells in 10 µl of buffer per treatment. To a separate tube, 10 µl of cell mixture and AO 
were mixed before being drawn into a 10 µl Neon® tip using a Neon® Pipette. The pipette and 
tip were then placed into Neon® tube containing 3 ml of Electrolytic Buffer E and electroporated 
with a protocol optimised in-house for dermal fibroblasts consisting of 3 pulses at 1650 volts 10 
milliseconds apart. Transfected cells were divided between a total of 5 wells. Two wells were 
seeded with 5x104 cells for RNA analysis, two wells with 1x105 cells for fibrillin-1 
immunofluorescence staining and one well with 15,000 cells for paraspeckle protein 
immunofluorescence staining. 
Cell harvesting and RNA extraction 
Following the specified incubation period, transfected cells were harvested using MagMAX™ 
lysis binding solution. Total RNA was extracted with the MagMAX™ express-96 machine 
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(Applied Biosystems) and RNA isolation kit according to the manufacturer’s protocol using a 
modified version of the program AM1830. Modifications include an additional 5 min of mixing 
during the lysis binding step and an extra 90 seconds for all washing steps. Samples were eluted 
into 42 µl of elution buffer and quantified using the NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher Scientific). 
Polymerase chain reaction and gel electrophoresis 
Target regions of the FBN1 transcript were amplified via reverse transcription-polymerase 
chain reaction (RT-PCR) using the SuperScript™ III One-Step RT-PCR System with Platinum™ 
Taq DNA Polymerase as per the manufacturer’s protocol. The components of each PCR reaction 
were as follows; 25 ng of the RNA template, 25 ng of each forward and reverse primer, along 
with provided 2x buffer and SuperScript™ III mixtures to a final volume of 12.5 µl. The COL1A2, 
exon 4 to 20, and SMN1,exon 4 to 8, gene transcripts were used as a housekeeping and control 
respectively. These transcripts were similarly amplified through RT-PCR with the following 
modifications. For the COL1A2 amplicon, a lower 10 ng of each primer was used, while for SMN1 
transcript amplification, 50 ng of template RNA was used. The primers and thermocycling 
conditions for each gene are described in Table 2.4. Each primer is labelled according to the 
nomenclature set out in Figure 2.2. 
A second control, COL7A1 was amplified between exons 72 and 77 using a two-step process. 
Firstly, cDNA was synthesised using SuperScript™ IV First-Strand Synthesis System as per the 
manufacturer’s protocol with 70 ng RNA as a template in a 10 µl reaction. With 35 ng of cDNA 
as a template, a second round of amplification was performed using TaKaRa LA Taq® DNA 
Polymerase, with an annealing temperature of 60°C for 34 cycles. 
Figure 2.2: Primer nomenclature  
Primer ID includes species, gene, target, primer direction and addition information as required 
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Table 2.4: List of primer sets. 





Primer Sequence (5′-3′) Cycling conditions 
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55°C for 30 min 
94°C for 2 min 
94°C for 30 sec 
55°C for 1 min 25 cycles 









55°C for 30 min 
94°C for 2 min 
94°C for 30 sec 
55°C for 1 min 18 cycles 
68°C for 1 min 
AmpliTaqGold, gDNA template 




TGATTGTCCTGTGCTTTCCTA 94°C for 6 min 




GCACATTGTATTTGACAAGTCCC 94°C for 30 sec 




TCGGGTTCTTTGCATTCGTC 55°C for 1 min 30 cycles 




TATTCAATACACCTTTTTCCCCC 72°C for 2 min 
Two steps, SSIV and TaKaRa 







94°C for 6 min 
94°C for 30 sec 
60°C for 1 min 34 cycles 
72°C for 1 min 
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Gel electrophoresis 
After thermal cycling, the products of RT-PCR were mixed 4:1 (v:v) with gel-loading buffer 
and fractionated on 2% agarose gels in TAE buffer for approximately 90 minutes at 100 volts. In 
the first and last lanes, 2 µl of 100 bp DNA ladder was loaded to indicate product sizes. To detect 
the products, gels were immersed in RedSafe™ Nucleic Acid Staining Solution for 10 min under 
constant agitation, followed by washing in water for 30-60 minutes. Gels images were captured 
using the Fusion capture advance FX7 software on a Vilber Lourmat Fusion FX system (Vilber, 
Collégien, France). Bright artefacts were removed using the capture software, with an artefact 
correction radius of two pixels and a threshold of 1000. Images were cropped using Adobe 
Photoshop CC and analysed using ImageJ software.156 
Amplicon identity and mutation confirmation 
Amplicon identity was confirmed using an isolation method called bandstab157 and Sanger 
sequencing. Agarose gel electrophoresis and staining were performed as described in section 
2.2.5, however, before imaging, gels were visualised using a blue-light transilluminator. A sample 
of each band of interest was collected by stabbing the gel with a P200 pipette tip, without any 
visible carryover agarose. The pipette tip was transferred immediately into a tube with a pre-
prepared PCR mix containing, 50 ng of each forward and reverse primers, 5 nM dNTPs and 25 
mM MgCl2, 10x buffer and AmpliTaq Gold DNA Polymerase made to a total volume of 50 µl 
with sterile filtered water. Primers and thermocycling conditions are described in Table 2.4. 
Amplicons were fractionated on 2% agarose gel to confirm isolation and purity of the targeted 
product. 
For mutation confirmation at the genomic level; genomic DNA was extracted from cell pellets 
using a PureLink™ genomic DNA mini kit following the manufacturer’s protocol. After 
extraction, the FBN1 region of interest was amplified using AmpliTaq Gold™ DNA polymerase 
and appropriate primers (Table 2.4) with 50 ng of gDNA as template. For confirmation at the 
cDNA level, cDNA was derived from patient RNA using RT-PCR as described in section 2.2.5. 
For analysing splicing mutations, the full-length and skipped transcript products were isolated 
through bandstab. 
Amplicons were purified using Diffinity RapidTips® (Sigma-Aldrich) as per the 
manufacturer’s instructions. Purified samples were mixed with the appropriate primer and 
submitted to the Australian Genome Research Facility (AGRF, Perth Australia) for Sanger 
sequencing. Sequencing results were analysed using Chromas version 2.6.6 and SnapGene® 
Viewer 5.1 software. 
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Immunofluorescent staining analysis 
Cell culture and fixation 
For fibrillin-1 staining, nucleofected and Neon transfected fibroblasts were seeded onto 13 
mm No.1 round uncoated glass coverslip (ProSciTech, QLD, Australia) in 100 µl of 5% FCS 
DMEM at a density of 1 x105 cells per coverslip. Cells were incubated at 37°C for 30 minutes to 
allow cells to adhere to the coverslip before an additional 400 µl of 5% FCS DMEM was added. 
The cells were then incubated for a further 24 hours to 14 days, with media replaced every 3-4 
days as necessary. 
For paraspeckle protein staining of Lipofectamine 3000 transfected cells, approximately 
15,000 cells were dotted onto coverslips in ‘colonies’. Cells were allowed to adhere for 30 minutes 
before adding growth media and incubating for 24 hours before transfection. Post transfection 
cells were incubated for a further 24 hours. For paraspeckle protein staining of Neon transfected 
cells, post-transfection 15,000 cells were seeded in colonies and similarly left to adhere before 
adding 400 µl of 5% FCS DMEM and incubating for 24 hours. 
After the incubation period, all coverslips were washed once with cold 1x PBS and fixed in 
ice-cold acetone-methanol (1:1) for 4 min on ice. Samples were stored at -80°C in slide sleeves 
until required.  
Fibrillin-1 immunofluorescence staining 
As required, coverslips were thawed to room temperature and maintained at room temperature 
unless stated otherwise. Coverslips were re-hydrated with 1x PBS before incubation with 10x 
blocking buffer (1x PBS + 10% Goat serum) for 30 min. Anti-fibrillin-1 primary antibody was 
applied at a dilution of 1:100 in 1x blocking buffer (1x PBS + 1% Goat serum) and coverslips 
were incubated at 4°C overnight (~16 hours). Following primary antibody incubation, coverslips 
were washed in 1x PBS three times for 5 min each and incubated for 1 hour in goat-anti-mouse 
Alexa Fluor 568 secondary antibody diluted to 1:400 in 1x blocking buffer. Coverslips were 
washed four times for 5 min each, with Hoechst 33342 (1:160) added to the second to last wash. 
Finally, coverslips were mounted with ProLong™ Gold antifade reagent, allowed to dry in the 
dark for 1 hour and then stored at 4°C. 
Paraspeckle protein Immunofluorescence staining 
Coverslips were thawed and maintained at room temperature, unless stated otherwise. After 
rehydration with 1x PBS, coverslips were washed with 1% Triton X-100 PBST for 5 min followed 
by two 5 min washes with PBS to remove excess Triton X-100. Coverslips were incubated for 1 
h with primary antibody diluted in 0.05% Tween-20 PBST to 1:1,500 or 1:1,000 for PSPC-
43 
1/NONO and SFPQ antibodies, respectively. Coverslips were washed three times for 5 min each 
with 0.2% Triton X-100 PBST before incubation for 1 hour with appropriate secondary antibody 
diluted to 1:400 in 0.05% Tween-20 PBST. Coverslips were washed with 0.2% Triton X-100 
PBST three times for 5 min each, followed by incubation with Hoechst (1:160) for 3 min. 
Coverslips were washed with PBS a final time before mounting with ProLong™ Gold antifade 
reagent. All details of antibodies and nuclei stain are provided in Table 2.5 
Imaging and Post-imaging modifications: 
Imaging was performed using two microscopes; a Nikon 80i microscope using NIS-Elements 
Advanced Research software, and an Echo Revolve microscope with built-in software. Images 
were taken with either a 20x or 40 x lens. Texas red and FITC filters were used to capture fibrillin-
1 and paraspeckle proteins, respectively. Hoechst was visualised using UV-2A (Nikon) or DAPI 
(Echo) filters. All conditions were maintained between images within an experiment. 
Brightness and contrast of individual channel images were altered on the whole image and 
were altered equally for each image using Adobe Photoshop CC. Channels were then merged and 
the merged image cropped from original 1280px by 1024px size. A scale bar of 20 µm was added 
using ImageJ software.156
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Merck Millipore mAb2502 
2859140 
2910144 
1:100 4°C, 16 hr 
Anti-SFPQ Rabbit Polyclonal Abcam ab38148 GR314817-1 1:1000 25°C, 1 hr 
Anti-PSPC-1/NONO Mouse 
Gift from 
Prof. Archa Fox 
UWA, Australia 
1:1500 25°C, 1 hr 
Secondary Antibodies 
anti-Mouse IgG Goat Alexa Fluor 568 Thermo Fisher Scientific A-11004 1613919 1:400 25°C, 1 hr 
anti-Mouse IgG Goat Alexa Fluor 488 Thermo Fisher Scientific A-11001 1890503A 1:400 25°C, 1 hr 
anti-Rabbit IgG Goat Alexa Fluor 488 Thermo Fisher Scientific A-11008 790311 1:400 25°C, 1 hr 
Nuclei stain 
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3.1 Introduction 
Marfan syndrome (MFS, MIM 154700) is one of the most common dominantly inherited 
connective tissue diseases, affecting an estimated 2-3 in 10,000 individuals,27,28 in a family of 
disorders called the type-1 fibrillinopathies.26 Marfan syndrome is characterised by extreme 
height with disproportionate limb and digit length in comparison to the torso, coupled with a 
myriad of other skeletal, ocular, skin and cardiovascular abnormalities.34 However, it is the 
progressive growth of the aorta often eventuating into aortic dissection and rupture that is the 
most common cause of death.35  
Marfan syndrome was linked in the early 1990s to mutations in the, then recently discovered,11 
fibrillin-1 gene (FBN1).1,158 Since then over 2800 disease-causing mutations have been reported.2 
The fibrillin-1 gene encodes a large 350 kDa glycoprotein of the same name that is secreted from 
the cell and deposited into the extracellular matrix (ECM).11 In a healthy individual, fibrillin-1 
monomers aggregate into multimer units within the first few hours after secretion.17 Fibrillin-1 
multimers form the backbone of microfibrils11 that are essential in the majority of connective 
tissues and to which many microfibril associated proteins bind.159 It is in the microfibril form that 
fibrillin-1 exerts its structural and regulatory roles, acting as a backbone of microfibrils,13 
maintaining the stability of elastic fibres,14 and regulating the bioavailability of signalling proteins 
such as transforming growth factor-beta (TGF-β).12,16  
In an MFS patient, the disease-causing FBN1 mutation results in a lack of functional 
microfibrils, in turn leading to instability of the ECM that is further compounded by the 
dysregulation of TGF-β.13,72 The loss of functional microfibrils leads to an increase in bioavailable 
TGF-β that activates a signalling cascade resulting in, among other outcomes, an increase in 
matrix metalloproteinase expression.16 Matrix metalloproteinases degrade fibrillin-1 and other 
matrix proteins leading to further destabilisation of the ECM.16,160 The initial loss of functional 
microfibrils is theorised to depend on the type of mutation. In general, missense mutations, that 
do not affect a conserved cysteine, as well as splicing mutations are thought to be dominant 
negative. Such mutations result in the production of a dominant aberrant monomer that disrupts 
the assembly of the wild-type protein into microfibrils.68 In contrast, the majority of nonsense and 
frameshifting mutations are associated with haploinsufficiency.31,69 This haploinsufficiency is the 
result of transcript instability that leads to degradation and thus a reduction in fibrillin-1 
expression.161 A small subgroup of nonsense and frameshift mutations that affect the C-terminal 
region can produce stable transcripts that are translated into protein rather than being 
degraded.52,66 Such mutations have been associated with intracellular retention of fibrillin-1, the 
outcome of which is a similar lack of microfibrils in the ECM.66,69 
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The most common type of mutations are missense mutations that result in the disruption of a 
cysteine residue.2,3 The fibrillin-1 protein has several repeated domains including 47 epidermal 
growth factor (EGF)-like domains; 43 of which are involved in calcium-binding (cbEFG-like), 
seven TGF-β binding protein-like (TB) domains and two hybrid domains.20,21 Each of these 
domains are cysteine-rich with 6-8 conserved cysteine residues that play a critical role in the 
folding and stability of the fibrillin-1 protein.20,24 Mutations affecting a conserved cysteine have 
been shown to either increase the susceptibility of fibrillin-1 to proteolysis15,23 or disrupt the 
folding and secretion of fibrillin-1 leading to intracellular retention.25 The outcome of either 
scenario is a similar decreased microfibril stability and abundance.  
Following the discovery that mutations in fibrillin-1 result in TGF-β dysregulation, a research 
area emerged focussing on the antagonism of TGF-β as a therapeutic strategy.79,83 However, no 
breakthroughs have yet been made in the field and treatment of MFS patients remains heavily 
focused on symptom management. The current standard of care includes surgical correction of 
scoliosis, ectopia lentis, pectus deformities and aortic dilatation, as well as pain management and 
the use of β-adrenergic receptor blockers33 or angiotensin II receptor type 1 blockers79,80 that slow 
the progressive aortic dilation and reduce the associated complications.27,33 Here we propose that 
personalised medicines using antisense oligonucleotides (AO) to alter FBN1 exon selection 
during the splicing process, may be an appropriate therapeutic approach for Marfan syndrome. 
Antisense oligonucleotides are short sequences, generally between 15 to 30 bases in length, 
that are single-stranded analogues of nucleic acids. Antisense oligonucleotides are designed to be 
complementary to the region of interest binding to the target RNA or DNA through Watson-Crick 
base pairing. When bound to the target sequence, AOs can work through two main mechanisms; 
recruiting RNase-H to cleave the target leading to degradation108,109 or physically blocking the 
binding of regulatory factor or machinery of the transcription,111 translation112 or splicing107,162 
processes. Several studies have outlined the potential and efficiency of AOs in the treatment of 
genetic diseases. Several notable examples of which; Eteplirsen,123,140 Nusinersen145,163 and more 
recently Golodirsen142 and Viltolarsen164 have now been approved by the United States Food and 
drug authority (FDA). All four drugs are a class of AO commonly referred to as splice switching. 
Splice switching AOs function by blocking the splicing machinery or regulatory features, altering 
the normal splicing process. 
Splicing is an essential process for all multi-exon genes; removing the non-coding introns and 
re-joining the coding exons, before translation. The splicing process is, therefore, tightly regulated 
by several cis- and trans-acting elements. The majority of multi-exon genes, however, also 
undergo a process called alternative splicing.89 Alternative splicing allows the production of 
multiple transcripts, and thus proteins, from a single gene, significantly increasing genetic 
complexity and diversity. To maintain the precise removal of introns, as well as supporting 
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alternative splicing, the regulation of these processes is multi-layered and complex while 
maintaining a level of flexibility in the definition of an exon. 
This flexibility in exon selection is reliant on a balance of positive and negative splicing 
regulators that determine if a region bounded by canonical splice sites is to be defined as exonic 
or intronic in a tissue, developmental or environmental specific manner. The presence, or absence, 
of sufficient regulatory motifs determines if the spliceosome will recognise a region as exonic, 
ultimately determining if the region will be included in the mature transcript. Taking advantage 
of the inherent flexibility of exon definition, Eteplirsen, Nusinersen, Golodirsen and Viltolarsen 
all confer therapeutic value by altering exon selection. Eteplirsen, Golodirsen and Viltolarsen are 
designed to restore the reading frame of dystrophin mRNA in patients with amenable mutations 
by inducing the exclusion of exon 51123,144 and exon 53,143,165 respectively. Conversely Nusinersen 
is designed to induce the inclusion of SMN2 exon 7, restoring the expression of a functional full-
length transcript.145 These opposing applications are achieved by targeting different regulatory 
elements involved in the splicing process.  
To induce exon exclusion, AOs are commonly targeted to motifs involved in exon recognition 
and processing, such as the acceptor and donor splice sites, as well as hotspots for splicing 
enhancers either in the intron (ISE) or exon (ESE). Targeting enhancer sites can block the binding 
of positive splicing factors, thus decreasing the definition and recognition of an exon sufficiently 
to result in its exclusion.103,104 In contrast, targeting exonic splicing silencer (ESS) or intronic 
splicing silencer (ISS) sequences can inhibit the binding of negative splicing factors, increasing 
exon recognition leading to inclusion.104,139 
The affinity, specificity, efficiency, stability and tolerance of an AO can be increased by 
modifying the compounds chemical structure. There are two widely used chemistries utilised in 
this study. First of which has 2′O-methyl (2′OMe) ribose ring modifications with a negatively 
charged phosphorothioate (PS) backbone. The resulting 2′OMe-PS compounds are robust RNase-
H independent AOs that are nuclease resistant and relatively cost-effective to synthesise. The 
second chemistry is the phosphorodiamidate morpholino oligomer (PMO) that completely 
replaces the ribose sugar moiety with a morpholino ring and has phosphorodiamidate linkages.120 
The PMO chemistry is RNase-H independent, and has a neutral charge that does not interact with 
proteins, greatly reducing the possibility of off-target effects.118,166. While the PMO chemistry is 
both more technically challenging and costly to synthesise than 2′OMe-PS AOs, PMOs are 
generally recognised as both safe and effective in a clinical setting, making it a promising 
chemistry for drug development.123,124 
As described previously, fibrillin-1 monomers are secreted from the cell and rapidly 
aggregated into multimer units to form the backbone of fibrillin-1 microfibrils.17 Mutations in 
FBN1 disrupt the formation of microfibrils, ultimately leading to a disease phenotype; either 
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Marfan syndrome or another type-1 fibrillinopathy. Therefore, we propose that removal of a 
mutation harbouring exon from all FBN1 transcripts during the splicing process could result in 
the production of fibrillin-1 proteins that are able to form functional microfibrils restoring ECM 
stability. To assess the viability of this hypothesis, we addressed three preliminary questions using 
FBN1 exon 52 as a model. (1) Can an exon be specifically removed from FBN1 pre-mRNA using 
antisense oligonucleotides, (2) Can sufficient exon skipping be achieved, and (3) can the 
internally truncated fibrillin-1 protein form microfibrils. 
3.2 Results 
The FBN1 transcript and antisense oligonucleotide design 
The fibrillin-1 transcript (LRG_778t1) contains 11,695 bases separated into 66 exons, 65 of 
which encode the 350 kDa fibrillin-1 protein (Figure 3.1.a). Exon 52 of FBN1 encodes a total of 
22 amino acids and makes up a portion of the sixth, of seven, TB domain. Over 20 disease-causing 
mutations have been reported to affect exon 52, the majority of which result, or are predicted to 
result, in aberrant exon 52 splicing.2,3 To excise exon 52, along with the flanking introns during 
the splicing process, five AOs were designed across exon 52 targeting the acceptor, and donor 
splice sites as well as ESE and ISE sites predicted using the webtool SpliceAid153 (Figure 3.1.c). 
SpliceAid studies the exonic and intronic sequence of interest and determines associated silencer 
and enhancer sites. Each site is given a score of 1 to 10 which indicates the strength of the site 
with the value closest to 10 being the strongest ESE sites
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Figure 3.1: Schematic of FBN1 pre-mRNA highlighting the region between exons 47 and 54 as well as AO binding sites 
a) Full fibrillin-1 pre-mRNA transcript with each box representing an exon. Colours indicate the domain that the exon encodes. The solid black line represents introns (not to scale) b) Highlighting the
region between exons 47 forward and 54 reverse primers and antisense oligonucleotide binding sites (purple bars). Chevron sides indicate exons bounded by partial codons. Pink and yellow fill indicate
regions encoding cbEGF-like and TB domains, respectively. The black dotted line indicates partial introns 51 and 52. c) Antisense oligonucleotide binding sites and the regulatory motifs they target
predicted using spliceAid.153 Each box represents a predicted enhancer (purple) or silencer (orange) site. The height of the box represents the strength of the site with 1 being the weakest and 10 being
the strongest. Exonic and intronic sequences are shown in upper- and lower-case respectively
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Evaluation of AOs to induce exon 52 skipping from FBN1 
transcripts 
Initial AO screening was performed using AOs composed of 2′OMe-PS molecules. An 
unrelated control AO that does not anneal to any transcript was included in all transfections as a 
sham treatment to observe any chemistry or delivery related effects on cell health and transcript 
abundance. A complete list of AOs can be found in Table 3.1.  
Table 3.1: Sequences and binding co-ordinates of control and FBN1 exon 52 AOs  
The name, ID, sequence and chemistry of AOs designed to induce FBN1 exon 52 exclusion. Two control sequences 
were used to reveal any chemistry-related effects. AO nomenclature described in Figure 3.5. The AOs targeting exons 
52 were designed by Mr Kane Greer (unpublished, 2017). 
Nomenclature 
(FBN1 H…) 
Name Sequence (5ʹ-3ʹ) Chemistry 
52A(+29+53)N AO52.1n 
AUC AGG UCC CAC GAU GAU CCC ACU U 
ATC AGG TCC CAC GAT GAT CCC ACT T 
2′OMe-PS 
PMO 
52A(+29+53)M AO52.1m AUC AGG UCC CAC AAU GAU CCC ACU U 2′OMe-PS 
52A(-08+17) AO52.2 UAU CUG GCG GAA GGC CUC UGU GGU G 2′OMe-PS 
52D(+13-12) AO52.3 CAG GCA ACU GAC CAA CUG CUG AAU C 2′OMe-PS 
52A(-23+02) AO52.4 CUC UGU GGU GGA GAC ACU CAU UAA U 2′OMe-PS 
52A(+03+27) AO52.5 CAU AAG GAC AUA UCU GGC GGA AGG C 2′OMe-PS 
Unrelated control Ctrl GGA UGU CCU GAG UCU AGA CCC UCC G 2′OMe-PS 
GeneTools Control GTC CCT CTT ACC TCA GTT ACA ATT TAT A PMO 
All 2′OMe-PS AOs were transfected into fibroblasts, derived from a healthy control subject, 
at three concentrations (200 nM, 100nM and 50 nM) and incubated for 24 hours before collection 
for RNA extraction and RT-PCR analysis to assess exon skipping efficiencies. The 24-hour 
transfection incubation period was chosen after a time course of 24, 48 and 72 hours revealed 
negligible changes in skipping efficiency over time (data not shown). However, treated cells, in 
particular those treated with the higher concentration, were observed to change in morphology 
and begin to die after 48 hours (data not shown). 
Analysis of PCR amplicons revealed the presence of two transcript products in several 
samples; the expected full-length (FL) product between exon 47 forward and exon 54 reverse 
primers, as well as a smaller product corresponding to the expected product of exon 52 skipping 
(Δ52)(Figure 3.2.a). The identity of the amplicons was confirmed by band purification and Sanger 
sequencing, confirming the precise removal of all 66 bases of exon 52 (Figure 3.2.b and c).  
The most efficient exon 52 skipping was induced by AO52.1n, with 41% of transcripts lacking 
exon 52 after transfection at 200 nM (Figure 3.2.a). However, three other sequences; AO52.1m, 
AO52.3 and AO52.5 were also relatively efficient, inducing up to 40%, 37% and 22% skipping 
respectively (Figure 3.2.a). The remaining two sequences did not induce any measurable exon 52 
skipping. The sequences, AO52.1n and AO52.1m differ by a single base, with each being an exact 
complementary pair for the wild-type and a known Marfan syndrome patient cell line, 
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respectively. This AO was designed in the hopes of understanding the mechanism behind the 
mutation that is known to cause mis-splicing of exon 52. The one base-pair mismatch did not 
greatly reduce the efficiency of AO52.1m in healthy control cells. 
Exon skipping efficiency was dose dependent with the most efficient skipping at a transfection 
concentration of 200 nM. There was negligible cell death evident for any of the three 
concentrations tested. A higher concentration of 400 nM was tested for selected samples in an 
attempt to further increase skipping efficiency. However, the increase in concentration did not 
translate into increased efficiency and instead induced up to 80% cell death (data not shown). 
Figure 3.2: Evaluation of AOs designed to induce FBN1 exon 52 skipping. 
a) Screening of 2′OMe-PS AOs targeting exon 52. Healthy control fibroblasts were transfected with AOs as lipoplexes
at three concentrations, 200, 100 and 50 nM. The values below each gel image indicate the percentage of exon 52
skipped (Δ52) transcripts in each sample. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated
control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. b) Sanger sequencing analysis
showing the junction between exons 51 and 52 in full-length transcripts (FL, 859bp); c) Sanger sequencing analysis
showing the junction between exon 51 and 53 exon 52-skipped transcripts (Δ52, 793bp).
Following initial AO screening, removal of exon 52 was deemed an appropriate option. In an 
attempt to further enhance exon exclusion, two AOs targeting FBN1 exon 52 were combined into 
cocktails and evaluated. This method has previously been shown to boost skipping efficiency 
through synergy between the two AOs.167 All AO cocktails reported were co-transfected into 
healthy control fibroblast at equimolar ratios, with total transfection concentrations of 200 nM, 
100 nM and 50 nM. Six of the eight cocktails tested, induced between 23% and 42% exon 52 
skipping at 200 nM (Figure 3.3). However, the efficiency was suggestive of an additive or 
baseline effect, similar to that achieved with a single AO. The combination of AO2.1n with 
AO52.2 or AO52.3 was antagonistic resulting in no measurable exon skipping (Figure 3.3). No 
synergistic cocktails were identified therefore AO52.1n was chosen as the most promising 
candidate and the sequence was synthesised as a PMO for further analysis (Table 3.1). 
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Figure 3.3: Evaluation of AO cocktails designed to induce FBN1 exon 52 skipping. 
Healthy control fibroblasts were transfected with AOs at three concentrations, 200, 100 and 50 nM. The values below 
each gel image indicate the percentage of exon 52 skipped (Δ52) transcripts in each sample. Ctrl: an unrelated 
sequence used as a sham treatment, UT: untreated control, ve: RT-PCR negative control. 100 bp molecular marker 
used for size reference. 
PMO52 induces efficient exon 52 skipping and an increase 
in fibrillin-1 immunofluorescent staining. 
To both confirm the efficiency of the AO52.1n sequence as a PMO, and to assess the effect of 
exon 52 skipping on fibrillin-1 microfibril formation, PMO52 was transfected into healthy control 
fibroblasts. An electroporation-based transfection method, Nucleofection, was used to deliver 
PMO52 into control cells at two concentrations; 250 µM and 50 µM, as calculated in a 20 µl 
cuvette. Transfected cells were plated either directly into 24 well plates or onto coverslips and 
incubated for 72 hours before cells were collected for RNA analysis and coverslips fixed for 
immunofluorescent staining.  
Representative results of healthy control cells treated with PMO52 are presented in Figure 
3.4.a. These representative RT-PCR results reflect exon 52 removal from approximately 100% of 
transcripts, with no measurable FL product remaining. The lower AO concentration was observed 
to induce approximately 50% skipping, with no endogenous exon 52 skipping observed in either 
the control or untreated samples (Figure 3.4.a). Analysis of RT-PCR amplicons across four 
replicates revealed relatively consistent dose-dependent exon 52 skipping. On average Δ52 
transcripts constituted 91% of total FBN1 transcripts from cells transfected at the higher 
concentration and 55% at the lower concentration (Figure 3.4.b). The lowest skipping efficiency 
at the highest concentration was 74%; in the same experiment, the lower concentration maintained 
the average 55% skipping efficiency (Figure 3.4.b). 
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Fibrillin-1 protein was detected through immunofluorescent staining using a fibrillin-1 
specific primary antibody and a fluorescently tagged secondary. Staining of the untreated sample 
revealed the long-thin extracellular fibre-like formations expected of fibrillin-1 (Figure 3.4.c.iii). 
Notably, the morphology of fibres in the sample with more than 90% skipping is comparable to 
those seen in the untreated healthy control (Figure 3.4.c.i and iii). The abundance of fibrillin-1 
staining, as well as the abundance of fibre-like formations is, however, noticeably reduced in the 
250 µM treated samples. In contrast to the fibre formation in both untreated and high 
concentration of PMO52, healthy control cells treated with 50 µM of PMO52, present with a 
complete loss of fibrillin-1 fibres and an overall reduction in fibrillin-1 staining (Figure 3.4.c.ii). 
Figure 3.4: Efficiency and effect of PMO52 
Healthy control fibroblasts were harvested for protein and RNA analysis, 72 h after Nucleofection with PMO52 at 
concentrations of 250 µM and 50 µM; calculated in the 20 µl nucleofection cuvette. a) Agarose gel fractionation of 
FBN1 exons 47 to 54 amplicons showing full-length (FL, 859bp) and exon 52-skipped (Δ52, 793bp) transcripts. The 
values below the gel image indicate the percentage of Δ52 transcripts. GTC: Gene Tools control PMO used as a sham 
treatment, UT: Untreated control, -ve: RT-PRC negative control, 100bp molecular marker used as a size reference. 
The gels were cropped for presentation. b) The percentage of full-length transcripts across four biological replicates 
(means plus error bars. Error bars = standard deviation, n = 4). c) Fibrillin-1 protein analysed via immunofluorescent 
staining. Merged fluorescence images of Hoechst staining of the nucleus (blue) and fibrillin-1 (red) with ‘healthy’ fibre-
like morphology of fibrillin-1 indicated by white arrowheads. Negative: No primary antibody added, to control for non-
specific binding of the secondary antibody. Untreated: no PMO added. Scale bar = 20 µm. 
3.3 Discussion 
Although Marfan syndrome is well established as an inherited connective tissue disorder 
caused by mutations in the fibrillin-1 gene, the exact mechanism of pathogenesis has not been 
fully resolved. Current understanding suggests that the pathogenesis is dependent on the mutation 
type with an overarching basis that a lack of functional fibrillin-1 microfibrils leads to TGF-β 
dysregulation, further compounding ECM destabilisation.16,71 Therefore, we propose that removal 
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of a mutation-associated exon from all FBN1 transcripts could result in the production of 
internally truncated fibrillin-1 proteins that retain some function and are able to form microfibrils. 
We addressed this hypothesis by designing antisense oligonucleotides to induce exon 52 
exclusion from unaffected FBN1 pre-mRNA. We suggest that many fibrillin-1 gene lesions will 
be amenable to the removal of the affected exon for two main reasons. Firstly, fibrillin-1 is highly 
repetitive suggesting the possibility of functional redundancy. Secondly, excluding exons 2, 3, 
64, 65 and 66, the majority of fibrillin-1 exons are in-frame, and therefore, can be removed 
without disrupting the reading frame. 
Here, we describe evidence for the efficient removal of FBN1 exon 52. Of the five 2′OMe-PS 
AOs tested three were found to induce exon 52 skipping. Earlier dystrophin screening studies 
similarly found that 2 out of 3 AOs induced some skipping, albeit at different efficiencies 167 Our 
data also shows that skipping of exon 52 is not only possible but is even more efficient and 
consistent when using PMOs. Immunofluorescent staining of fibrillin-1 in treated cells supports 
the hypothesis that fibrillin-1Δ52 proteins can interact to form multimers. We observed fibre 
formation, mirroring that of the untreated control cells, when more than 90% exon 52 skipping 
was induced. We also established that inducing approximately 50% exon 52 skipping results in a 
complete loss of fibrillin-1 fibre staining in healthy control fibroblasts mimicking the disease-like 
state caused by splicing mutations. Together, these results demonstrate proof-of-concept that the 
internally truncated fibrillin-1Δ52 proteins produced through efficient exon 52 skipping are able to 
form multimers. 
Of particular interest, is the total loss of microfibril formation caused by inducing a mixture 
of wild-type and FBN1Δ52 transcripts that results from sub-optimal levels of the PMO. This finding 
not only supports the dominant-negative pathogenic model; demonstrating the inability of a 
heterogeneous population of fibrillin-1 proteins to form microfibrils, but also has relevance to 
mapping of amenable FBN1 exons that could be targeted in a splice intervention therapy. The 
elimination of fibrillin-1 fibres with 50% exon skipping and subsequent re-appearance of fibrillin-
1 fibres with increased skipping efficiency could prove to be an invaluable tool in optimisation of 
fibrillin-1 AO sequences as well as identification of target exons. Importantly, being able to 
induce a disease-like state would allow the use of healthy control cells, rather than specific patient 
cells, for the identification of exons that when removed do not affect the expression or function 
of fibrillin-1.  
We predict that the AOs reported here can manipulate FBN1 splicing such that, at lower 
skipping efficiencies disease characteristics can be induced in healthy control cells and upon 
increased efficiency, sufficient skipping can be induced to reduce the key phenotype of MFS. 
This prediction is based on the dominant-negative model that suggests that in the presence of two 
protein isoforms, the aberrant protein disrupts the formation of microfibrils by the wild-type 
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protein68 It is unknown exactly what ratio of wildtype to aberrant proteins would negate the 
dominant negative effects. However, the results presented here suggest that this tolerable 
threshold may be approximately 95%. We demonstrate that fibrillin-1 fibres can be formed when 
exon 52 skipping is sufficient, likely >90% skipping, such that more than 95% of total multimers 
that are formed would be of the fibrillin-1Δ52-fibrillin-1Δ52 structure. We also note, however, that 
mutations resulting in haploinsufficiency lead to disease. Therefore, we believe that the 
abundance of microfibrils has to be maintained, as a minimum, above that observed in 
haploinsufficiency patients.31,161 
While we demonstrated efficient and consistent exon skipping using PMO52, the 
concentrations used are relatively high, when compared to similar studies targeting other 
genes.167,168 One of the possible explanations for the high concentration required is the abundance 
of fibrillin-1 transcripts. Fibrillin-1 RNA is expressed in the vast majority of cell types and is 
maintained at relatively high levels throughout the body.169 We noted the efficient PCR 
amplification of FBN1 transcripts; requiring 20 or fewer rounds of amplification coupled with the 
need for very low template concentrations (25 ng). While the in vitro PMO transfection 
concentrations used seem relatively high, we noticed no changes in morphology or health of cell 
cultures up to four days post-transfection with PMO52. The PMO chemistry is generally 
considered to be safe with no off-target effects nor toxicity.123–125 Nevertheless, while the PMO 
chemistry may be safe and a higher concentration required due to the level of fibrillin-1 
expression, there are still several ways in which the efficiency of an AO can be improved, 
including optimisation of AO delivery, sequence, length and chemistry. Further optimisation 
could allow for the use of a significantly lower dosage that in turn would not only reduce the 
possibility of off-target effects or toxicity but also lower the cost of treatment. 
The fibrillin-1 protein produced by excising exon 52 is predicted to be internally truncated, 
fibrillin-1Δ52, and lacking the last seven amino acids of the sixth TB domain. This isoform has 
only been reported in the context of exon 52 mutations, where it is known to act in a dominant 
negative manner against the wild-type protein and result in a severe lack of functional 
microfibrils.151,170 Liu et al.170 also reported that an exon 52 splicing mutation leads to reduced 
fibrillin-1 synthesis, less than 50% of that observed in healthy controls, while the mutant mRNA 
levels remain unchanged, suggesting that the fibrillin-1Δ52 proteins are unstable. Liu et al.170 
suggests this instability may result from the partial deletion of a TB domain that leads to 
misfolding of the fibrillin-1 protein increasing its susceptibility to proteolysis. If this is the case 
then attempts to induce exon skipping of other exons encoding partial TB domains;10, 11, 17, 18, 
38, 39, 42, 43 and 51, would likely face the same issue. It is possible that removal of the two 
exons encoding the TB domain as a pair could solve this problem. However, we show that the 
fibrillin1Δ52 proteins studied here are able to be synthesised, secreted from the cell and form fibre-
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like structures. Nevertheless, the synthesis, deposition and function of fibrillin-1Δ52, especially in 
the absence of wild-type fibrillin-1, needs to be investigated further. 
Here we illustrate that when fibrillin-1Δ52 is the predominant product it is able to be both 
synthesised and secreted from the cell, with no evidence of intracellular staining. We also 
demonstrate that fibrillin-1Δ52 proteins can form fibres; provided that FBN1Δ52 transcripts make 
up more than 90% of total FBN1 transcripts. These results suggest that the fibrillin-1Δ52 protein is 
functional, although further protein analysis is required to assess if the fibres formed can interact 
with the microfibril associated proteins with which fibrillin-1 naturally interacts. The ability of 
fibrillin-1Δ52 proteins to sequester TGF-β also needs to be assessed. If removal of exon 52 disrupts 
the regulation of TGF-β, then regardless of the high skipping efficiency and fibre formation that 
is observed, symptoms such as aortic growth would continue to progress with no benefit from this 
treatment.  
As previously noted, our results support the hypothesis that fibrillin-1Δ52 can form fibres. 
However, while the morphology of fibres is superficially similar to that of the untreated, healthy 
control, their abundance is reduced. The reduction of abundance could be the result of the 
experimental design and protocols. For example, Nucleofection is known to cause cell stress 
reducing fibrillin-1 expression, or the transfection incubation time could be insufficient to allow 
more efficient formation of microfibrils after treatment. However, it is likely that, as reported by 
Liu et al.,170 fibrillin-1Δ52 synthesis is reduced in comparison to the wild-type. Western blotting 
analysis of intracellular and extracellular fibrillin-1 was attempted, however, due to poor signal 
and resolution in samples from healthy control fibroblasts we were unable to confirm any changes 
in fibrillin-1 abundance. Further optimisation of the Western blot protocol to produce reliable 
results is required before the effect of FBN1 exon skipping on the abundance of fibrillin-1 can be 
assessed. While restoring microfibril abundance and function to a ‘normal’ state would be ideal, 
this may not be possible. We believe that any increase in functional microfibrils could provide a 
therapeutic benefit by reducing disease progression and severity.  
As discussed earlier, the current standard of care for individuals living with MFS relies heavily 
on invasive surgical interventions and the lifelong use of medicines such as β-adrenergic receptor 
blockades that slow the progression of aortic dilation.33,76,78 These interventions have proven 
lifesaving, as well as life-extending.35,75 However, the burden of MFS on quality of life, and the 
economic stress, for both patients and their families, remains substantial.171,172 In more recent 
years major efforts have been made to discover and develop therapeutics for MFS.37,78,79,83 
Research has focused on slowing aortic growth as well as a continued improvement upon current 
treatment strategies for the main symptoms of MFS. With FDA approval of AO therapeutics to 
restore gene function in spinal muscular atrophy145 and Duchenne muscular dystrophy,123,144 we 
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suggest that antisense oligonucleotide-mediated splice switching as described here could be an 
appropriate direction for the development of therapies for Marfan syndrome. 
In conclusion, this study assessed the ability of a suite of AOs to induce targeted exon 52 
skipping from full-length FBN1 mRNA transcripts expressed in healthy control fibroblasts. The 
most efficient sequence, and the consequences of splice modification, was further evaluated in 
healthy control fibroblasts. We showed in vitro, that AO52.1n, AO52.1m and AO52.3 as well as 
PMO52 induced dose-dependent exon 52 skipping. Encouragingly the presence of more than 90% 
of one transcript type; wild-type or FBN1Δ52, corresponded with the formation of fibrillin-1 fibres. 
In contrast, a mixed transcript pool resulted with the complete loss of fibrillin-1 fibres, mimicking 
the disease-like state. 
While this study is a preliminary, in vitro investigation, our candidate PMO consistently 
induces efficient exon 52 exclusion while maintaining fibrillin-1Δ52 fibre formation. With 
increasing numbers of AO therapeutics being approved for clinical use, our results suggest that 
PMO52 may be an attractive therapeutic option for the treatment of Marfan syndrome caused by 
mutations in fibrillin-1 exon 52. This study provides proof-of-concept and a foundation for the 
further development of antisense oligonucleotide therapies for Marfan syndrome. 
3.4 Materials and methods 
 Design and synthesis of antisense oligonucleotides. 
478BAntisense oligonucleotides were designed to target splicing regulatory motifs at the exon-
intron junctions as well as exonic splicing enhancer sequences predicted using the spliceAID web 
tool.153 AO sequences were also analysed using NCBI nucleotide BLAST173 to identify any 
possible off-target annealing. Antisense oligonucleotides with 2′OMe-PS chemistry were 
purchased from TriLink biotechnologies (Maravai LifeSciences, San Diego, CA, USA), and 
PMOs were purchased from GeneTools LLC (Philomath, OR, USA). Two unrelated sequences, 
one for each chemistry, were used as sham treatments. These controls allow for the observation 
of any sequence-independent chemistry-related effects. The nomenclature of AOs is based on that 
described in Mann et al.155 and provides information on the gene, exon, annealing co-ordinates 
and species (Figure 3.5). A full list of AOs used in this study are provided in Table 3.1. 
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Figure 3.5: Nomenclature of antisense oligonucleotides 
783BThe name of each AO is unique and includes information on the gene, specific, target exon, splice site and sequence 
co-ordinates. Figure adapted from Mann et al. 155 
Cell culture and transfection 
480BHealthy control fibroblasts were originally sourced from a dermal biopsy derived from a 
healthy volunteer with informed consent. The use of human cells for this research was approved 
by the Murdoch University Human Ethics Committee, approval numbers 2013_156 and The 
University of Western Australia Human Research Ethics Committee; approval number 
RA4/1/2295. Fibroblasts were maintained in Dulbecco’s Modified Essential Medium (DMEM, 
Gibco; Life Technologies, Melbourne, Australia) supplemented with 10% foetal bovine serum 
(FBS, Scientifix, Cheltenham, Australia) and incubated at 37°C with 5% CO2.  
481BAntisense oligonucleotides (2′OMe-PS chemistry) used for target site screening were 
transfected into healthy control fibroblasts using Lipofectamine 3000 ( Life Technologies, VIC, 
Australia). Transfections were prepared by incubating the AO with 3 µl of Lipofectamine 3000, 
at room temperature in 50 µl of Opti-MEM (Gibco; Thermo Fisher Scientific, VIC, Australia), 
according to manufacturer’s protocol. The transfection mixture was then diluted to the desired 
AO concentration in a final volume of 1 ml and applied to cells. Transfected cells were incubated 
for 24 hrs before collection. 
482BThe PMO was delivered using the 4D-Nucleofector™ and P3 Nucleofection kits (Lonza, VIC, 
Australia). One microliter of stock PMO (5 mM), either undiluted (250 µM) or diluted 1:4 in 
sterilised water (50 µM), was added into a cuvette along with 300,000 fibroblasts resuspended in 
19 µl of pre-warmed transfection solution. The mixture of fibroblasts and PMO was subsequently 
nucleofected using the pulse code, CA 137, previously optimised in our laboratory for dermal 
fibroblasts. Nucleofected fibroblasts were maintained in DMEM supplemented with 5% FBS 
before collection after 3 or 4 days. 
FBN1 H 52 A (±xx ±yy)GENE
eg. fibrillin-1 (FBN1)
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RNA extraction and RT-PCR analysis 
483BTotal RNA was extracted using MagMax™ nucleic acid isolation kits (ThermoFisher 
Scientific, Melbourne, Australia) as per the manufacturer’s protocol. Total RNA concentration 
and purity were determined using a Nanodrop 1000 spectrophotometer (ThermoFisher Scientific). 
Transcripts were amplified using one-step SuperScript® III reverse transcriptase with 25ng of 
total RNA as a template. To observe exon 52 skipping, FBN1 transcripts were amplified using 
exon 47 Forward (5′-GGTTTCATCCTTTCTCACAAC-3′) and exon 54 Reverse 
(5′-TCACATGTCATCATTGGACC-3′) primers (Integrated DNA Technologies, IDT, NSW, 
Australia). The cycling conditions were as follows; 55°C for 30 min, 94°C for 2 min followed by 
20 cycles of 94°C for 30 sec, 55°C for 30 sec and 68°C for 1min. The PCR amplicons were 
fractionated on 2% agarose gels in Tris-Acetate-EDTA buffer. Images were analysed using 
ImageJ (version 1.8.0_112) imaging software (NIH, Bethesda, MD, USA)156 to determine the 
relative density of amplicons. 
Immunofluorescence 
484BImmediately after Nucleofection, 100,000 fibroblasts were seeded into each well of a 24-well 
plate lined with a 13 mm No.1 round uncoated glass coverslip. Cells were incubated for 72 hours 
before being fixed in ice-cold acetone: methanol (1:1, v:v) and allowed to air dry. Fixed cells 
were washed once with PBS to rehydrate before blocking with 10% goat serum in PBS for 1 hour 
at room temperature. The primary antibody, Anti-fibrillin-1 antibody clone 26 (Merck Millipore, 
Sydney, Australia), was applied at a dilution of 1:100 in 1% goat serum-PBS and incubated 
overnight at 4°C. Secondary antibody; AlexaFluor568 anti-mouse IgG (Thermo Fisher Scientific, 
VIC, Australia) was applied, 1:400, for 1 hour at room temperature, and co-stained with Hoechst 
33342 (Sigma-Aldrich) for nuclei detection (1 mg/mL diluted, 1:125). Coverslips were mounted 
using ProLong™ Gold antifade mountant (Thermo Fisher Scientific, VIC, Australia). Fibrillin-1 
was detected using a Nikon 80i microscope with NIS-Elements software (Nikon, Australia). The 
brightness and contrast of individual channel images were altered equally for each image, then 
merged. The merged image was cropped from the original 1280 x 1024 pixel image using Adobe 
Photoshop CC. A 20 µm scale bar was added using ImageJ software.156 
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Chapter 4 
Multiple Mutations One Drug 
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4.1 Introduction 
The complexity of the type 1 fibrillinopathies 
485BThe type-1 fibrillinopathies are a complex and diverse family of diseases that can be caused 
by many types of mutations affecting the fibrillin-1 gene (FBN1). Numerous features 
characteristic of the type-1 fibrillinopathies hinder diagnosis and the development of therapeutics, 
including (a) highly variable prevalence from 2-3 in 10,000 for Marfan syndrome (MFS) and less 
than 1 in 1,000,000 for Stiff skin syndrome (SSKS), Geleophysic dysplasia 2 (GPHYSD2) and 
Marfan lipodystrophy syndrome (MFLS); (b) over 28002 unique mutations; (c) a high rate (25-
30%3) of de novo mutations; (d) phenotypic overlap between the type-1 fibrillinopathies and other 
diseases and (e) extensive intra- and inter-familial phenotypic variability. Examples of this 
complexity and the impact on diagnosis and therapy development are outlined below. 
Asymmetric Marfan syndrome 
486B efore the association of Marfan syndrome with fibrillin-1 mutations, Burgio et al.174 and 
Godfrey et al.175 described a case of asymmetric Marfan syndrome resulting from a postzygotic 
mutation. Only one half of the patient’s body was affected, resulting in a unique case in which 
the patient’s left-hand side was 4 cm longer than the right before the age of seven years old.175 
Not only did this case provide insight into the exact symptoms of Marfan syndrome, it also 
enabled Godfrey et al.175 to observe the lack of microfibril formation on the left-hand side, 
signifying the importance of fibrillin-1 fibre formation in Marfan syndrome. 
Phenotypic and genotypic overlap 
487BOne major hurdle in the development of cost-effective and efficient diagnostic tests for the 
type-1 fibrillinopathies, is the overlap in phenotypes between the different fibrillinopathies as well 
as with other diseases. The type-1 fibrillinopathies form a spectrum of severity from mild 
disorders that affect a single organ system, such as Ectopia lentis syndrome, to severe phenotypes 
affecting the entire body, as seen in MFS. However, across the whole spectrum, each disease 
shares phenotypic similarities. Ectopia lentis, for example, is characteristic of Ectopia lentis 
syndrome, MFS and MFLS, while short stature, is common to Weill-Marchesani Syndrome 2, 
GPHYSD2 and acromicric dysplasia (ACMID). 
488BThe overlap in phenotypes is further complicated by genotypic overlap whereby several FBN1 
mutations are reported to result in different disease phenotypes in various individuals. Examples 
of such overlap are ACMID and GPHYSD2. While clinically distinct, these two diseases share 
the majority of phenotypic characteristics such as; short stature, short fingers and toes, joint 
stiffness and skin thickening. A lack of cardiac involvement in acromicric dysplasia is one of the 
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only features that distinguished these conditions. While both diseases are incredibly rare, two 
mutations; p.Tyr1699Cys and p.Ala1728Thr have been attributed with causing both phenotypes 
in different individuals.57 
489B oth phenotypic and genotypic overlap pose significant hurdles in the diagnosis of the type-1 
fibrillinopathies. However, this overlap could prove useful in therapy development. Due to the 
overlap in genotype, and phenotype, therapies designed to treat the cause of disease, FBN1 
mutations, could potentially apply to all type-1 fibrillinopathies. 
Recessive Marfan syndrome 
490BMarfan syndrome is primarily considered an autosomal dominant disease caused by 
heterozygous mutations in the fibrillin-1 gene. However, there are a small number of cases in 
which inheritance is recessive, with individuals homozygous for the mutation exhibiting the MFS 
phenotype. In these cases, relatives that are heterozygous for the mutation or have no mutation 
are unaffected. Such cases are highlighted in Hilhorst-Hofstee et al.32, Khan et al.176 and de Vries 
et al.31 Supposing that such instances are representative of a true recessive mode of inheritance, 
this suggests that some FBN1 mutations result in monomers capable of forming microfibrils with 
wild-type monomers, but incapable of forming microfibrils with other mutant monomers. This 
opposes the dominant-negative pathogenesis model and suggests that there is some other 
mechanism at play. 
491BInterestingly some ‘recessive’ mutations manifest as dominantly inherited in other individuals 
or families, indicating the involvement of additional unknown factors. Overwater et al.177 reports 
two unrelated families with an autosomal dominant inheritance of a c.1453C>T, p.Arg485Cys 
FBN1 mutation. The same mutation was previously reported by De Vries et al.31, who describes 
a family with an affected homozygous individual and unaffected heterozygous relatives. 
Overwater et al.177 suggests that the age of patients at the time of clinical assessment, as well as 
clinical variability may account for the lack of clinical phenotype observed in heterozygous 
individuals. Aubart et al.178 explored possible modifier genes that could explain the lack of disease 
phenotype, including other extracellular matrix proteins and several matrix metalloproteinases. 
However, the study found no conclusive evidence of such associations and further research into 
the field is still required. On the other hand, Aoyama et al.69 advocates that the effect of the 
mutation on the synthesis and deposition of fibrillin-1 in the extracellular matrix is the reason we 
observe so much phenotypic variability. 
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Mutation classification and pathogenesis 
492BFibrillin-1 proteins are known to assemble into multimer units immediately after secretion 
from the cell, forming the backbone of microfibrils.14,179 Microfibrils are essential in the majority 
of connective tissues, and it is in the microfibril form that fibrillin-1 plays a crucial part in elastic 
fibre formation and stability,14,15 while also regulating signalling proteins such as transforming 
growth factor-beta (TGF-β).180,181 The dysregulation of TGF-β, as a result of insufficient 
functional microfibrils, is now considered the leading factor in the pathogenesis of Marfan 
syndrome.16,71,74 
493BThe cause and severity of the reduction in microfibrils has been linked with the type of FBN1 
mutation and its effect on the synthesis, secretion and function of the resulting fibrillin-1 proteins. 
Aoyama et al.69 proposed five groups of FBN1 mutations according to the levels of fibrillin-1 
synthesis and deposition as compared to those in healthy controls. These groups include mutations 
that result in (I) reduced synthesis and deposition, (II) reduced synthesis and severely reduced 
deposition, (III) intermediate synthesis and mildly reduced deposition, (IV) intermediate synthesis 
and severely reduced deposition and (V) a small group with normal synthesis and deposition.69 
These groups are summarised in Table 4.1.
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755BTable 4.1: FBN1 mutation groups according to fibrillin-1 synthesis and deposition.  
732BThe majority of FBN1 mutations can be classified into one of five groups. These groups describe the relationship between pathogenesis, mutation outcome and the observed synthesis and deposition of 
fibrillin-1 protein. Adapted from Aoyama et al.69 
3746BGroup 3747BSynthesis 3748BDeposition 3749BPathogenesis 3750BMutation outcome 
2256BUnaffected 2257B100% 2258B100% 
2259BNormal fibrillin-1 monomer 
2260BNormal fibrillin-1 monomer 
2261BI 2262B<70% 2263B≥35% 2264BHaploinsufficiency 
2265BNormal fibrillin-1 monomer 
2266BTruncation or no protein produced 
2267BII 2268B<70% 2269B<35% 2270BDominant negative 
2271BNormal fibrillin-1 monomer 
2272BC-terminal truncation
2273BNormal fibrillin-1 monomer 
2274BInternal truncation 
2275BIII 2276B≥70% 2277B35-70%
2278BLoss of function 
2279Bor degradation 
2280BNormal fibrillin-1 monomer 
2281Bmonomer with abnormal function 
2282BNormal fibrillin-1 monomer 
2283BNo protein produced 
2284BIV 2285B≥70% 2286B<35% 2287BDominant negative 
2288BNormal fibrillin-1 monomer 
2289BAbnormal monomer 
2290BV 2291B≥70% 2292B≥70% 2293BLoss of function 
2294BNormal fibrillin-1 monomer 
2295BNon-functional monomer 
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494BGroup I mutations, and some group III mutations, are predicted to result in fibrillin-1 
haploinsufficiency.69 As such, mutations in these groups are often nonsense, frameshift or out-of-
frame splicing mutations that result in either no protein production from the affected allele or an 
unstable protein that is degraded.182 A small subset of premature termination codon (PTC) 
mutations, usually affecting the C-terminal, are associated with average fibrillin-1 synthesis and 
reduced deposition due to intracellular retention.66 The remainder of type III mutations result in 
stable fibrillin-1 monomers that are capable of forming microfibrils but are either non-functional 
or have an abnormal function.69 
495BA large proportion of FBN1 mutations result in abnormal fibrillin-1 monomers that interfere 
with the assembly of normal monomers. Such mutations fall into either group II or IV and are 
referred to as dominant negative.69 Type II mutations result in a reduction of both fibrillin-1 
synthesis and deposition and have been associated with frameshift, nonsense, splicing and 
missense mutations.61,69,170 Type IV mutations are most commonly missense, deletion and splicing 
mutations that do not affect the reading frame resulting in stable but abnormal monomers.25,69,182 
496BThe mechanism behind group V mutations, which do not affect fibrillin-1 synthesis or 
deposition, is not fully understood. However, we theorise that such mutations may be loss-of-
function. That is the mutation-associated fibrillin-1 monomers can be synthesised and assembled 
into microfibrils, but these microfibrils are non-functional or unable to interact with microfibril-
associated proteins.  
Aims and rationale 
497BDue to the many characteristics described above; clinical and molecular diagnosis, symptom 
management, and therapy development for the type-1 fibrillinopathies has been difficult and 
slowly evolving. We hypothesise that personalised medicines utilising antisense oligonucleotides 
(AO) designed to target particular sets of mutations may be the most appropriate therapeutic 
approach to reduce the severity of FBN1 mutations. We propose the use of AOs, as they present 
a highly customisable and specific platform capable of intervening in the splicing process to 
achieve the desired exon exclusion or inclusion. Previously, we demonstrated proof-of-concept, 
showing that exon 52 could be efficiently removed from the FBN1 mRNA and that when 
removed, from 90% of transcripts, the encoded proteins could form the characteristic fibrillin-1 
fibrils. Here, we extend this proof-of-concept to patient cell models as well as an additional FBN1 
exon. 
498BOf the four patient cell lines used in this study, two are reported to harbour mutations affecting 
exon 52. Exon 52 is one of the smallest exons in FBN1; with only 66 bases and is associated with 
over 20 disease-causing mutations. The majority of mutations in exon 52 either directly affect the 
canonical splice sites or alter splicing indirectly, resulting in the in-frame removal of exon 52 
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during the splicing process. Since exon 52 can be removed without disrupting the reading frame 
and the majority of mutations in this exon are associated with exon exclusion, we proposed two 
hypotheses. Firstly, enhancing definition of the exon sufficiently to override the silencing effect 
of a mutation could result in the inclusion of exon 52 in affected transcripts, restoring all fibrillin-
1 proteins to their healthy, functional form. Or as shown previously, the removal of exon 52 from 
all transcripts, encoded by both the healthy and disease-causing alleles, can result in the 
production of internally truncated but identical fibrillin-1 proteins from all transcripts allowing 
them to form functional microfibrils, thus reducing disease severity. 
499BThe remaining two patient cell lines harbour mutations affecting exon 59. Similar to exon 52, 
FBN1 exon 59 is in-frame and linked to 22 unique disease-causing variants. Exon 59 is larger 
than exon 52 at 123 bases, and encodes one of the 43 calcium-binding epidermal growth factor 
(cbEGF)-like domains that make up the majority of the fibrillin-1 protein. We hypothesise that 
removal of an amenable but potentially dispensable exon from all transcripts will result in 
functional microfibrils regardless of the original mutation type. Therefore, we propose that all 
mutations affecting an exon can be overcome with the same AO, given that efficient exon 
skipping is induced. 
500BWe rationalise that the removal of an amenable mutation-associated exon will result in one of 
the following scenarios; 
711BMissense mutations 
• 712BExclusion of the exon from both affected and unaffected transcripts. 
o 713BRemoval of aberrant cysteines allowing for correct disulphide bond arrangement. 
o 714BRestoration of fibrillin-1 monomer homogeneity. 
715BMutations resulting in exon skipping 
• 716BExclusion of the exon from unaffected transcripts. 
o 717BRestoration of fibrillin-1 monomer homogeneity. 
718BOR 
• 719BRetention of the exon in the disease-causing transcript. 
o 720BRestoration of healthy, functional fibrillin-1 monomers. 
721BNonsense and frameshift mutations 
• 722BExclusion of the exon from both the disease-causing and healthy transcripts. 
o 723BRemoval of PTC and restoration of the reading frame. 
o 724BRestoration of the C-terminal region allowing secretion from the cell. 
o 725BRestoration of fibrillin-1 monomer homogeneity. 
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4.2 Confirming mutations in patient cells 
501BA total of five cell lines were used in this chapter. The use of human cells for this research was 
approved by the Murdoch University Human Ethics Committee; approval numbers 2013_156 and 
2017_101 and The University of Western Australia Human Research Ethics Committee; approval 
number RA4/1/2295. Healthy control fibroblasts were cultured from a dermal biopsy of a healthy 
volunteer taken after informed consent.  
502BThe following cell lines were obtained from the NIGMS Human Genetic Cell Repository at 
the Coriell Institute for Medical Research: GM21941, GM21952, GM21937 and GM21992. The 
mutation profile of each patient cell line was confirmed using Sanger sequencing (Figure 4.1.a). 
Mutation nomenclature was determined with respect to the FBN1 gene Locus Reference Genomic 
sequence transcript 1 (LRG_778t1) in which the start codon is in the second of 66 exons. 
503BThe GM21941 cell line, hereafter referred to as MFSΔ52, was reported to be heterozygous for 
the synonymous change, c.6354C>T that changes codon 2118 from AUC to AUU, both of which 
encode isoleucine. However, Liu et al.151 also identified that this mutation results in skipping of 
exon 52 that is in-frame. It was later noted that this mutation results in reduction of fibrillin-1 
synthesis (41%) and a severe reduction in fibrillin-1 deposition (5%) compared to that in healthy 
controls, placing the mutation into group II.69,170 Both the c.6354C>T mutation and the resulting 
exon 52 skipping; r.6314_6379del, were confirmed using Sanger sequencing (Figure 4.1.a). In 
silico analysis of the healthy and mutation-harbouring sequences using the web tools spliceAid153 
and SpliceAid2154 revealed that the c.6354C>T mutation alters the balance of predicted splicing 
enhancer (ESE) and silencer (ESS) elements within exon 52. The mutation disrupts six predicted 
ESE sites ranging in strength from two to ten whilst also forming three predicted ESS sites (Figure 
4.1.b). 
504BThe GM21952 (MFSC2111R) patient cell line was reported to carry a missense mutation, 
c.6331T>C, predicted to result in p.Cys2111Arg, disrupting one the highly conserved cysteine
residues of the sixth TGF-β binding protein-like (TB) domain. This mutation was confirmed by 
sequencing both the gDNA and cDNA (Figure 4.1.a). 
505BThe GM21992 (MFSR2414*) cell line was reported to harbour a c.7240C>T mutation that 
resulted in the creation of a PTC, p.Arg2414*.61 This mutation was confirmed by gDNA 
sequencing (Figure 4.1.a). However, the mutant transcript was undetectable by cDNA sequencing 
(Figure 4.1.a), suggesting the mutant transcripts are subjected to very efficient nonsense-mediated 
decay (NMD). This is supported by the findings of Schrijver et al.61 who categorised this mutation 
as group II, reporting reduced fibrillin-1 synthesis (41%) and deposition (21%) in patient cells 
compared to those from a healthy control subject. 
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506BFinally, the GM21937 (MFSΔ59) cell line were confirmed to carry the splice site mutation, 
c.7205-2A>G, reported by Liu et al.183 (Figure 4.1.a) This mutation alters the conserved AG
canonical acceptor splice site of exon 59 to GG and is confirmed to result in skipping of exon 59 
that is in-frame, generating the r.7205_7330del transcript (Figure 4.1.a). Liu et al.183 reported that 
this mutation results in a mild reduction of fibrillin-1 synthesis, yielding 92% of the protein 
present in the control, however, fibrillibn-1 deposition is severely reduced to only 14%, making 
this a group IV mutation. 
1069B
Figure 4.1 Confirmation of patient cell line mutations 
784Ba) The reported disease-causing mutation for each patient cell line was confirmed via Sanger sequencing using gDNA,
or cDNA derived from fibroblast RNA, as a template. b) In silico analysis of FBN1 exon 52 ESE and ESS sequences 
showing those that differ between the wild-type (purple) and MFSΔ52 mutation (orange) sequence. Those in grey are 
shared between the two sequences. ESE and ESS sites predicted by, and diagram adapted from spliceAid153 and 
SpliceAid 2.154 
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4.3 AO design and synthesis 
507BThe first generation of 2′OMe-PS AO sequences designed to induce exon 52 exclusion or 
promote exon 52 inclusion were designed by Mr Kane Greer (unpublished, 2017; Table 4.2). 
Several AO sequences were similarly designed by the author to induce exon 59 skipping, targeting 
both splicing regulatory motifs at the exon-intron junctions as well as additional regulatory 
sequences within the body of the exon. Sequences designed to mediate exon exclusion AOs were 
targeted to exon splice enhancers while exon inclusion were targeted toward intronic splice 
silencers predicted using both SpliceAid153 and SpliceAid 2154. Two sequences unrelated to FBN1, 
one for each chemistry, were used as sham treatments. These controls allow for the observation 
of any sequence-independent chemistry-related effects. The AOs used in this chapter are listed in 
Table 4.2. 
756BTable 4.2: Antisense oligonucleotide sequences used in this study 
733BThe name, ID, sequence and chemistry of AOs designed to target FBN1 exons 52 and 59. Two control sequences 
were also used to reveal any chemistry-related effects. AO nomenclature described in Chapter 2, Figure 2.1. The AOs 
targeting exon 52 were designed by Mr Kane Greer (Unpublished, 2017). 
3751BAO name 
3752B(FBN1 H…) 
3753BID 3754BSequence (5′-3′) 3755BChemistry 
3756BExon 52 exclusion 
2296B52A(+29+53)M 2297BAO52.1m 1175BAUC AGG UCC CAC AAU GAU CCC ACU U 2298B ′OMe-PS 
2299B52A(+29+53)N 2300BAO52.1n, Pos 1176BAUC AGG UCC CAC GAU GAU CCC ACU U 2301B ′OMe-PS 
2302B52A(+29+53)N 2303BPMO52 1177BATC AGG TCC CAC GAT GAT CCC ACT T 2304BPMO 
2305B 2A(-08+17) 2306BAO52.2 1178BUAU CUG GCG GAA GGC CUC UGU GGU G 2307B ′OMe-PS 
2308B52D(+13-12) 2309BAO52.3 1179BCAG GCA ACU GAC CAA CUG CUG AAU C 2310B ′OMe-PS 
2311B52A(-23+02) 2312BAO52.4 1180BCUC UGU GGU GGA GAC ACU CAU UAA U 2313B ′OMe-PS 
2314B52A(+03+27) 2315BAO52.5 1181BCAU AAG GAC AUA UCU GGC GGA AGG C 2316B ′OMe-PS 
3757BExon 52 inclusion 
2317B52A(-181-157) 2318BAOi51.1 1182BCCC UAA GAU GUU GUG UCU ACU CCU U 2319B ′OMe-PS 
2320B52A(-130-106) 2321BAOi51.2 1183BAAU GAU GGA AAA AAC AAG CCC AGA A 2322B ′OMe-PS 
2323B52A(-44-20) 2324BAOi51.3 1184BUAA UAG AUA GAA CAA UAG CAA UUC A 2325B ′OMe-PS 
2326B52D(-01-25) 2327BAOi52.1 1185BUGA GAA UCC AGC ACA GGC AAC UGA C 2328B ′OMe-PS 
2329B52D(-46-74) 2330BAOi52.2 
1186BAAA AUA AGA AUA ACU AGA GAA GAA GCA 
GA 
2331B ′OMe-PS 
2332B52D(-98-122) 2333BAOi52.3 1187BAAU GAA GGG ACA AAA AAG UAG CAC U 2334B ′OMe-PS 
3758BExon 59 Exclusion 
2335B 9A(-21+04) 2336BAO59.1 1188BAUA UCU GUA AUU UAA CAA AUA UAA A 2337B ′OMe-PS 
2338B59A(+41+65) 2339BAO59.2 1189BUCC UCU GUC AUU GAC ACA UUC CCC A 2340B ′OMe-PS 
2341B59A(+41+65) 2342BPMO59 1190BTCC TCT GTC ATT GAC ACA TTC CCC A 2343BPMO 
2344B59A(+86+110) 2345BAO59.3 1191BAGU UAU AUC UGG AGU GUA CCC AGU U 2346B ′OMe-PS 
2347B59A(+36+60) 2348BAO59.2+5 1192BUGU CAU UGA CAC AUU CCC CAU UUC G 2349B ′OMe-PS 
2350B 9A(+46+70) 2351BAO59.2-5 1193BUAU GAU CCU CUG UCA UUG ACA CAU U 2352B ′OMe-PS 
3759BControls 
2353BUnrelated control 2354BCtrl 1194BGGA UGU CCU GAG UCU AGA CCC UCC G 2355B ′OMe-PS 
2356BGeneTools control 2357BGTC 1195BCCT CTT ACC TCA GTT ACA ATT TAT A 2358BPMO 
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4.4 AO-mediated selection of FBN1 exon 52 
Assessment of AO-mediated inclusion of exon 52 
508BA total of six 2′OMe-PS AOs were designed to promote exon 52 inclusion, targeting silencer 
sequences within flanking introns 51 and 52 (Figure 4.2.a). These AOs were transfected into the 
MFSΔ52 patient cell line. Three concentrations; 200 nM, 100 nM and 50 nM were tested, and 
transfected cells incubated at 37 °C for 24 hours. The proportion of full-length (FL) FBN1 
transcripts is noted below each gel lane in Figure 4.2. None of the six AOs induced clear exon 
inclusion, and no dose-response was evident, with each sample showing full-length product 
within 5% of the baseline of 57% in the untreated control. The positive control, AO52.1n, was 
previously determined to be the most efficient of the exon skipping AOs tested. When MFSΔ52 
cells are treated with this positive control, Δ52 transcripts make up over 70% of total transcripts, 
indicating that the transfection efficiency is not compromised (Figure 4.2.b). 
509BIn an attempt to increase the efficiency of AO-mediated inclusion, each compound was tested 
in combination with another non-overlapping AO in a cocktail. Each AO was added to the cocktail 
in equimolar amounts, with total cocktail concentrations of 200 nM and 50 nM tested. Evaluation 
of the two-AO combinations did not reveal any synergistic effect, and no increase in exon 52 
inclusion was evident (Figure 4.2.c). 
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1070B
Figure 4.2: Evaluation of AO sequences designed to induce exon 52 inclusion 
785Ba) The region of FBN1 between exons 47 and 54 and the location of the 2′OMe-PS AOs (Orange bars) are shown. RT-
PCR amplicons from MFSΔ52 fibroblasts transfected with b) individual 2′OMe-PS AOs (200, 100 and 50 nM) and c) 
cocktails of two 2′OMe-PS AOs (200 and 50 nM). The proportion of full-length transcripts are noted under each gel 
lane. The optimal exon exclusion AO AO52-1n was used as a positive control (Pos) to assess transfection efficiency. 
Screening of 2′OMe-PS AOs targeting exon 52. Healthy control fibroblasts were transfected with AOs as lipoplexes at 
three concentrations, 200, 100 and 50 nM. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated 
control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. 
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Assessment of AO-mediated exclusion of exon 52 in patient 
fibroblasts 
510BThe AOs designed to induce exon 52 exclusion described in the previous chapter were 
transfected into healthy control fibroblasts, as well as into the two MFS patient cell lines 
harbouring exon 52 mutations. In-line with the results of chapter 3, AO52.1n induced the most 
efficient exon 52 skipping in healthy control fibroblasts (Figure 4.3.a). Similarly, AO52.1n was 
the most efficient AO in the MFSC2111R cells inducing up to 49% exon 52 skipping (Figure 4.3.c). 
While not as effective in MFSΔ52 cells, that already have approximately 46% skipping, as a result 
of the synonymous mutation, AO52.1n remains the most efficient of the AOs tested, increasing 
Δ52 transcripts to ~58% (Figure 4.3.b). 
511BIn each cell line, AO52.3 was also a relatively effective candidate, albeit to a lesser extent than 
AO52.1n, with 30%, 53% and 41% exon 52 skipping at the highest concentration tested in healthy 
control, MFSΔ52 and MFSC2111R cell lines, respectively (Figure 4.3). The AO52.1m sequence 
differs from AO52.1n by one base, with AO52.1m complimentary to the c.6354C>T mutation 
sequence of MFSΔ52 cells. This AO was designed in the hope of taking advantage of the effect 
that the silent mutation has on exon selection, increasing the AO efficiency. However, AO52.1m 
is less efficient than AO52.1n in the two cell lines tested; 22% exon skipping induced in the 
healthy control and 49% in the MFSΔ52 cells (Figure 4.3.a and b). 
512BCocktails of AOs were previously identified as either ineffective or antagonistic; therefore, the 
majority of cocktails were not re-tested. However, two cocktails were tested in MFSC2111R cells to 
identify any synergism derived from the use of the two most efficient AOs, AO52.1n and AO52.3, 
and AO52.5, which is ineffective, inducing no skipping. However, in both cases, AO52.5 
negatively impacts on exon 52 skipping, resulting in lesser skipping than with AO52.1n and 
AO52.3 alone (Figure 4.3.c). 
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1071B
Figure 4.3: Evaluation of AOs designed to induce skipping of FBN1 exon 52 
786BRT-PCR amplicons generated from a) healthy control b) MFSΔ52 and c) MFSC2111R fibroblasts transfected with 2′OMe-
PS AOs at three (a, b); 200, 100, 50 nM or two (c); 200 and 50 nM, concentrations. The values below each gel image 
indicate the percentage of exon 52 skipped (Δ52) transcripts in each sample. Ctrl: an unrelated sequence used as a 
sham treatment, UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. 
Optimisation of post-transfection incubation period. 
513BTo identify the optimal time point for assessing exon skipping efficiency, PMO52, the PMO 
version of the AO52.1n sequence, was nucleofected into healthy control fibroblasts that were then 
collected at multiple time points; 24, 48 and 72 hours as well as four and ten days after 
transfection. The efficiency of exon 52 skipping increased at every timepoint until four days post-
transfection (Figure 4.4.a). Between four- and ten-days after transfection, cell health began to 
deteriorate, and treated cells began to die. The result of which was the regrowth of cells and a 
corresponding decrease in the skipping efficiency for both cell lines (Figure 4.4.a). 
514BPreviously, PMO52 resulted in the formation of fibrillin-1 fibres in healthy control cells when 
more than 90% skipping was induced; however, fibre abundance was reduced. The duration of 
incubation after transfection was proposed as a possible contributing factor. Therefore, the 
optimal length of time for fibrillin-1 fibres to form was also assessed using untreated healthy 
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control fibroblasts to define a baseline. Fibrillin-1 staining revealed fibre formation as early as 24 
h; however, fibres at this time point were fragmented and in low abundance (Figure 4.4.b.i). After 
four days, long thin fibres were observed with a more continuous morphology and higher 
abundance, covering the majority of the coverslip in a uniform layer (Figure 4.4.b.ii). The 
intensity, length and abundance of fibres continued to increase at each, 7- 10- and 14-day, 
timepoint (Figure 4.4.b.iii-v). Taking both exon skipping efficiency and fibre formation dynamics 
into account, two timepoints; four- and ten-days, were used for remaining studies. 
1072B
Figure 4.4: Exon 52 skipping efficiency and fibrillin-1 fibre formation post-transfection. 
787Ba) PMO52-mediated skipping induced at 250 µM, calculated in a 20 µl cuvette, in healthy control and MFSΔ52
fibroblasts; 24, 48 and 72 hours as well as 4 and 10 days after transfection. b) Immunofluorescent staining of fibrillin-1 
(red) in healthy control fibroblasts after 24 hours, then 4, 7, 10 and 14 days. Counterstained with Hoechst (blue) for 
nuclei detection. No primary antibody control (No Ab ctrl) used to observe non-specific binding of the secondary and 
autofluorescence. Scale bar = 20 µm 
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Evaluation of PMO52-mediated exon skipping and 
fibrillin-1 morphology 
515BTo assess PMO52-mediated exon 52 skipping and consequences on fibrillin-1 protein the AO 
was nucleofected into both MFSΔ52 and MFSC2111R patient cell lines and healthy control 
fibroblasts. Two concentrations, 250 µM and 50 µM; calculated in the Nucleofection cuvette 
containing 300,000 cells in 20 µl of transfection reagent, were tested, and cells were incubated 
for four or ten days. After four days, Δ52 transcripts averaged 85%, 97% and 85% of total 
transcripts in healthy control, MFSΔ52 and MFSC2111R fibroblasts, respectively (Figure 4.5). An 
apparent decrease in the average skipping efficiency, at a transfection concentration of 250 µM, 
was observed after incubation for ten days. Healthy control and MFSC2111R fibroblasts, in 
particular, were the most affected by the longer incubation period with skipping efficiency 
reduced to 72% and 67%, respectively. However, a decrease in skipping efficiency from 97% to 
91% was also observed in MFSΔ52 cells (Figure 4.5). We also noted variable cell death between 
experiments (data not shown) and a corresponding increase in the variability of skipping 
efficiency between biological replicates after ten days in comparison to four days (Figure 4.5). 
1073B
Figure 4.5: AO-mediated FBN1 exon 52 skipping across three replicates. 
788BDensitometric analysis of exon 52 skipping in fibroblasts from the healthy control, MFSΔ52 and MFSC2111R patients after 
treatment with PMO52 at two concentrations; 250 µM and 50 µM, calculated in the 20 µl nucleofection cuvette volume, 
and collected after incubation for 4 or 10 days. Means plus error bars. Error bars = standard deviation, n = 3. GTC: 
Gene Tools control PMO used as a sham treatment, UT: untreated control. 
516BResults of one of these replicate exon skipping experiments are shown in Figure 4.6; this 
replicate saw particularly efficient skipping in all three cell lines. Previously, the average skipping 
efficiency, over the three replicates, in both healthy control and MFSC2111R cells was poorer than 
that observed in the MFSΔ52 cells that show a baseline skipping of approximately 50% (Figure 
4.5). However, in this replicate, after treatment with 250 µM of PMO52, Δ52 transcripts made up 
92% of total transcript product in both MFSΔ52 and healthy control fibroblasts, and 95% of 
transcripts in MFSC2111R cells (Figure 4.6). 
517BAfter transfection, cells were stained with an anti-fibrillin-1 antibody to identify the fibrillin-
1 fibres. Immunofluorescent staining revealed the expected long thin fibres that form a lattice in 
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the untreated and GTC treated healthy control samples (Figure 4.6.b.xi, xii). These fibres were 
abundant, covering the majority of the field-of-view at any given location on the coverslip. In 
contrast, no fibrillin-1 fibres were observed in the untreated and GTC treated samples from either 
patient, with minimal fibrillin-1 staining in these samples overall (Figure 4.6.b.iii, iv, vii, viii).  
518BThe PMO52-mediated exon 52 skipping was dose dependant, with poorer skipping efficiency 
after transfection at a lower concentration. After treatment with 50 µM, Δ52 transcripts 
constituted 64%, 23% and 41% of the total transcript products from MFSΔ52, MFSC2111R and 
healthy control fibroblasts, respectively (Figure 4.6.a). Not surprisingly, the presence of both FL 
and Δ52 transcripts correlate with reduced fibrillin-1 staining in all three cell lines (Figure 4.6.b.ii, 
vi, x). This staining mirrors that of the untreated patient samples with no fibres and minimal 
fibrillin-1 staining overall (Figure 4.6.b). 
519BThe higher PMO52 concentration of 250 µM induces more than 90% exon 52 skipping in all 
three cell lines. The corresponding immunofluorescent staining, however, reveals a different story 
for each cell line. In healthy control cells, 92% skipping is associated with fibrillin-1 fibre 
formation (Figure 4.6.b.ix), mirroring that seen previously. However, in comparison to the fibres 
formed in the untreated healthy control sample, the fibres formed by healthy control cells 
transfected with 250 µM of PMO52 are fragmented and less abundant (Figure 4.6.b.ix, xii) 
520BIn the samples of MFSC2111R cells treated with 250 µM of PMO52, the corresponding 
immunostaining revealed an increase in fibrillin-1, compared to the untreated patient samples 
(Figure 4.6.b.v). However, minimal fibrillin-1 fibre formation is observed, and the staining 
instead appears to be sponge-like with no defined organisation. Sanger sequencing of the FL 
amplicons in the untreated, as well as 250 µM and 50 µM, treated MFSC2111R samples revealed no 
change in the ratio of healthy full-length (FL) and mutation-associated full-length (FLc.6331T>C) 
transcripts when exon 52 skipping was induced (Figure 4.6.c). 
521BEncouragingly, in MFSΔ52 cells treated with the high concentration, fibrillin-1 fibres were 
present and have a continuous, non-frayed morphology comparable to those seen in the untreated 
healthy control cells (Figure 4.6.b.i). The fibres are also relatively abundant, filling the majority 
of the field-of-view; however, they are not as plentiful as those seen in the untreated healthy 
control, which form a multi-layer lattice (Figure 4.6.b.i, xii). 
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Figure 4.6: Evaluation of PMO52-mediated exon 52 skipping and fibrillin-1 morphology 
789BHealthy control, MFSΔ52 and MFSC2111R patient fibroblasts were transfected with PMO52, Gene Tools control PMO 
(GTC) or left untreated (UT). Two concentrations were tested; 250 μM and 50 μM, calculated in the 20 µl nucleofection 
cuvette volume, and cells were collected after 4 days for a) RT-PCR analysis and b) Immunofluorescent staining. Cells 
were stained for Fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary 
antibody added. Scale bar = 20 µm. The values below each gel image indicate the percentage of exon 52 skipped 
(Δ52) transcripts in each sample. -ve: RT-PCR negative control. 100bp molecular marker used for size reference. c) 
Sanger sequencing of the FL amplicons from MFSC2111R cells showing the ratio of healthy full-length and full-
lengthc.6331T>C transcripts, with and without treatment. See Figure A2.1 for a larger version of part b. 
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4.5 Targeting Exon 59 
Exon 59 exclusion screening and optimisation 
522BIn the same way that AOs targeting exon 52 were assessed, 2′OMe-PS AOs targeting exon 59 
were screened in healthy control fibroblasts. Initial screening was performed using three AO 
sequences designed to target the exon 59 acceptor splice site as well as ESE sites predicted using 
the in silico tool spliceAid153,154 (Figure 4.7.c). Exon skipping efficiencies were determined by 
amplification of FBN1 transcripts between exon 56 (forward) and exon 62 (reverse primers) 
(Figure 4.7.b). Additional sequences were then designed up-stream and down-stream of the most 
efficient AO target site identified in the first screen (Figure 4.7.c). 
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Figure 4.7: Schematic of FBN1 pre-mRNA structure highlighting exons 56 to 62 and the binding sites of antisense oligonucleotides targeted to exon 59. 
790Ba) The full fibrillin-1 pre-mRNA from exons 2 to 66, b) highlighting the region between exon 56 forward and exon 62 reverse primers. Chevron sides indicate exons bounded by partial codons; the split
codon at the junction of exons 58 and 59 is shown above the diagram. The dotted line represents partial introns 58 and 59. The pink and yellow fills represent the cbEGF-like and TB domains encoded 
by these exons. c) The ESE/ISE (purple) and ESS/ISS (orange) sites that are targeted by the antisense oligonucleotides designed to skip exon 59 are shown. The exonic and intronic sequences are 
represented by upper- and lower- case, respectively. Figure modified from the report generated by spliceAid153 
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The original three AOs were transfected at two concentrations; 200 nM, and 50 nM into 
healthy control fibroblasts that were harvested 24 hours later for RNA extraction and RT-PCR to 
assess exon skipping. One of the three AOs, AO59.2, induced exon 59 skipping in a dose-
independent manner; with 32% and 33% Δ59 transcript products induced at 200 nM and 50 nM, 
respectively (Figure 4.8.a). The remaining two AOs did not induce measurable exon skipping. 
Sanger sequencing of the upper (FL) and lower (Δ59) transcript products confirmed that they 
differ only by the loss of exon 59 in the Δ59 transcript product (Figure 4.8.d and e). 
524BAn unrelated control AO sample (Ctrl) was included in all transfections as a sham treatment 
to reveal any chemistry-related effects on the growth and health of treated cells. However, an 
additional control, using the transfection reagent Lipofectamine 3000 (L3K) without any AO was 
also performed to reveal any changes in cell health as a result of the transfection process. Neither 
control induced any exon skipping, however, both controls caused a minor decrease in total RNA 
concentration compared to the untreated cells. 
525BTwo additional AO sequences were designed by micro-walking around the AO59.2 target site. 
This involved shifting the sequence five bases upstream (-5) or downstream (+5) from the original 
target while maintaining the 25-mer length. Neither of the micro-walked sequences was more 
efficient than the original AO59.2, both inducing less than 20% skipping of exon 59 (Figure 
4.8.b). 
526BCocktails of two AOs together were also tested to identify any synergistic effects; however, 
while increasing efficiency marginally, this effect is additive at most and not sufficient to warrant 
the use of two AOs. Several cocktails, notably AO59.1 combined with AO59.2, resulted in 
substantial cell death, especially at a higher concentration (Figure 4.8.b). 
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1076B
Figure 4.8:Evaluation of AO sequences targeting exon 59 
791BHealthy control cells were transfected with a) individual AOs, b) micro-walked AOs or c) AO cocktails at 200 nM and 
50 nM total AO concentrations. The values below each gel image indicate the percentage of exon 59 skipped (Δ59) 
transcripts in each sample. Ctrl: an unrelated sequence used as a sham treatment, L3K: transfection control with 
Lipofectamine 3000 regent and no AO, UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker 
used for size reference. Sanger sequencing of the d) FL and e) Δ59 amplicons showing the exon junctions.  
The effect of exon 59 skipping on fibrillin-1 morphology 
527BThe most promising 2′OMe-PS candidate sequence, AO59.2, was synthesised as a PMO, 
PMO59. The efficiency of PMO59 was assessed in healthy control and both MFSΔ59 MFSR2424* 
patient fibroblasts. Transfected cells were incubated for four and ten days then collected for RNA 
analysis and immunofluorescent staining with a fibrillin-1 specific antibody. Representative 
results from two independent replicates are presented in Figure 4.9. 
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1077B
Figure 4.9: Evaluation of PMO59-mediated exon 59 skipping and fibrillin-1 morphology. 
792BHealthy control, MFSΔ59 and MFSR2414* fibroblasts were nucleofected with PMO59 at 250 µM, and 50 µM; calculated in the 20 µl nucleofection cuvette volume, in two replicate experiments. Total RNA 
was collected a) 10 days and b) 4 days after transfection to assess exon 59 skipping efficiency. The values below each gel image indicate the percentage of exon 59 skipped (Δ59) transcripts in each 
sample. GTC: Gene Tools control PMO used as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. c) and d) show representative 
immunofluorescent images for replicates one and two after 10 and 4 days respectively. Transfected cells were stained for fibrillin-1 (red) and counterstained with Hoechst (blue) for detection of the nuclei. 
No Ab control: no primary antibody added, to control for non-specific binding of the secondary antibody. Scale bar = 20 µm. See Figure A2.2 and Figure A2.3 for larger versions of part c and d respectively. 
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528BIn the first replicate, the higher concentration of PMO59 induced relatively efficient exon 59 
skipping in both MFSΔ59 (89%), and MFSR2414* (79%) fibroblasts after ten days incubation (Figure 
4.9.a). In contrast, PMO59 was less efficient in healthy control cells in which only 50% skipping 
was induced (Figure 4.9.a). In the second replicate, however, a high level of cell death, up to 30%, 
was evident in all samples, including the untreated cells (data not shown). Cell death led to the 
expansion of the remaining cells over the four- and ten-day incubation periods, diluting the effects 
of PMO59. The skipping efficiency was reduced in all three cell lines; 74% for MFSΔ59, 64% for 
MFSR2414* and 36% for healthy control fibroblasts at the highest concentration tested after four 
days (Figure 4.9.b). After the full 10-day incubation period, skipping efficiency had decreased 
further to 50%, 37% and 16% for MFSΔ59, MFSR2414* and healthy control fibroblasts, respectively 
(data not shown) 
529BThe difference in skipping efficiency between the two replicates was reflected in the 
corresponding fibrillin-1 immunofluorescent staining. In both replicates, untreated and GTC 
treated healthy control fibroblast samples present with abundant fibrillin-1 fibres throughout the 
coverslips (Figure 4.9.c.iii, iv and d.iii, iv). Similarly, the low concentration of PMO59 had little 
to no effect on fibre formation in the first replicate in which no skipping was induced (Figure 
4.9.c.ii). However, yielding 12% skipping in replicate two correlated with a decrease in fibre 
abundance (Figure 4.9.d.ii). 
530BIn both replicates, untreated and GTC treated MFSR2414* fibroblasts presented with thin fibres 
that, while covering approximately half of the coverslip, showed low staining intensity and were 
fragmented (Figure 4.9.c.xi, xii and d.xi, xii). In the first replicate, these fibres were entirely lost 
when the cells were treated with 50 µM of PMO59 that induced 40% skipping (Figure 4.9.c.x). 
Increasing the concentration of PMO59 to 250 µM resulted in 79% skipping and the formation of 
fibrillin-1 fibres (Figure 4.9.a and c.ix). The fibrillin-1 staining was robust with long thin fibres; 
however, as seen previously, the abundance of fibres is reduced in comparison to the untreated 
healthy control. The reduced skipping efficiency in replicate two correlated with no change in 
staining pattern, compared to the untreated samples (Figure 4.9.d.ix) 
531BIn the first replicate, untreated and GTC treated MFSΔ59 cells had minimal fibrillin-1 staining 
(Figure 4.9.c.vi, vii). In the second replicate, however, more cells remained on the coverslip, with 
an increase in fibrillin-1 staining. This staining was diffuse and likely intracellular, most often 
surrounding the nucleus (Figure 4.9.d.vi, vii). 
532BThe proportion of Δ59 transcripts induced in MFSΔ59 cells, which have 50% endogenous exon 
59 skipping, was greater for every treatment group in both replicates than either MFSR2414* or 
healthy control fibroblasts (Figure 4.9.a and b). In both replicates, treatment with either 
concentration of PMO59 increased the abundance of fibrillin-1 staining. However, this staining 
was sponge-like rather than fibre-like in morphology (Figure 4.9.c.v, vi and d.v, vi). Fibres were 
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infrequently observed in the 250 µM treated cells in the first replicate; however, the fibres were 
frayed, fragmented and at very low abundance, an example of this staining is highlighted with a 
white arrow in Figure 4.9.c.v. 
4.6 Discussion 
533BWe have previously shown proof-of-concept that an AO sequence can efficiently mediate 
skipping of FBN1 exon 52, the result of which is the generation of apparently functional fibrillin-
1Δ52 fibres in healthy control cells. In this chapter, we aimed to extend this concept further, 
determining if; the same AO sequence is efficient in cell lines with different disease-causing 
mutations; different mutation types would respond in the same way and finally if the same concept 
of re-aligning fibrillin-1 monomers could be applied to exon 59. 
534BEncouragingly the ‘most efficient’ AO targeting exon 52 showed consistent effects across the 
three cell lines tested, indicating that the AO sequence does not need to be customised for the 
different patients. Interestingly, this AO anneals across the synonymous mutation associated with 
exon skipping in the MFSΔ52 cell line.151 We determined that this mutation disrupts the balance of 
predicted silencer and enhancer sequences,154 thus resulting in exon skipping. Identifying other 
silent or missense mutations that impact on splicing could help in designing AOs. The universal 
mutation database reports four synonymous mutations in amenable FBN1 exons,3 all of which are 
predicted to alter the balance of ESE and ESS sequences (Figure A2.1).154 AOs targeted to these 
regions could prove to be especially efficient. 
535BWhile the sequence of the most effective AO for each cell line remained constant, the 
efficiency of exon skipping varied considerably between cell lines. This variability was 
particularly apparent when using the PMO chemistry and suggests that the required dose may 
need to be altered according to mutation type, with splicing mutations likely requiring a lower 
dose than missense mutations. That said, variability between experiments revealed that the PMO 
is capable of inducing efficient skipping in all three cell lines. The key implication is that the 
skipping efficiency needed to negate the dominant-negative effects of heterogeneous fibrillin-1 
monomers is likely to be very high. Therefore, it is expected that a high PMO concentration will 
be required to ensure sufficient skipping regardless of the mutation type. 
536BThe effect of exon 52 skipping on fibrillin-1 fibres varied between mutation type. We note that 
skipping efficiency of more than 80% in MFSΔ52 cells results in the formation of fibrillin-1 fibres. 
However, the same skipping efficiency in the MFSC211R cell line increases fibrillin-1 staining 
without restoring fibre formation. This poses two new questions, why are these fibrillin-1 
monomers not forming fibres? And what fibrillin-1 abundance and morphology need to be 
induced for there to be a therapeutic effect? Addressing the former, we can speculate that the 
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presence of three different transcripts; FBN1, FBN1c.6331T>C and FBN1Δ52 could affect either or 
both the synthesis and assembly of fibrillin-1Δ52 monomers. To possibly overcome this, after PMO 
treatment, the cells could be treated with an RNase-H-dependent AO targeted to exon 52. This 
would lead to degradation of both FL transcripts leaving only Δ52 monomers to form microfibrils 
without resulting in haploinsufficiency. Targeted transcript degradation has been reported several 
times with promising efficiency.113 The FDA approved drugs Vitravene148 (discontinued) and 
Kynamro149 are both examples of RNase-H-dependent AOs. However, both drugs have been 
associated with undesired side-effects148–150; thus, any RNase-H AO targeting FBN1 is more likely 
to be used as a research tool rather than a therapeutic one. 
537BAntisense oligonucleotides targeted to exon 59 were, for the most part, relatively ineffective, 
although one sequence mediated relatively efficient exon 59 skipping. As a PMO this AO 
sequence exhibited variable efficiency not only between cell lines but between experiments. For 
the most part, this variability was associated with cell health rather than the efficiency of PMO 
itself; however, PMO59 was never as efficient as PMO52. Encouragingly, when sufficient 
skipping was induced in MFSR2414* cells, the result was the formation of strong fibres, 
morphologically similar to untreated healthy controls. This provides proof that exon 59 is a 
potentially amenable target. However, the efficiency and reproducibility of PMO59 must be 
improved before the effects of exon 59 skipping can be fully assessed.  
538BThe variability in skipping efficiency between replicate one and two of the exon 59 skipping 
experiments illustrates the risk of inefficient skipping as this would most certainly lead to no 
benefit. As evidenced by the loss of the minimal endogenous fibres in MFSR2424* cells, insufficient 
exon skipping could lead to a more severe phenotype than if left untreated. The major difference 
between these experiments was the level of cell death that ultimately resulted in cell proliferation, 
diluting the effects of the PMO. The safety of PMOs have been demonstrated in cells, mouse 
models and human clinical trials; PMOs themselves do not usually result in cell death or adverse 
effects. However, we have noticed that Nucleofection, the delivery method used here, is 
associated with some cell death, regardless of the AO sequence. Unfortunately, PMO delivery 
and efficiency both in vitro and in vivo in its current stage is somewhat unpredictable and limited. 
Intense efforts to enhance AO delivery to target organs and cells are underway and include; 
nanoparticles enclosing or decorated with the AO;184–186 cell penetrating peptides;134,187,188 
lipids189,190 and nucleic acid aptamers.191,192 These advances are reviewed by Roberts et al.193. A 
more efficient PMO delivery method would have been ideal for this study, however, in the 
meanwhile, further optimisation of the sequence including additional micro-walking, increased 
or decreased length and alternative chemistries could improve the efficiency of the AO. 
539BThe exon-skipping approach, when efficient skipping was achieved showed considerable 
promise. However, the requirement for extremely efficient skipping in order to restore transcript 
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homogeneity, is a major challenge. In a recent report, McNamara et al.194 induced fibrillin-1 exon 
30 skipping in a patient-derived IPSC cell line. While the group identified a cocktail of AOs that 
induced relatively efficient skipping in their model, they concluded that the proportion of skipping 
achieved was likely insufficient to alleviate the MFS phenotype.194 The group used the 2′OMe-
PS AO chemistry and reported comparable skipping efficiency to that achieved with 2′OMe-PS 
AOs in this study. The relative exon skipping efficiencies shown by 2′OMe-PS and PMO versions 
of the same sequence was discussed by Adams et al.167 in relation to Duchenne muscular 
dystrophy, showing that effective 2′OMe-PS sequences most often translate into more efficient 
PMOs. It has since been revealed that not all AO sequences are more efficient as PMOs than there 
2′OMe-PS counterparts.195 However, here we observe that the PMO versions are not only more 
efficient but also tolerated at a higher concentration and are active for a more extended period of 
time. Therefore, we suggest that while 2′OMe-PS AOs provide a useful tool in the design and 
optimisation of therapeutic AOs, the PMO counterpart would be a more appropriate choice for 
further development. 
540BSince the 1970s AOs have been moulded into a versatile and useful tool in the treatment of 
genetic diseases. To-date, eleven AO drugs have been approved by the FDA196,197 for the treatment 
of a range of conditions including cytomegalovirus associated retinitis148, SMA145, DMD143,144,198 
and familial hypercholesterolemia149. This includes one drug, Milasen, that was approved for the 
treatment of a single patient in an n=1 clinical trial199 indicating an incredible and encouraging 
movement toward more personalised medicine. Here we hypothesised that identification of a 
single AO for each amenable FBN1 exon could allow for the treatment of any patient with a 
mutation affecting that exon. We successfully identified AO sequences that mediate the skipping 
of FBN1 exons 52 and 59. We also demonstrated in patient cells with two different mutation types 
that exon skipping can result in the formation of fibrillin-1 fibres. 
541BWhile we showed that the same AO induced exon skipping in multiple cell lines, the efficiency 
of skipping varies. Additionally, our findings suggest that the tolerable threshold of truncated 
monomer abundance is different, depending on the type of mutation, demonstrating the 
importance of identifying the most efficient AO sequences. The development of AO therapies for 
Marfan syndrome is obviously still in its infancy, however with further studies building on the 
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5.1 Fibrillin-1 mutation landscape 
542BAs previously discussed, the type-1 fibrillinopathies are caused by mutations in the large 
fibrillin-1 (FBN1) gene that encodes for the extracellular glycoprotein fibrillin-1. To-date over 
2,800 unique mutations have been reported,2,3 the vast majority of which are private mutations, 
meaning they are unique to a single individual or family.2,3 the remaining 25% to 30% of FBN1 
mutations arise spontaneously with no prior family history.29,200 
543BDisease-causing mutations are spread across the entire FBN1 sequence with no hotspots with 
a higher mutation density (Figure 5.1.a). The number of mutations in each exon is roughly 
correlated to exon size. Exon 64, for example, is associated with 3.5% of all mutations (Figure 
5.1.a) but is also the largest coding exon contributing 2.7% of the total 8,613 bases of FBN1 
mRNA. 
1078B
Figure 5.1: Distribution of FBN1 mutations by exon and type 
793Ba) The frequency of mutation types by exon as a proportion of total mutations for that exon. b) distribution of mutations
by type, the ‘other’ segment is highlighted in a bar graph to allow further resolution. 
544BThe roughly half (54%) of disease-causing variants affecting the fibrillin-1 gene are missense 
mutations, in particular, those resulting in the substitution of a conserved cysteine residue are very 
common; approximately 32% (Figure 5.1.b). Fibrillin-1 is cysteine-rich, made up of repeated 
domains, each containing between 6-8 conserved cysteine residues that form disulphide bonds in 
specific patterns.20,24 These bonds are essential for calcium-binding as well as the folding and 
stability of the fibrillin-1 protein.20,22 Mutations that either create or more commonly disrupt these 
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cysteine residues result in loss of calcium-binding and thus are associated with increased 
proteolysis of fibrillin-1.23 
545BWhile missense mutations are the most common, other mutation types have also been 
associated with Marfan syndrome. Nonsense and frameshifting mutations that lead to a premature 
termination codon (PTC) account for a further 31% of mutations (Figure 5.1.b). Such mutations 
often result in nonsense-mediated decay (NMD) and thus follow a haploinsufficiency pathogenic 
model.201,202 Other PTC mutations can ‘escape’ NMD resulting in the synthesis and secretion of 
truncated fibrillin-1 monomers incapable of forming functional microfibrils.202 Lastly, some PTC 
mutations that affect the C-terminal result in the synthesis of a stable protein lacking a cleavage 
site essential for secretion from the cell and lead to intracellular retention.66 Such mutations 
disrupt production of the protein-hormone Asprosin. Asprosin is cleaved from the C-terminal of 
the fibrillin-1 preproprotein post-translation, and its disruption leads to the rare type-1 
fibrillinopathy known as Marfanoid lipodystrophy disorder.52,65 
546BIt is estimated that up to 15%203 of all single nucleotide variants result in altered mRNA 
splicing, most commonly exon skipping, or the creation or activation of cryptic splice sites and 
retention of intronic sequences. In the HGMD database2 (accessed November 17, 2020) splice 
site mutations; those directly affecting the splice sites or flanking sequences, account for 9% of 
total mutations across all genes and 11% of total mutations within FBN1. However, both figures 
are likely underestimates since the majority of mutations are identified through sequencing of 
genomic DNA. Therefore, any missense, nonsense and synonymous mutations, or deep-intronic 
mutations that affect splicing and exon selection would not be identified. A prime example of this 
is the synonymous mutation c.6354C>T, p.(Ile2118Ile) discussed in chapter 4, that disrupts the 
balance of the cis-acting regulatory silencer and enhancer sequences resulting in exon 52 skipping 
(r.6314_6379del). 
Multi-exon skipping strategy 
547BThus far, we have discussed using AOs to mediate inclusion or exclusion of a single FBN1 
exon to treat dominant-negative mutations or restore the reading frame. The overarching 
hypothesis is that the production of identical fibrillin-1 monomers will allow for functional 
microfibrils to form, reducing the severity and progression of the Marfan phenotype. Both 
exclusion and inclusion of a disease associated-exon using antisense oligonucleotides (AO) have 
been applied to many different diseases with varying levels of efficacy, including Pompe 
disease,204 Duchenne muscular dystrophy (DMD),143,144 spinal muscular atrophy205 and 
spinocerebellar ataxia type 3.168,206 However, a now relatively well-established approach 




548BAn example of multi-exon skipping was described by Adkin et al.,207 who assessed the 
efficiency of double exon skipping involving DMD exonic regions 19-21 and 50-52. Fall et al. 211 
similarly assessed multi-exon skipping in DMD successfully excluding exons 19-25 using a 
cocktail of AOs. Both reports recognized that some exons are more challenging to skip than 
others, requiring a combination of two AOs for one exon, within the multi-exon skipping 
cocktail.207 A similar study by Yokota et al.208 demonstrated the efficacy of a multi-AO cocktail 
in inducing skipping of exons 6 and 8 flanking the exon 7 splice site mutation that causes golden 
retriever muscular dystrophy,212 resulting in triple-exon skipping.  
549BMulti-exon skipping has three main advantages: (1) allowing restoration of the reading frame 
for mutations that require the removal of more than one exon; (2) enabling the treatment of greater 
number of patients with fewer drugs, potentially resulting in a more consistent patient response 
to treatment and (3) enabling the truncated protein to be more fully optimised to produce the most 
effective isoform. For DMD it is estimated that only 70% of deletion patients and 47% of 
nonsense mutation patients are amenable to single exon skipping, while over 90% of all patients 
are theoretically treatable with multi-exon skipping.213 
550BWe propose that a multi-exon skipping approach could also be applied to FBN1 to treat the 
type-1 fibrillinopathies. However, rather than to restore the reading frame, since most fibrillin-1 
exons are in-frame, we suggest that the main advantage of a multi-exon skipping approach for 
MFS will be the potential to treat more patients with fewer compounds. This is particularly 
important since MFS is a rare disease with no mutation hotspots and many mutation types. Of the 
66 exons of FBN1 exons, 60 can be skipped without disrupting the reading-frame therefore, 
approximately 90% of all mutations are theoretically amenable to an exon-skipping strategy, 
assuming that the deleted exon does not completely compromise function. However, a different 
AO would be required for each exon, with each AO only effective against approximately 1.5% of 
mutations. 
551BWe hypothesised that efficient multi-exon skipping, much like single exon skipping, would 
result in identical internally truncated fibrillin-1 monomers capable of assembling into 
microfibrils. We also suggest that; if efficient, this multi-exon skipping approach could be used 
for any patient with a mutation in one of the targeted exons. We chose the region from exons 45 
to 47 as our model as we had access to two patient cell lines, one with genomic deletion of exons 
45, 46 and 47, and the second with a splice site mutation resulting in exon 47 skipping. 
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5.2 Confirmation of patient mutations 
552BThe use of human cells for this research was approved by the Murdoch University Human 
Ethics Committee; approval numbers 2013_156 and 2017_101 and The University of Western 
Australia Human Research Ethics Committee; approval number RA4/1/2295. Healthy control 
fibroblasts were cultured from a dermal biopsy of a healthy volunteer taken after informed 
consent.  
553BThe following cell lines were obtained from the NIGMS Human Genetic Cell Repository at 
the Coriell Institute for Medical Research: GM21934 and GM21940. Both patients have been 
previously characterised by Liu et al. in articles published in 1996183 and 2001170. Please note that 
mutation nomenclature was determined with respect to the FBN1 gene Locus Reference Genomic 
sequence transcript 1 (LRG_778t1) in which the non-coding 5′ exon is considered as exon 1, and 
the translation start codon is located in exon 2. Therefore, the exons under investigation will be 
referred to as exon 47 and exon region 45-47. The GM21934 cells hereafter referred to as MFSΔ47, 
were originally reported to harbour a donor splice site mutation resulting in skipping of exon 46. 
The GM21940 (MFSΔ45-47) cells were originally reported to have a genomic deletion of exons 44-
46. 
554BThe patient cell line mutations were confirmed using Sanger sequencing. Genomic DNA was 
extracted from a MFSΔ47 fibroblast pellet, and the region of FBN1 between exon 47 forward and 
intron 47 reverse primers was amplified using AmpliTaqGold polymerase. Fibrillin-1 cDNA, 
between exons 42 and 49, was derived from total RNA extracted from MFSΔ47 and MFSΔ45-47 
fibroblasts. 
Confirming the MFSΔ47 mutation 
555BThe MFSΔ47 fibroblasts were confirmed to harbour the reported c.5788+5G>A splice site 
mutation that results in exon 47 skipping using both gDNA (Figure 5.2.a) and cDNA as 
sequencing templates (Figure 5.2.b). This mutation was one of the first recurrent mutations to be 
described and has been reported over 30 times, making it the second most common FBN1 
mutation.3,183,214 However, during fractionation of amplicons between FBN1 exons 42 and 49 a 
third product, larger than both the expected 797 bp exon skipping product (Δ47) and 914 bp full-
length (FL) product, was identified (Figure 5.2.d). This band on the gel was initially thought to 
be a heteroduplex. However, the band was consistently present after RT-PCR at various annealing 
temperatures and after using a two-step PCR protocol with a single annealing and elongation step, 
a method used to reduce the presence of heteroduplexes (data not shown). Finally, with two 
additional primers between exons 45 and 49 and exons 45 and 50 the product band was identified 
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as approximately 20-50 bp larger than the expected full-length amplicon, constituting 
approximately 23% of the total transcripts and 45% of the non-full-length product (Figure 5.2.d). 
556B and purification and Sanger sequencing of the RT-PCR product revealed that the larger 
amplicon contains 33 bases of retained intron 47 (Figure 5.2.c). The insertion of 33 bases of intron 
47 is in-frame and does not introduce any premature termination sites. The presence of a single 
‘A’ peak at c.5788+5 in transcripts with the 33 bp insertion confirmed that this inclusion does not 
occur in the wildtype allele and that it results from the splice site mutation and lack of the donor 
splice site recognition (Figure 5.2.c). This insertion is predicted to introduce 11 additional amino 
acids, GACAKLCISKGN, into the beginning of the 29th cbEGF-like domain. Within these amino 
acids are two cysteines that likely disrupt the folding and stabilisation of fibrillin-1. 
557BFurther in silico investigation using the web-based tool, Human Splicing Finder 3.0215 revealed 
that this insertion into the transcript terminates at a predicted alternative donor splice site sequence 
in intron 47 before continuing directly into exon 48. This alternative donor site is of average 
strength with a consensus score of 82%, while the natural donor site has a score of 88% that is 
reduced to 78% as a result of the c.5788+5 G>A mutation (Table A3.1). We suggest that in most 
mutant transcripts, the spliceosome bypasses the canonical splice sites of exon 47, due to loss of 
donor site recognition, utilising exon 46 donor and exon 48 acceptor sites and leading to exon 47 
skipping (Figure 5.2.d). However, a small portion of affected transcripts undergo splicing of 
intron 46 correctly utilising the exon 46 donor and exon 47 acceptor sites. Then, during splicing 
of intron 47, the spliceosome uses a cryptic donor splice site 33 bases into intron 47 and the 
canonical exon 48 acceptor site. This proposed splicing is depicted in Figure 5.2.d. The 
c.5788+5G>A mutation has previously been associated with activation of cryptic splice sites,214
however, this particular site has not been described. 
95 
1079B
Figure 5.2: Mutation confirmation in MFSΔ47 fibroblasts 
794BThe reported disease-causing mutation harboured by MFSΔ47 patient fibroblasts was confirmed via Sanger sequencing 
using a) gDNA, and b) cDNA derived from fibroblast RNA, as a template. c) Analysis of Sanger sequencing results 
showing the retention of 33 bases of intron 47 that occurs as a secondary outcome of the splice site mutation. d) RT-
PCR amplification of healthy control (hCtrl) and MFSΔ47 patient fibroblast RNA with four primer sets, showing the full-
length (FL), exon 47 skipped (Δ47) and full-length plus 33 bases of retained intron 47 (FL+33b) transcript products. 100 
bp molecular marker used for size reference. A diagram showing the probable splice sites being utilised for each 
product is shown to the right.  
Confirming the MFSΔ45-47 mutation 
558BThe mutation affecting MFSΔ45-47 cells was similarly confirmed at the cDNA level after Sanger 
sequencing; revealing the deletion of exons 45, 46 and 47 in their entirety (Figure 5.3.a). Liu et 
al.170 reported that the breakpoints for this genomic deletion occurs within an ‘atttt’ pentamer at 
positions -282 to -278 of intron 44 and -325 to -321 of intron 47 (Figure 5.3.b). These breakpoints 
were not confirmed at the gDNA level. Loss of exons 45-47 in this patient is associated with a 
severe neonatal Marfan syndrome phenotype. This severe phenotype combined with the mutation 
being classified as type IV with 109% synthesis and only 13% deposition69,170 suggests an extreme 




Figure 5.3: Mutation confirmation in MFSΔ45-47 fibroblasts 
795Ba) Mutation confirmation for MFSΔ45-47 cells at the cDNA/RNA level. b) schematic of the genomic deletion harboured 
by MFSΔ45-47 cells reported by Liu et al.170 showing the breakpoints in introns 44 and 47. 
5.3 Antisense oligonucleotide design 
559BThe first panel of AOs were designed to target the acceptor and donor splice sites, as well as 
potential exonic splicing enhancers as predicted by SpliceAid.153 Once an AO capable of inducing 
FBN1 exon skipping in healthy control fibroblasts was identified, additional overlapping AOs 
were designed in an attempt to further increase the skipping efficiency. Two un-related AOs 
sequences, one for each chemistry, were included in cell transfections as sham treatments. All AO 
sequences used in this chapter are described in Table 5.1. Exon sequence maps showing the AO 
binding sites in relation to enhancer and silencer motifs predicted by SpliceAid153 are presented 
in the supplementary Figure A3.1. 
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757BTable 5.1: List of antisense oligonucleotides used in Chapter 5 
734BThe name, ID, sequence, and chemistry of AOs designed to induce skipping of exons 45, 46 and 47. Two control 
sequences were also used to reveal any chemistry-related effects. AO nomenclature described in Chapter 2, Figure 
2.1. The AOs targeting exons 45 and 46 were designed by Mr Kane Greer (unpublished, 2017). 
3760BAO name 
(FBN1 H…) 
3761BID 3762BSequence (5′-3′) 3763BChemistry 
3764BExon 45 
2359B45A(+15+39) 2360BAO45.1 1196BUGC GCU GGC ACA CUG GGC CGU UCU G 2361B ′OMe-PS 
2362B45A(+15+39) 2363BPMO45 1197BTGC GCT GGC ACA CTG GGC CGT TCT G 2364BPMO 
2365B45A(+49+73) 2366BAO45.2 1198BCGG UAG CUG CCU GCA GUG UUG AUG C 2367B ′OMe-PS 
2368B45A(+87+111) 2369BAO45.3 1199BCUG UGG AGG UGA AGC GGU AGC CGG G 2370B ′OMe-PS 
2371B45D(+21-04) 2372BAO45.4 1200BAUA CCA UUG CAC UGU CCU GUG GAG G 2373B ′OMe-PS 
3765BExon 46 
2374B 6A(-09+16) 2375BAO46.1 1201BUGA CAU UCA UUA CGA UCU GUA AAU A 2376B ′OMe-PS 
2377B46A(+72+96) 2378BAO46.2 1202BUAA AAC CAG UGU GGC AAA GGC AAU A 2379B ′OMe-PS 
2380B46D(+12-13) 2381BAO46.3 1203BAUU GCA UAC UUA CCC AAG CAC AUG G 2382B ′OMe-PS 
2383B46D(+12-13) 2384BPMO46 1204BATT GCA TAC TTA CCC AAG CAC ATG G 2385BPMO 
2386B46A(-03+22) 2387BAO46.4 1205BAUU UCU UGA CAU UCA UUA CGA UCU G 2388B ′OMe-PS 
3766BExon 47 
2389B47A(-03+20) 2390BAO47.1 1206BUCU UUC ACA UUC AUU UAU GUC UA 2391B ′OMe-PS 
2392B47A(+58+77) 2393BAO47.2 1207BGCA GCG GCA GUU GAA GGA AC 2394B ′OMe-PS 
2395B47A(+58+77) 2396BPMO47 1208BGCA GCG GCA GTT GAA GGA AC 2397BPMO 
2398B47A(+83+102) 2399BAO47.3 1209BUGU GAG AAA GGA UGA AAC CA 2400B ′OMe-PS 
2401B 7D(+05-15) 2402BAO47.4 1210BAUU UUG CAC ACG CAC CUA UA 2403B ′OMe-PS 
2404B 7A(+44+68) 2405BAO47.5 1211BGUU GAA GGA ACC AAU UGU GUU CCG G 2406B ′OMe-PS 
2407B 7A(+69+93) 2408BAO47.6 1212BGGA UGA AAC CAU GAU UGC AGC GGC A 2409B ′OMe-PS 
2410B 7D(+24-01) 2411BAO47.7 1213BCCU AUA CAG UCA UUG UUG UGA GAA A 2412B ′OMe-PS 
2413B 7A(+56+80) 2414BAO47.2-25mer 1214BAUU GCA GCG GCA GUU GAA GGA ACC A 2415B ′OMe-PS 
2416B 7A(+53+82) 2417BAO47.2-30mer 1215BUGA UUG CAG CGG CAG UUG AAG GAA CCA AUU 2418B ′OMe-PS 
2419B 7A(+53+82) 2420BPMO47-30mer 1216BTGA TTG CAG CGG CAG TTG AAG GAA CCA ATT 2421BPMO 
3767BControls 
2422BUnrelated control 2423BCtrl 1217BGGA UGU CCU GAG UCU AGA CCC UCC G 2424B ′OMe-PS 
2425BGeneTools control 2426BGTC 1218BCCT CTT ACC TCA GTT ACA ATT TAT A 2427BPMO 
5.4 Identifying candidate AOs for FBN1 exons 45, 46 
and 47 
Exon 45 and 46 
560BThree AOs were initially designed for each exon 45 and 46, covering the majority of the exons 
sequence. Each AO was transfected into healthy control fibroblasts at two concentrations; 200 
nM and 50 nM. Cells were incubated for 24 hours before collection for RNA analysis to assess 
skipping efficiency. Of the three AOs tested for exon 45, only AO45.1 and AO45.2 induced any 
exon 45 skipping. However, the efficiency of exon removal was poor with only 3% and 9% Δ45 
transcripts for AO45.1 and AO45.2, respectively (Figure 5.4.a). Exon 46 AOs were similarly 
ineffective, with AO46.3 the most efficient inducing up to 10% skipping (Figure 5.4.b). 
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561BIn an attempt to increase skipping efficiency, cocktails of two AOs together were tested. The 
cocktails of AO46.1 and AO46.3 induced substantially more exon skipping than either AO 
individually, up to 32% (Figure 5.4.b). However, none of the other exon 46 cocktails nor those 
for exon 45 were effective. One additional sequence, AO45.4 and AO46.4, were designed for 
each exon targeting the donor and acceptor site of exon 45 and 46, respectively. Neither of these 
additional AOs induced exon skipping (Figure 5.4.a and b). Despite their poor skipping ability 
AO45.1, AO45.2, AO46.1 and AO46.3 were deemed the most appropriate sequences to induce 
triple exon skipping. 
1081B  
Figure 5.4: Evaluation of AOs designed to induce skipping of FBN1 exon 45 and 46  
796BHealthy control fibroblasts were transfected with 2′OMe-PS AOs targeted to a) exon 45 and b) exon 46. Two 
concentrations; 200 nM and 50 nM were tested, and treated cells were collected after 24 hours to assess skipping 
efficiency. The values below each gel image indicate the percentage of exon 45 (∆45) or 46 (∆46) skipped transcripts 
in each sample. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR negative 
control. 100bp molecular marker used for size reference. 
 Exon 47 
562BFour 2′OMe-PS AOs designed to induce exon 47 skipping were transfected into healthy 
control fibroblasts, and exon skipping was assessed after 24 hours. Three concentrations were 
tested: 200, 100 and 50 nM. Initial AO screening identified AO47.1, AO47.2 and AO47.3 as 
capable of inducing exon 47 skipping, albeit at different efficiencies (Figure 5.5.a). The most 
efficient AOs; AO47.2 and AO47.3, yielded 28% and 27% skipping at 200 nM, respectively 
(Figure 5.5.a). No measurable exon skipping was observed in samples treated with any 
concentration of AO47.4. 
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563BAs previously undertaken, all non-overlapping combinations of two AO cocktails were tested 
to identify any synergistic effects. Every cocktail tested induced more than 30% skipping at the 
highest concentration tested, with the combination of AO47.3 and AO47.4 causing as much as 
43% skipping (Figure 5.5.b). However, these skipping efficiencies were more suggestive of a 
additive effect, with each AO inducing approximately 20% skipping. 
564BTwo additional AOs, AO47.5 and AO47.6, were designed around the AO47.2 and AO47.3 
target sites to further optimise the skipping efficiency. Due to the shorter 20-mer length of 
AO47.2, two longer versions, a 25-mer and 30-mer, were also designed, to ascertain if the 
extending the AOs would increase exon skipping efficiency. Each of these additional AO 
sequences was transfected into healthy control fibroblasts at two concentrations: 200 nM and 50 
nM. The AO47.5 and AO47.6 sequences induced 24% and 10% exon skipping, respectively, 
however, AO47.7 was not effective with no measurable skipping evident (Figure 5.5.c). The 25-
mer and 30-mer versions of AO47.2 induced more than 40% skipping making them as efficient 
as the 20-mer (Figure 5.5.c). The AO47.2 and AO47.3 were selected for further study to induce 
triple-exon skipping. The AO47.2 sequence was also synthesised as a PMO for assessment in 
MFSΔ47 cells. 
1082B
Figure 5.5: Evaluation of AOs designed to induce FBN1 exon 47 skipping. 
797BExon 47 skipping efficiency in healthy control fibroblasts treated with a) individual 2′OMe-PS AOs, b) cocktails of two 
AOs or c) additional 2′OMe-PS AOs designed to improve upon the most efficient sequence by extending the length 
and micro-walking up-and down-stream of the original target site. Either three concentrations; 200 nM, 100 nM and 50 
nM (a and b) or two concentrations; 200 nM and 50 nM (c) were tested, and all cells were collected for RNA analysis 
after 24 hours. The values below each gel image indicate the percentage of exon 47 skipped transcripts (∆45) in each 
sample. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 
100bp molecular marker used for size reference. 
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5.5 Evaluation of PMO47-mediated exon skipping 
565BThe screening of 2′OMe-PS AOs targeted to exon 47 identified AO47.2 as the most efficient, 
this sequence was synthesised as a PMO (PMO47) and nucleofected into healthy control and 
MFSΔ47 patient fibroblasts. The proportion of exon 47 skipped transcripts (Δ47) were assessed 
after four and ten days. In MFSΔ47 fibroblasts, the PMO47 sequence induced efficient exon 47 
skipping averaging 92% after four days and 95% after ten days across two and three replicates, 
respectively (Figure 5.6). In healthy control fibroblast, where there is no endogenous skipping, 
exon 47 skipping efficiency was reduced, with an average of 75% and 62%, across three 
replicates, after four and ten days, respectively (Figure 5.6). 
1083B
Figure 5.6: PMO47 mediated exon 47 skipping 
798BDensiometric analysis over multiple replicates of MFSΔ47 patient and healthy control fibroblasts transfected with PMO47 
at two concentrations; 250 µM and 50 µM, calculated in the 20 µl nucleofection cuvette volume, and incubated for 4 
or 10 days. Means plus error bars, error bars = standard deviation, n=3. For MFSΔ47 4-day treatment groups n=2. GTC: 
Gene Tools control PMO used as a sham treatment, UT: untreated control. 
566BThe fibrillin-1 immunofluorescence results from one biological replicate collected after four 
days are displayed in Figure 5.7. Transfected fibroblasts were immunolabelled with an anti-
fibrillin-1 antibody to reveal the morphology and abundance of fibrillin-1 fibres. Untreated 
healthy control and MFSΔ47 patient samples were found to exhibit similar fibrillin-1 abundance, 
however, MFSΔ47 patient fibroblasts have a stark lack of fibrillin-1 fibres (Figure 5.7.b.iv and 
viii). As seen previously, untreated healthy control fibroblasts have consistent long thin fibres that 
form a lattice and cover most of the coverslip (Figure 5.7.b.viii). In contrast, the MFSΔ47 patient 
fibroblasts show diffuse staining throughout the cells, suggesting intracellular retention and no 
evidence of microfibril formation (Figure 5.7.b.iv). In both cell lines, the morphology and 
abundance of fibrillin-1 are unchanged after treatment with the GTC sham control (Figure 5.7.b.iii 
and vii) indicating no chemistry-related effects. 
567BTreatment with the lower concentration of PMO resulted in a similar mid-range exon skipping 
in both cell lines; 52% and 61% for healthy control and MFSΔ47 fibroblasts, respectively. The 
effect of the 50 µM PMO47 treatment was also similar for both cell lines, with a substantial 
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decrease in fibrillin-1 abundance (Figure 5.7.b.ii and vi). In healthy control fibroblasts, the 50 µM 
treatment eliminates fibrillin-1 fibre formations (Figure 5.7.b.ii). 
568BWhen the PMO47 concentration was increased to 250 µM, a corresponding increase in 
skipping efficiency was evident; 89% and 92% in healthy control and patient fibroblasts, 
respectively (Figure 5.7.a). Treatment with 250 µM of PMO47 resulted in both an increase in 
fibrillin-1 abundance, compared to that in the 50 µM treated cells, as well as the re-appearance of 
fibrillin-1 fibres (Figure 5.7.b.i and v). In the healthy control and patient fibroblasts treated with 
250 µM of PMO47, fibrillin-1 fibre morphology is similar to that seen when skipping exon 52 
previously; with long and thin but occasionally fragmented fibres. These fibres are relatively 
abundant in both cell lines, covering more than 75% of any given field of view. One change in 
morphology from that seen when skipping exon 52 is additional sponge-like staining that is 
particularly noticeable in the treated healthy control sample (Figure 5.7.b.i). The sponge-like 
staining pattern could indicate intracellular retention or extracellular fibrillin-1 that has not 
correctly formed fibrils. 
569BOf note is that treatment of MFSΔ47 cells with PMO47 appears to eliminate the additional 947 
bp intron 47 inclusion transcript that occurs as a secondary effect of the c.5788+5G>A mutation 
(Figure 5.7.a). The 947 bp product could not be detected when isolating and amplifying the full-
length product generated from the 250 µM treated patient cell sample (data not shown). The 




Figure 5.7: Evaluation of PMO47-mediated exon 47 skipping and fibrillin-1 morphology 
799BHealthy control and MFSΔ47 cells were nucleofected with PMO47, Gene Tool control PMO (GTC) or left untreated (UT) then collected after four days. Two concentrations were tested; 250 µM and 50 µM, 
calculated in the 20 µl nucleofection cuvette volume. a) RT-PCR amplicons between FBN1 exons 42 and 49 showing full-length (FL; 914 bp) and exon 47 skipped (Δ47; 797 bp) transcript products. The 
values below the gel image indicate the percentage of ∆47 transcripts in each sample. -ve: RT-PCR negative control. 100bp molecular marker used for size reference. b) representative images of treated 
cells stained for fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale bar = 20 µm. See Figure A3.2 for a larger version of part b.
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5.6 Triple-exon skipping 
Identification of promising cocktails 
570BCocktails of AOs to skip exons 45, 46 and 47 simultaneously were assessed in healthy control 
and MFSΔ45-47 fibroblasts. These cocktails varied by AO as well as the number of AOs targeted 
to each exon. All multi-exon skipping cocktails are described in Table 5.2.  
758BTable 5.2: Cocktails of 2′OMe-PS AOs designed to induce triple-exon skipping 2′OMe-PS AO cocktails. 




3771BExon 45 3772BExon 46 3773BExon 47 

























3775BSingle AO per exon cocktails (3 AOs) 
2452BCT-5 2453BAO45.1 [45A(+15+39)] 2454BAO46.1 [46A(-09+16)] 2455BAO47.2 [47A(+58+77)] 
2456BCT-6 2457BAO45.1 [45A(+15+39)] 2458BAO46.1 [46A(-09+16)] 2459BAO47.3 [47A(+83+102)] 
2460BCT-7 2461BAO45.1 [45A(+15+39)] 2462BAO46.3 [46D(+12-13)] 2463BAO47.2 [47A(+58+77)] 



















The first-generation cocktails consisted of two AOs targeting each of exons 45 and 46 that 
were challenging to skip, and a single AO targeting exon 47 that is more readily removed (Table 
5.2). These cocktails did not induce any measurable triple exon skipping in healthy control 
fibroblasts, with the only skipping observed corresponding in size to single and double exon 
skipping (Figure 5.8.a). The identity of the exons being skipped could not be simply determined 
by gel fractionation due to their similar sizes; 123, 126 and 117 bases for exons 45, 46 and 47, 
respectively. The use of additional primer sets revealed that each exon was skipped at low levels, 
generating the intermediate sized amplicons (data not shown). 
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572BThe same cocktails were tested in MFSΔ45-47 patient cells. No intermediate products were 
detected; however, the intensity of the full-length band was reduced (Figure 5.8.b). While the 
ratio of Δ45-47 transcripts to the full-length product was increased, considering the lack of triple 
exon skipping in the healthy control cells, we suggest that the loss of full-length product is due to 
knockdown rather than skipping. This knockdown could be the result of intron retention, 
incomplete pre-mRNA processing or undesired skipping. However, further investigation found 
no evidence to suggest that either of the exons containing the primer annealing sites were skipped, 
nor was there any intron retention (data not shown). We also note a five-AO cocktail increases 
the level of cell death, despite using the same total AO concentration; 200 nM and 50 nM, as used 
for previous screening experiments. 
1085B  
Figure 5.8: Evaluation of five-AO cocktails designed to induce exon 45-47 skipping. 
800BRT-PCR results from a) healthy control and b) MFSΔ45-47 patient fibroblasts treated with a cocktail of 2′OMe-PS AOs 
targeting exons 45, 46 and 47. Two concentrations, 200 nM and 50 nM, were tested, these are total cocktail 
concentrations and are made up of an equimolar ratio of each AO. The full-length (FL) transcript is 914 bp, the triple 
exon skipping (Δ45-47) transcript is 548 bp. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated 
control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. The relative density of each 
band was determined using Image J and is displayed in the graph as the proportion of total transcript contributed by 
each isoform. 
573BThe second generation of cocktails attempted to streamline triple-exon skipping by reducing 
the number of AOs with only a single AO for each exon. These cocktails were more effective 
than the five-AO cocktails and resulted in less cell death. All single-AO per exon cocktails (Table 
5.2) resulted in a laddered splicing pattern, with full-length, single exon skipping, double exon 
skipping and triple exon skipping being induced (Figure 5.9.a). Both CT-7 and CT-8 induced the 





574BTreatment with the second-generation cocktails resulted in a similar decrease in the intensity 
of the full-length product band without a proportionate increase in triple-exon or intermediate 
skipping products. The amplification of COL1A2 as a housekeeping gene transcript revealed that 
the relative amounts of PCR product in each well are similar (Figure 5.9.a and b). When the 
proportion of each transcript in patient samples was normalised against the AO control, the total 
amount of transcripts is noticeably reduced in the majority of treated samples (Figure 5.9.c). 
575BTreatment of patient fibroblasts with any of the four cocktails, CT-5, CT-6, CT-7, or CT-8 
resulted in an increase in the Δ45-47 transcript product (Figure 5.9.a and c). However, in the 
healthy control cells, only CT-7 and CT-8 were shown to induce a robust amount of triple-exon 
skipping (Figure 5.9.a). In addition, the CT-7 formulation contains AO47.2 that was previously 
shown to be the most effective AO at inducing exon 47 skipping; therefore, CT-7 was chosen for 
further study. The exon 45 and 46 AO sequences, as well as the 30-mer version of AO47.2, were 
synthesised as PMOs. 
576BWe also tested four cocktails with two exon 45 AOs and one exon 47 AO, but no AO targeting 
exon 46 (Table 5.2). These were designed to determine if the exon 45-47 region could be skipped 
as a single unit by targeting only the flanking exons. This approach has been previously described 
for DMD where two AOs, one targeted to exon 45 and the other to exon 51 of the DMD gene, 
resulted in the skipping of the entire regions between the two exons.209 The cocktails in this study 
did not result in any triple exon skipping, although they did result in both single and double exon 
skipping (Figure 5.9.a and b). 
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1086B
Figure 5.9: Evaluation of additional cocktails designed to induce exon 45-47 skipping. 
801BCocktails of AOs targeted to exon 45, 46 and 47, or 45 and 47 alone, were transfected into a) healthy control and b) 
MFSΔ45-47 fibroblasts at two concentrations: 200n M and 50 nM. The Full-length (FL) transcript is 914 bp, the triple exon 
skipping (Δ45-47) transcript is 548 bp. The values below the first gel image indicate the percentage of ∆45-47 
transcripts in each sample. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR 
negative control. 100bp molecular marker used for size reference. c) The relative abundance of each isoform in, 
MFSΔ45-47 fibroblasts, as a proportion of total transcripts normalised against the control sample.  
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Evaluation of PMO cocktails for triple exon skipping 
577BWe have shown that the relatively efficient 2′OMe-PS AO47-2 sequence translated into an 
efficient PMO. However, the ‘best’ sequences for exons 45 and 46 induced minimal exon 
skipping as 2′OMe-PS AOs. Therefore, it was unknown what effect the PMO chemistry would 
have on the efficiency of these sequences. Nevertheless, the AO sequences for exons 45 (AO45.1) 
and 46 (AO46.3), that were found to be most effective when used as a cocktail with AO47.2, were 
synthesized as PMOs. An additional sequence targeting exon 47; a 30-mer version was also 
synthesised as a PMO. 
Optimisation of cocktail concentration 
578BCocktails of PMO45, PMO46 and either the original 20-mer PMO4720 or longer 30-mer 
PMO4730 (Table 5.3) were nucleofected into MFSΔ45-47 patient fibroblasts. The efficiency of triple 
exon skipping was determined after incubation for ten days. Originally cocktail concentrations of 
250 µM and 50 µM were tested. These concentrations are calculated in the 20 µl cuvette of the 
nucleofector system and are the total PMO concentration made up of equimolar amounts of each 
AO. Neither concentration induced sufficient triple-exon skipping and the intermediate products 
were likely too abundant to be able to provide any potential benefit (Figure 5.10.a). 
759BTable 5.3: Optimal triple-exon skipping cocktails. 




3780BExon 45 3781BExon 46 3782BExon 47 
2484BCT-7 2485BAO45.1 [45A(+15+39)] 2486BAO46.3 [46D(+12-13)] 2487BAO47.2 [47A(+58+77)] 
2488BCT-720 2489BPMO45 [45A(+15+39)] 2490BPMO46 [46D(+12-13)] 2491BPMO4720 [47A(+58+77)] 
2492BCT-730 2493BPMO45 [45A(+15+39)] 2494BPMO46 [46D(+12-13)] 2495BPMO4730 [47A(+53+82)] 
579B 
To identify the PMO concentration required to achieve sufficient skipping a concentration 
titration with two additional total cocktail concentrations; 720 µM and 150 µM, was performed. 
These results reveal that while there is no defined dose-response below 250 µM, the higher 750 
µM concentration induces up to 78% triple-exon skipping (Figure 5.10.b). We also note that the 
cocktail is more efficient with PMO4730 than with PMO4720. The CT-730 formulation induces 
both more triple-exon skipping and less intermediate transcripts (Figure 5.10.b). 
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1087B
Figure 5.10: Optimisation of PMO concentration required to induce exon 45-47 skipping. 
802BTwo cocktails of PMOs targeting exons 45, 46 and 47 were nucleofected into MFSΔ45-47 patient fibroblasts at a total 
cocktail concentration of a) 250 µM and 50 µM or b) 750 µM, 250 µM, 150 µM and 50 µM. Concentrations are 
calculated in 20 µl transfection volume and are the total concentration of the cocktail containing equimolar amounts of 
each PMO. Treated cells were collected for RNA analysis after ten days. The full-length (FL) transcript is 914 bp, the 
triple exon skipping (Δ45-47) transcript is 548 bp. The values below each gel image indicate the percentage of exon 
45 (∆45) or 46 (∆46) skipped transcripts in each sample. GTC: Gene Tools control PMO used as a sham treatment, 
UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. 
Effect of triple-exon skipping on fibrillin1 fibre formation 
580BUsing the optimised cocktail; CT-730, and concentrations; 750 µM and 150 µM, both healthy 
control and MFSΔ45-47 patient fibroblasts were nucleofected then incubated for 4- or 10-days. 
Treated cells were collected for both RNA analysis and immunofluorescence staining, the results 
of which are shown in Figure 5.11. 
581BAs reported in previous chapters, exon skipping efficiency was reduced after ten days 
compared to the 4-day time point (Figure 5.11.a and b). The proportion of intermediate products, 
however, was greater after ten days. This increase in intermediate products could indicate that the 
single and double exon skipped transcripts are more readily produced or accumulate with time 
than the triple-exon skipped products. Another difference between the two time-points is the 
additional product present below the Δ45-47 transcript products at four days (Figure 5.11.a). This 
band was confirmed via Sanger sequencing to be lacking exons 45, 46, 47 and 48 (Δ45-48) in 
their entirety (Figure 5.11.a and d). The Δ45-48 transcript product is lost after ten days; this could 
mean that this product is either diluted by cell growth and lost due to low initial abundance, or 
susceptible to degradation. 
582BImmunofluorescent staining of treated cells revealed the expected strong fibrillin-1 fibres in 
the untreated, and GTC treated healthy control cells (Figure 5.11.c.iii and iv). However, patient 
control samples presented with diffuse fibrillin-1 staining throughout the cells on the coverslip, 
with no fibre formation (Figure 5.11.c.vii and viii). In both healthy control and patient cells treated 
with either concentration of CT-730, a severe reduction in overall fibrillin-1 abundance was 
observed (Figure 5.11.c). This reduction was particularly noticeable in the 150 µM treated healthy 
control cells where no fibrillin-1 staining was observed (Figure 5.11.c.ii). The diffuse fibrillin-1 
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staining seen in the untreated patient cell line was also absent after PMO47 treatment (Figure 
5.11.c.v and vi).  
583BThe treatment of either cell line with 750 µM of CT-730 resulted in the formation of fibrillin-
1 aggregates. The morphology of these aggregates was dissimilar to fibrillin-1 fibres seen 
previously, with staining of low-intensity fibres linking ‘spots’ of high intensity (Figure 5.11.c.i, 
v and vi). The same staining pattern was observed in MFSΔ45-47 cells treated with 150 µM of CT-
730, which is to be expected as they have a similar proportion of Δ45-47 transcripts; 78% and 77% 
for 750 µM and 150 µM respectively (Figure 5.11.a). 
584BThe efficiency of triple-exon skipping after four days; up to 78% (Figure 5.11.a), is lower than 
that achieved with PMO52 or PMO47, both of which result in the formation of fibrillin-1 fibres. 
This lower triple exon skipping efficiency, combined with intermediate skipping products, is 
likely why we see no fibrillin-1 fibre formation. We also note that while the triple-exon skipping 
is more efficient after 4-days, this time point is also associated with the presence of the Δ45-48 
transcript product. The Δ45-48 transcripts account for up to 24%, and 18% of total transcripts in 
healthy control and MFSΔ45-47 fibroblasts respectively (Figure 5.11.a) and the resulting fibrillin-1 
isoform; if synthesised, is likely to interact negatively with the other isoforms present.
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Figure 5.11: Evaluation of triple exon skipping mediated by a PMO cocktail. 
Healthy control and MFSΔ45-47 fibroblasts nucleofected with a cocktail of PMO45, PMO46 and PMO4730, a Gene Tool control PMO (GTC) or left untreated (UT). Two concentrations were tested; 750 µM 
and 150 µM, calculated in the 20 µl nucleofection cuvette volume. RT-PCR amplicons from cells collected a) 4 days and b) 10 days after transfection showing transcript products between FBN1 exons 
42 and 49. The values below each gel image indicate the percentage of ∆45-47 transcripts in each sample. -ve: RT-PCR negative control. 100bp molecular marker used for size reference. c) Representative 
images of treated cells (4 days) stained for fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale bar = 20 µm. See Figure A3.3 for 
a larger version of part c. d) Analysis of Sanger sequencing of the FL, Δ45-47 and Δ45-48 products confirming their identity. 
111 
5.7 Discussion 
585BThe application of AOs to alter exon selection to restore the reading frame, or re-establish 
homogeneity between fibrillin-1 proteins, has been discussed throughout this thesis. However, 
the focus has been on the removal of a single exon to overcome a mutation, in a personalised 
approach. This chapter explored the possibility of multi-exon skipping to increase the proportion 
of patients that would be amenable to a single therapeutic preparation. Here we report two 
strategies that could address mutations affecting exons 45, 46 and 47. The first, as previously 
described, is the more personalised approach of skipping each exon individually. The second 
strategy is to induce multi-exon skipping, the excision of all three exons simultaneously. If 
efficient triple exon skipping could be achieved and the resulting protein isoform was functional, 
this strategy would be amenable to 5% of total mutations; more than any single exon skipping 
approach. 
586BThis study had four key findings: (1) Fibrillin-1 exons 45 and 46 are challenging to skip; (2) 
Exon 47 is readily skipped, and its efficient removal results in the re-appearance of fibrillin-1 
fibres; (3) While triple-exon skipping is possible, the current study was unable to demonstrate 
sufficient exon skipping in order to assess fibrillin-1 fibre formation and (4) A single mutation 
can result in multiple outcomes. While we show here that both single and triple-exon skipping are 
promising therapeutic strategies for MFS, there are many limitations to this study that in turn, 
limit the conclusions that can be made, including; inefficient skipping, imbalance in skipping 
efficiency, lack of synergistic AO effects, and unexpected exon skipping. These findings, 
limitations and future research directions are discussed in more detail below. 
Imbalance in skipping efficiency 
587BFor the first time, we describe two FBN1 exons that were not readily skipped with at least one 
of the initial AOs tested. Exons 45 and 46 proved extremely difficult to skip using 2ʹOMe-PS 
AOs, even when combined into two-AO cocktails. Calculation of the splice site scores for exons 
45 and 46 revealed them to be average or above average for constitutive exons and of a similar 
strength to exon 47,216 suggesting splice site strength is not the cause of the inefficient skipping 
observed here. However in silico analysis of the mRNA secondary structure of exon 45, 46 and 
47 using the online tool, RNAfold.217 shows the predicted effect of AO binding. The predicted 
structure of exon 45 mRNA is made up of hair-pin loops, to one of which PMO45 binds, 
indicating the AO must overcome strong secondary structures in order to anneal (Figure A3.4.a). 
The exon 46 mRNA has a similarly simple hair-pin loop structure (Figure A3.5.a). For both exons 
AO binding significantly alters the predicted structure leading to a more complex structure with 
additional hair-pin loops. We speculate that this altered secondary structure influences splicing 
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factor binding, limiting the efficacy of the AOs. Conversely binding of PMO4720 does not appear 
to significantly alter the predicted exon 47 mRNA secondary structure (Figure A3.6) 
588BAn additional sequence was designed to target each exon, meaning almost the entire exon was 
assessed for AO target sites (Figure A3.1). However, no AO targeting either exon induced more 
than 10% skipping. Despite evaluating the majority of the exon sequence, the ‘optimal’ AO 
sequence was not identified. A strategy that evaluates the entire exon for all possible AO target 
sites would reveal the most efficient sequence. However, there are 149 possible 25-mers across 
exon 45 alone, adding 25 bases of flanking intron at the donor and acceptor sites, and considering 
limitation on resources make this approach unfeasible. Nevertheless, further optimisation of the 
sequences targeting exons 45 and 46 is undoubtedly required. Identification of a more efficient 
AO could both enable comparison between single and multi-exon skipping and increase multi-
exon skipping efficiency. However, it needs to be noted that AO-mediated exclusion is not 
necessarily applicable to every one of the 60 in-frame FBN1 exons and therefore the cost of 
investigation must be weighed against the benefits to determine practical targets. 
589BContrary to the minimal skipping efficiency of AOs targeting exons 45 and 46, exon 47 was 
much more readily skipped. Of the nine AOs tested in total, seven AOs induced exon skipping, 
albeit at different efficiencies. In particular, the AO47.2 and PMO47 sequence was found to 
induce extremely efficient exon 47 skipping in both healthy control and patient fibroblasts. Not 
only was the exon 47 skipping efficient but immunofluorescent staining of treated cells mirrored 
that seen when skipping exon 52. Fibrillin-1 fibre formation was lost entirely after approximately 
50% skipping of exon 47 was induced, and then fibres were able to be formed when more than 
80% exon skipping was induced. These results further support the concept that identical fibrillin-
1 monomers can assemble into fibres despite being internally truncated. 
590BThe imbalance in skipping efficiency between the three exons is the likely cause of the 
intermediate transcript products we observe. One way Adams et al.167 achieved greater multi-exon 
skipping was by altering the ratios of each AO in the cocktail, increasing or decreasing the amount 
of an AO depending on its ability to skip targeted exons. Changing the AO ratio resulted in fewer 
intermediate products with skipping of just one exon and a higher proportion of the desired 
transcript.167 The same could be applied to the FBN1 AOs discussed here. By increasing the ratio 
of PMO45 and PMO46 in relation to PMO47, the overall triple-exon skipping efficiency could 
be improved. 
591BAn additional question left unanswered by this study is; are different ratios of AOs required 
for different mutation types and mutations in each of the three exons? In both the healthy control 
and MFSΔ45-47 models used, each exon is present at equal levels in the endogenous transcript. 
However, treatment of MFSΔ47 may require a different ratio of exon 47 to exon 45 and 46 AOs to 
be effective, since only ~50% of the transcripts contain exon 47. If a different ratio is required, 
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the multi-exon skipping approach is unlikely to be an effective therapeutic strategy; therefore, 
these factors need to be fully explored. 
Absence of AO synergy 
592B ased upon earlier DMD exon skipping studies, some AO sequences are known to work 
synergistically when combined, while others work additively or even antagonistically.167 
However, it is unknown what characteristics of the AO influence this relationship. The PMO45, 
PMO46 and PMO4730 sequences used here do not appear to have a synergistic relationship when 
combined into a cocktail. A high concentration of each AO is required to achieve relatively 
efficient skipping of its respective exon. The initial exon skipping attempt with the PMO cocktail 
at a total concentration of 250 µM, which was effective for PMO47, PMO52 and PMO59, was 
inefficient when attempting to induce triple exon skipping. The AOs discussed here may lack 
synergy due to their individual inefficiencies, however, Adams et al.167 reported that synergistic 
cocktails do not always result from the most efficient AOs and that two ineffective AOs can work 
synergistically. We speculate this is due to one AO binding and altering the mRNA secondary 
structure sufficiently to allow the second AO to bind to its target. However, it is also probable 
that AO synergy works differently when the AO sequences target different exons. As discussed 
previously, one of the most effective and achievable ways to increase AO efficiency and possibly 
synergy is optimising the sequences themselves or altering the ratios of each AO in the cocktail. 
593BApart from the clear requirement for extremely efficient exon skipping to create a homogenous 
population of fibrillin-1 proteins, increasing AO efficiency and synergy could allow for the use 
of lower cocktail concentrations. The high concentration of PMOs used in this study would lead 
to more expensive treatment and an increased risk of off-target and side effects. Currently 
approved AO therapies for DMD cost upward of $US300,000 per year218,219 meaning every effort 
should be made to increase efficiency and decrease the cost of these drugs. A longer AO length 
decreases the likelihood of the AO being complimentary to a sequence other than its intended 
target and has been linked with increased activity,220 however, shorter AOs are more cost effective 
to synthesise. Here we demonstrated that the 30-mer version of PMO47 was more effective at 
mediating triple-exon skipping along with PMO45 and PMO46. However, the 20-mer PMO47 
sequence was extremely efficient at inducing skipping of exon 47 alone. In circumstances where 
20-mer and 30-mer AO sequences result in a similar exon skipping efficiency, other
considerations such as cost, and ease of synthesis become more relevant. 
Functionality of fibrillin-1Δ45-47 
594BFibrillin-1 exons 45, 46 and 47 all encode for cbEGF-like domains. The cbEGF-like domains 
bind to calcium, essential for fibrillin-1 stabilisation, tertiary structure, protein-protein 
interactions and protection against proteolysis.21,221,222 Calcium-binding relies on the structure of 
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a cbEGF-domain that in-turn is determined by the disulphide bonds formed between conserved 
cysteine residues within each domain.214,222 It is well established that heterozygous mutations 
affecting these domains; generally associated with disrupting domain structure and calcium-
binding, cause MFS.2,3 However the function and stability of the fibrillin-1Δ45-47 isoform in the 
presence only of other fibrillin-1Δ45-47 monomers is unknown. 
595BThe results of this study are unable to demonstrate that the fibrillin-1Δ45-47 protein is functional. 
The skipping achieved was insufficient to result in only one fibrillin-1 isoform; thus, no fibre 
formation was observed. However, we did show that efficient removal of exon 47 does result in 
fibre formation, suggesting possible redundancy in the cbEGF-like domains. However, further 
functional analysis of the internally truncated proteins produced is required to determine if they 
can perform their other functions such as interaction with microfibril associated proteins and 
regulation of TGF-β.  
596BHomozygous mutations could provide insight into the effect of 100% exon skipping. However, 
no homozygous deletions of this region, or any similar region, have been reported; therefore, the 
resulting phenotype is unknown if there is one. Of the ten reported homozygous FBN1 mutations 
associated with MFS, none are deletion mutations.3,223 Two of the homozygous mutations 
reported affect the first base of an exon; c.6998A>C3 and c.7454A>T32 potentially altering pre-
mRNA splicing. The c.6998A>C mutation was never studied at the cDNA level, so it is unknown 
if this mutation results in altered splicing. However, Hilhorst-Hofstee et al.32, confirmed that the 
c.7454A>T mutation did not result in aberrant mRNA splicing. The lack of homozygous deletions
and splicing mutations could be explained by one of the following; they have yet to be identified 
due to low frequency of homozygous mutations, they are embryonic lethal, or they do not result 
in an MFS phenotype. 
Unexpected exon 48 skipping 
597BThe majority of transcript products observed when efficiently inducing triple-exon skipping 
was the expected Δ45-47 product; however, an additional splicing product was also created. This 
transcript was confirmed to result from exon 45-48 skipping. The Δ45-48 transcript maintains the 
reading frame and is therefore capable of being translated into a protein. The presence of the Δ45-
48 and Δ45-47 transcript products, along with traces of full-length, single-exon skipping and 
double exon skipping products means there are up to nine different transcripts generated. Each 
transcript could be translated into a different fibrillin-1 isoform, each interacting negatively with 
one another. The expected outcome of which is the absence of fibrillin-1 microfibril formation 
precisely as we observed. 
598BOne possible mechanism for this unexpected exon skipping is non-sequential intron removal. 
The supraspliceosome model outlined by Shefer et al.224 suggests that the supraspliceosome is 
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composed of four active spliceosomes connected by a single pre-mRNA, enabling the splicing of 
four introns simultaneously. However, intron removal is not necessarily in numerical order.224 
Following this model the removal of introns 47 and, or 48 may occur prior to introns 45 or 46 and 
as a consequence exon 48 is removed along with the exon 45-47 region. The order of removal for 
the introns in the FBN1 exon 45-48 region could be assessed using a method outlined by Kessler 
et al.225 and recreated by Ham et al.226. By determining the order of intron removal, we might 
reveal the mechanism behind the unexpected exclusion of exon 48 that we observe. 
599BThe skipping of exon 48 without being targeted by an AO is interesting as it mirrors a study 
described by Aartsma-Rus et al.209 in which a two AO cocktail was sufficient to induce skipping 
of a seven-exon region at very low levels; 45-51, in the DMD gene. We evaluated a similar 
strategy to induce the skipping of exons 45-47 with AOs targeting only exons 45 and 47. 
However, consistent with the DMD example this strategy was ineffective, resulting only in single 
and double exon skipping. This strategy may only apply to ready skippable exons or those AOs 
that naturally induce multi-exon skipping despite having only a single target. Therefore, skipping 
of the exon 45-47 region with only two AOs, considering the recalcitrant nature of exons 45 and 
46 and poor triple-exon skipping with three AOs, is unlikely to be a viable strategy. 
600BThe ability to induce exon 48 skipping without a specific AO targeting the exon, suggests that 
exon 48 is potentially highly amenable to the splice-stitching strategy. Determining which of the 
PMOs in CT-730 leads to exon 48 exclusion could also prove useful. If occurring due to a single 
PMO, changing this AO sequence could abolish the quadruple-exon skipping effect decreasing 
the number of undesired transcripts. Alternatively increasing the proportion of exon 45-48 
skipped transcripts could allow for the treatment of patients with mutations in any of these four 
exons. Reducing the number of AOs required in a cocktail could also allow for more manageable 
cocktail concentrations with more efficient skipping results. Major challenges for multi-exon 
skipping strategy will include safety testing and the requirement for approval of multiple 
sequences, especially when some AOs would not be necessary for some mutations. The multi-
exon skipping strategy is very ambitious and may prove impracticable, especially for FBN1, 
however, testing our hypothesis led to the identification of a promising candidate for exon 47 and 
demonstrated that the concurrent skipping of multiple FBN1 exons is possible. 
Alternate mutation outcome 
601BThe mutation harboured by MFSΔ47; c.5788+5G>A splicing mutation resulting exon 47 
skipping, was one of the first recurrent mutations to be identified and reported in over 30 different 
cases making it the second most frequent mutation.2,3 In this study, we determined that the 
outcome of this splice site mutation, in this particular patient cell line, is twofold with the co-
occurrence of the expected skipping of exon 47 as well as retention of exon 47, with a 33 base 
116 
insertion of intron 47 (FBN1+33b). This insertion is in-frame and is predicted to result in eleven 
additional amino acids between the 28th and 29th cbEGF-like domains. 
602BWe suggest that this aberrant splicing results from activation of a predicted cryptic donor splice 
site within intron 47.215 In silico analysis comparing the ‘strength’ of the natural, c.5788+5G>C 
and predicted cryptic donor sites showed that the mutation results in the expected decrease in 
consensus value of more than 10% signifying the sites disruption (Table A3.1).215 Furthermore 
the ‘strength’ of the cryptic splice site (82%) confirms that it is likely able to be utilised as a donor 
splice site.215 The same cryptic splicing and 33 base insertion has been described previously, 
however, was associated with a c.5788+1 mutation.227 This was the first, and largest, reported 
FBN1 cryptic splicing event that results in a stable fibrillin-1 protein with additional amino 
acids.227 To our knowledge, there are no reports of co-existence of the FBN1Δ47 and FBN1+33b 
transcripts nor the fibrillin-1 isoforms they encode. 
603BThe co-existence of these splicing products is predicted to further exacerbate the Marfan 
phenotype in this patient. Hutchinson et al.227 showed that the 33 base insertion leads to the 
delayed secretion of resulting fibrillin-1 isoform. The synthesis of the fibrillin-1 isoform encoded 
by the FBN1+33b transcript is also mildly reduced; to 89% of the healthy control183 together these 
findings suggest the mutation results in haploinsufficiency. However, in this patient the mutation 
is classified as group IV since it results in a severe reduction in fibrillin-1 deposition in the 
extracellular matrix; 11% of the healthy control.69,183 These findings combined demonstrate 
characteristics of both the haploinsufficiency and dominant negative pathogenesis models. 
Encouragingly PMO47 appears to target the cryptic splicing product with equal affinity as to the 
full-length. Thus, treatment of MFSΔ47 with PMO47 results in the complete elimination of the 
FBN1+33b transcript products. 
Conclusions 
604BThis chapter showed that triple-exon skipping can be achieved in vitro, albeit requiring a 
higher concentration than single exon skipping. Due to disruption by several undesired 
intermediate splicing products, we could not confirm if the fibrillin-1Δ45-47 isoform is capable of 
forming fibres. However, we did demonstrate that much like exon 52, skipping of exon 47 alone 
is both efficient and results in the formation of fibrillin-1 fibres in MFSΔ47 patient cells. While 
these results do not discount the multi-exon skipping strategy, they provide even more support 
for the single skipping approach. For MFS, multi-exon skipping is an ambitious strategy. Further 
optimisation to produce an ideal AO cocktail could allow for the treatment of many more 
mutations with fewer drugs making it a worthwhile path to pursue, however, this is not currently 
viable. Overall this chapter provides additional evidence for the applicability of antisense 
oligonucleotides in treating the type-1 fibrillinopathies.
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Chapter 6 
Alternative Targets and  




 Fibrillin-1 structure and potential targets 
605BIn this thesis so far, we have discussed successful development of antisense oligonucleotides 
(AO) sequences targeting exons 47, 52, 59 and 45-47 of the fibrillin-1 gene (FBN1). However, 
the nature of this splice-switching strategy means that a different AO is required for each targeted 
exon. Assuming 100% effectiveness for all mutation types, which we acknowledge is unrealistic, 
the AOs described in previous chapters are effective against approximately 7.7% of all fibrillin-1 
mutations. However, FBN1 is a large gene spanning over 200Kb with an 8613 base coding 
sequence separated into 65 exons.6 Disease-causing mutations are found in all 65 exons and are 
distributed relatively evenly across the gene. Therefore, other amenable exons should be 
identified to develop a suite of optimal AO sequences. 
606BTo reiterate, the domain structure of fibrillin-1 is highly repetitive. Fibrillin-1 consists of a 
large number of cysteine-rich domains, including four epidermal growth factor-like (EGF-like) 
domains, 43 EGF-like domains with an additional calcium-binding motif (cbEGF-like), seven 
TGF-β binding protein-like (TB) domains and two hybrid-domains20,21 (Figure 6.1). While each 
domain's exact functions are unknown, the various domain types have been associated with 
different features of the fibrillin-1 protein.22,23,228 
607BThe interaction of the cbEGF-like domains and calcium is essential for the stability of fibrillin-
1 and protection from proteolysis.23 Due to the abundance of cbEGF-like domains, most fibrillin-
1 mutations occur in these domains, many of which directly affect their ability to bind to 
calcium.2,3 Thus far, all the exons targeted in this thesis; except exon 52, encode cbEGF-like 
domains. These exons were initially chosen due to the abundance of the cbEGF-like domain that 
indicates the possibility of functional overlap and thus redundancy. The skipping of these exons 
has been relatively efficient, and some formation of fibrillin-1 fibres has been observed. 
Therefore, we designed AOs to target additional cbEGF-like domains encoded by in-frame exons 
15, 16, 26, 27, 31, 32, 44, and 49 (Figure 6.1). 
608BThe fibrillin-1 protein contains seven TB domains encoded by a total of 12 exons. Little is 
known about the exact function of the TB domain. However, they have been associated with the 
construction of the extracellular matrix and storage of latent TGF-β.228–230 These two functions 
are essential for the extracellular matrix's stability and, consequently mutations in these domains 
have been associated not only with Marfan syndrome, but also non-marfanoid type-1 
fibrillinopathies such as acromicric dysplasia.3,57 We note that exon 52, which encodes the C-
terminal portion of the 6th TB domain, is readily skipped and its efficient removal results in re-
appearance of fibrillin-1 fibres in a patient cell line carrying a splicing mutation. To accomplish 
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similar outcomes elsewhere in the fibrillin-1 molecule, we designed AOs targeting exon 39 that 
makes up the C-terminal portion of the 4th TB domain (Figure 6.1). 
609BLastly, the third type of cysteine-rich motif is the hybrid domain. Fibrillin-1 consists of two 
hybrid-domains that share similarities with both the EGF-like and TB domains.21 The hybrid 
domains have been shown to play an integral role in fibrillin-1 folding and microfibril 
assembly.21,22 The effect of exon skipping of this target has not yet been described. Therefore, we 
designed AOs targeted to exon 22 that encodes the N-terminal portion of the second hybrid 
domain to investigate the outcome (Figure 6.1). 
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Figure 6.1: Fibrillin-1 gene map. 
804BEach box indicates an exon with the exon number and exon length in bases shown inside. Chevron sides indicate 
exons bounded by partial codons. The domain encoded by each exon is indicated by coloured fill. Exons donned by a 
red cross are not amenable to splice-switching strategies as their removal would disrupt the reading frame or contains 
the start codon or stop codon. Black bars indicate the approximate binding sites of AOs tested with the 2′OMe-PS 
chemistry, Yellow bars indicate those AO that were tested as both 2′OMe-PS and PMO. 
Antisense oligonucleotide chemistries 
610BAntisense oligonucleotides are versatile tools that can be utilised to manipulate gene 
expression in several ways, depending on the chemistry. RNase-H dependent chemistries are 
generally used to induce transcript degradation and the “classical” antisense down-regulation 
approach.108–110 However, this thesis focuses on RNase-H independent chemistries that can anneal 
to and physically block motifs in the target sequence to redirect splicing.113 This class of steric 
blocking AO can mediate exon inclusion105 or exclusion,106,107 induce transcription inhibition111 
or inhibit translation.112  
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611BThe 2′OMe-PS and PMO chemistries have been the focus of this thesis due to their respective 
advantages in the screening process and in vivo or clinical setting. The phosphorothioate (PS) 
backbone modification was introduced to overcome the high susceptibility of the phosphodiester 
backbone to nucleases, that generally resulted in AOs with a very short half-life.231 The 
replacement of the non-bridging oxygen with sulphur to form the PS backbone confers greater 
stability to the AO, thereby increasing its half-life. The negative charge of the PS backbone allows 
for relatively efficient cellular uptake in a variety of cell type in vitro.232 The PS backbone also 
increases AO affinity for serum proteins such as heparin, allowing the AO to be maintained in 
circulation for longer and delaying its removal by the liver.117 However, this protein binding and 
other off-target effects have been associated with increased toxicity.113,118  
612BThe PS backbone modification can be used in combination with the 2′-O-methyl (2′OMe), 
modification to the sugar moiety, producing the 2′OMe-PS chemistry (Figure 6.2). This 2′ 
modification engenders RNA properties and results in an increased affinity of the AO for the 
target and increased nuclease resistance, further extending the AO half-life. Another key feature 
is the inability of 2′-modified AOs to recruit and induce RNase-H activity.233,234 This RNase-H 
independence eliminates the applicability of the AO to RNase-H mediated RNA downregulation, 
but enhances their steric blockade applications. 
613BThe PMO chemistry is of particular interest for this study due to the high binding affinity,113 
specificity,118,122 nuclease resistance121 and importantly, excellent safety profile.123–125 The PMO 
chemistry replaces the deoxyribose sugar and negatively charged backbone with morpholine 
rings, joined by phosphorodiamidate linkages (Figure 6.2).120 The neutral charge of the PMO 
chemistry allows the AO to bind to RNA or DNA with higher specificity and affinity, while not 
recruiting RNase-H, thereby making these compounds excellent steric blockers. Due to these 
advantages, and their incredible stability, PMOs have been studied extensively in animal models 
and clinical trials, and are recognised as both safe and effective in a clinical setting.123–125. On the 
other hand, the neutral charge leads to decreased plasma half-life and inefficient cellular uptake.113 
Nevertheless several PMO compounds have received accelerated approval for DMD.140,142,164 
These PMOs are well tolerated, even at the relatively high doses used.144,235 In addition, among 
other strategies, PMOs can and have been conjugated with cell penetrating peptides that have 
proven very efficient at increasing the delivery of the PMO to target tissues.236,237 Clinical trials 
are currently underway for peptide conjugated PMO compounds for the treatment of DMD.238,239 
614BThis chapter investigates a third more recently described chemistry called the 
Thiophosphoramidate Morpholino Oligomer (TMO). The TMO chemistry incorporates features 
of both the PMO and 2′OMe-PS chemistries to form a morpholino-PS hybrid (Figure 6.2). The 
use of a thiophosphoramidate backbone, rather than a phosphorodiamidate backbone, allows the 
oligomer to be more readily generated on conventional nucleic acid synthesisers, and enables the 
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incorporation of other chemical modifications such as 2′OMe, 2′-O-methoxyethyl.240 The 
morpholine ring rigidity results in high affinity for RNA and the combination of morpholino bases 
and phosphorothioate linkages results in excellent stability against nucleases. While the synthesis, 
stability and pharmacokinetics of this AO chemistry are now more established,240 the chemistry 
is still relatively new. Therefore, we aim to evaluate the efficiency of TMOs at inducing fibrillin-
1 exon skipping and compare this chemistry to both the 2′OMe-PS and PMO chemistries used 
previously. 
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Figure 6.2: Chemical representation of PMO, TMO and 2′OMe-PS compounds 
805BFigure modified from Langner et al.240 and Kole and Krieg241 
6.2 Additional FBN1 targets 
Antisense oligonucleotide design 
615BTo minimise screening costs, three AOs were designed for each targeted exon for the initial 
screen. In general, one AO was designed to cover each of the canonical splice sites and a third 
AO designed to target a region predicted to be rich in ESE sites. Upon the identification of strong 
exon skipping potential, further overlapping sequences were designed around the most efficient 
AO. As previously, two unrelated sequences were used as a sham control, one for each chemistry. 
These controls allow for the assessment of any sequence-independent chemistry-related effects. 
All AOs tested in this chapter are described in Table 6.1. Exon sequence maps showing the AO 
binding sites in relation to enhancer and silencer motifs predicted by SpliceAid153 are presented 
in the supplementary Figure A4.1. 
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760BTable 6.1: List of antisense oligonucleotides used in Section 6.2 
737BThe target exon, name, ID, Sequence and chemistry of the AOs screened in Section 6.2. The AO nomenclature is 




3785BID 3786BSequence (5′-3′) 3787BChemistry 
3788BExon 15 
2496B15A(-15+10) 2497BAO15.1 1219BUCA UCC AUA UCU GAA AAU ACA AAA C 2498B ′OMe-PS 
2499B15A(+41+65) 2500BAO15.2 1220BACU GCC AUC UUC AUU GAU ACA CAU U 2501B ′OMe-PS 
2502B15D(+12-13) 2503BAO15.3 1221BUUA UAG CAC GAA CCU UUG CAA UAA C 2504B ′OMe-PS 
3789BExon 16 
2505B16A(-14+11) 2506BAO16.1 1222BCUC GUU AAU GUC UGU GGC AGA GAA A 2507B ′OMe-PS 
2508B16A(+27+51) 2509BAO16.2 1223BUGA CGC AAC GCC CAU UCA UGC AGA U 2510B ′OMe-PS 
2511B 6D(+14-11) 2512BAO16.3 1224BUGU UUU CUU ACC AAC ACA CAC ACG G 2513B ′OMe-PS 
2514B 6A(+22+46)  2515BAO16.2+5 1225BCAA CGC CCA UUC AUG CAG AUC CCA G 2516B ′OMe-PS 
2517B 6A(+32+56)  2518BAO16.2-5 1226BAGU GUU GAC GCA ACG CCC AUU CAU G 2519B ′OMe-PS 
2520B16D(+09-16)  2521BAO16.3-5 1227BCAU GAU GUU UUC UUA CCA ACA CAC A 2522B ′OMe-PS 
3790BExon 22 
2523B 2A(-13+12)  2524BAO22.1 1228BCCU UGA UGG UUU CUG CAG AGG AGG G 2525B ′OMe-PS 
2526B 2A(+45+69)  2527BAO22.2 1229BUGG CUC CAU UGA UGU UGA UCU CAC A 2528B ′OMe-PS 
2529B 2A(+84+108) 2530BAO22.3 1230BCAC GCA GCA CCG AGG GAG GAG CAG C 2531B ′OMe-PS 
2532B 2D(+16-09) 2533BAO22.4 1231BUUC UCU UAC CAA CUU GGC AUA GGG U 2534B ′OMe-PS 
3791BExon 26 
2535B 6A(-18+07) 2536BAO26.1 1232BUUG AUA UCU UCA AGA AUA AGA AAA U 2537B ′OMe-PS 
2538B 6A(+70+94) 2539BAO26.2 1233BAAG CCG CUG UCA CAC CUG CAC UUA A 2540B ′OMe-PS 
2541B 6D(+22-03) 2542BAO26.3 1234BGAC CUG UGC AGU UCC UUU CUU CAG A 2543B ′OMe-PS 
2544B 6A(+75+99)  2545BAO26.2-5 1235BGAG CAA AGC CGC UGU CAC ACC UGC A 2546B ′OMe-PS 
2547B 6A(+100+124)  2548BAO26.3+5 1236BGUG CAG UUC CUU UCU UCA GAA UCA A 2549B ′OMe-PS 
3792BExon 27 
2550B 7A(-25-01) 2551BAO27.1 1237BCUG CAC AAA AAC AGC AAG UGG CAG C 2552B ′OMe-PS 
2553B 7A(+38+62) 2554BAO27.2 1238BAGG GGU GUU CAC ACA CUG GCC UCU G 2555B ′OMe-PS 
2556B 7A(+105+129) 2557BAO27.3 1239BCCA UGC AGU UCU UCA UCA UCA UGA A 2558B ′OMe-PS 
3793BExon 31 
2559B31A(-21+04) 2560BAO31.1 1240BAUG UCU GCA AAG AAU AAA ACC AAC A 2561B ′OMe-PS 
2562B31A(+76+100) 2563BAO31.2 1241BGCC AUG AAU CCA UCA UAA CAC AAG C 2564B ′OMe-PS 
2565B31D(+13-12) 2566BAO31.3 1242BUUC UUU GCU UAC CUA CAC AAG UCU U 2567B ′OMe-PS 
3794BExon 32 
2568B32A(-13+12) 2569BAO32.1 1243BACU CAU UGA CAU CUG UAA AAC AUA U 2570B ′OMe-PS 
2571B32A(+47+71) 2572BAO32.2 1244BAAA UGA GCC UUU CGU GUU UUC ACA G 2573B ′OMe-PS 
2574B32A(+47+71) 2575BPMO32 1245BAAA TGA GCC TTT CGT GTT TTC ACA G 2576BPMO 
2577B32D(+14-11) 2578BAO32.3 1246BAAC AAA CAC ACC UGU ACA GCC AGU U 2579B ′OMe-PS 
2580B32A(+42+66)  2581BAO32.2+5 1247BAGC CUU UCG UGU UUU CAC AGG UCC C 2582B ′OMe-PS 
2583B 2D(+09-16)  2584BAO32.3-5 1248BACU UGA ACA AAC ACA CCU GUA CAG C 2585B ′OMe-PS 
2586B32A(-08+17)  2587BAO32.1-5 1249BGUC ACA CUC AUU GAC AUC UGU AAA A 2588B ′OMe-PS 
2589B32A(+52+76)  2590BAO32.2-5 1250BCAG AUA AAU GAG CCU UUC GUG UUU U 2591B ′OMe-PS 
2592B32D(+19-06)  2593BAO32.3+5 1251BACA CAC CUG UAC AGC CAG UUU UUC C 2594B ′OMe-PS 
3795BExon 39 
2595B39A(-12+13) 2596BAO39.1 1252BAUU UUG UAC UCG GCU AUU GAA ACA A 2597B ′OMe-PS 
2598B39A(-12+13) 2599BPMO39 1253BATT TTG TAC TCG GCT ATT GAA ACA A 2600BPMO 
2601B39A(+31+55) 2602BAO39.2 1254BGUG AUA GGA UUU GGU CGG AAA CCU U 2603B ′OMe-PS 
2604B39D(+04-16) 2605BAO39.3 1255BAAG GAA ACA CAA UUA CCU UC 2606B ′OMe-PS 
2607B39A(-07+18)  2608BAO39.1-5 1256BAAA GAA UUU UGU ACU CGG CUA UUG A 2609B ′OMe-PS 
2610B39A(+36+60)  2611BAO39.2-5 1257BUAA CGG UGA UAG GAU UUG GUC GGA A 2612B ′OMe-PS 
2613B 9A(+13+37)  2614BAO39.4 1258BAAA CCU UCC CCU CCA GGA CAA AGA A 2615B ′OMe-PS 
2616B39D(+16-09)  2617BAO39.5 1259BCAC AAU UAC CUU CCA AUA UAA CGG U 2618B ′OMe-PS 
3796BExon 44 
2619B44A(+14+38) 2620BAO44.1 1260BUUC ACA GAC CCC UGG GAU CUC CCG G 2621B ′OMe-PS 
2622B44A(+44+68) 2623BAO44.2 1261BGCU GCC AAC CAU GUU GAU ACA CAC U 2624B ′OMe-PS 
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2625B44D(+19-06) 2626BAO44.3 1262BACU UAC CUU CAC AAA CCA ACA ACU U 2627B ′OMe-PS 
3797BExon 49 
2628B49A(-13+12) 2629BAO49.1 1263BAUU CAU UGA UAU CUG CAA AGA AAA G 2630B ′OMe-PS 
2631B49A(+19+43) 2632BAO49.2 1264BCCU GGU GCA CAU UUU CUG GGU UCU A 2633B ′OMe-PS 
2634B 9A(+83+107) 2635BAO49.3 1265BAUU UUG AAG ACU GUA UCC AGG UGG G 2636B ′OMe-PS 
3798BControl AOs 
2637BUnrelated Control 2638BCtrl 1266BGGA UGU CCU GAG UCU AGA CCC UCC G 2639B ′OMe-PS 
2640BGeneTools control 2641BGTC 1267BCCT CTT ACC TCA GTT ACA ATT TAT A 2642BPMO 
Screening of 2′OMe-PS AOs 
616BEvaluation of the exon skipping activity of 2′OMe-PS AOs was performed in healthy control 
fibroblasts. Fibroblasts were transfected using Lipofectamine 3000 with two AO concentrations; 
200 nM and 50 nM, and cells were collected 24 hours after addition of the 2′OMe-PS AOs. The 
results of this screening are shown in Figure 6.3. The RT-PCR results revealed that for five of the 
ten exons targeted (15, 16, 27, 31 and 49), a single AO was not sufficient to mediate exon skipping 
at the transfection concentrations used (Figure 6.3). Through the use of two AO cocktails, exons 
15, 16 and 31 were able to be excised from the mature mRNA, albeit at a very low efficiency for 
both exons 15 (8%; Figure 6.3.a) and 31 (14%; Figure 6.3.f), and marginally more efficient for 
exon 16 (22%; Figure 6.3.b). Exons 27 and 49 could not be skipped with any of the single AOs 
or cocktails tested (Figure 6.3.e and j). 
617BConversely, skipping of exons 22, 32 and 39 was relatively efficient using either single AOs 
or cocktails. A total of four AOs targeting exon 22 were tested, two of which induced moderate 
levels of exon 22 skipping. The AO22.2 sequence was the most efficient, inducing up to 32% 
skipping (Figure 6.3.c). The lower AO concentration; 50 nM, induced more efficient exon 
skipping than the higher concentration, a phenomenon observed several times during our AO 
evaluation studies (Figure 6.3). The combination of AO22.2 with either AO22.1 or AO22.3 was 
counter-productive and inhibited exon 22 exclusion (Figure 6.3.c). The combination of AO22.4 
and AO22.2 resulted in a marginal increase in skipping efficiency, increasing the proportion of 
skipped products to 36% (Figure 6.3.c). 
618BFor exons 32 and 39, all three ‘first generation’ AOs tested induced some level of exon 
skipping. The AOs targeting exon 39 were relatively efficient, with all three inducing more than 
30% skipping (Figure 6.3.h). The AO32.2 and AO39.1 sequences were the most efficient inducing 
up to 36% and 43% skipping of their respective target exon (Figure 6.3.g and h). Combining any 
two exon 32 AOs into a cocktail was also effective resulting in either additive or synergistic levels 
of exon skipping. The cocktail of AO32.1 and AO32.2 that induce 7% and 36% skipping at 50 
nM, respectively, induced an additive 50% exon 32 skipping after transfection at 100 nM (Figure 
6.3g). The combination of AO32.1 and AO32.3 that induced 7% and 11% exon skipping at 50 
nM respectively, was synergistic, resulting in 42% skipping after transfection at 100 nM (Figure 
6.3.g). Conversely, at the 400 nM transfection concentration, the effect of combining two AOs 
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targeting exon 39 into cocktails was not evident. All three cocktails targeting exon 39 resulted in 
similar skipping efficiencies to the individual AOs that were transfected at 200 nM (Figure 6.3.h). 
Furthermore, the lower total cocktail concentration of 100 nM resulted in a higher level of exon 
39 skipping than 400 nM (Figure 6.3.h). 
1091B
Figure 6.3: Evaluation of 2′OMe PS AOs targeting specific FBN1 exons for removal. 
806BAOs were transfected as lipoplexes at two concentrations, 200 and 50 nM, except for the exon 32 and exon 39 cocktails 
that were transfected at total AO concentrations of 400 nM and 100 nM. RT-PCR amplification was used to amplify the 
appropriate region of the fibrillin-1 mRNA and gel fractionation of products revealed the following transcripts (a) Ex 13-
20 FL=843 bp, Δ15=720bp, (b) Ex 13-20 FL=843 bp, Δ16=720 bp, (c) Ex 19-27 FL=969 bp, Δ22=831 bp, (d) Ex 24-28 
FL=628 bp, Δ26=502 bp, (e) Ex 24-28 FL=628 bp, Δ27=499 bp, (f) Ex 29-34 FL=670 bp, Δ31=544 bp, (g) Ex 29-34 
FL=670 bp, Δ32=544 bp, (h) Ex 37-42 FL=618 bp, Δ39=549 bp, (i) Ex 42-48 FL=720 bp, Δ44=594 bp, j) Ex 46-53 
FL=812 bp, Δ49=692 bp. The values below each gel image indicate the percentage of transcript from which the target 
exon has been skipped. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR 
negative control. 100bp molecular marker used for size reference. 
Micro-walking around the AO target site and additional sequence design 
619BIn an attempt to further optimise the efficiency of excising targeted exons, additional AOs 
were designed around the existing target sites. Micro-walking AO sequences, shifted up or 
downstream of an existing AO target site while maintaining the same AO length, are labelled as 




620BThree additional AOs were designed to target exon 16 by micro-walking around AO16.2 and 
AO16.3. None of the additional, ‘second generation’ sequences induced any exon skipping, 
meaning that of six AOs targeting this exon, none were effective when used individually (Figure 
6.4.a). Two additional AOs were designed to target exon 26, one shifted upstream of AO26.2 the 
other downstream of AO26.3, AO26.2-5 was much more efficient than the original AO26.2 
inducing up to 26% exon skipping (Figure 6.4.b). Lastly, five additional AOs targeting exon 32 
were designed by micro-walking around all three original AO target sites. Except for AO32.3-5, 
each of these AOs induced 32 skipping with equal or greater efficiency to the original. The 
AO32.1-5 and AO32.3+5 sequences were both more efficient than their respective original 
sequences (Figure 6.4.c). The sequences designed by micro-walking around AO32.2 induced 
similar skipping efficiencies, with 37%, 34% and 33% exon 32 skipping, respectively (Figure 
6.4.c). 
1092B  
Figure 6.4: Evaluation of micro-walking AOs. 
807BThe micro-walking and original 2′OMe-PS AOs targeting exons a) 16, b) 26 and c) 32 were transfected into healthy 
control cells at two concentrations, 200 and 50 nM, and collected after 24 hours. RT-PCR amplification and gel 
fractionation revealed the following transcripts a) Ex 13-20 FL=843 bp, Δ16=720 bp, b) Ex 24-28 FL=628 bp, Δ26=502 
bp and c) Ex 29-34 FL=670 bp, Δ32=544 bp. The values below each gel image indicate the percentage of transcript 
from which the target exon has been skipped. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated 
control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. 
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Overlapping cocktails 
621BGenerally, AO cocktails are created by combining non-overlapping AOs, limiting the number 
of potential combinations. However, here the skipping efficiency of cocktails created by 
combining two overlapping AOs, was investigated, allowing several additional cocktails to be 
tested. Overlapping-AO cocktails were tested for exon 16; for which skipping is challenging, and 
exon 32 that is readily skipped. The cocktails used in this section are outlined in Table 6.2, 
including an alignment of their respective sequences. Each AO overlaps with its cocktail partner 
by either 15 or 20 bases. 
761BTable 6.2: Overlapping AO cocktails 
738BThe aligned sequences in each overlapping-AO cocktail, a dash indicates bases that do not overlap. 



































































622BAll the overlapping-AO cocktails targeting exon 16 were essentially ineffective. Two of the 
four cocktails resulted in traces of exon 16 skipping, with only 2-3% skipping achieved (Figure 
6.5.a). More efficient skipping was achieved with the non-overlapping combination of AO16.2 
and AO16.3 that induced up to 22% exon skipping (Figure 6.3.b). Conversely, cocktails of 
overlapping AOs targeting exon 32 induced relatively efficient exon skipping (Figure 6.5.b). 
While the overlapping exon 32 cocktails did induce strong skipping, the efficiency was generally 
lower than that of either the AOs alone or the non-overlapping cocktails. Side by side comparison 
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of skipping efficiency of each AO individually, and their combination in a cocktail revealed that 
the majority of overlapping cocktails are less efficient than at least one of the single AOs (Figure 
6.5.c). We also observed that even when the combination induced more efficient skipping, it was 
usually only a marginal improvement and not a cumulative effect of the two AOs. The exception 
to this was the combination of AO32.1 and AO32.1-5 that resulted in up to 50% skipping (Figure 
6.5.b) despite the inefficiency of both AOs individually; 7% and 22% skipping respectively. Other 
cocktails, such as the combination of AO32.2 and AO32.2-5, were less effective than each AO 
individually demonstrating antagonism (Figure 6.5.b and c). 
1093B
Figure 6.5: Evaluation of overlapping-AO cocktails targeting FBN1 exon 16 and 32 
808BHealthy control fibroblasts were transfected with cocktails consisting of two overlapping AOs for exons a) 16 and b) 32. 
The skipping efficiency was assessed after 24 hours. The values below each gel image indicate the percentage of 
exon 16 (∆16) or 32 (∆32) skipped transcripts in each sample. Ctrl: an unrelated sequence used as a sham treatment, 
UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. c) Comparison 
of AO sequences targeting exon 32 showing the skipping efficiency of the first AO in the cocktail (AO1) in purple, the 
overlapping-AO cocktail in yellow and the second AO in the cocktail (AO2) in pink. 
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 Promising sequences 
623BThe most promising AO sequences targeting exon 32 (AO32.2) and exon 39 (AO32.1) were 
synthesised as PMOs. The efficiencies of PMO32 and PMO39 were assessed in healthy control 
and patient cells. Two Marfan syndrome patient cell lines were obtained from the NIGMS Human 
Genetic Cell Repository at the Coriell Institute for Medical Research: GM21936 and GM21932. 
The GM21936 (MFSΔ32) cell line was reported by Liu et al.183 to harbour a heterozygous acceptor 
splice site mutation; c.3839-1G>A, resulting in skipping of exon 32. The GM21932 (MFSC1589F) 
cell line was reported to harbour a c.4766G>T missense mutation predicted to result in 
substitution of a cysteine residue for phenylalanine; p.(C1589F) in exon 39.242 The mutations 
harboured by both patients were confirmed via Sanger sequencing using amplicons generated 
from cDNA derived from total RNA or gDNA as sequencing templates (Figure 6.6.a) 
624BInitially, PMO32 was transfected into healthy control and MFSΔ32 cells using Nucleofection 
and incubated for 72 hours. The proportion of skipping, while relatively efficient, up to 62% in 
healthy control and 72% in MFSΔ32 fibroblasts (Figure 6.6.b), was deemed insufficient to rescue 
the phenotype. Therefore, two additional delivery methods were tested to determine if they would 
allow for more efficient PMO delivery and therefore improved exon skipping efficiency. 
Lipofectamine 3000 was used in the same manner as 2′OMe-PS AO transfection (Chapter 2, 
section 2.2.3). However, the delivery of PMO32 with Lipofectamine 3000 was ineffective, 
resulting in only 14% skipping in healthy control cells at the highest concentration; 5 µM in 1 ml 
transfection volume (Figure 6.6.c). The second transfection reagent used, Endo-Porter, is 
designed by Gene Tools for the delivery of PMOs.129 Endo-Porter was tested in only patient 
fibroblasts due to minimal available reagent. Approximately 12% additional skipping was 
achieved with Endo-Porter, increasing the proportion of Δ32 transcripts from the endogenous 
48%, resulting from the splice site mutation, to 60%, with PMO32 at 10 µM (Figure 6.6.d). 
625BHealthy control and MFSC1589F cells were similarly transfected with PMO39 using both 
Nucleofection and Lipofectamine 3000 (Figure 6.6.e and f). Nucleofection again proved more 
effective than Lipofectamine 3000. However, the 49% and 54% exon 39 skipping induced in 
healthy control and MFSC1589F cells, respectively (Figure 6.6.e) using Nucleofection is again 
insufficient to provide any therapeutic benefit, based on our current hypothesis. Delivery of 
PMO39 using Lipofectamine 3000 was similarly less efficient than Nucleofection, inducing up 
to 16% and 22% skipping in healthy control and MFSC1589F cells, respectively (Figure 6.6.f). 
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1094B
Figure 6.6: Evaluation of PMO32 and PMO39 in healthy control and MFS patient fibroblasts 
809Ba) Sanger sequencing results confirming mutations harboured by MFSΔ32 and MFSC1589F patient fibroblasts. Healthy
control and MFSΔ32 fibroblasts were transfected with PMO32 using b) Nucleofection, c) Lipofectamine 3000 and d) 
Endo-Porter. Healthy control and MFSC1589F fibroblasts were transfected with PMO39 using e) Nucleofection and f) 
Lipofectamine 3000. The concentrations used were calculated in the transfection volume: 250 µM and 50 µM in 20 µl 
volume for Nucleofection, 5 µM and 1 µM in 1 ml volume for Lipofectamine 3000 and 10 µM and 2.5 µM in 500 µl 
volume for Endo-Porter. All transfected cells were collected after 72 hours. The values below each gel image indicate 
the percentage of exon 32 (∆32) or 39 (∆39) skipped transcripts in each sample. GTC: Gene Tools control PMO used 
as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size 
reference. 
6.3 Alternative AO chemistry 
626BWhile there are many potential target exons within FBN1, many have proven to be very 
challenging to skip from the mature mRNA. However, only two chemistries; 2′OMe-PS and 
PMOs have been discussed. During the course of this project a third chemistry, the 
thiophosphoramidate morpholino oligomer (TMO), became available for evaluation. In 
collaboration with Distinguished Professor Marvin Caruthers (University of Colorado Boulder, 
USA), two 20-mer versions of the best performing exon 52 AO were synthesised as TMOs. One 
limitation in using the TMO chemistry is length, and only 20-mer AOs were available initially. 
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The 20-mer AOs were designed by removing five bases from either the 5′ (52-1) or 3′ (52-2) end 
of the original AO52.2 sequence. To ensure comparability, the same 20-mer AO sequences were 
also synthesised as both PMO and 2′OMe-PS chemistries. The details of these AOs, along with 
the control sequences used, are outlined in Table 6.3. 
762BTable 6.3: Optimal exon 52 AO identified in the original screen and details of 20-mer versions used in 
chemistry comparison experiments. 
739BThe target gene and exon, AO name, ID, sequence and chemistry of AOs used in this section. The AO nomenclature 
is outlined in Chapter 2, Figure 2.1. 




1276BAUC AGG UCC CAC GAU GAU CCC ACU U 
ATC AGG TCC CAC GAT GAT CCC ACT T 
2696B ′OMe-PS 
PMO 
2697BFBN1 H52A(+29+48) 2698B52-1 
      1277BG UCC CAC GAU GAU CCC ACU U 
      1278BG TCC CAC GAT GAT CCC ACT U 




2701BFBN1 H52A(+34+53) 2702B52-2 
1280BAUC AGG UCC CAC GAU GAU CC 
1281BATC AGG TCC CAC GAT GAT CC 





2705BSMN2 H7A(+13+32) 2706BSMN-7 
1283BCAC CUU CCU UCU UUU UGA UU 
1284BCAC CTT CCT TCT TTT TGA TU 




2709BCOL7A1 H73A(+21+40) 2710BCOL-73 
1286BCGC CCU UCA GCC CGC GUU CU 
1287BCGC CCT TCA GCC CGC GTT CU 




2713BControl AO1 2714BCtrl AO1 1289BATG TCC TGA GTC TAG ACC CU 2715BTMO 
2716BGeneTools control-20mer  2717BCtrl 
  1290BU CUU ACC UCA GUU ACA AUU U 
  1291BT CTT ACC TCA GTT ACA ATT U 
2718B ′OMe-PS 
TMO 
2719BGeneTools control 2720BCtrl 1292BCCT CTT ACC TCA GTT ACA ATT TAT A 2721BPMO 
    
 Delivery method optimisation 
627BTo determine the most appropriate delivery method for TMOs, heathy control cells were 
transfected with both TMO sequences either un-complexed or as Lipofectamine 3000 lipoplexes. 
Transfected cells were collected 24 hours after transfection and analysed for exon 52 skipping. 
No skipping was evident in cells transfected without a transfection reagent (Figure 6.7). 
Conversely, delivery of TMO52-1 and TMO52-2 using Lipofectamine 3000 resulted in up to 71% 
and 69% skipping respectively, demonstrating the efficacy of the TMOs when using the 
Lipofectamine 3000 transfection reagent (Figure 6.7). An unexpected product was also identified 
in control AO1 treated cells (Figure 6.7), purification and Sanger sequences of this product 
identified it as Δ52 (data not shown). This finding was consistent across multiple replicates 
indicating contamination of the control sequence with either TMO52-1 or TMO52-2, and 
therefore this control AO preparation was not used for further experiments. The control was 
replaced by a 20-mer TMO version of the standard Gene tools control sequence used for PMO 





Figure 6.7: Optimisation of TMO delivery in healthy control fibroblasts. 
810BThe TMO52-1 and TMO52-2 sequences were delivered into healthy control fibroblasts using either Lipofectamine 3000 
or without a transfection reagent. Two concentrations; 200 nM and 50 nM were used, and cells were collected after 24 
hours. The values below the gel image indicate the percentage of exon 52 (∆52) skipped transcripts in each sample. 
Ctrl AO1: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 
100bp molecular marker used for size reference. 
 Comparison between TMO and 2′OMe-PS AOs 
628BTo compare the TMO and 2′OMe-PS chemistries, healthy control fibroblasts were transfected 
with AOs composed of both chemistries over a range of concentrations from 200 nM to 5 nM. 
All four AOs induced relatively efficient exon 52 skipping, with the 20-mer 2′OMe-PS AOs 
inducing similarly efficient exon skipping to the original 25-mer AO. The 2′OMe-PS 52-1 
sequence was slightly more efficient, inducing up to 44% skipping compared to the 38% by 
2′OMe-PS 52-2 (Figure 6.8.b). Both TMO versions were more efficient than the 2′OMe-PS 
counterparts, with approximately 20% more skipping when using a TMO compared to the 2′OMe-
PS AO (Figure 6.8). Both TMO sequences induced similar levels of exon 52 skipping, with 60% 
of transcript missing exon 52 after transfection at 200 nM (Figure 6.8.a). The TMOs induced a 




Figure 6.8: Comparison of exon 52 skipping efficiency of 2′OMe-PS and TMO chemistries 
811BHealthy control cells were transfected, using Lipofectamine 3000, with a) TMO and b) 2′OMe-PS AOs. Cells were 
transfected at a range of concentrations; 200 nM, 100 nM, 50 nM, 10 nM and 5 nM, and were collected for RNA analysis 
after 24 hours. The values below each gel image indicate the percentage of exon 52 (∆52) skipped transcripts in each 
sample. Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 
100bp molecular marker used for size reference. 
Assessing off-target effects of 2′OMe-PS and TMO chemistries 
629BIt is now well established that the phosphorothioate (PS) backbone interacts with and 
sequesters paraspeckle and other nuclear proteins, limiting their availability for normal cellular 
functions and leading to toxicity.243,244 However, the effect of the TMO chemistry on nuclear 
proteins is unknown. Therefore, the localisation of the paraspeckle protein non-POU domain-
containing octamer-binding protein (NONO) was assessed after treatment with either 2′OMe-PS 
AOs or TMOs of the same sequence. Before transfection, 15,000 healthy control fibroblasts were 
seeded onto coverslips in colonies. All AOs were transfected at 100 nM using Lipofectamine 
3000 and left for 24 hours. Coverslips were fixed and subsequently immunolabelled using a 
NONO primary antibody (a gift from Prof. Archa Fox) and counterstained with Hoechst for nuclei 
detection. 
630BA minimum of 250 cells were counted for each treatment group, and each cell was categorised 
as having one of the following staining patterns. (1) normal; diffuse staining throughout the 
nucleus with minimal spots of high intensity, this was considered normal since it was observed in 
all untreated cells, (2) foci; multiple high-intensity aggregates within the nucleus, with minimal 
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diffuse staining, (3) filaments; elongated aggregates within the nucleus, with minimal diffuse 
staining (4) cytoplasmic; multiple high-intensity aggregates within the cytoplasm, with diffuse 
nuclei staining. Representative images of NONO and Hoechst staining in each treatment group 
are shown in Figure 6.9.b. The percentage of cells showing aberrant NONO staining following 
AO treatment is shown in Figure 6.9.c. The skipping efficiency in transfected cells was also 
assessed to ensure cells had been successfully transfected (Figure 6.9.a) 
631BImmunofluorescent staining of NONO revealed that all 2′OMe-PS sequences, including the 
control AO, altered NONO staining (Figure 6.9.b). Both punctate foci and filament aggregates 
were observed, with foci forming more frequently (Figure 6.9.b and c). In particular, the 
2′OMe-PS 52-2 sequence caused aggregates in more than 50% of cells. The staining in TMO 
treated cells was for the most part consistent with untreated cells, with diffuse NONO staining 
throughout the nucleus and occasional spots of higher staining intensity (Figure 6.9.b and c). The 
TMO 52-1 and SMN-7 sequences did not induce any abnormal NONO staining (Figure 6.9.c). 
However, TMO 52-2 resulted in foci in approximately 5% of cells (Figure 6.9.c). Cytoplasmic 
aggregates were observed to form in cells treated with the TMO control AO and TMO COL-73 
(Figure 6.9.b and c). However, the TMO COL-73 sequence did not result in any exon skipping in 
this experiment (Figure 6.9.b and c) where previously the sequence was found to induce 




Figure 6.9: Evaluation of skipping efficiency and NONO immunofluorescence staining after transfection 
with TMO and 2′OMe-PS AOs. 
812BHealthy control fibroblasts were transfected, using Lipofectamine 3000, with 100 nM of TMO or 2′OMe-PS AOs. a) RT-
PCR amplicons from cells collected 24 hours after transfection showing transcripts between FBN1 exons 42 and 49, 
SMN exons 4 and 8 and COL7A1 exons 72 and 77. b) representative images of treated cells stained for NONO (green), 
and nuclei (blue). The upper and lower panels of each set of immunofluorescence images show the NONO and merged 
images, respectively. No Ab control: no primary antibody added. Scale bar = 20 µm. See Figure A4.2 for a larger 
version of part b. c) Percentage of healthy control fibroblasts showing disrupted NONO staining. 
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TMO, 2′OMe-PS and PMO chemistry comparison 
632BLastly, all three chemistries, 2′OMe-PS, PMO and TMO, were compared. In order to use the 
same concentration for each of the AO chemistries in the most cost-effective way, a different 
delivery method called Neon transfection was used. Similar to Nucleofection, Neon transfection 
uses electroporation to deliver the AO into cells, however the transfection volume for the Neon 
protocol is only 10 µl allowing the use of less reagent. Two concentrations were tested; 20 µM 
and 5 µM, as calculated in the 10 µl tip, which are equivalent amounts of AO as used for 200 nM 
and 50 nM 2′OMe-PS screening experiments. Transfected cells were left for both 24 hours and 
10 days.  
633BAfter 24 hours, relatively efficient exon skipping was achieved with all three chemistries, 
where both the 52-1 and 52-2 sequences induced similar levels of targeted exon skipping. 
However, the 52-1 sequence was marginally more efficient across the board, inducing up to 79%, 
68% and 81% exon 52 skipping as TMO, 2′OMe-PS and PMO chemistries respectively after 24 
hours (Figure 6.10.a). The skipping efficiency using the 2′OMe-PS AOs was slightly more 
efficient than seen previously with this chemistry with both sequences inducing more than 60% 
skipping after 24 hours at both concentrations tested after Neon transfection. 
634BAt the 24-hour time-point, the PMO sequences induced the most efficient skipping (Figure 
6.10.a). However, after 10 days, the proportion of Δ52 transcripts was reduced both in cells treated 
with PMOs and in cells treated with the 2′OMe-PS AOs (Figure 6.10.b). Cell death was observed 
in treated samples from both chemistries, and cells had begun to regrow in PMO samples (data 
not shown). Conversely, the TMO treated cells had an increased proportion of skipping after the 
10-day incubation. The TMO 52-1 and TMO 52-2 sequences induced up to 92% and 84% exon
skipping, respectively (Figure 6.10.b). The 10-day time point also revealed a greater difference in 
efficiency between the 52-1 and 52-2 sequences, with 52-1 consistently inducing more skipping 
across all three chemistries (Figure 6.10.b). 
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1098B
Figure 6.10: Evaluation of two AO sequences targeting FBN1 exon 52 as the 2′OMe-PS, TMO and PMO 
chemistries. 
813BHealthy control cells were Neon transfected with the indicated AO or left untreated (UT) before collection after a) 24 
hours or b) 10 days. Two concentrations were used; 20 µM and 10 µM, calculated in the 10 µl Neon transfection 
volume. The proportion of skipped product (Δ52) is shown below each lane. Ctrl: an unrelated sequence used as a 
sham treatment, UT: untreated control, -ve: RT-PCR negative control. 100bp molecular marker used for size reference. 
Fibrillin-1 fibre morphology and abundance after AO treatment 
635BThe TMO, 2′OMe-PS and PMO sequences were again Neon transfected into healthy control 
fibroblasts, as well as the two patient cell lines; MFSΔ52 and MFSC2111R, described in chapter 4. 
Despite the lower exon skipping efficiency known to result from transfection of both 2′OMe-PS 
and PMO sequences after 10 days, this time point was chosen to perform fibrillin-1 protein 
staining. 
636BThis repeated experiment revealed robust skipping, with the TMO sequences inducing 88% 
and 81% skipping (Figure 6.11) compared with 92% and 84% seen previously (Figure 6.10.b). 
Similar skipping efficiency to that achieved in healthy control cells was seen in both patient cell 
lines (Figure 6.10.b and c), with the TMO sequences again the most efficient across all three cell 
lines. The TMO52-1 sequence, in particular, induced the most efficient skipping in both healthy 
control (88%) and MFSΔ52 (99%) cells (Figure 6.11.a and b). However, in MFSC2111R patient cells, 
the TMO52-2 sequence was slightly more efficient, inducing up to 89% exon 52 skipping (Figure 
6.11.c). Cell death was evident in all samples treated with PMO or 2′OMe-PS AOs, with the cell 
death particularly apparent in MFSC2111R cells treated with the two 2′OMe-PS AOs, resulting in 
dropout of the RT-PCR in these samples (Figure 6.11.c) 
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1099B
Figure 6.11: Comparison of AO chemistry efficacy in control and MFS patient fibroblasts. 
814BThe TMO, 2′OMe-PS and PMO sequences were Neon transfected into a) Healthy control, b) MFSΔ52 and c) MFSC2111R 
fibroblasts. Two concentrations were tested; 20 µM and 5 µM, calculated in the 10 µl Neon transfection volume, and 
cells were incubated for 10 days prior to collection. The proportion of skipped product (Δ52) is shown below each lane. 
Ctrl: an unrelated sequence used as a sham treatment, UT: untreated control, -ve: RT-PCR negative control. 100bp 
molecular marker used for size reference. 
637BA portion of Neon transfected cells were seeded onto coverslips and incubated for 10 days. 
These coverslips were immunolabelled for fibrillin-1 and counterstained with Hoechst for nuclei 
detection. Representative immunofluorescent images are displayed in Figure 6.12. 
Healthy control fibroblasts 
638BUntreated healthy control cells present with strong, unfragmented fibrillin-1 fibres across the 
entire coverslip (Figure 6.12.a.xvi). Similarly, control cells treated with any one of the three 
control AOs exhibit intense fibre staining (Figure 6.12.a.xiii, xiv, xv). The fibre morphology, and 
fibrillin-1 staining overall was lost in healthy control cells treated with the lower concentration of 
either TMO that induces approximately 50% skipping (Figure 6.12.a.iv, x). Increased TMO 
concentration, and skipping efficiency resulted in a restoration of fibrillin-1 staining and the 
presence of fibres (Figure 6.12.a.i, vii). However, the morphology of these fibres was fragmented, 
and their abundance was reduced, compared to the untreated healthy control. 
639BThe opposite staining pattern is observed in healthy control cells treated with 2′OMe-PS AOs. 
Cells treated with the lower concentration of either 2′OMe-PS AO; both of which induce less than 
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15% skipping, present with fibres. However, these fibres have a similar low abundance and 
fragmented morphology to those seen in 20 µM TMO treated cells (Figure 6.12.a.v, xi). Healthy 
control cells treated with the higher concentration of 2′OMe-PS AOs have no fibre formations. 
The cell density was also greatly reduced, consistent with the high level of cell death observed 
(Figure 6.12.a.ii, viii). The 2′OMe-PS control sequence resulted in higher cell viability than either 
AO targeting FBN1, despite being used at the same 20 µM concentration. 
640BThe lower exon skipping efficiency induced by the PMO sequences in this experiment (Figure 
6.11.a); compared to that previously seen at 24 hours or 4 days, corresponds with the lack of fibre 
formation observed. Treatment of healthy control cells with either concentration of PMO5-1 or 
20 µM PMO52-2 resulted in the complete loss of fibres, mimicking the disease-like state (Figure 
6.12.a.iii, vi, ix). Cells treated with 5 µM of PMO52-2, which induced only 13% skipping, present 
with highly fragmented fibrillin-1 fibres (Figure 6.12.a.xii) 
Patient fibroblasts 
641BSamples from untreated MFSΔ52 and MFSC2111R cell lines present with a distinct lack of 
extruded fibrillin-1 fibres. Although untreated MFSΔ52 cells have minimal fibrillin-1 staining 
overall (Figure 6.12.b.xvi), untreated MFSC2111R cells have some diffuse fibrillin-1 staining seen 
throughout the monolayer culture (Figure 6.12.c.xvi). The fibrillin-1 staining pattern remains 
unchanged in both cell lines after treatment with any of the control sequences. We also observed 
very little change in the fibrillin-1 staining pattern of MFSC2111R cells in any of the treatment 
groups, including when efficient; 87% and 89%, skipping was induced with TMO52-1 and 
TMO52-2 respectively (Figure 6.12.c). The only noticeable divergence in fibrillin-1 staining is in 
the 20 µM 2′OMe-PS treatment group in which widespread cell death led to very few cells 
remaining on the coverslip and thus minimal fibrillin-1 staining (Figure 6.12.c.ii, viii). 
642BSimilarly, treatment of MFSΔ52 cells with 2′OMe-PS and PMO AOs had minimal effect on the 
fibrillin-1 staining pattern. The 2′OMe-PS AOs also cause a extensive MFSΔ52 cell death, 
especially at the higher AO concentration tested, leading to minimal fibrillin-1 staining (Figure 
6.12.b). Treatment of MFSΔ52 cells with 20 µM of PMO52-1; which induces 62% skipping, 
increased diffuse fibrillin-1 staining; however, no fibres were observed (Figure 6.12.b.iii). 
Conversely, treatment of MFSΔ52 cells with 20 µM of either TMO 52-1 or 52-2 resulted in the 
formation of fibrillin-1 fibres (Figure 6.12.b.i, vii). These fibres are of high staining intensity and 
have a similar unfragmented morphology to those seen in the untreated healthy control cells. 
However, the fibres are less abundant, covering approximately half of any given field of view. 
Fibrillin-1 fibres were also observed in the 5 µM TMO52-1 and TMO52-2 treated cells where 
75% and 71% skipping was induced respectively (Figure 6.12.b.iv, x). However, the fibres were 




Figure 6.12: Fibrillin-1 morphology and abundance after transfection with TMOs, 2′OMe-PS AOs or PMOs 
815BRepresentative immunofluorescent images of a) healthy control, b) MFSΔ52 and c) MFSC2111R fibroblasts Neon transfected with TMOs, 2′OMe-PS AOs or PMOs and collected after 10 days. Two 
concentrations 20 µM and 5 µM; calculated in a 10 µl transfection volume, were tested. Treated cells were immunolabelled for fibrillin-1(red) and nuclei (blue). Ctrl: an unrelated sequence used as a 
sham treatment, UT: untreated control, No Ab control: no primary antibody added. Scale bar = 20 µm. See Figure A4.3, Figure A4.4 and Figure A4.5 for larger versions of part a, b and c respectively. 
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Comparing the effects of AO chemistries on paraspeckle proteins 
643BThe 2′OMe-PS sequences were previously shown to result in aggregates of the nuclear protein, 
NONO, while all of the TMO sequences tested resulted in very few visible aggregates. This 
experiment was repeated to assess the effect of the PMO chemistry on a paraspeckle protein. 
Healthy control cells were Neon transfected with 10 µM of each AO or left untreated and seeded 
onto coverslips in colonies. Coverslips were fixed after a 24-hour incubation and immunolabelled 
for the paraspeckle protein Splicing Factor Proline and Glutamine Rich (SFPQ) that normally co-
localises with NONO. The staining pattern of SFPQ was categorised as normal, foci, filaments or 
cytoplasmic. A minimum of 300 cells per treatment group were counted and categorised. The 
proportion of nuclei within each category are displayed in Figure 6.13. 
644BThe 2′OMe-PS sequences resulted in a large proportion of nuclei with abnormal SFPQ 
staining. Of the 2′OMe-PS treated cells with abnormal SFPQ staining, the majority have foci, 
with the 52-2 sequence transfection resulting in foci in 42% of cells (Figure 6.13). While foci 
were most common in the 2′OMe-PS treated samples, only a small proportion (<1%) of cells 
treated with any of the PMOs or TMO52-2 also showed foci after staining for SFPQ (Figure 6.13). 
The number of samples showing cytoplasmic aggregates was greater in this experiment than that 
described in Section 6.3.2. Abnormal SFPQ localisation and distribution occurred in all treatment 
groups, although with very different severity and pattern of staining. The cytoplasmic aggregates 
were most common in the 2′OMe-PS treated samples and were occasionally an extension of foci, 
with a single cell able to present with both morphologies. Except for TMO52-2, all other AOs 
resulted in less than 1% of cells with cytoplasmic aggregates (Figure 6.13). The TMO52-2 
sequence resulted in cytoplasmic aggregates in 1.9% of cells (Figure 6.13). Untreated cells were 




Figure 6.13: SFPQ staining in fibroblasts after treatment with TMO, 2′OMe-PS AOs or PMOs 
816BPercentage of healthy control fibroblasts showing disrupted SFPQ staining 24 hours after transfection with 10 µM of 
TMO, 2′OMe-PS AOs or PMOs. A minimum of 300 cells were counted, and the staining of SFPQ aggregates was 
assessed as being either normal, foci, filaments or forming cytoplasmic foci. Ctrl: an unrelated sequence used as a 
sham treatment, UT: untreated control. 
6.4 Discussion 
645BThus far we have demonstrated AO-mediated skipping of FBN1 exons 52, 59, 47 and the exon 
region from 45-47 and that this splicing is relatively efficient, especially when using the PMO 
chemistry. However, the basis of a splice-switching therapy for MFS patients means that each 
exon region requires a different therapeutic compound. In theory 60 of the 66 fibrillin-1 exons 
can be skipped individually, without disrupting the reading frame, presenting numerous potential 
therapeutic targets. Therefore, the first aim of this chapter was to identify and evaluate AOs 
targeted to additional fibrillin-1 exons. The second aim here was to assess the efficiency and 
applicability of a third AO chemistry that is a hybrid chemistry between 2′OMe-PS, which can be 
efficiently delivered but result in some non-antisense off-target effects, and the extremely safe 
PMO chemistry that is hampered by poor cellular uptake. 
Additional AO screening 
646BThrough screening of 2′OMe-PS AOs, we clearly demonstrated that not all FBN1 exons are 
readily skipped. We screened AOs against an additional ten fibrillin-1 exons and found that half 
of the exons could not be skipped using any of the initial three AO sequences designed. Adams 
et al.167 reported that approximately 2 out of 3 of AOs tested induced dystrophin exon skipping, 
although with very different efficiencies. Here, we found that a lower 36 of the total 69 sequences 
tested (52%) induced some skipping of the target exon (Table A4.1). Screening of additional AO 
sequences targeting these exons could reveal that targeting a particular set of ESE or splice sites 
would prove effective. 
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647BWe wrote a simple python script that generates a list of all possible oligomers of a chosen 
length across the target exon (Figure A4.6). When used in conjunction with a tool for splicing 
regulator prediction such as SpliceAid153,154 or Human Splicing Finder,215 this script provides a 
relatively efficient way to design and name AOs. However, AO synthesis costs and the costs of 
screening multiple AO sequences means that it is not feasible to test every possible sequence for 
every exon, especially if AO length is also varied . For example, for the five ‘difficult to skip’ 
exons presented here there are over 750 possible 25-mer AO sequences, given 25 bases of 
flanking intron is included in the targeting. 
648BFor the majority of these difficult-to-skip or recalcitrant exons, we found that the use of a two 
AO cocktail enabled the exon to be removed from a portion of transcripts. However, for exons 27 
and 49 neither single nor two-AO cocktails induced any exon skipping. One explanation for the 
lack of skipping could be that all three AOs targeting exon 27 bind to ESE sites rather than 
completely covering either the acceptor or donor splice sites. These sequences were chosen as 
they targeted regions with multiple predicted ESE sites (Figure A4.1). Similarly, none of the AOs 
targeting exon 49 bind to the donor splice site. Therefore, it is possible that the sequences 
themselves are not targeting the optimal motifs. Thus, testing additional sequence that cover these 
splice sites could lead to the identification of an effective AO. However, of all the AOs tested 
thus far those targeting the ESEs have most successfully induced exon skipping, with 68% of all 
ESE-targeting AOs having some effect on exon selection (Table A4.2). For those AOs targeting 
the donor splice site, only 44% result in skipping, this is further reduced to 33% for AOs targeting 
the acceptor splice site (Table A4.2) 
649BAdams et al.167 reported that when testing AO cocktails against the recalcitrant exons in the 
dystrophin gene transcript, AO cocktails that were clearly synergistic were not necessarily 
composed of those AOs targeting the splice sites nor was efficient skipping associated with the 
number of ESE sites targeted. Here, we found that for those exons where single AOs were 
ineffective, but a two AO cocktail induced some exon skipping, the combination of an AO 
targeting one of the splice sites and a region of ESEs were those that induced skipping. In none 
of these cases did the combination of AOs targeting both the acceptor and donor sites induce any 
exon skipping, and in only one case did two AOs solely targeting ESE sites induce exon skipping. 
This finding further suggests the importance of assessing AO sequences targeting the splice sites 
of FBN1 exons 27 and 49. 
650BOther factors that could limit the splice-switching potential of AO sequences include pre-
mRNA secondary structure and splice site ‘strength’. The secondary structure of pre-mRNA has 
been shown to play a crucial role in both the splicing process245 and AO binding, with certain 
secondary structures limiting the binding affinity of an AO to its target.246 We also speculate that 
synergistic cocktails rely on one AO changing the secondary pre-mRNA structure allowing the 
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second AO to bind and block splicing. Therefore, further investigation of the pre-mRNA 
secondary structure of exons 27 and 49, could reveal optimal sequences to target to increase the 
strength of AO binding. Alternatively, it is possible that exons 27 and 49; which encode cbEGF-
like domains, are essential in some way to the function or stability of fibrillin-1 and therefore their 
selection during splicing is more tightly regulated. The splice site scores for exon 27 and 49 are 
relatively ‘strong’ with consensus values for the donor of both exons and acceptor of exon 49 
greater than average for constitutive exons (Table A4.3). While splice site scores are only a 
predicted measurement of the likelihood of the splicing machinery recognising the splice site, the 
relatively ‘strong’ splice site scores for exon/introns around exon 27 and 49 could impact AO 
efficacy. 
651BWhile exons 15, 16, 26, 31, and 44 were extremely difficult to skip and required two-AO 
cocktails, the skipping of exon 22, 32 and 39 was relatively efficient using both single AOs and 
when using cocktails. This led to the identification of promising sequences for each exon 32 and 
exon 39. Interestingly the combination of two overlapping AOs targeting exon 32 resulted in a 
synergistic effect. We speculate that this occurs, due to AO binding being a dynamic, rather than 
static process, in which the AO might anneal to the target mRNA at the 5′ end, release and then 
anneal again from the 3′-end or centre. This ‘breathing’ effect could allow for the partial binding 
of the first AO to facilitate changes to the mRNA structure that enhances the binding of the second 
AO, allowing both sequences to be active. The synergy observed here between two overlapping 
AOs indicates that overlapping-AO cocktails should not be discounted during the screening 
process. 
652BThe FBN1 exons we have targeted for exon skipping, mainly encode the cbEGF-like domains 
that make up 43 of the 55 cysteine-rich motifs, as described in the previous chapters. However, 
skipping of a hybrid domain had not been attempted. The hybrid domains share similarities with 
both the EGF-like and TB domains and have been shown to play an integral role in fibrillin-1 
folding and microfibril assembly.21,22 This could suggest that the encoded domain is critical and 
therefore this exon is unsuitable for exon skipping. However, we note that skipping of exon 22 
that encodes part of the second hybrid-domain, is quite efficient using 2′OMe-PS AOs. Further 
assessment of the AOs targeting exon 22 as PMOs or TMOs, could reveal either an optimal target 
or the creation of a non-functional fibrillin-1 protein, unable to assemble into microfibrils. Either 
outcome would provide further evidence toward the identification of amenable FBN1 exon 
skipping targets. 
653BThe correlation in splice-switching efficacy between 2′OMe-PS and PMO compounds of the 
same sequence is well established for DMD both in vitro167 and in mouse models.247 This 
correlation shows that the PMO version of an AO sequence is generally at least, if not more 
efficient than its 2′OMe-PS counterpart. This correlation is expected because the neutral backbone 
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of the PMO chemistry prevents electrostatic repulsion by the negatively charged RNA or DNA, 
enabling these oligomers to bind to their targets with much higher specificity and affinity.113 
However, other reports have shown that an efficient 2′OMe-PS sequence does not always translate 
into an effective PMO.195,248 These reports also suggest that some differences in efficiency are 
sequence and exon-specific rather than due to the different chemistries.195,248 We have similarly 
identified examples of poor translation between chemistries, in some cases conceivably the result 
of poor synthesis or quality rather than the AO sequence. Such issues are extremely expensive to 
investigate and bring forth the dilemma of re-synthesise or re-design. 
654BIn chapters 3, 4 and 5, we reported that the PMO version of an AO sequence usually induces 
a higher proportion of skipped products than the 2′OMe-PS version. However, here we show that 
PMO32 and PMO39 are not as efficient as might be expected. Two very different delivery 
methods and transfection concentrations make a direct comparison between the two chemistries 
impossible. We also observed a larger proportion of skipped products when using the PMO than 
the 2′OMe-PS AO. However, PMO32 and PMO39 are much less efficient than PMO52, PMO59 
or PMO47 when used at the same concentration, despite the 2′OMe-PS AO equivalents of all five 
sequences inducing similar skipping efficiencies. These findings suggest that the PMO32 and 
PMO39 sequences are not as efficient as expected from the 2′OMe-PS AO screening.  
655BConsidering factors such as sequence length, base composition and self-complementarity, the 
only apparent separation between the design of the PMOs targeting exons 32 and 39 and those 
targeting exons 47, 52 and 59 was their GC content. Both PMO32 and PMO39 have lower GC 
content, 40% and 32%, respectively, than PMO47 (60%), PMO42 (52%) or PMO59 (48%). In 
silico analysis of the FBN1 exon 32 and 39 mRNA secondary structure showed that PMO32 
(Figure A4.7) and PMO39 (Figure A4.8) both target tight hair-pin loop structures. These AOs 
must therefore overcome tight secondary structures in order to anneal to the respective targets. 
However, neither the GC content nor the annealing site’s secondary structure is specific to the 
PMO chemistry. Consequently, the cause of the lower than expected PMO efficiency is unknown. 
Further investigation to assess the quality and purity of the batch of PMO used, would indicate if 
poor synthesis is at fault. 
656BThe level of exon skipping induced by PMO32 and PMO39, while relatively good under some 
circumstances were insufficient for the purposes of this study where transcript homogeneity is 
vital. We speculated that the lower exon skipping efficiency was related to poor delivery of the 
PMO and therefore, we tested two additional delivery methods, Lipofectamine 3000 and Endo-
Porter. It is generally considered that Lipofectamine 3000 transfection is applicable only to the 
delivery of negatively charged compounds; however, Aung-Htut et al.131 demonstrate that 
Lipofectamine 3000 can, in some instances, result in robust delivery of PMOs. On the other hand, 
Endo-Porter was designed by Gene Tools specifically for the delivery of PMOs.129 Despite the 
145 
efficacy of these delivery methods in different situations, neither technique resulted in more 
efficient exon skipping than Nucleofection. We discovered very late in the project that the recently 
acquired Neon transfection system is incredibly efficient at delivering not only PMOs, but also 
TMO and 2′OMe-PS sequences. However, the Neon transfection system was not used to deliver 
the PMO32 and PMO39 sequences. Delivery of these PMOs using Neon transfection could allow 
for sufficient exon skipping to assess the effects of exon removal on the fibrillin-1 protein 
structure and function. However, we also believe that the sequences themselves should be further 
optimised to ensure the most efficient skipping, regardless of the delivery method. 
Alternative chemistry 
657BWhile there are many possible target exons within the fibrillin-1 gene, we have shown during 
the screening process that many are not readily skipped from the mature mRNA. We also showed 
that an efficient 2′OMe-PS AO sequence identified during screening does not always translate 
into a more efficient PMO. However, previously we had only tested two AO chemistries despite 
the many available options. We tested a third chemistry, the TMO, that shares similarities with 
both PMO and 2′OMe-PS chemistries. The TMO chemistry proved to be very efficient at inducing 
exon 52 skipping, more so than any 2′OMe-PS tested, and at 10 days after transfection more so 
than the PMO chemistry. 
658BWe found that the TMO and PMO sequences tested were consistently more efficient than their 
2′OMe-PS counterparts. The TMO sequences were more effective at inducing target exon 
skipping after transfection using both Lipofectamine 3000 and the Neon transfection system. 
Since the 2′OMe-PS AOs can be delivered using the same systems as the TMOs the difference in 
efficiency is unlikely to be related to poor delivery of the 2′OMe-PS AOs. We also demonstrate 
that the 2′OMe-PS sequences result in marked cell death, especially after 10 days. Cell death was 
also observed in PMO treated cells; however, the remaining cells were observed to continue 
proliferating, which would have resulted in the dilution of PMO in treated cells. Similar levels of 
cell death were seen previously when using the Nucleofection transfection system, but this was 
thought to be associated with the stress of the Nucleofection process and the use of a relatively 
high PMO concentration. However, here a much lower concentration was used, and cell death 
was still evident. 
659BFurther investigation to determine the cause of lowered cell viability after PMO transfection 
could allow for modification to the transfection protocol to improve cell survival. Interestingly 
the TMO chemistry resulted in minimal cell death, even after 10 days and was more effective 
than both PMO and 2′OMe-PS sequences at this time-point. Extension of this incubation period 
could reveal the residence time of the TMO chemistry in cells and possibly better reflect the 
quality of the extruded fibrillin-1. Such experiments would be essential prior to embarking on in 
vivo work, which requires a more defined timeline and outcome measures. 
146 
660BSince TMOs carry a negatively charged backbone, these AOs can be efficiently delivered 
using Lipofectamine 3000, similar to 2′OMe-PS and other negatively charged AOs. The use of 
cationic liposome preparations could not be applied to deliver PMO32 and PMO39, prompting 
the evaluation of a second electroporation-based method, the Neon transfection system. We found 
Neon transfection to be extremely efficient, achieving similar exon skipping efficiencies to 
Nucleofection in the same number of cells, while using 12.5 times less of the total PMO amount 
required for Nucleofection. Employing the Neon transfection method for further studies should 
allow for sufficient and reproducible exon skipping mediated by additional sequences. 
Furthermore, this would enable additional fibrillin-1 functional assays to be performed, 
evaluating if exon skipping allows for not only the formation of fibrillin-1 fibres but also the 
formation of functional fibrillin-1 microfibrils.  
661BThe PS backbone is known to interact with and sequester numerous nuclear proteins, including 
paraspeckle proteins, forming nuclear and cytoplasmic aggregates that can disrupt normal cellular 
function.113,243,244 The exact effect of nuclear protein aggregates on cell biology is not clearly 
defined. However, these aggregates are of particular importance as the majority of the proteins 
involved are RNA-binding proteins,249,250 and are involved in cellular processes such as regulation 
of transcription, transport, splicing and ribosomal RNA processing.249,250 Therefore, the 
aggregates observed could be expected to disrupt the nuclear structure and compromise global 
cellular functions, such as gene expression and splicing, ultimately leading to apoptosis.243,244 
662BWe observed disrupted staining of both NONO and SFPQ in cells treated with 2′OMe-PS AOs. 
We also confirmed that the disruption of paraspeckle protein staining was not delivery-method 
specific, with very similar results arising from both Lipofectamine 3000 and Neon transfection 
systems. In contrast, the NONO and SFPQ staining in TMO and PMO treated cells was, for the 
most part, consistent with untreated cells. The absence of abnormal staining in PMO treated cells 
is consistent with the report by Flynn et al.244 who similarly observed extensive disruption of 
paraspeckle protein staining with 2′OMe-PS AOs and normal staining in PMO treated cells using 
several different delivery methods. We note that while the vast majority of cells retained their 
normal staining pattern, cytoplasmic foci formed in all of the Neon transfected samples, indicating 
cellular stress resulting from the Neon transfection process. This is further supported by the lack 
of abnormal staining in the untreated cells that were not subjected to the Neon transfection 
process. The minimal disruption of staining in TMO treated cells despite sharing some similarity 
with the 2′OMe-PS chemistry further supports the safety profile and tolerability of the TMO 
chemistry. These findings support the use of TMOs and PMOs, over 2′OMe-PS AOs for further 
pre-clinical investigation of splice switching AOs for FBN1. 
663BImmunofluorescent staining of fibrillin-1 in cells treated with each of the three chemistries 
revealed a similar story, as seen in chapters 3 and 4 of this thesis. Skipping efficiencies that result 
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in a mixture of fibrillin-1 transcripts and thus proteins, result in the complete loss of fibrillin-1 
staining in healthy control cells and maintenance of no fibrillin-1 fibre staining in MFSΔ52 cells 
and MFSC2111R patient cells. This was consistent across all three chemistries. In contrast, fibrillin-
1 fibres formed in healthy control and MFSΔ52 cells after transfection with the TMO sequences 
that resulted in more than 80% exon skipping. However, as seen previously, even extremely 
efficient exon skipping is insufficient to result in fibrillin-1 fibre formation in the MFSC2111R cells. 
The exact cause of this remains elusive, as previously hypothesised the presence of a small 
amount of each of the FBN1 and FBN1c.6331T>C transcripts could be causing this lack of fibrillin-1 
fibre formation. 
664BInterestingly due to both extremely efficient exon skipping (>80%) in some cases and poor 
exon skipping (<20%) in others, we observed fibre formation when the proportion of either FL or 
Δ52 transcripts was above a certain threshold. This threshold was particularly noticeable in 
healthy control fibroblasts treated with the lower concentration of either 2′OMe-PS sequence 
when the low level of exon 52 skipping (<20%) resulted in a very similar fibrillin-1 fibre 
morphology and abundance as seen when inducing greater than 80% exon 52 skipping. Therefore, 
for exon 52, this threshold appears to be approximately 80-85%. Unfortunately, the skipping 
efficiencies of the 2′OMe-PS and PMO AOs were insufficient to overcome this threshold and 
thus, no fibrillin-fibre formation was observed. We propose that additional research with 
additional time-points identifying each chemistry's optimal incubation time could reveal that all 
three chemistries result in a similar staining pattern when inducing sufficient exon skipping. 
665BWhile Eteplirsan and Golodirsen have been found to have positive impacts on clinical 
endpoints,144,251 they need only result in the expression of trace amounts of dystrophin to be 
beneficial in the treatment of DMD.252,253 However, for an AO to be of therapeutic value for MFS, 
it must consistently and robustly induce sufficient exon skipping to result in a homogenous 
population of fibrillin-1 monomers. Therefore, the variable and insufficient exon skipping 
observed here pose a significant barrier, especially when moving forward into in vivo studies 
where AO delivery is a major limiting factor, particularly since AOs tend to accumulate in the 
liver and kidney.254,255  
666BOf several efforts that have been made to enhance the delivery of AOs to the target tissue, one 
promising method is the conjugation of the AO with a cell-penetrating peptide.134,187,188 Cell-
penetrating peptides are typically short peptide fragments derived from naturally occurring 
protein translocation motifs193 that can greatly improve the delivery of AOs. Peptide-PMO 
(PPMO) conjugates designed to treat DMD have demonstrated efficacy in mouse models of 
DMD;236,237 however, some arginine-rich cell-penetrating peptides result in toxicity at high 
doses.132,133 Nevertheless, a clinical trial is currently underway for the PPMO SRP-5051 (Sarepta 
Therapeutics), targeting DMD patients amenable to exon 51 skipping (NCT04004065). Sarepta 
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therapeutics released an announcement in July 2020 that SRP-5051 shows improved tissue 
exposure, exon skipping, and dystrophin production at a lower dose than Eteplirsen, with no 
negative renal findings.256 The clinical trial is ongoing to date. The application of peptide 
conjugated PMOs and possibly TMOs is particularly relevant to this project, where AO-mediated 
exon skipping must be consistent and robust to facilitate a homogenous population of fibrillin-1 
monomers. 
667BIn the previous chapters of this thesis, we described promising AO sequences that can mediate 
the exclusion of FBN1 exons 47, 52 and 59 and lead to the formation of fibrillin-1 fibres under 
certain conditions. This chapter focused on screening AO sequences targeting additional fibrillin-
1 exons to identify a suite of AOs with therapeutic potential. We found that not all FBN1 exons 
are readily skipped and that there is significantly more work that can be done to optimise this 
therapeutic strategy further. We also investigated the efficacy of a third chemistry. We found that 
the TMOs tested were more efficient than their 2′OMe-PS counterparts and at 10 days, more so 
than the PMO equivalents. We also demonstrate that both the PMO and TMO chemistries result 
in minimal disruption of the paraspeckle proteins NONO and SFPQ, further demonstrating their 
safety and supporting their use in further therapy development. The use of antisense 
oligonucleotides is rapidly evolving, and we believe that the research presented here shows the 
great advantage and promise of antisense therapies for the type-1 fibrillinopathies. 
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Chapter 7 
Final Discussion and Conclusions 
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7.1 Current knowledge and splice-switching 
strategies 
668BMarfan syndrome (MFS) is a dominantly inherited connective tissue disorder characterised by 
progressive skeletal, ocular and cardiovascular abnormalities.34 The MFS phenotype varies 
drastically both between and within affected families, leading to a spectrum of severity.4 In the 
most severe form; neonatal MFS, patients begin showing symptoms as neonates and have a life 
expectancy of fewer than 24 months.49 However, for the majority of patients, life expectancy is 
approximately 70 years.75 This life expectancy is more than 30 years longer than that estimated 
in the 1970s, primarily due to advances in surgical intervention and symptom management.35,75,257 
However, despite these advancements, a diagnosis of MFS still places a considerable burden on 
the livelihood and quality of life of those affected,28,171,258 and there are currently no therapeutic 
options that address the primary aetiology of the disease. 
669BMarfan syndrome is caused by mutations in the fibrillin-1 gene (FBN1),1 with over 2800 
unique disease-causing mutations reported that are spread throughout the FBN1 sequence.2,3 
Immediately after translation and secretion the fibrillin-1 protein, encoded by 65 of the 66 FBN1 
exons, the fibrillin-1 monomers aggregate to form the backbone of microfibrils to which other 
microfibril associated proteins bind.11,13,17 Fibrillin-1 is expressed in most connective tissues and 
has both structural11 and regulatory roles.12 An essential function of fibrillin-1 is the regulation of 
transforming growth factor-beta (TGF-β) bioavailability, and thus its activity through 
sequestration and regulated release.12,16 This regulation is critical to maintaining extracellular 
matrix stability; dysregulation due to loss of functional fibrillin-1 microfibrils is one of the 
keystones of the MFS pathogenesis.16,71,72 The way in which FBN1 mutations result in loss of 
functional microfibrils is dependent on the mutation type. Broadly speaking, mutations can result 
in haploinsufficiency,31,161 dominant-negative interaction,68 increased susceptibility to 
proteolysis,15,23 intracellular retention25,52,66 or loss of function.69 
670BThe approvals of the splice-switching antisense oligonucleotide (AO) drugs Eteplirsen,140 and 
Nusinersen163 by the United States Food and Drug Administration (FDA) in late 2016 led to the 
conception that splice-switching strategies could be applied to address fibrillin-1 mutations. We 
hypothesised that removing an amenable mutation-associated exon from all FBN1 transcripts 
would result in internally truncated but identical fibrillin-1 monomers, capable of forming 
microfibrils regardless of the original mutation type. 
671BWe hypothesised that the removal of an amenable exon would result in one of the following 
scenarios. For missense mutations, removing the mutation-associated exon from affected and 
unaffected transcripts would eliminate the aberrant sequence and restore homogeneity between 
fibrillin-1 monomers. For splice-site and in-frame deletion mutations, excluding the mutation-
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associated exon(s) from the remaining unaffected transcripts would also restore the domain 
periodicity and monomer homogeneity. Alternatively, enhancing exon selection could negate the 
effects of splicing mutations and lead to exon inclusion, restoring monomers to the full-length 
state. Lastly, for nonsense and intra-exonic frame-shifting insertion or deletion mutations, 
excluding the mutation-associated exon from the affected transcripts would restore the reading 
frame, rescuing transcript functionality. The mutation-associated exon would also need to be 
removed from the unaffected transcripts to maintain monomer homogeneity. For each of these 
scenarios, we hypothesised that the internally truncated proteins produced would be capable of 
forming microfibrils, given a sufficiently homogenous monomer population. 
7.2 Main findings and study limitations 
672BThe main focus of this thesis was the development of a suite of antisense oligonucleotides 
applicable for therapeutic applications in MFS. We developed AOs to mediate the exclusion of 
the target exon from the FBN1 pre-mRNA and assessed efficacy in healthy control and patient-
derived cells. We also assessed the effects of exon skipping on microfibril formation through 
immunofluorescent staining of fibrillin-1. 
Proof-of-concept 
673BAs an initial proof-of-concept for this project 2′OMe-PS AOs targeting FBN1 exon 52 were 
assessed in healthy control fibroblasts where they were shown to induce exon 52 exclusion. A 
promising AO sequence was then evaluated as a Phosphorodiamidate morpholino oligomer 
(PMO) in healthy control fibroblasts, the result of which was an encouraging increase in induced 
products missing exon 52 in a strong dose-dependent manner. These titration experiments were 
invaluable, allowing us to observe the formation of healthy fibres with 0% exon skipping, loss of 
fibrillin-1 fibres with 50% skipping and subsequent re-appearance of fibrillin-1 fibres with greater 
than 80% skipping. This finding provided the initial evidence that AOs can mediate exclusion of 
a FBN1 exon leading to the formation of fibrillin-1 fibres. 
674BThe dose-response observed in healthy control cells further supports the dominant-negative 
pathogenic model; demonstrating the inability of a heterogenous population of fibrillin-1 proteins 
to form microfibrils. However, this finding also has relevance to mapping potentially amenable 
FBN1 exons that could be targeted with splice-switching therapies. Importantly, being able to 
induce a disease-like state would allow for the use of healthy control cells, rather than specific 
patient cells, to identify exons that when removed do not disrupt the expression or function of 
fibrillin-1. This would be especially applicable to mutations that result in the loss of an exon as 
the target of the AO sequence in such cases is the healthy exon rather than the mutation-
harbouring exon. 
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675BAfter demonstrating initial proof-of-concept, we further extended the research question, asking 
whether the same AO sequence is efficient in multiple cell lines with different mutations? And 
are all mutation types affecting the targeted exon amenable to this splice-switching strategy? 
Further assessment of the PMO52 sequence in fibroblasts from two patients with exon 52 
mutations revealed that the most effective AO sequences were optimal in all cell lines tested. 
However, the effect of exon skipping in the two patient cell lines in response to PMO52 treatment 
differed. The MFSΔ52 cell line, with a heterozygous synonymous mutation that resulted in exon 
52 skipping, responded in much the same way as the healthy control cells, with no fibre formation 
at 50% exon skipping and re-appearance of fibres with more than 80% skipping. However, in the 
MFSC2111R fibroblasts carrying a missense mutation, no fibres were formed even when 95% exon 
skipping was induced. This finding highlights the necessity for extremely efficient exon skipping. 
We suggest the lack of fibres is due to the presence of both wild-type and mutant full-length 
proteins that impedes the ability of the fibrillin-1Δ52 monomers to aggregate. However, further 
investigation, such as removing all full-length transcripts using RNase-H mediated cleavage, will 
reveal if this is truly the case. Conversely, some FBN1 missense mutations may result in a 
negative gain of function or dominant negative effect and hence may not be amenable to this 
splice-switching strategy. 
676BExtending the concept further, we endeavoured to identify effective AOs targeting other FBN1 
exons. Screening of additional 2′OMe-PS AOs revealed promising candidate sequences targeting 
exons 32, 39, 47 and 59. However, for the most part, the PMO equivalents for these sequences 
induced insufficient exon skipping to meet the high demand required for transcript and therefore 
protein homogeneity. The PMO targeting exon 47 was the exception to this, inducing extremely 
efficient skipping in healthy control and MFSΔ47 patient fibroblasts. The resulting fibrillin-1 
staining pattern mirrored that observed after exon 52 skipping. That is, strong fibres in the 
untreated healthy control, total lack of fibres with ~50% skipping and subsequent re-appearance 
of extracellular fibrillin-1 fibres, albeit at a lower abundance, correlated with greater than 80% 
skipping. This finding further supported our hypothesis and cemented the idea that splicing 
mutations are particularly responsive to this treatment strategy. 
677BConversely, the levels of exon skipping induced by PMO32 and PMO39 were insufficient to 
overcome the dominant-negative interaction between differing fibrillin-1 monomers. We 
speculated that a more effective delivery method could increase exon skipping levels in vitro; 
however, neither Lipofectamine 3000 nor Endo-Porter enhanced exon 32 or 39 skipping. It is 
likely that with further optimisation of the AO sequences, chemistry and delivery method, more 
efficient exon skipping could be achieved. For example, as shown in chapter 6, the TMO 
chemistry is very effective and Neon transfection is incredibly efficient. Assessment of AO 
sequences targeting exons 32, 39 and 59 using the TMO chemistry and Neon transfection could 
allow for sufficient skipping to evaluate function of the resulting fibrillin-1 isoforms. 
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678BInconsistent exon skipping across multiple experiments proved to be a major limitation when 
assessing the efficacy of PMO59. In one replicate, PMO59 induced sufficient skipping (79%) in 
the MFS2414* patient cell line to induce some extruded fibrillin-1 fibres; although at a relatively 
low abundance. However, a second replicate saw a large decrease in exon skipping efficiency and 
a resulting lack of fibrillin-1 fibres. Further repeats of this experiment are required to gain a robust, 
and reproducible, understanding of the effects of exon 59 skipping in this patient cell line. 
Furthermore, it would appear that the threshold for ‘sufficient’ exon skipping that results in 
fibrillin-1 fibre formation, may be mutation or cell-line specific. Evidence for this is that more 
than 80% skipping of FBN1 exon 47 or 52 was associated with fibre formation; however, 89% 
skipping of exon 59 resulted in only an increase in diffuse fibrillin-1 staining with minimal fibre 
formation in the MFSΔ59 patient cell line. However, inconsistent skipping efficiencies across 
experimental replicates made it impossible to accurately ascertain the abundance and morphology 
of the fibrillin-1 isoforms created. Determining and rectifying the cause of varying skipping 
efficiencies; most likely resulting from experimental design rather than the PMO itself, would 
allow for a more accurate measure of the effects of exon 59 skipping. 
Recalcitrant FBN1 exons 
679BFurther screening to identify additional FBN1 exons amenable to exon skipping revealed that 
4 of the 15 exons targeted could not be excluded from the transcript using any of the AOs designed 
initially. For a further three exons, a single AO induced less than 10% skipping. In contrast, 
previous studies investigating skipping of dystrophin exons found that 77 of 79 exons could be 
excised, and 2 out of 3 AOs induced some skipping, albeit at different efficiencies.167 However, 
only 36 out of the 69 FBN1 AO sequences tested here induced any exon skipping. 
680BDevelopment of AOs that successfully target these recalcitrant FBN1 exons may be as simple 
as screening additional sequences. On the other hand, modification to the AO chemistry could 
result in more efficient skipping. A recent report identified that the addition of locked nucleic acid 
bases to produce LNA/2′OMe-PS mixmers resulted in more effective AOs.259 However, the cost 
of this improved skipping was the activation of cryptic splicing and other unwanted effects.259 
Therefore, while mixmer AOs could reveal an effective sequence that could be further optimised, 
the balance between benefit and risk of such AOs would need to be evaluated prior to further 
development. Alternatively, we have shown that the TMO chemistry is extremely efficient at 
mediating exon 52 skipping. Assessment of TMO sequences for recalcitrant exons could yield a 
promising sequence that could then be further optimised and developed. Lastly, there is a strong 
likelihood that certain FBN1 exons are not amenable to AO-mediated exon exclusion. Low 
skipping efficiency could be an indicator of necessity or particularly strong exon definition, and 
therefore exclusion of the exon could have negative impact on the function of fibrillin-1. 
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681BThe use of AO cocktails to enhance antisense intervention has been reported several 
times167,260,261 and can greatly increase the level of exon skipping that is achieved compared to 
when using a single AO. We speculate that synergistic cocktails rely on one of the AOs altering 
the secondary structure, allowing the second AO to bind and block splicing. This theory could 
explain why the combination of two effective AOs can be antagonistic, as one may prevent the 
other from binding. The sequence features that result in these differing relationships has not been 
resolved and most likely will differ between targets. Here, we identified that the majority of 
cocktails evaluated resulted in similar skipping efficiencies expected from the two AOs 
individually. However, some synergistic cocktails were identified, most consisted of one AO 
targeting a splice site and the other AO targeting a region enriched for predicted ESEs. However, 
the number of AOs tested for each exon was limited, generally three, and therefore further 
investigation exploring a large number of AOs could reveal a more robust trend and aid in the 
design of optimal splice switching AOs. 
Multi-exon skipping 
682BAs an alternative strategy to single exon skipping, we attempted to induce skipping of three 
consecutive exons simultaneously. Supported by the successful pre-clinical application of multi-
exon skipping for DMD,262–264 the rationale is that effective multi-exon skipping would increase 
the number of individuals that could be treated with a single therapeutic preparation. The 
treatment of a greater number of patients with fewer therapies would prove particularly useful for 
MFS as FBN1 mutations are spread throughout the gene with no mutation hotspots. On average, 
each single-exon skipping AO preparation could only be applied to 1.5% of all FBN1 mutations. 
683BThe region from exon 45 to 47 was chosen as a model for multi exon skipping due to the 
availability of a patient cell line with genomic deletion of exons 45-47 (MFSΔ45-47). Despite low 
skipping efficiencies achieved when screening 2′OMe-PS AOs targeting exons 45 and 46, the 
combination of PMO45, PMO46 and PMO47 induced triple-exon skipping in the majority of 
FBN1 transcripts. Unfortunately, to induce such ‘efficient’ skipping, an extremely high total PMO 
cocktail concentration was required. The tolerability of this PMO concentration, and how it would 
translate to in vivo studies, has not been explicitly reported. However, the high the concentration 
is likely to be a major limiting factor in the further development of multi-exon skipping strategies 
for MFS. Especially since the higher the concentration required, the higher the cost of treatment 
and risk of toxicity.  
684BA second limitation we identified was the unexpected exclusion of exon 48 along with exons 
45, 46 and 47. Non-specific or unexpected AO-mediated exon exclusion has been reported for 
other genes.226,265 However, this was the first time we observed non-specific skipping in FBN1 
transcripts. The reason why exon 48 is also skipped has not been fully explored; however, binding 
of the AOs to nearby exons likely disrupts the motifs influencing exon 48 selection, resulting in 
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its exclusion. The fact that exon 48 seems to be readily excluded indicates that it may be a prime 
target for future therapy development. In addition, if efficient exon 45-48 skipping could be 
achieved, and the resulting protein was functional, such a preparation could be applied as a 
therapy to an even larger number of patients. Nevertheless, while we demonstrate that multi-exon 
skipping is possible for FBN1, it is not currently viable, at least for the FBN1 exon 45-47 region. 
Furthermore, while the multi-exon skipping strategy would be exceptionally useful if successful, 
multicomponent drugs can be less favourable, especially if some components of the drug are not 
always required. Therefore, at this point, further research into this strategy for Marfan syndrome 
will likely be out of scientific curiosity; for example, to determine if other regions of FBN1 are 
more readily removed. 
Alternative chemistry 
685BThe final focus of this research project was the evaluation of the exon skipping induced by the 
newly developed TMO chemistry. The TMO combines properties of both 2′OMe-PS and PMO 
chemistries to form a morpholino-PS hybrid.240 The combination results in high affinity for RNA 
and excellent stability against nucleases.240 We identified that AO sequences targeting FBN1 exon 
52 were more efficient when applied as the TMO chemistry than as the 2′OMe-PS chemistry, 
regardless of the delivery method or duration of incubation. The TMOs and PMOs demonstrated 
similar exon skipping efficiencies 24 hours after transfection. After ten days, the PMO resulted 
in a loss of cell viability; subsequent cell proliferation then diluted the PMOs effects. In contrast, 
the TMO continued to show increased exon skipping over the ten-day period. One of the major 
advantages of the TMO chemistry is the ease of synthesis, compared to PMOs, that does not 
require specialised equipment other than a conventional nucleic acid synthesiser.240 The 
thiophosphoramidate backbone of the TMO chemistry also enables the incorporation of other 
chemical modifications allowing further customisation of the oligo.240 Therefore, the equal, or 
possibly greater, skipping efficiency of the TMO chemistry combined with its ease of synthesis 
provides strong support for its further evaluation and addition to the repertoire of chemistries 
routinely used in studies developing antisense therapeutics. 
686BA second, unexpected outcome of the TMO evaluation process was the acquisition of the 
Neon® Transfection System (Life technologies, Thermo Fisher Scientific) and consequent 
efficient transfection of TMOs. The Neon system was initially evaluated as it requires a lower 
transfection volume and thus requires less reagent. We found this method to be incredibly efficient 
at delivering not only TMOs, but also PMOs and 2′OMe-PS AOs. One of the major advantages 
being the use of 12.5 times less PMO than required when using the 4D-Nucleofector™ (Lonza). 
Reassessment of the PMO AOs described throughout this thesis, using the Neon transfection 
system could result in sufficient skipping to accurately and reproducibly assess the effects of exon 
skipping on the function of the fibrillin-1 isoforms produced. It is important to note, however, 
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that while efficient in vitro delivery may provide proof-of-concept and efforts to enhance AO 
delivery to target organs and cells are underway184,188,190,191 in vivo delivery still faces significant 
challenges that must be overcome.132,193 
687BOne of the main drawbacks of the 2′OMe-PS AOs that we have reported is their propensity to 
cause cell death and impact on cellular functions.244 This cell death limits the concentration and 
incubation period that can be tested, consequently limiting the exon skipping. We reported 
interaction between the PS backbone and paraspeckle and other nuclear proteins, leading to 
sequestration and the formation of nuclear and cytoplasmic aggregates, ultimately leading to 
apoptosis.113,243,244 Flynn et al.244 reported that PMO sequences do not induce the formation of 
aggregates. However, the effect of the TMO chemistry on paraspeckle proteins was unknown at 
that time. We demonstrate that while the 2′OMe-PS AOs caused aggregates in a large proportion 
of cells, the paraspeckle protein staining in TMO and PMO treated cells was, for the most part, 
consistent with untreated cells. 
688BAntisense oligonucleotides with a PS-backbone have a varied history in the clinic. While some 
trials are on-going,197 the Drisapersen DMD studies were suspended after failing to meet primary 
and secondary endpoints, while also associated with life threatening side effects including 
injection site reactions, renal effects and thrombocytopenia.266–268 The hepatotoxicity observed 
may, in-part, be the result of off-target hybridization, however, the exact cause of the injection 
site reactions remains unknown.269 Some groups have reported evidence suggesting the toxicity 
is mediated at least in part by the non-specific interaction of nuclear proteins with the PS 
backbone.243,244,270 Therefore, while further assessment of TMOs is certainly required to assess 
their tolerability and safety in vivo, the minimal disruption of SFPQ or NONO localisation in 
TMO-treated cells, despite the TMO sharing similarities with the 2′OMe-PS chemistry, provides 
promising evidence for the TMO chemistry's safety and tolerability. These findings further 
support use of the TMO and PMO chemistries, over 2′OMe-PS AOs, when further developing 
AO for potentially therapeutic applications. 
7.3 Unanswered questions and future challenges 
689BThis study has shown proof-of-concept for the potential therapeutic benefit of AO mediated 
splice-switching to restore the homogeneity of fibrillin-1 monomers, at least for some mutations. 
However, this study has several limitations and questions left unanswered for which further 
investigation is required. 
The function of the fibrillin-1 isoforms created 
690BThe primary finding of this study was the re-appearance of extracellular fibrillin-1 fibres in 
certain cell lines after more than 80% skipping was induced. This result demonstrated that the 
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fibrillin-1Δ47, fibrillin-1Δ52 and fibrillin-1Δ59 proteins could form fibre-like aggregates in the near-
absence of wild-type fibrillin-1 monomers. However, we were not in the position to further 
explore the function of the fibrillin-1 isoforms produced. To be of therapeutic value, the proteins 
produced must be capable of forming the microfibril backbone, interacting with microfibril 
associated proteins and regulating proteins such as TGF-β. Methods to evaluate particular 
functions of fibrillin-1 have been described,23,230,271,272 however, such functional analysis was 
outside of the scope of this thesis.  
691BEach domain type in fibrillin-1 is associated with particular functions, however, the specific 
functions of each domain and the possibility of functional redundancy have not been fully 
explored. With the current knowledge of the fibrillin-1 domain types, we can begin to make 
assumptions about the effects of exon exclusion and indicate what particular function(s) the 
removal of the domain could disrupt. For example, the majority of exons we targeted encode for 
cbEGF-Like domains that bind to calcium. Most mutations affecting these domains disrupt 
calcium-binding, leading to proteolysis23 or disruption of fibrillin-1 secondary or tertiary structure 
and microfibril assembly.25,183,273 We hypothesised that removal of the entire exon encoding these 
domains will negate the altered domain structure. Therefore, assessing the calcium-binding 
capacity and proteolysis of fibrillin-1 isoforms lacking these domains would be essential. 
692BSimilarly, targeting exons 39 and 52 lead to the partial removal of TB domains, while skipping 
of exon 22 leads to the partial removal of a hybrid domain. Homozygous mutations that result in 
skipping or in-frame deletion of these exons have not been reported; therefore, the function and 
stability of the fibrillin-1 isoforms lacking these partial domains are unknown. The hybrid 
domains are reported to play an integral role in fibrillin-1 folding and microfibril assembly.21,22 
Therefore, changes in microfibril morphology, and bead-to-bead periodicity between wild-type 
and AO-induced isoforms could be revealed using electron microscopy.272,274 Less is known about 
the function of the TB domains, however, they are involved in extracellular matrix construction 
and storage of latent TGF-β.228–230 The importance of these domains could mean that a fibrillin-1 
isoform lacking one domain may be non-functional. Therefore, the ability of the AO-induced 
fibrillin-1 isoforms to regulate TGF-β also needs to be assessed. 
693BAnother key finding to be addressed by further research is the overall decrease in fibrillin-1 
staining abundance we observe when inducing exon skipping. We were unable to resolve the 
cause or effect of this loss of fibres. Attempts to isolate and visualise intracellular and extracellular 
fibrillin-1 via western blotting were inconsistent with poor fibrillin-1 detection in healthy control 
samples. This meant that possible changes in the abundance of fibrillin-1; that could explain loss 
of fibre formation, were unable to be assessed. One possible explanation is that the extruded 
fibrillin-1 fibrils are too unlike the normal protein and are degraded. Nevertheless, we know that 
fibrillin-1 haploinsufficiency leads to the MFS phenotype. Therefore, further investigation should 
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be performed to determine 1) the cause of reduced fibrillin-1 expression, 2) the amount of 
fibrillin-1 fibres required to reduce the MFS phenotype and 3) a way to increase the expression 
of the fibrillin-1 isoforms being produced. To better understand the function of the fibrillin-1 
isoforms induced in vivo models would be required. 
Fibroblast and animal models in therapy development 
694BFibroblasts derived from skin biopsies are a common model for in vitro studies because they 
are readily obtainable compared to many other cell types. Fibrillin-1 is expressed throughout the 
body, including dermal fibroblasts169 making them a viable cell model for our initial 
investigations. However, Aubert et al.161 demonstrated that several different mechanisms, 
including fibrillin-1 expression, are involved in determining the severity of MFS symptoms, and 
that these mechanisms differ between organ, tissue and cell types. Therefore, while a fibroblasts 
model may be sufficient for initial screening and proof-of-concept, further investigation of splice-
switching therapies should include assessment across multiple cell and tissue types. 
695BAnimal models, in particular mouse models, have greatly advanced our understanding of 
diseases, their mechanisms and enable pre-clinical assessment of therapeutic preparations.275–277 
There are multiple mouse models available in which mutations have been generated in the mouse 
Fbn1. These mouse models have been reviewed by Sakai et al.278 and Rurali et al.275 Some of the 
phenotypes of Marfan syndrome were successfully recapitulated, and different models 
demonstrate the effects of hypomorphic, missense and in-frame deletion mutations. Of particular 
interest to this study are mouse models with in-frame deletions, as they could provide insight into 
exon skipping. The mgΔloxPneo has an in-frame deletion of Fbn1 exons 19-24.279 In a heterozygous 
state mgΔloxPneo display a MFS phenotype while homozygous animals die 4-8 days after birth.279 
This finding appears to conflict with our current hypothesis, however, quantification of the Fbn1 
mRNA levels revealed 47% expression of the wild-type protein.279 Therefore, this model is 
demonstrating a haploinsufficiency pathogenic mechanism. 
696BTwo other mouse models arise from Fbn1 in-frame deletions of exon 7280 and exons 9-11,180 
however, in both cases, heterozygous and homozygous animals live long lives. Unfortunately, 
none of the currently available mouse models accurately demonstrate the effect of splice site 
mutations or the effects of exon skipping in a heterozygous or homozygous state. Due to the exon-
specific nature of splice-switching AOs, a different mouse model would be required for each 
exon. Consequently, this is where the ability to create a disease-like state in normal cells through 
skipping the target exon in 50% of transcripts could prove useful in the initial testing of promising 
candidates. 
697BWhile mouse models are, at this stage, unavoidable in pre-clinical assessment of potential 
therapies, the clinical relevance of splice-switching AOs in mouse models has limitations. Animal 
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models are often unable to fully recapitulate the human condition.281,282 An example of this is the 
mdx mouse in which a null allele due to stop codon results in no major phenotype despite 
disrupted dystrophin expression.283,284 Another major limitation is that the splicing machinery and 
regulatory sequences differ between species. Therefore, splicing outcomes in a mouse model do 
not always translate into those in human cells and vice versa. We previously reported a human-
mouse comparison for dystrophin AO target sites showing that approximately 1/3 transferred 
coordinates, 1/3 had minor correlation and 1/3 worked in one species and not the other.260 
698BThe domain organisation of fibrillin-1 is conserved through evolution from jellyfish through 
to humans.285,286 However, regulatory motifs likely differ between the mouse and human 
sequences due to variability in the splicing factors themselves. Additionally, the mRNA 
secondary structure will vary between species, due to variation in the sequence and interaction 
with RNA binding proteins, resulting in an altered splicing pattern.245 Both factors are likely to 
alter the efficacy of specific AO sequences. Another consideration is that while fibrillin-1 is the 
predominant form in cells derived from a human adult skin biopsy, in mice in vivo there are 
two, and in humans, three, fibrillin genes and associated proteins.5 Since fibrillin-2 and to an 
extent fibrillin-3, would be involved in microfibril formation in vivo,5,18 it would be 
interesting to determine how this affects the efficacy, and specificity of the FBN1 targeting 
AOs. It is possible that a pre-existing microfibril matrix could enhance the positive effects we 
observe as a result of exon skipping (L Sakai, 2021, personal communication 14 June). 
Conversely, other factors such as non-specific binding to the similar FBN2 and FBN3 gene 
transcripts could result in undesired splicing or sequester the AOs from their intended FBN1 
target. Such factors should be considered when moving forward into in vivo studies. 
699BAlignment of the optimal AO sequences for exons 47, 52 and 59 with mouse Fbn1 
demonstrates both the sequence similarity and the narrow margin for variation. The AO 
sequences targeting FBN1 exons 47 and 59 differ from the mouse sequence by three bases 
(Table 7.1). The exon 52 AO sequence differs by only two bases between mouse and human 
(Table 7.1). Interestingly, one of these two bases corresponds to the synonymous c.6354C>T 
mutation identified in the MFSΔ52 patient151 that results in exon 52 skipping by disrupting the 
balance between ESE and ESS motifs. The presence of a ‘C’ rather than a ‘T’ at this position 
without resulting in exon 52 skipping further indicates that the splicing motifs of the mouse 
Fbn1 differ from those of the human gene. Mitrpant et al.260 reported a similar finding where 
two overlapping AO sequences designed to induce exon 53 skipping in mouse dystrophin 
resulted in cryptic splicing, however, no cryptic splicing was observed when targeting the same 
co-ordinates in the human dystrophin transcript. Nevertheless, animal models are currently the 
best available option for the pre-clinical evaluation of AOs. Therefore, the AOs tested here 
should follow this development pipeline. However, the limitations of these models should be 
taken into consideration when interpreting the results.  
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726BTable 7.1: Alignment of the optimal AOs targeting FBN1 exons 47, 52 and 59 with the mouse Fbn1 
3807BAO47.2 / PMO47 
2722BHuman 1293BG 1294BT 1295BT 1296BC 1297BC 1298BT 1299BT 1300BC 1301BA 1302BA 1303BC 1304BT 1305BG 1306BC 1307BC 1308BG 1309BC 1310BT 1311BG 1312BC 
1313B| 1314B* 1315B| 1316B| 1317B| 1318B| 1319B| 1320B| 1321B| 1322B| 1323B| 1324B| 1325B| 1326B* 1327B| 1328B| 1329B| 1330B| 1331B| 1332B* 
2723BMouse 1333BG 1334BC 1335BT 1336BC 1337BC 1338BT 1339BT 1340BC 1341BA 1342BA 1343BC 1344BT 1345BG 1346BT 1347BC 1348BG 1349BC 1350BT 1351BG 1352BT 
3808BAO52.1n / PMO52 
2724BHuman 1353BA 1354BA 1355BG 1356BT 1357BG 1358BG 1359BG 1360BA 1361BT 1362BC 1363BA 1364BT 1365BC 1366BG 1367BT 1368BG 1369BG 1370BG 1371BA 1372BC 1373BC 1374BT 1375BG 1376BA 1377BT 
1378B| 1379B| 1380B| 1381B| 1382B| 1383B| 1384B| 1385B| 1386B| 1387B| 1388B| 1389B| 1390B* 1391B| 1392B| 1393B| 1394B| 1395B| 1396B* 1397B| 1398B| 1399B| 1400B| 1401B| 1402B| 
2725BMouse 1403BA 1404BA 1405BG 1406BT 1407BG 1408BG 1409BG 1410BA 1411BT 1412BC 1413BA 1414BT 1415BT 1416BG 1417BT 1418BG 1419BG 1420BG 1421BC 1422BC 1423BC 1424BT 1425BG 1426BA 1427BT 
3809BAO59.2 / PMO59 
2726BHuman 1428BT 1429BG 1430BG 1431BG 1432BG 1433BA 1434BA 1435BT 1436BG 1437BT 1438BG 1439BT 1440BC 1441BA 1442BA 1443BT 1444BG 1445BA 1446BC 1447BA 1448BG 1449BA 1450BG 1451BG 1452BA 
1453B| 1454B| 1455B| 1456B| 1457B| 1458B| 1459B* 1460B| 1461B| 1462B| 1463B| 1464B| 1465B| 1466B| 1467B| 1468B* 1469B| 1470B| 1471B| 1472B| 1473B| 1474B| 1475B| 1476B| 1477B* 
2727BMouse 1478BT 1479BG 1480BG 1481BG 1482BG 1483BA 1484BG 1485BT 1486BG 1487BT 1488BG 1489BT 1490BC 1491BA 1492BA 1493BC 1494BG 1495BA 1496BC 1497BA 1498BG 1499BA 1500BG 1501BG 1502BG 
Clinical trials for rare diseases 
700BAnother major challenge to the future of AO therapies for MFS and other rare diseases is the 
current clinical trial format that is less conducive to the development and assessment of 
personalised medicines. Some of the main limitations being small patient numbers, extensive 
phenotypic variation between patients, uncertain endpoints as well as varying ages and degree of 
disease progression. The ethical dilemma of treating an individual with a known disease outcome 
with a placebo drug should also be considered, especially when involving children. The FDA has 
now granted accelerated approval for three antisense drugs for DMD.140,142,164 However, before 
the approval of Eteplirsen in late 2016,140,144 concerns were raised over its efficacy, in particular, 
due to the small number of patients in the trial (12) and the lack of a placebo cohort. The rarity of 
such genetic disorders combined with the personalised nature of splice-switching therapies limits 
the number of patients able to participate in clinical trials. Therefore, clinical trials need to be 
adapted to overcome these limitations and additional clinical trial formats developed for rare 
diseases for which n-of-1, or similarly low participant numbers, are likely to be required. 
701BTo compensate for the small patient numbers robust surrogate outcome measures and 
biomarkers are used. For DMD, among a suite of other ambulation-based outcome measures,287 
changes in muscle dystrophin is quantified and used to verify the efficacy of the treatment under 
evaluation.288 Evaluation of therapeutics for DMD also relies heavily on the well-established 
genotype:phenotype correlations between Duchenne- and Becker- muscular dystrophy that 
provides unequivocal evidence that some internally truncated dystrophin isoforms are 
functional.289–291 The known natural history of DMD could also aid in drug evaluation by acting 
as a ‘placebo-like’ comparison-point when assessing outcome measures.292,293 However many of 
these strategies would be less applicable to drug evaluation for MFS. Quantification of fibrillin-
1 alone would be insufficient to determine if the protein is forming microfibrils and preforming 
its other regulatory roles, making quantification an inaccurate outcome measure. Similarly, the 
variability in phenotype within and between MFS families30,273,294 hinders the ability to establish 
an unequivocal disease trajectory to use as a comparison point. While mild Marfan phenotypes 
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have been reported,295,296 the genotype-phenotype correlations are not as well established as they 
are for Duchenne- and Becker- muscular dystrophy. However other measures can be used, one of 
the most common biomarkers for MFS is serum levels of transforming growth factor‐β (TGF‐
β).297 High levels of TGF‐β in serum is correlated with faster aortic root growth and therefore 
changes in TGF‐β levels has substantial prognostic value.297 For clinical trials evaluating 
Irbesartan, a drug aimed at decreasing dilatation of the aorta in MFS patients, the rate of aortic 
root dilatation was assessed as the primary endpoint.298 Identification of additional measures for 
more of the MFS phenotype could further increase the strength of such drug evaluation. 
702BAnother limitation in the clinical evaluation of many splice-switching therapies is the inability 
to assess the safety and tolerability of the drug in healthy volunteers. We have clearly 
demonstrated that less than 80% skipping in healthy control cells results in a disease-like loss of 
fibrillin-1 fibres. We also show that even with 80% skipping, the abundance of fibres can be 
greatly reduced. Therefore, assessment of FBN1 AOs in individuals without MFS would likely 
result in deleterious effects. We suggest that while the safety of each AO chemistry needs to be 
evaluated in a clinical setting, the safety of individual AO sequences should be assessed in pre-
clinical animal studies and patient cell-derived models.  
703BThe way in which safety studies are undertaken regarding dose escalation and selection of the 
maximum tolerated dose should also be considered. One class of phase 1 trial designs widely used 
is known as up-and-down designs that assess dose escalation and de-escalation based on 
prespecified algorithms.299–301 One of the most well-known is the 3 + 3 design in which cohorts 
of three patients are sequentially enrolled, with each cohort receiving an increasingly high 
dose.299,300 However, for splice-switching therapies, the required dose and possible associated 
adverse events of one patient will not necessarily be consistent across all patients, especially when 
considering the extreme phenotypic variability of Marfan syndrome.30,273,294 A possible way to 
address this could be personalised dose-escalation. In this approach, following an initial dose, if 
the drug is well-tolerated, the dose is incrementally increased while monitoring adverse events 
until a change in specified biomarkers is observed. We believe that a more personalised approach 
to design, development and clinical evaluation of AO-mediated exon skipping therapies for the 
type-1 fibrillinopathies will be the most appropriate. 
7.4 Final remarks and conclusions 
704BThis primary focus of this thesis was developing a suite of AOs that efficiently and specifically 
excise targeted exons from the FBN1 pre-mRNA, thereby restoring fibrillin-1 microfibril 
assembly. Although this study is a preliminary, in vitro investigation, we demonstrate several 
novel findings. (1) Our candidate PMOs for exons 47, 52 and 59 induce efficient exclusion of the 
target exons. (2) Demonstrating proof-of-concept; more than 80% skipping of these exons can 
162 
result in fibrillin-1 fibre formation in healthy control and some of the patient fibroblasts. (3) Of 
particular significance, we demonstrate that in healthy control cells inducing approximately 50% 
skipping results in a disease-like loss of fibrillin-1 staining. This finding supports the dominant-
negative model and indicates that healthy control cells could be used in place of specific patient 
samples for preliminary studies.  
705BThroughout this thesis, we have demonstrated strong exon skipping across multiple FBN1 
exons. However, we also found that not all FBN1 exons are as readily excluded signifying the 
extensive work that remains in developing this therapeutic strategy further. Lastly, we report on 
the more recently developed TMO chemistry. The TMO chemistry showed promising efficiency 
and tolerability in vitro; therefore, we believe it will become commonplace alongside PMOs in 
the development of Antisense therapies. While the requirement for extremely efficient exon 
skipping was one of the most significant limitations to this study, several other challenges and 
new questions were raised. Other factors that will need to be considered for future studies include 
the functionality of the fibrillin-1 isoforms produced, the effect of lowered fibrillin-1 abundance, 
the relatively high AO concentrations used, and inconsistency between experiments. 
706BAdvancements made to the management and surgical correction of MFS symptoms have 
significantly increased patients' life expectancy over the last 4-5 decades.35,75,257 However, 
therapies targeting the cause of disease could provide significant clinical benefit to patients; 
therefore, our search into AO-mediated therapies continues. The strategy presented here could be 
extended to several other genetic disorders with similar mechanisms, including the other type-1 
fibrillinopathies. With the recent success of splice-switching AO therapies, namely the approval 
of Nusinersen,163 Eteplirsen,140 Golodirsen142 and Viltolarsen,164 the number of clinically available 
antisense drugs has grown, and numerous pre-clinical and clinical trials are on-going. The use of 
antisense oligonucleotides is rapidly evolving, and we believe that the research presented here 





Appendix 1 Chapter 2 supplementary data 
Fibrillin-1 antisense oligonucleotides 
Table A1.1: A full list of antisense oligonucleotides used in this study. 
740BThe name, ID, GC content, length, chemistry and designer for each AO used in this study. The AO nomenclature is outlined in Chapter 2, Figure 2.1. 
741BKG: Mr Kane Greer , JC: Ms Jessica Cale. 
3810BAO Name 
3811B(FBN1 H…) 






2728B15A(-15+10) 2729BAO15.1 1503BUCA UCC AUA UCU GAA AAU ACA AAA C 2730B 5 2731B ʹOMe-PS 2732BKG 
2733B15A(+41+65) 2734BAO15.2 1504BACU GCC AUC UUC AUU GAU ACA CAU U 2735B 5 2736B ʹOMe-PS 2737BKG 
2738B15D(+12-13) 2739BAO15.3 1505BUUA UAG CAC GAA CCU UUG CAA UAA C 2740B 5 2741B ʹOMe-PS 2742BKG 
2743B16A(-14+11) 2744BAO16.1 1506BCUC GUU AAU GUC UGU GGC AGA GAA A 2745B 5 2746B ʹOMe-PS 2747BJC 
2748B16A(+27+51) 2749BAO16.2 1507BUGA CGC AAC GCC CAU UCA UGC AGA U 2750B 5 2751B ʹOMe-PS 2752BJC 
2753B16D(+14-11) 2754BAO16.3 1508BUGU UUU CUU ACC AAC ACA CAC ACG G 2755B 5 2756B ʹOMe-PS 2757BJC 
2758B16A(+22+46) 2759BAO16.2+5 1509BCAA CGC CCA UUC AUG CAG AUC CCA G 2760B 5 2761B ʹOMe-PS 2762BJC 
2763B16A(+32+56) 2764BAO16.2-5 1510BAGU GUU GAC GCA ACG CCC AUU CAU G 2765B 5 2766B ʹOMe-PS 2767BJC 
2768B16D(+09-16) 2769BAO16.3-5 1511BCAU GAU GUU UUC UUA CCA ACA CAC A 2770B 5 2771B ʹOMe-PS 2772BJC 
2773B 2A(-13+12) 2774BAO22.1 1512BCCU UGA UGG UUU CUG CAG AGG AGG G 2775B 5 2776B ʹOMe-PS 2777BJC 
2778B 2A(+45+69) 2779BAO22.2 1513BUGG CUC CAU UGA UGU UGA UCU CAC A 2780B 5 2781B ʹOMe-PS 2782BJC 
2783B 2A(+84+108) 2784BAO22.3 1514BCAC GCA GCA CCG AGG GAG GAG CAG C 2785B 5 2786B ʹOMe-PS 2787BJC 
2788B 2D(+16-09) 2789BAO22.4 1515BUUC UCU UAC CAA CUU GGC AUA GGG U 2790B 5 2791B ʹOMe-PS 2792BJC 
2793B 6A(-18+07) 2794BAO26.1 1516BUUG AUA UCU UCA AGA AUA AGA AAA U 2795B 5 2796B ʹOMe-PS 2797BJC 
2798B 6A(+70+94) 2799BAO26.2 1517BAAG CCG CUG UCA CAC CUG CAC UUA A 2800B 5 2801B ʹOMe-PS 2802BJC 
2803B 6D(+22-03) 2804BAO26.3 1518BGAC CUG UGC AGU UCC UUU CUU CAG A 2805B 5 2806B ʹOMe-PS 2807BJC 
2808B 6A(+75+99) 2809BAO26.2-5 1519BGAG CAA AGC CGC UGU CAC ACC UGC A 2810B 5 2811B ʹOMe-PS 2812BJC 
2813B 6A(+100+124) 2814BAO26.3+5 1520BGUG CAG UUC CUU UCU UCA GAA UCA A 2815B 5 2816B ʹOMe-PS 2817BJC 
2818B 7A(-25-01) 2819BAO27.1 1521BCUG CAC AAA AAC AGC AAG UGG CAG C 2820B 5 2821B ʹOMe-PS 2822BKG 
2823B 7A(+38+62) 2824BAO27.2 1522BAGG GGU GUU CAC ACA CUG GCC UCU G 2825B 5 2826B ʹOMe-PS 2827BKG 
2828B 7A(+105+129) 2829BAO27.3 1523BCCA UGC AGU UCU UCA UCA UCA UGA A 2830B 5 2831B ʹOMe-PS 2832BKG 










2838B 1A(+76+100) 2839BAO31.2 1525BGCC AUG AAU CCA UCA UAA CAC AAG C 2840B 5 2841B ʹOMe-PS 2842BKG 
2843B 1D(+13-12) 2844BAO31.3 1526BUUC UUU GCU UAC CUA CAC AAG UCU U 2845B 5 2846B ʹOMe-PS 2847BKG 









2860B32D(+14-11) 2861BAO32.3 1529BAAC AAA CAC ACC UGU ACA GCC AGU U 2862B 5 2863B ʹOMe-PS 2864BJC 
2865B32A(-08+17) 2866BAO32.1-5 1530BGUC ACA CUC AUU GAC AUC UGU AAA A 2867B 5 2868B ʹOMe-PS 2869BJC 
2870B32A(+42+66) 2871BAO32.2+5 1531BAGC CUU UCG UGU UUU CAC AGG UCC C 2872B 5 2873B ʹOMe-PS 2874BJC 
2875B32A(+52+76) 2876BAO32.2-5 1532BCAG AUA AAU GAG CCU UUC GUG UUU U 2877B 5 2878B ʹOMe-PS 2879BJC 
2880B32D(+19-06) 2881BAO32.3+5 1533BACA CAC CUG UAC AGC CAG UUU UUC C 2882B 5 2883B ʹOMe-PS 2884BJC 









2897B39A(+31+55) 2898BAO39.2 1536BGUG AUA GGA UUU GGU CGG AAA CCU U 2899B 5 2900B ʹOMe-PS 2901BJC 
2902B39D(+04-16) 2903BAO39.3 1537BAAG GAA ACA CAA UUA CCU UC 2904B 0 2905B ʹOMe-PS 2906BJC 
2907B44A(+14+38) 2908BAO44.1 1538BUUC ACA GAC CCC UGG GAU CUC CCG G 2909B 5 2910B ʹOMe-PS 2911BKG 
2912B44A(+44+68) 2913BAO44.2 1539BGCU GCC AAC CAU GUU GAU ACA CAC U 2914B 5 2915B ʹOMe-PS 2916BKG 
2917B44D(+19-06) 2918BAO44.3 1540BACU UAC CUU CAC AAA CCA ACA ACU U 2919B 5 2920B ʹOMe-PS 2921BKG 
2922B45A(+15+39) 2923BAO45.1 1541BUGC GCU GGC ACA CUG GGC CGU UCU G 2924B 5 2925B ʹOMe-PS 2926BKG 
2927B45A(+49+73) 2928BAO45.2 1542BCGG UAG CUG CCU GCA GUG UUG AUG C 2929B 5 2930B ʹOMe-PS 2931BKG 
2932B45A(+87+111) 2933BAO45.3 1543BCUG UGG AGG UGA AGC GGU AGC CGG G 2934B 5 2935B ʹOMe-PS 2936BKG 
2937B45D(+21-04) 2938BAO45.4 1544BAUA CCA UUG CAC UGU CCU GUG GAG G 2939B 5 2940B ʹOMe-PS 2941BJC 
2942B 6A(-09+16) 2943BAO46.1 1545BUGA CAU UCA UUA CGA UCU GUA AAU A 2944B 5 2945B ʹOMe-PS 2946BKG 
2947B 6A(+72+96) 2948BAO46.2 1546BUAA AAC CAG UGU GGC AAA GGC AAU A 2949B 5 2950B ʹOMe-PS 2951BKG 
2952B46D(+12-13) 2953BAO46.3 1547BAUU GCA UAC UUA CCC AAG CAC AUG G 2954B 5 2955B ʹOMe-PS 2956BKG 
2957B46A(-03+22) 2958BAO46.4 1548BAUU UCU UGA CAU UCA UUA CGA UCU G 2959B 5 2960B ʹOMe-PS 2961BJC 









2974B 7A(+83+102) 2975BAO47.3 1551BUGU GAG AAA GGA UGA AAC CA 2976B 0 2977B ʹOMe-PS 2978BJC 
2979B47D(+05-15) 2980BAO47.4 1552BAUU UUG CAC ACG CAC CUA UA 2981B 0 2982B ʹOMe-PS 2983BJC 
2984B 7A(+44+68) 2985BAO47.5 1553BGUU GAA GGA ACC AAU UGU GUU CCG G 2986B 5 2987B ʹOMe-PS 2988BJC 










2994B 7D(+24-01) 2995BAO47.7 1555BCCU AUA CAG UCA UUG UUG UGA GAA A 2996B 5 2997B ʹOMe-PS 2998BJC 




1557BUGA UUG CAG CGG CAG UUG AAG GAA CCA 




3011B49A(-13+12) 3012BAO49.1 1558BAUU CAU UGA UAU CUG CAA AGA AAA G 3013B25 3014B2ʹOMe-PS 3015BKG 
3016B49A(+19+43) 3017BAO49.2 1559BCCU GGU GCA CAU UUU CUG GGU UCU A 3018B25 3019B2ʹOMe-PS 3020BKG 
3021B49A(+83+107) 3022BAO49.3 1560BAUU UUG AAG ACU GUA UCC AGG UGG G 3023B 5 3024B ʹOMe-PS 3025BKG 





























3056B 2A(-08+17) 3057BAO52.2 1565BUAU CUG GCG GAA GGC CUC UGU GGU G 3058B25 3059B2ʹOMe-PS 3060BKG 
3061B52D(+13-12) 3062BAO52.3 1566BCAG GCA ACU GAC CAA CUG CUG AAU C 3063B25 3064B2ʹOMe-PS 3065BKG 
3066B52A(-23+02) 3067BAO52.4 1567BCUC UGU GGU GGA GAC ACU CAU UAA U 3068B25 3069B2ʹOMe-PS 3070BKG 
3071B52A(+03+27) 3072BAO52.5 1568BCAU AAG GAC AUA UCU GGC GGA AGG C 3073B25 3074B2ʹOMe-PS 3075BKG 









3088B59A(+86+110) 3089BAO59.3 1571BAGU UAU AUC UGG AGU GUA CCC AGU U 3090B25 3091B2ʹOMe-PS 3092BJC 
3093B59A(+36+60) 3094BAO59.2+5 1572BUGU CAU UGA CAC AUU CCC CAU UUC G 3095B25 3096B2ʹOMe-PS 3097BJC 
3098B59A(+46+70) 3099BAO59.2-5 1573BUAU GAU CCU CUG UCA UUG ACA CAU U 3100B25 3101B2ʹOMe-PS 3102BJC 
3819BExon 52 inclusion 
3103B52A(-181-157) 3104BAOi51.1 1574BCCC UAA GAU GUU GUG UCU ACU CCU U 3105B25 3106B2ʹOMe-PS 3107BKG 
3108B52A(-130-106) 3109BAOi51.2 1575BAAU GAU GGA AAA AAC AAG CCC AGA A 3110B25 3111B2ʹOMe-PS 3112BKG 
3113B52A(-44-20) 3114BAOi51.3 1576BUAA UAG AUA GAA CAA UAG CAA UUC A 3115B25 3116B2ʹOMe-PS 3117BKG 
3118B52D(-01-25) 3119BAOi52.1 1577BUGA GAA UCC AGC ACA GGC AAC UGA C 3120B 5 3121B ʹOMe-PS 3122BKG 
3123B52D(-46-74) 3124BAOi52.2 
1578BAAA AUA AGA AUA ACU AGA GAA GAA GCA 
GA 










3128B52D(-98-122) 3129BAOi52.3 1579BAAU GAA GGG ACA AAA AAG UAG CAC U 3130B25 3131B2ʹOMe-PS 3132BKG 
3820BControl AOs 
3133BUnrelated Control 3134BCtrl 1580BGGA UGU CCU GAG UCU AGA CCC UCC G 3135B25 3136B2ʹOMe-PS 
3137BControl AO 1 3138BCtrl AO1 1581BATG TCC TGA GTC TAG ACC CU 3139B20 3140BTMO 
3141BGeneTools control 3142BGTC 1582BCCT CTT ACC TCA GTT ACA ATT TAT A 3143B25 3144BPMO 
3145BModified GeneTools control 3146BmGTC 1583BTCT TAC CTC AGT TAC AAT TU 3147B20 3148B2ʹOMe-PS / TMO 
3149BSMN H7A(+13+32) 3150BSMN-7 1584BCAC CTT CCT TCT TTT TGA TU 3151B20 3152B ʹOMe-PS / TMO 
3153BCOL7A1 H73A(+21+40) 3154BCOL-73 1585BCGC CCT TCA GCC CGC GTT CU 3155B20 3156B2ʹOMe-PS / TMO 
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Patient cell lines 
Table A1.2: Details of all Marfan syndrome patient cell lines used in this study. 
742BAll patient cells were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research. Mutations were previously reported by the indicated reference. All mutations 
were confirmed via Sanger sequencing. F: female, M: male, cMFS: classic Marfan syndrome, nMFS: Neonatal Marfan syndrome. Type refers to the five groups outlined by Aoyama et al.69 with S and D 
representing synthesis and deposition of fibrillin-1, respectively, as a proportion of that observed in a healthy control. 
3821BCoriell ID 3822BID 3823BSex/Age 3824BDiagnosis 3825BExon 3826BVariant in DNA/RNA 3827BPredicted Protein change 3828BMutation type 3829BType 3830BReference 









3169BLiu et al.183 





3178BTynan et al.242 









3190BLiu et al.170 





3199BIn-frame loss of Exon 47 + 





3203BLiu et al.183 










3216BLiu et al.151 





3225BKörkkö et al.302 
3226BGM21992 3227BMFSR2414* 3228BF/22 
3229BSevere 
MFS 
3230B59 3231Bc.7240C>T 3232Bp.(Arg2414*) 3233BNonsense 
3234BType II  
3235BS:41% 
3236BD:21% 
3237BSchrijver et al.61 




3246BIn-frame loss of Exon 59 
3247BSplice site 
3248BType IV  
3249BS:88% 
3250BD:16% 
3251BLiu et al.183 
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Enlarged immunofluorescence images 
Figure A2.1: Enlarged immunofluorescence staining images from Figure 4.6 
Healthy control, MFSΔ52 and MFSC2111R patient fibroblasts were transfected with PMO52, Gene Tools control PMO (GTC) or left untreated (UT). Two concentrations were tested; 250 μM and 50 μM, 
calculated in the 20 µl nucleofection cuvette volume, and cells were collected after 4 days. Cells were stained for Fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: 
no primary antibody added. Scale bar = 20 µm. 
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Figure A2.2: Enlarged immunofluorescence staining images from Figure 4.9 part c. 
Healthy control, MFSΔ59 and MFSR2414* fibroblasts were nucleofected with PMO59 at 250 µM, and 50 µM; calculated in the 20 µl nucleofection cuvette volume, in two replicate experiments and cells were 
collected after 10 days. GTC: Gene Tools control PMO used as a sham treatment, UT: untreated control. Transfected cells were stained for fibrillin-1 (red) and counterstained with Hoechst (blue) for 
detection of the nuclei. No Ab control: no primary antibody added. Scale bar = 20 µm. 
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Figure A2.3: Enlarged immunofluorescence staining images from Figure 4.9 part d. 
Healthy control, MFSΔ59 and MFSR2414* fibroblasts were nucleofected with PMO59 at 250 µM, and 50 µM; calculated in the 20 µl nucleofection cuvette volume, in two replicate experiments and cells were 
collected after 4 days. GTC: Gene Tools control PMO used as a sham treatment, UT: untreated control. Transfected cells were stained for fibrillin-1 (red) and counterstained with Hoechst (blue) for 
detection of the nuclei. No Ab control: no primary antibody added. Scale bar = 20 µm. 
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Synonymous mutations affecting FBN1 
1102B
Figure A2.4: Enhancer and silencer motifs that are predicted to be altered by synonymous FBN1 
mutations. 
817BSpliceAid 2154 reports of predicted ESE (above line) and ESS (below line) motifs that differ between the normal FBN1 
sequence and corresponding sequence harbouring a known synonymous mutation. Only those sites that differ between 
the two sequences are shown. 
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Predicted splicing motifs and the AO annealing sites targeted to exclude 
FBN1 exons 45, 46 and 47. 
1103B
Figure A3.1: The location of predicted regulatory splicing motifs and AO annealing sites targeted to 
remove FBN1 exons 45, 46 and 47. 
818BShowing the 2′OMe-PS AO tested and where they anneal to FBN1 exon a) 45, b) 46 and c) 47 in regard to the 
intronic/exonic enhancer (above) and silencer (below) sites predicted by SpliceAid.153 The exonic and intronic 
sequences are written in upper- and lower- case, respectively.
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Enlarged immunofluorescence images 
Figure A3.2: Enlarged immunofluorescence staining images from Figure 5.7 
Healthy control and MFSΔ47 cells were nucleofected with PMO47, Gene Tool control PMO (GTC) or left untreated (UT) then collected after four days. Two concentrations were tested; 250 µM and 50 µM, 
calculated in the 20 µl nucleofection cuvette volume. Cells were stained for Fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale 
bar = 20 µm. 
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Figure A3.3: Enlarged immunofluorescence staining images from Figure 5.11 
Healthy control and MFSΔ45-47 fibroblasts nucleofected with a cocktail of PMO45, PMO46 and PMO4730, a Gene Tool control PMO (GTC) or left untreated (UT) and collected after 4 days. Two concentrations 
were tested; 750 µM and 150 µM, calculated in the 20 µl nucleofection cuvette volume. Cells were stained for Fibrillin-1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: 
no primary antibody added. Scale bar = 20 µm. 
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In silico analysis of the mRNA secondary structure of FBN1 exon 45, 46 
and 47 using RNAfold 
1104B
Figure A3.4: In silico prediction of the FBN1 exon 45 mRNA secondary structure using the RNAfold web 
server217 
819Ba) the FBN1 exon 45 sequence without AO annealing, and b) the FBN1 exon 45 sequence following PMO45 binding.
Bases targeted by PMO45 are highlighted in yellow 
1105B
Figure A3.5: In silico prediction of the FBN1 exon 46 mRNA secondary structure using the RNAfold web 
server.217 
820Ba) the FBN1 exon 46 sequence without AO annealing, and b) the FBN1 exon 46 sequence following PMO46 binding.
Bases targeted by PMO46 are highlighted in yellow 
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1106B
Figure A3.6: In silico prediction of the FBN1 exon 47 mRNA secondary structure using the RNAfold web 
server217 
821Ba) the FBN1 exon 47 sequence without AO annealing, and b) the FBN1 exon 47 sequence following PMO4720 binding.
Bases targeted by PMO4720 are highlighted in yellow 
Splice site scores of FBN1 exon 47 
Table A3.1: Donor splice site scores of human FBN1 exon 47  
743BThe splice site score of the natural donor, donor created through the c.5788+5G>A mutation and a predicted cryptic 
donor calculated by Human Splicing Finder 3.0.215 
3831BSplice site 3832BSlice site 
3833BConsensus value 
3834B(0-100) 
3252BNatural donor 1586BTAGgtgcgt 3253B87.93 
3254Bc.5788+5G>A donor 1587BTAGgtgcat 3255B78.36 
3256BCryptic donor 1588BGAAgtcagt 3257B82.64 
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Appendix 4 Chapter 6 supplementary data 






Figure A4.1: The location of predicted splicing motifs and AO annealing sites. 
822BShowing the 2′OMe-PS AO tested and where they anneal to FBN1 exon a) 15, b) 16, c) 22, d) 26, e) 27, f) 31, g) 32, 
h) 39, i) 44and j) 49 in regard to the intronic/exonic enhancer (above) and silencer (below) sites predicted by
SpliceAid.153 The exonic and intronic sequences are written in upper- and lower- case, respectively.
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Enlarged immunofluorescence images 
Figure A4.2: Enlarged immunofluorescence staining images from Figure 6.9 
Healthy control fibroblasts were transfected, using Lipofectamine 3000, with 100 nM of TMO or 2′OMe PS AOs and collected after 24 hours. Treated cells were stained for NONO (green) and counterstained 
with Hoechst (blue) for nuclei detection. The upper and lower panels of each set of immunofluorescence images show the NONO and merged images, respectively. No Ab control: no primary antibody 
added. Scale bar = 20 µm. 
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Figure A4.3: Enlarged immunofluorescence staining images from Figure 6.12 part a. 
Healthy control fibroblasts were Neon transfected with TMO, 2′OMe PS or PMO AOs and collected after 10 days. Two 
concentrations 20 µM and 5 µM; calculated in a 10 µl transfection volume, were tested. Cells were stained for Fibrillin-
1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale 
bar = 20 µm. 
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Figure A4.4: Enlarged immunofluorescence staining images from Figure 6.12 part b. 
MFS∆52 fibroblasts were Neon transfected with TMO, 2′OMe PS or PMO AOs and collected after 10 days. Two 
concentrations 20 µM and 5 µM; calculated in a 10 µl transfection volume, were tested. Cells were stained for Fibrillin-
1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale 
bar = 20 µm. 
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Figure A4.5: Enlarged immunofluorescence staining images from Figure 6.12 part c. 
MFSC2111R fibroblasts were Neon transfected with TMO, 2′OMe PS or PMO AOs and collected after 10 days. Two 
concentrations 20 µM and 5 µM; calculated in a 10 µl transfection volume, were tested. Cells were stained for Fibrillin-
1 (red) and counterstained with Hoechst (blue) for nuclei detection. No Ab control: no primary antibody added. Scale 
bar = 20 µm. 
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Details of 2′OMe-PS AO sequences screened 
Table A4.1: The skipping efficiencies of 2′OMe-PS AOs assessed in this thesis 
744BThe name, ID, GC content, binding site, designer, and highest proportion of skipping induced for each of the 2′OMe-PS 
AOs that were assessed. The proportion of skipping is in healthy control cells transfected at either 200 nM or 50 nM 
using Lipofectamine 3000. Site indicates if the AO anneals over the canonical acceptor or donor splice site or solely 
binds to a region containing exonic splicing enhancer (ESE) motifs. The AO nomenclature is outlined in Chapter 2, 











3258B15A(-15+10) 3259BAO15.1 3260B 8% 3261BAcceptor 3262B0% 3263BKG 
3264B15A(+41+65) 3265BAO15.2 3266B 6% 3267BESE 3268B0% 3269BKG 
3270B15D(+12-13) 3271BAO15.3 3272B 6% 3273BDonor 3274B0% 3275BKG 
3276B16A(-14+11) 3277BAO16.1 3278B44% 3279BAcceptor 3280B % 3281BJC 
3282B16A(+27+51) 3283BAO16.2 3284B52% 3285BESE 3286B0% 3287BJC 
3288B16D(+14-11) 3289BAO16.3 3290B44% 3291BDonor 3292B0% 3293BJC 
3294B16A(+22+46) 3295BAO16.2+5 3296B56% 3297BESE 3298B0% 3299BJC 
3300B16A(+32+56) 3301BAO16.2-5 3302B52% 3303BESE 3304B % 3305BJC 
3306B16D(+09-16) 3307BAO16.3-5 3308B 6% 3309BDonor 3310B % 3311BJC 
3312B 2A(-13+12) 3313BAO22.1 3314B56% 3315BAcceptor 3316B0% 3317BJC 
3318B22A(+45+69) 3319BAO22.2 3320B44% 3321BESE 3322B 2% 3323BJC 
3324B 2A(+84+108) 3325BAO22.3 3326B72% 3327BESE 3328B0% 3329BJC 
3330B22D(+16-09) 3331BAO22.4 3332B44% 3333BDonor 3334B11% 3335BJC 
3336B26A(-18+07) 3337BAO26.1 3338B20% 3339BAcceptor 3340B % 3341BJC 
3342B 6A(+70+94) 3343BAO26.2 3344B52% 3345BESE 3346B9% 3347BJC 
3348B26D(+22-03) 3349BAO26.3 3350B48% 3351BDonor 3352B0% 3353BJC 
3354B26A(+75+99) 3355BAO26.2-5 3356B 0% 3357BESE 3358B26% 3359BJC 
3360B26A(+100+124) 3361BAO26.3+5 3362B40% 3363BESE 3364B9% 3365BJC 
3366B27A(-25-01) 3367BAO27.1 3368B52% 3369BAcceptor 3370B % 3371BKG 
3372B 7A(+38+62) 3373BAO27.2 3374B60% 3375BESE 3376B0% 3377BKG 
3378B27A(+105+129) 3379BAO27.3 3380B40% 3381BESE 3382B0% 3383BKG 
3384B 1A(-21+04) 3385BAO31.1 3386B 2% 3387BAcceptor 3388B0% 3389BKG 
3390B 1A(+76+100) 3391BAO31.2 3392B44% 3393BESE 3394B % 3395BKG 
3396B 1D(+13-12) 3397BAO31.3 3398B 6% 3399BDonor 3400B % 3401BKG 
3402B 2A(-13+12) 3403BAO32.1 3404B28% 3405BAcceptor 3406B7% 3407BJC 
3408B 2A(+47+71) 3409BAO32.2 3410B 0% 3411BESE 3412B 6% 3413BJC 
3414B 2D(+14-11) 3415BAO32.3 3416B 4% 3417BDonor 3418B 3% 3419BJC 
3420B 2A(-08+17) 3421BAO32.1-5 3422B 6% 3423BAcceptor 3424B 2% 3425BJC 
3426B 2A(+42+66) 3427BAO32.2+5 3428B52% 3429BESE 3430B 7% 3431BJC 
3432B 2A(+52+76) 3433BAO32.2-5 3434B 6% 3435BESE 3436B 3% 3437BJC 
3438B 2D(+19-06) 3439BAO32.3+5 3440B 8% 3441BDonor 3442B 3% 3443BJC 
3444B 2D(+09-16) 3445BAO32.3-5 3446B 4% 3447BDonor 3448B0% 3449BJC 
3450B 9A(-12+13) 3451BAO39.1 3452B 2% 3453BAcceptor 3454B 3% 3455BJC 
3456B 9A(+31+55) 3457BAO39.2 3458B 4% 3459BESE 3460B 2% 3461BJC 
3462B 9D(+04-16) 3463BAO39.3 3464B 5% 3465BDonor 3466B 1% 3467BJC 
3468B 4A(+14+38) 3469BAO44.1 3470B64% 3471BESE 3472B0% 3473BKG 
3474B 4A(+44+68) 3475BAO44.2 3476B 8% 3477BESE 3478B28% 3479BKG 
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3480B 4D(+19-06) 3481BAO44.3 3482B 6% 3483BDonor 3484B27% 3485BKG 
3486B 5A(+15+39) 3487BAO45.1 3488B68% 3489BESE 3490B % 3491BKG 
3492B 5A(+49+73) 3493BAO45.2 3494B60% 3495BESE 3496B % 3497BKG 
3498B 5A(+87+111) 3499BAO45.3 3500B68% 3501BESE 3502B % 3503BKG 
3504B 5D(+21-04) 3505BAO45.4 3506B 2% 3507BDonor 3508B % 3509BJC 
3510B46A(-09+16) 3511BAO46.1 3512B 8% 3513BAcceptor 3514B % 3515BKG 
3516B46A(+72+96) 3517BAO46.2 3518B40% 3519BESE 3520B % 3521BKG 
3522B46D(+12-13) 3523BAO46.3 3524B 4% 3525BDonor 3526B10% 3527BKG 
3528B46A(-03+22) 3529BAO46.4 3530B 2% 3531BAcceptor 3532B0% 3533BJC 
3534B 7A(-03+20) 3535BAO47.1 3536B26% 3537BAcceptor 3538B11% 3539BJC 
3540B 7A(+58+77) 3541BAO47.2 3542B60% 3543BESE 3544B 3% 3545BJC 
3546B 7A(+83+102) 3547BAO47.3 3548B 0% 3549BESE 3550B27% 3551BJC 
3552B47D(+05-15) 3553BAO47.4 3554B 0% 3555BDonor 3556B0% 3557BJC 
3558B47A(+44+68) 3559BAO47.5 3560B48% 3561BESE 3562B 4% 3563BJC 
3564B 7A(+69+93) 3565BAO47.6 3566B 2% 3567BESE 3568B10% 3569BJC 
3570B47D(+24-01) 3571BAO47.7 3572B 6% 3573BDonor 3574B0% 3575BJC 
3576B47A(+56+80) 3577BAO47.2-25mer 3578B 2% 3579BESE 3580B45% 3581BJC 
3582B47A(+53+82) 3583BAO47.2-30mer 3584B 7% 3585BESE 3586B42% 3587BJC 
3588B49A(-13+12) 3589BAO49.1 3590B28% 3591BAcceptor 3592B0% 3593BKG 
3594B 9A(+19+43) 3595BAO49.2 3596B48% 3597BESE 3598B0% 3599BKG 
3600B49A(+83+107) 3601BAO49.3 3602B44% 3603BESE 3604B % 3605BKG 
3606B52A(+29+53)M 3607BAO52.1m 3608B48% 3609BESE 3610B40% 3611BKG 
3612B52A(+29+53)N 3613BAO52.1n 3614B52% 3615BESE 3616B41% 3617BKG 
3618B52A(-08+17) 3619BAO52.2 3620B 0% 3621BAcceptor 3622B0% 3623BKG 
3624B52D(+13-12) 3625BAO52.3 3626B52% 3627BDonor 3628B 7% 3629BKG 
3630B52A(-23+02) 3631BAO52.4 3632B44% 3633BAcceptor 3634B0% 3635BKG 
3636B52A(+03+27) 3637BAO52.5 3638B52% 3639BESE 3640B22% 3641BKG 
3642B59A(-21+04) 3643BAO59.1 3644B12% 3645BAcceptor 3646B0% 3647BJC 
3648B59A(+41+65) 3649BAO59.2 3650B48% 3651BESE 3652B 3% 3653BJC 
3654B 9A(+86+110) 3655BAO59.3 3656B40% 3657BESE 3658B0% 3659BJC 
3660B59A(+36+60) 3661BAO59.2+5 3662B44% 3663BESE 3664B17% 3665BJC 
3666B59A(+46+70) 3667BAO59.2-5 3668B 6% 3669BESE 3670B15% 3671BJC 
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Binding sites of 2′OMe-PS AOs. 
Table A4.2: Proportion of effective FBN1 2′OMe-PS AO based on binding site. 





3672BAcceptor 3673B5 (33%) 3674B10 3675B15 
3676BESE 3677B24 (63%) 3678B14 3679B 8 
3680BDonor 3681B7 (44%) 3682B9 3683B16 
3684BTotal 3685B 6 (52%) 3686B 3 3687B 9 
Splice site scores of exons 27 and 49 
Table A4.3: The splice site scores for FBN1 exons 27 and 49. 
746BSplice site scores are an expression of how similar a splice site is to the consensus sequence. The scores were 
calculated using a Splice Site Score Calculation webtool.216  
3850BTarget 
3851B ′ splice site 
3852BScore (donor) 
3853B ′ splice site 
3854BScore (acceptor) 
3688BExon 27 3689B .1 3690B7.1 
3691BExon 49 3692B8.3 3693B12.2 
3694BAverage for 
3695Bconstitutive exons 
3696B8.1 3697B .9 
188 
Blanket AO Python script 
print "Please save sequence data in .txt format"







filename = raw_input("Please enter the filename followed by .txt: ")
print "Processing...."
intron = ["a", "c", "t", "g"]
exon = ["A", "C", "T", "G"]
fin = open(filename, "r")
fout = open("Raw AOs.txt","w")
print "Enter a gene name: "
gene_name = str(raw_input())
print "enter first exon number, eg 2:"
exon_number = int(raw_input())
for line in fin:
if line[0] == '>':
fout.write(line[:])
print "Processing sequence: ", line
continue
ao_raw = list()




for ao in ao_raw:
valid = False
for ex in exon:




if ao[0] in intron:
#Label as H_A intron
introns = 0
for char in ao:




elif ao[0] in exon:
if ao[-1:] in intron:
#label as H_D
introns = 0
for char in ao:
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for ao in ao_labeled:





fin = open("Raw AOs.txt", "r")










for line in fin:
if line[0] == ">":
fout.write(line)









print "Raw DNA AOs and final AO sequences stored as 'Raw AOs.txt' and 
'Blanket AOs.txt'"
raw_input("Press enter to exit")
Figure A4.6: Blanket AO Python script 
823BA simple script written in Python 2.7 that when executed will produce a list of all possible 25-mer antisense 
oligonucleotides across the provided sequence. The input must be in FASTA format and flanked by 25 bases of intronic 
sequence. Small changes to the code itself allow for the length of the AO to be altered. 
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In silico analysis of the mRNA secondary structure of FBN1 exon 32 and 
39 using RNAfold 
1109B
Figure A4.7: In silico prediction of the FBN1 exon 32 mRNA secondary structure using the RNAfold web 
server217 
824Ba) the FBN1 exon 32 sequence without AO annealing, and b) the FBN1 exon 32 sequence following PMO32 binding.
Bases targeted by PMO32 are highlighted in yellow 
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1110B
Figure A4.8: In silico prediction of the FBN1 exon 39 mRNA secondary structure using the RNAfold web 
server217 
825Ba) the FBN1 exon 39 sequence without AO annealing, and b) the FBN1 exon 39 sequence following PMO39 binding.
Bases targeted by PMO39 are highlighted in yellow.
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Abstract
Type-1 fibrillinopathies are a family of connective tissue disorders with major clinical manifestations in the
skeletal, ocular and cardiovascular systems. The type-1 fibrillinopathies are caused by mutations in the fibrillin-1
gene (FBN1), which encodes fibrillin-1, a large glycoprotein and a major component of the extracellular matrix
microfibrils, providing both structural and regulatory support to connective tissues. The type-1 fibrillinopathies have
been associated with over 1800 unique mutations within the FBN1 and demonstrate a wide range of phenotypic
variability. This, in conjunction with a number of other factors has impacted on the identification of genotype-
phenotype correlations, pathogenesis and diagnostic tests for this family of diseases, leaving many open-ended
theories.
Current standard of care relies heavily on surgical intervention and lifelong use of β-blockers to slow disease
progression, with research focused heavily on antagonism of transforming growth factor β, which is known to be
dysregulated in patients with FBN1 mutations. Antisense oligonucleotides present a novel therapeutic strategy for
the type-1 fibrillinopathies, by mediating the alteration of exon arrangement of both the normal and disease-causing
mRNA transcripts, to re-establish the periodicity of fibrillin-1. The induced proteins, while internally truncated, should
be homologous and thus be able to form multimer units. This treatment alone or in association with isoform
switching, TGF-β antagonism or enhanced/inhibited protein degradation could facilitate the assembly of fibrillin-1
monomers into multimers and consequently a decrease in phenotypic severity.
This review presents a basic overview of the past and current knowledge about the spectrum of type-1
fibrillinopathies with a particular focus on Marfan syndrome, as well as presenting novel potential therapeutic
strategies.
Keywords: Type-1 fibrillinopathies; Marfan syndrome; Fibrillin-1; 
Genetic therapy
Introduction to the Type-1 Fibrillinopathies
The type-1 fibrillinopathies are a family of heritable connective 
tissue disorders characterised by skeletal, ocular and cardiovascular 
abnormalities. These diseases are caused by mutations in the fibrillin-1 
gene (FBN1)  [1], with over 1800 unique mutations, spread throughout 
the FBN1  sequence, described in the universal mutation database 
(UMD) [2]. The majority of mutations described are missense 
mutations, however, insertions, deletions and splice site mutations 
have also been described [2,3].
FBN1  is one of three distinct genes in the fibrillin family, along with 
fibrillin-2 and fibrillin-3, all of which share sequence similarities [4]. 
FBN1  is a large gene consisting of 66 exons spanning over 200 Kb [5]. 
While exon 1 of FBN1  does not directly contribute to the translated 
product, the exon numbering system used in this review is based on 
the full 66 exon transcript (GenBank reference sequence 
NM_000138.4). The remaining 65 exons encode a 2871 amino acid 
preproprotein, which is cleaved, by the protease furin, into the large 
glycoprotein fibrillin-1 and the protein hormone asprosin [6,7].
Fibrillin-1 is present in the majority of connective tissues and has
both structural and regulatory roles. As a major structural element of
microfibrils fibrillin-1 acts as a backbone to which other microfibril
associated proteins bind [8,9], while also being essential for the
stability of elastic fibres [10,11]. The assembly of fibrillin into
microfibrils is initiated immediately after synthesis and secretion when
fibrillin-1 monomers aggregate into multimer units, bound by
disulphide bonds between the first 4 cysteine residues at the N-
terminus [12]. Heterodimers between fibrillin-1 and the other fibrillin
monomers have not been observed, suggesting that the proline-rich
sequence at the N-terminus (Figure 1), unique to fibrillin-1, provides
the specificity responsible for this binding [13].
The structure of fibrillin-1 is complex and highly repetitive,
consisting of a number of cysteine-rich repeats (Figure 1). These
include 47 epidermal growth factor (EFG)-like repeats, seven
transforming growth factor β binding protein-like (TB) domains and
two domains that share similarities with both EGF-like and TB
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Figure 1: The domain structure of the fibrillin-1 preproprotein.
Made up of four EGF-like domains and 43 calcium binding EGF-
like (cbEGF-like) domains interspaced with seven TGF-β binding
protein-like (TB) domains and two hybrid domains. A proline rich
region toward the N-terminus has been implicated in the assembly
and specificity of fibrillin-1 multimers [13].
Of the 47 EGF-like repeats, 43 contain a consensus sequence for
calcium binding, which is essential for protein stability and protection
from proteolysis [16], these repeats are therefore further denoted
cbEFG-like domains [15]. Each EGF-like, TB and hybrid domains has
6-8 highly conserved cysteines [14,17] that form disulphide bonds in
specific patterns that assist in protein folding and enhance protein
function. Mutations that disrupt these bonds are the most common
cause of the type-1 fibrillinopathy, Marfan syndrome [18].
Spectrum of Type-1 Fibrillinopathies
Marfan syndrome
Marfan syndrome (MFS, MIM 154700) is the most common of the
type-1 fibrillinopathies [19], with a consistent prevalence of 2-3 in
10,000 individuals across gender, ethnicity and geographical
distribution [20,21]. MFS is inherited in an autosomal dominant
manner with approximately 25% to 30% of mutations arising de novo
[22,23]. However, despite consistently being referred to as an
autosomal dominant condition, as of 2017, twelve cases of homozygous
mutations have been recorded in the UMD-FBN1 database [2]. A
number of these cases have an unequivocal autosomal recessive
inheritance pattern, with relatives of the proband being asymptomatic
heterozygous carriers [24,25]. This suggests that the inheritance
pattern of MFS is complex and still not fully understood.
Clinical features
MFS is a multisystem disorder characterised by skeletal,
cardiovascular and ocular abnormalities [26,27]. The most noticeable
features include increased height with dolichostenomelia and
arachnodactyly; the disproportionate overgrowth of long bones and
digits respectively, as well as joint hypermobility [26]. Spinal
deformities such as scoliosis and dural ectasia, and chest wall
deformities are also common features [26,27].
Ocular manifestations include myopia or near sightedness, and
ectopia lentis, which is the displacement of the crystalline lens from its
natural location [27]. Such features generally present early in disease
progression and are therefore important diagnostic indicators,
especially for children. However, these features are also common to a
multitude of other diseases including a number of other type-1
fibrillinopathies [26].
Cardiovascular abnormalities are the most common cause of death
of MFS patients especially in the most severe form, neonatal Marfan
syndrome (nMFS), which is characterised by the early onset of
cardiovascular manifestations [28,29]. These deaths are typically the
result of progressive aortic root enlargement and aortic aneurysm, that
can eventuate into aortic regurgitation, dissection or rupture [30].
Other cardiovascular features include mitral valve prolapse and mitral
regurgitation [27]. Due to their late onset and progressive nature, key
cardiovascular features are often not present or noticeable in younger
patients. However, with advances in technology, features such as aortic
enlargement can now be readily detected in suspected MFS patients
using echocardiography, allowing for much needed early intervention
[20].
Diagnostic odyssey
The diagnosis of MFS and delineation from other type-1
fibrillinopathies is challenging for a number of reasons, including the
large size of FBN1, number of unique mutations and the lack of
defined mutation hotspots [23,31]. These characteristics mean that,
despite progress in understanding the genetic basis of MFS, as well as
advances in genetic testing techniques, there is still no efficient, time
and cost effective molecular test for MFS [19,32]. Molecular diagnosis
is most often reserved for patients who either have a clinical diagnosis
or a diagnosed relative [33].
There are also diagnostic issues that arise from the extensive
phenotypic overlap between MFS and the other type-1
fibrillinopathies, as well as the phenotypic variability observed both
between and within affected families [23,31]. The progressive nature of
MFS, in particular the late onset of cardiovascular features also adds to
the challenge, especially in the diagnosis of children in which the
symptoms have not fully developed [34].
To overcome these limitations, the diagnosis of MFS is based on a
well-defined set of criteria, known as the Ghent nosology and
supplemented with molecular testing when appropriate [20,33]. These
criteria were first described by Beighton et al. [35] under the umbrella
of the Berlin nosology, which encompassed the diagnosis of a number
of connective tissue disorders. This document outlines features
considered major or minor in the MFS phenotype, organised
according to the organ system involved. The requirements of diagnosis
varied, depending on the presence of an affected relative and were
based on the involvement of at least 2 organ systems with a number of
major and minor manifestations [35].
These diagnostic criteria were subsequently updated in 1996 and
reworked into the Ghent nosology that is more specific to the diagnosis
of Marfan syndrome. These updated criteria provide more stringent
diagnosis for relatives of MFS individuals, revised skeletal involvement
and delineation of MFS and MFS-like disorders [36]. In 2010, the
Ghent nosology was revised again due to concerns about the sensitivity
of diagnosis, especially in regard to age-dependant manifestations and
the resulting potential for misdiagnosis of children [27]. The revised
criteria place more emphasis on aortic root aneurysm and ectopia
lentis, with less emphasis on features such as flat feet and pulmonary
artery dilation that are common to other type-1 fibrillinopathies [27].
Current diagnosis of a patient without a diagnosed relative requires the
major involvement of at least two organ systems with minor
involvement of a third. Individuals with known FBN1 mutations or a
first degree relative with a MFS diagnosis, are diagnosed based on the
presence of one major and one minor manifestation in different organ
systems [27].
Due to the considerable phenotypic variability amongst individuals
with type-1 fibrillinopathies, affected individuals are often classified
according to where they sit on the ‘Marfan spectrum’ [3]. At one end
are those diagnosed with neonatal Marfan syndrome, the most severe
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form of MFS, characterised by its early onset and life expectancy of less
than 24 months [37]. At the other end of the spectrum are those who
do not fully meet the Ghent nosology or have additional features not
observed in the Marfan phenotype. Such patients are most often
diagnosed with other type-1 fibrillinopathies, as described below.
Marfan lipodystrophy syndrome
Marfan lipodystrophy syndrome (MFLS, MIM 616914) is an
extremely rare autosomal dominant disease, with only 7 known cases
globally [38]. MFLS is characterised by congenital lipodystrophy, the
severe lack of fat in the subcutaneous tissues, as well as premature birth
and disproportionate growth to weight gain [39]. Affected individuals
also have distinctive facial features, including protruding eyes, down
slanting palpebral fissures and a posteriorly positioned lower jaw
resulting in a severe overbite [39]. Other features overlap with Marfan
syndrome including long limbs and digits, hyper extensible joints and
myopia [39,40]. Due to these similarities there are cases in which
individuals fulfil the Ghent nosology, however due to the characteristic
lack of subcutaneous fat tissue are diagnosed with MFLS [40].
MASS syndrome
MASS syndrome (MIM 604308) is the diagnosis given to
individuals who have MASS phenotypes involving the Mitral valve,
Aorta, Skeleton and Skin, but do not fulfil the Ghent nosology [41].
Despite not meeting the diagnostic criteria of MFS, the MASS
phenotype shares a number of features with MFS, including
disproportionately long limbs, chest deformities, mitral valve prolapse
and aortic root dilation [36,41]. Loeys et al. [27] suggests caution in the
diagnosis of MASS syndrome due to its ambiguity, the lack of
understanding of the underlying mutations and the potential for
disease progression into classic MFS.
Ectopia lentis syndrome
While ectopia lentis is a key feature of the MFS phenotype, ectopia
lentis syndrome (ELS, MIM 129600) describes patients who have
ectopia lentis but lack the cardiovascular involvement typical of MFS
[27]. ELS has an autosomal dominant inheritance pattern and affected
individuals present with dislocation of the lens due to abnormal
stretching of the zonular fibres and this can in turn result in acute or
chronic impaired vision [42]. Much like MFS, ELS is caused by
numerous mutations throughout the FBN1, with around 38% of
mutations that result in ELS also identified in MFS patients [43].
Stiff skin syndrome
Stiff skin syndrome (SSKS, MIM 184900) is another rare autosomal
dominant disorder, characterised by thick and hardened skin that leads
to reduced joint mobility [44]. Due to its rarity, the exact cause and
pathogenesis of SSKS remains unknown, however using pulse chase
analysis Loeys et al. [44] determined that while SSKS patients have
normal levels of fibrillin-1 secretion, they have increased deposition of
fibrillin-1; and elastin, in the dermis. The group also observed that
patient microfibrils were noticeably shorter than those seen in control
samples, suggesting that FBN1 mutations are implicated in this
syndrome [44].
Other type-1 fibrillinopathies
Weill-Marchesani syndrome 2 (WMS2, MIM 608328), acromicric
dysplasia (ACMID, MIM 102370) and geleophysic dysplasia 2
(GPHYSD2, MIM 614185) are allelic autosomal dominant disorders
characterised by severe short stature, brachydactyly and limited joint
movement [45,46]. While all three disorders share skeletal phenotypes,
WMS2 patients also present with lens abnormalities including
glaucoma and ectopia lentis [46]. GPHYSD2 differs from ACMID as
affected patients have additional cardiovascular abnormalities that
lower life expectancy [45]. ACMID also has unique craniofacial feature
including rounded face, with distinctive well-defined eyebrows and
eyelashes, bulbous nose and small mouth with thick lips [45].
Genotype-Phenotype Correlations
Several studies have attempted to correlate mutations in particular
regions of FBN1 with specific phenotypes. However, this has proved
difficult due to the high frequency of unique mutations, approximately
60% [2] and the extensive variability in phenotype between and within
families [3,47]. Despite these challenges, one trend that is well accepted
is the association of neonatal MFS with mutations within exons 25-33
(Figure 2) [18]. However, while the entire region most often quoted as
associated with nMFS, Booms et al. [37] reported that evidence
actually supports the presence of two nMFS hotspots. The first
encompasses exons 25-28 and mainly consists of missense mutations
and in-frame insertions [37]. The second hotspot spans exon 32 and
33, in which splice site mutations resulting in exon skipping most often
lead to nMFS [37].
Several of the studies attempting to unravel genotype:phenotype
associations have noted that the type of mutation, rather than its
location, influences the resulting phenotype [18,37,48,49]. A good
illustration of this trend is that missense mutations within exons 32
and 33 are most often associated with the classic MFS phenotype [2],
while donor or acceptor splice site mutations within this region lead to
the severe and early onset phenotype of nMFS [37]. Other examples
are the association of premature protein truncation mutations with
severe skeletal phenotypes, and cysteine substitutions with ectopia
lentis [18,50].
Figure 2: The type-1 fibrillinopathies and associated regions in
FBN1. In particular, the ‘neonatal’ (nMFS) region that spans exons
25-33, is associated with the most severe form of Marfan syndrome.
cMFS: classic Marfan syndrome, ELS: ectopia lentis syndrome,
SSKS: stiff skin syndrome, WMS-2: Weill-Marchesani syndrome 2,
ACMID: acromicric dysplasia, GPHYSD2: geleophysic dysplasia 2
and MFLS: Marfan lipodystrophy syndrome.
While mutations causing MFS and ELS are found throughout the
FBN1 sequence, many of the mutations associated with other type-1
fibrillinopathies are clustered within specific regions of FBN1 (Figure
2). For example, MFLS is associated with mutations that affect the
region of FBN1 that encodes asprosin. The mutations identified to date
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include 2 bp, 8 bp and 20 bp deletions in the 65th exon [39,51] as well
as mutations resulting in early protein truncation and the loss of the C-
terminus [52].
The majority of mutations that have been associated with WMS2,
ACMID and GPHYSD2 are within the 42nd and 43rd exons of FBN1
(Figure 2) [45,53]. It is the effect of these mutations that is thought to
result in the phenotypic differences between these diseases. For
example, mutations leading to GPHYSD2 have been shown to affect
residues with structural roles, such as the cysteines involved in
disulphide bond formation, while ACMID mutations are distributed
throughout exons 42 and 43 [45]. Le Goff et al. also suggest that short
stature and digits are associated with the disruption of the 5th TB
domain specifically, while mutations in the other TB domains lead to
other phenotypes [45]. For example mutations within the 4th TB
domain are associated with SSKS, which shares phenotypic similarity
with WMS2, ACMID and GPHYSD2 but lacks the short stature and
digits [44].
Models of Pathogenesis
The Marfan phenotype, particularly the cardiovascular
manifestations have been observed to progressively worsen with age.
The reason for this remains unknown, as the mechanism behind the
pathogenesis of MFS, and the other type-1 fibrillinopathies, is still not
fully understood. Based on current knowledge, this progression has
been attributed to both the compounding weakness of microfibrils and
continuing dysregulation of transforming growth factor beta (TGF-β)
[54].
Four models of MFS pathogenesis have been proposed to date. The
first is known as the dominant negative model, which describes
mutations resulting in an altered protein that acts antagonistically
against the normal protein [55]. In the case of MFS, this model
suggests that aberrant fibrillin-1 monomers bind incorrectly with
normal monomers, forming semi- or non-functional multimers and/or
prevent the normal assembly of microfibrils. This in turn would lead to
the disorganisation of the extracellular matrix and the observed
disease phenotype [55]. Therefore, based on this model, the severity of
disease is dependent on the level of fibrillin-1 expression [55].
The dominant negative model began to be questioned after the
identification of homozygous mutations and an autosomal recessive
form of MFS. de Vries et al. [24] studied two related individuals who
harboured homozygous c.1453C>T mutation (p.Arg485Cys), and
presented with classic MFS. Hilhorst-Hofstee et al. [25] similarly
identified a homozygous c.7454A>T mutation (p.Asp2485Val) in three
related individuals diagnosed with MFS. Both groups observed that in
the heterozygous state these mutations did not have a dominant
negative effect, conflicting with the dominant negative model [24,25].
de Vries et al. [24] suggested that in such cases the pathogenesis is
more in line with a haploinsufficiency model. That is a lack of
microfibrils or fibrillin-1 resulting from protein degradation,
intermolecular cross-linking or reduced fibrillin-1 synthesis [24,56].
The second model suggests that mutations in FBN1 increase the
sensitivity of fibrillin-1 to proteolysis, resulting in a steady decline in
microfibrils, parallel to the progression of disease severity [16]. This
model is particularly relevant to mutations affecting cbEGF-like
repeats, as calcium has been shown to be involved in the formation of
microfibrils, and specifically in their stabilisation and protection from
proteolysis [11].
The third model suggests that the major roles of fibrillin-1 is to 
maintain tissue homeostasis and therefore MFS is a result of a loss of 
homeostasis [11]. This model was based on findings from two mouse 
models showing that MFS, which caused a typical phenotype in the 
vesicular tissue and resulted in death, did not affect elastic fibres in 
other tissues [11]. Therefore, the authors came to the conclusion that 
the primary role of fibrillin-1 was not in the assembly of elastic fibres, 
rather in maintaining homeostasis of existing elastic fibres [11]. The 
model also suggests, a critical threshold of functional microfibrils 
required for tissue homeostasis, therefore mutations in FBN1 result in 
a decrease in microfibril abundance resulting in MFS [11]. This 
hypothesis was based on observations of the two mouse models 
showing that the ultimate outcome of both dominant negative and 
hypomorphic mutations is a similar decrease in the abundance of 
functional microfibrils [57].
The fourth model was proposed in the early 2000s, in light of more 
recent research that linked decreased fibrillin-1 deposition with the 
dysregulation of TGF-β, a multifunctional cytokine with a role in cell 
signalling and survival and subsequently with the development of 
phenotypic features associated with MFS [58]. The study by Neptune et 
al. [58] identified that the dysregulation of TGF-β lead to apoptosis in 
the lung during development. However, when TGF-β activation was 
neutralised lung apoptosis was reduced and alveolar development was 
rescued [58]. A number of other studies have now supported these 
finding, providing more evidence that TGF-β dysregulation is the main 
cause of pathogenesis in Marfan syndrome, favouring the fourth 
model and directing research focus [8,59].
Mutations in FBN1  lead to an increase in active TGF-β by 
disrupting the interaction between latent TGF-β binding protein 
(LTBP) and fibrillin-1 [60]. In the absence of organised microfibril 
lattices, the large latent complex (LLC), made up of TGF-β, latency-
associated protein and LTBP, is unable to anchor to microfibrils and as 
a result the components of the LLC remain uncomplexed [60]. This 
leaves free TGF-β to bind to its receptor, activating a phosphorylation 
cascade and a number of downstream effects [60,61]. One such effect is 
increased expression of matrix metalloproteinases leading to the 
degradation of elastin and the resulting loss of extracellular matrix 
stability [62].
The initial disruption of LTBP/fibrillin-1 interaction, could be 
the result of a number of different factors and is likely dependant on 
the type and position of a mutation. Aoyama et al. [56] suggested that 
the majority of FBN1  mutations can be categorised into 5 
groups depending on their effects on the synthesis and/or 
deposition of fibrillin-1. The group also suggested that FBN1 
mutations result in reduced synthesis and/or deposition in 
different ways, supporting dominant negative effects, 
haploinsufficiency and protein degradation, all of which are likely to 
result in the dysregulation of TGF-β [56].
Life Expectancy and Current Treatments
The mean age of death for Marfan patients was predicted in 1972 to 
be 32 years, with cardiovascular complications associated with aortic 
dilation the main cause [28]. A continuation of this study in 1995 
found that the mean age of death had increased significantly to 41 
years, with the average life expectancy increasing several decades [63]. 
The increased survival was attributed to an overall increase in life 
expectancy for the general population, an increase in the proportion of 
individuals diagnosed with milder phenotypes due to increased 
molecular genetic testing, and significant advances in medical
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intervention, specifically cardiovascular surgery [63]. There is,
however, still a significant burden on the livelihood and quality of life
of MFS patients and currently no cure [21].
The management of Marfan syndrome is multidisciplinary, most
often involving geneticists, ophthalmologists, orthopaedists and
cardiologists [26]. Current standard of care consists of lifelong use of
β-adrenergic receptor blockade or β-blockers [26], which have been
shown to slow progressive aortic dilation and reduce the associated
complications [64,65]. This is coupled with numerous surgical
interventions aimed at correcting major abnormalities in the chest,
eye, spine and cardiovascular system [20,26].
The progressive nature of type-1 fibrillinopathies means that
constant re-evaluation is required throughout life. For example, ocular
features such as lens dislocation are most often managed with
corrective lenses, however with increasing severity surgical
intervention such as aphakia, removal of the lens, may be required
[66]. Similarly, progressive scoliosis is initially managed with bracing,
however, patients are monitored throughout development and surgical
stabilisation is often required [67].
Following the implication of TGF-β dysregulation in the
pathogenesis of MFS, research into potential ways to antagonise TGF-β
has been the main research focus for potential therapeutics. The most
notable outcome of which is trials into the use of Losartan, a drug that
is currently used to treat hypertension [59]. Studies in mouse models
have shown that treatment with Losartan can prevent aortic root
aneurysm, as well as partially rescue lung structure [68]. However,
clinical trials comparing Losartan with β-blockers have shown that
while treatment with Losartan significantly reduces aortic dilation,
there was no significant difference in the outcome between the two
treatment groups [69,70].
Novel Therapies for Type-1 Fibrillinopathies
Due to the nature of MFS as a progressive multisystem disease, with
a dominant genetic basis, conventional therapeutic techniques such as
cell or gene replacement are unlikely to be applicable. The wide range
of causes of MFS also reduce the applicability of such techniques, for
example, while gene replacement has potential for cases of
haploinsufficiency, it would not be appropriate for FBN1 mutations
resulting in dominant negative effects. Similarly, techniques such as
siRNA induced allele specific silencing has potential for patients with
dominant negative mutations, however, MFS is also known to be
caused by insufficiency of FBN1 expression, therefore reduction in
fibrillin-1 expression is likely to result in disease. For these reasons, the
majority of current treatment options specifically target particular
clinical features. Antisense oligonucleotides provide a novel
therapeutic approach with the potential to treat many mutation types
by targeting the pre-mRNA directly.
The primary gene transcript (pre-mRNA) of a gene must be
processed in a number of ways, before the mature mRNA can be
translated into a protein. These include 5’ capping, splicing of exons
and removal of intervening sequences, cleavage, polyadenylation of the
3’ end and finally export to the cytoplasm [71]. The splicing of non-
coding regions (introns) and the subsequent joining of coding regions
(exons) is a highly complex and coordinated process that must take
place for most human gene transcripts. It is estimated that 95% of
multi-exon genes also undergo an additional process called alternative
splicing [72]. This process allows for further diversification of gene
expression in a highly regulated tissue or development specific manner.
Antisense oligonucleotides (AOs) are single stranded nucleic acid
analogues that can be used to achieve a number of outcomes to modify
gene expression, including exon skipping for reading frame
restoration, isoform switching and gene transcript knockdown. AOs
are typically 20-25 bp long and may be designed to bind specifically to
a targeted motif within the pre-mRNA of a gene of interest. There are
two broad classes of AOs; those that promote the degradation of
targeted mRNA, such as RNase H-dependent oligonucleotides or
siRNAs and those that physically block or inhibit the splicing or
translational machinery, steric-blocker oligonucleotides [73].
Antisense oligonucleotides, in particular steric blockers, have
therapeutic applications for a number of diseases. One notable case is a
splice-switching phosphorodiamidate morpholino oligomer, now
called Exondys51, that was granted accelerated approval by the Food
and Drug Administration as a treatment for Duchenne muscular
dystrophy [74]. Exondys51 was designed to induce skipping of
dystrophin exon 51 to restore the mRNA reading frame around frame-
shifting deletions that flank exon 51. Removal of dystrophin exon 51
from these amenable deletions allows translation of an internally
truncated dystrophin isoform, similar to that observed in patients with
the phenotypically milder Becker's muscular dystrophy [75,76].
Targeted switch splicing could also have potential therapeutic
applications for the type-1 fibrillinopathies. We hypothesise that the
skipping of exons harbouring disease-causing mutations from FBN1,
along with the corresponding exon from the normal transcript, could
re-establish periodicity of fibrillin-1 monomers. Due to their
homology, monomers from all transcripts should therefore be able to
correctly aggregate into multimer units forming an organised and
functional microfibril backbone.
There is also potential for therapeutic strategies by designing AOs
against associated targets. For example, an AO that inhibits the
activation of TGF-β could have therapeutic potential because while
Losartan proved no more effective than β-blockers, the antagonistic
effect of Losartan on TGF-β is effective at preventing aortic root
aneurysm and decreasing aortic dilation [68-70]. In particular, TGF-β
antagonism works efficiently in patients with FBN1 mutations that
result in haploinsufficiency [77].
Another example is isoform switching, which is a potential way of
increasing the expression of fibrillin-1. Burchett et al. [78] identified
two alternative isoforms, 54A-FBN1 and 57A-FBN1, that arise from
the incorporation of cryptic exons from introns 54 and 57 respectively.
57A-FBN1 in particular was observed to make up a significant portion
of the total number of FBN1 transcripts, approximately 10-40%
depending on the tissue and developmental stage [78]. Antisense
oligonucleotides can be designed to block inclusion of these cryptic
exons, pushing expression toward the normal transcript thus
increasing the abundance of normal fibrillin protein.
Lastly components of the protein degradation pathway could be
targeted in two ways depending on the pathogenesis of a mutation. For
patients who harbour dominant negative mutations, enhanced
proteolysis of aberrant fibrillin-1 would theoretically lead to a higher
portion of normal protein that could assemble into functional
multimers, as long as there was an increase in expression. Conversely
for mutations that result in increased proteolytic sensitivity, inhibiting
protein degradation could lead to increased fibrillin-1 abundance and
thus a decrease in disease severity. Along with targets within FBN1
itself these alternative targets mean there are numerous ways in which
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AOs could be used as a treatment for individuals suffering from MFS
and the other type-1 fibrillinopathies.
Final Remarks
Type-1 fibrillinopathies are a family of connective tissue disorders,
of which Marfan syndrome is the most common, with a prevalence of
2-3 in 10,000 individuals. These diseases are caused by mutations in
FBN1, which encodes fibrillin-1, a major component of the
extracellular matrix microfibrils providing both structural and
regulatory support. The type-1 fibrillinopathies have variable ages of
onset and are progressive in nature, affecting multiple body systems
with major clinical manifestations in the skeletal, ocular and
cardiovascular systems.
Current standard of care relies heavily on surgical intervention and
lifelong use of β-blockers to slow disease progression. Antisense
oligonucleotides present a novel therapeutic strategy for the type-1
fibrillinopathies, by mediating the alteration of exon structure of both
the normal and disease-causing mRNA transcripts to re-establish the
periodicity of fibrillin-1. Resulting proteins, while internally truncated,
would be homologous thus may be able to form functional multimer
units. This treatment alone or in association with isoform switching,
TGF-β antagonism or enhanced/inhibited protein degradation could
facilitate the assembly of fibrillin-1 monomers into multimers
increasing the abundance of microfibrils and decreasing phenotypic
severity.
References
1. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, et al. (1991)
Marfan syndrome caused by a recurrent de novo missense mutation in
the fibrillin gene. Nature 352: 337-339.
2. Collod-Beroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, et al.
(2003) Update of the UMD-FBN1 mutation database and creation of an
FBN1 polymorphism database. Hum Mutat 22: 199-208.
3. Robinson PN, Booms P, Katzke S, Ladewig M, Neumann L, et al. (2002)
Mutations of FBN1 and genotype-phenotype correlations in Marfan
syndrome and related fibrillinopathies. Hum Mutat 20: 153-161.
4. Corson GM, Charbonneau NL, Keene DR, Sakai LY (2004) Differential
expression of fibrillin-3 adds to microfibril variety in human and avian,
but not rodent, connective tissues. Genomics 83: 461-472.
5. Biery NJ, Eldadah ZA, Moore CS, Stetten G, Spencer F, et al. (1999)
Revised genomic organization of FBN1 and significance for regulated
gene expression. Genomics 56: 70-77.
6. Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, et al. (2016)
Asprosin, a fasting-induced glucogenic protein hormone. Cell 165:
566-579.
7. Lonnqvist L, Reinhardt D, Sakai L, Peltonen L (1998) Evidence for furin-
type activity-mediated C-terminal processing of profibrillin-1 and
interference in the processing by certain mutations. Hum Mol Genet 7:
2039-2044.
8. Sengle G, Sakai LY (2015) The fibrillin microfibril scaffold: A niche for
growth factors and mechanosensation? Matrix Biol 47: 3-12.
9. Sakai LY, Keene DR, Engvall E (1986) Fibrillin, a new 350 kD
glycoprotein, is a component of extracellular microfibrils. J Cell Biol 103:
2499-2509.
10. Kielty CM, Shuttleworth CA (1995) Fibrillin-containing microfibrils:
Structure and function in health and disease. Int J Biochem Cell Biol 27:
747-760.
11. Ramirez F, Gayraud B, Pereira L (1999) Marfan syndrome: New clues to
genotype-phenotype correlations. Ann Med 31: 202-207.
12. Reinhardt DP, Gambee JE, Ono RN, Bachinger HP, Sakai LY, et al. (2000)
Initial steps in assembly of microfibrils. Formation of disulfide-cross-
linked multimers containing fibrillin-1. J Biol Chem 275: 2205-2210.
13. Trask TM, Ritty TM, Broekelmann T, Tisdale C, Mecham RP, et al. (1999)
N-terminal domains of fibrillin 1 and fibrillin 2 direct the formation of
homodimers: A possible first step in microfibril assembly. Biochem J 340:
693-701.
14. Jensen SA, Iqbal S, Lowe ED, Redfield C, Handford PA, et al. (2009)
Structure and interdomain interactions of a hybrid domain: A disulphide-
rich module of the fibrillin/LTBP superfamily of matrix proteins.
Structure 17: 759-768.
15. Pereira L, D'Alessio M, Ramirez F, Lynch JR, Sykes B, et al. (1993)
Genomic organization of the sequence coding for fibrillin, the defective
gene product in Marfan syndrome. Hum Mol Genet 2: 961-968.
16. Reinhardt DP, Ono RN, Sakai LY (1997) Calcium stabilizes fibrillin-1
against proteolytic degradation. J Biol Chem 272: 1231-1236.
17. Jensen SA, Robertson IB, Handford PA (2012) Dissecting the fibrillin
microfibril: Structural insights into organization and function. Structure
20: 215-225.
18. Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U, et al. (1999)
Cysteine substitutions in epidermal growth factor-like domains of
fibrillin-1: Distinct effects on biochemical and clinical phenotypes. Am J
Hum Genet 65: 1007-1020.
19. Collod-Beroud G, Boileau C (2002) Marfan syndrome in the third
Millennium. Eur J Hum Genet 10: 673-681.
20. Ammash NM, Sundt TM, Connolly HM (2008) Marfan syndrome-
diagnosis and management. Curr Probl Cardiol 33: 7-39.
21. Pyeritz RE (2016) Recent progress in understanding the natural and
clinical histories of the Marfan syndrome. Trends Cardiovasc Med 26:
423-428.
22. Gray JR, Bridges AB, Faed MJ, Pringle T, Baines P, et al. (1994)
Ascertainment and severity of Marfan syndrome in a Scottish population.
J Med Genet 31: 51-54.
23. Pyeritz RE (2000) The Marfan syndrome. Annu Rev Med 51: 481-510.
24. de Vries BB, Pals G, Odink R, Hamel BC (2007) Homozygosity for a
FBN1 missense mutation: Clinical and molecular evidence for recessive
Marfan syndrome. Eur J Hum Genet 15: 930-935.
25. Hilhorst-Hofstee Y, Rijlaarsdam ME, Scholte AJ, Swart-van den Berg M,
Versteegh MI, et al. (2010) The clinical spectrum of missense mutations
of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a
recessive family. Hum Mutat 31: E1915-1927.
26. Judge DP, Dietz HC (2005) Marfan's syndrome. Lancet 366: 1965-1976.
27. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, et al.
(2010) The revised Ghent nosology for the Marfan syndrome. J Med
Genet 47: 476-485.
28. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA (1972)
Life expectancy and causes of death in the Marfan syndrome. N Engl J
Med 286: 804-808.
29. Stheneur C, Faivre L, Collod-Beroud G, Gautier E, Binquet C, et al.
(2011) Prognosis factors in probands with an FBN1 mutation diagnosed
before the age of 1 year. Pediatr Res 69: 265-270.
30. Ramirez F, Dietz HC (2007) Marfan syndrome: from molecular
pathogenesis to clinical treatment. Curr Opin Genet Dev 17: 252-258.
31. McBride ART, Gargan M (2006) Marfan syndrome. Current
Orthopaedics 20: 418-423.
32. Summers KM, West JA, Hattam A, Stark D, McGill JJ, et al. (2012) Recent
developments in the diagnosis of Marfan syndrome and related disorders.
Med J Aust 197: 494-497.
33. Stheneur C, Collod-Beroud G, Faivre L, Buyck JF, Gouya L, et al. (2009)
Identification of the minimal combination of clinical features in probands
for efficient mutation detection in the FBN1 gene. Eur J Hum Genet 17:
1121-1128.
34. Lipscomb KJ, Clayton-Smith J, Harris R (1997) Evolving phenotype of
Marfan's syndrome. Arch Dis Child 76: 41-46.
Citation: Cale JM, Fletcher S, Wilton SD (2018) A Review of the Type-1 Fibrillinopathies: Pathophysiology, Diagnosis and Novel Therapeutic
Strategies. J Genet Syndr Gene Ther 9: 323. doi:10.4172/2157-7412.1000323
Page 6 of 8
J Genet Syndr Gene Ther, an open access journal
ISSN:2157-7412
Volume 9 • Issue 1 • 1000323
35. Beighton P, de Paepe A, Danks D, Finidori G, Gedde-Dahl T, et al. (1988)
International nosology of heritable disorders of connective tissue, Berlin,
1986. Am J Med Genet 29: 581-594.
36. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE (1996)
Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62:
417-426.
37. Booms P, Cisler J, Mathews KR, Godfrey M, Tiecke F, et al. (1999) Novel
exon skipping mutation in the fibrillin-1 gene: Two 'hot spots' for the
neonatal Marfan syndrome. Clin Genet 55: 110-117.
38. Passarge E, Robinson PN, Graul-Neumann LM (2016) Marfanoid-
progeroid-lipodystrophy syndrome: A newly recognized fibrillinopathy.
Eur J Hum Genet 24: 1244-1247.
39. Takenouchi T, Hida M, Sakamoto Y, Torii C, Kosaki R, et al. (2013) Severe
congenital lipodystrophy and a progeroid appearance: Mutation in the
penultimate exon of FBN1 causing a recognizable phenotype. Am J Med
Genet A 161A: 3057-3062.
40. Graul-Neumann LM, Kienitz T, Robinson PN, Baasanjav S, Karow B, et
al. (2010) Marfan syndrome with neonatal progeroid syndrome-like
lipodystrophy associated with a novel frameshift mutation at the 3'
terminus of the FBN1-gene. Am J Med Genet A 152A: 2749-2755.
41. Glesby MJ, Pyeritz RE (1989) Association of mitral valve prolapse and
systemic abnormalities of connective tissue. A phenotypic continuum.
JAMA 262: 523-528.
42. Greene VB, Stoetzel C, Pelletier V, Perdomo-Trujillo Y, Liebermann L, et
al. (2010) Confirmation of ADAMTSL4 mutations for autosomal
recessive isolated bilateral ectopia lentis. Ophthalmic Genet 31: 47-51.
43. Chandra A, Patel D, Aragon-Martin JA, Pinard A, Collod-Beroud G, et al.
(2015) The revised ghent nosology; reclassifying isolated ectopia lentis.
Clin Genet 87: 284-287.
44. Loeys BL, Gerber EE, Riegert-Johnson D, Iqbal S, Whiteman P, et al.
(2010) Mutations in fibrillin-1 cause congenital scleroderma: stiff skin
syndrome. Sci Transl Med 2: 23ra20.
45. Le Goff C, Mahaut C, Wang LW, Allali S, Abhyankar A, et al. (2011)
Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are
responsible for acromicric and geleophysic dysplasias. Am J Hum Genet
89: 7-14.
46. Faivre L, Megarbane A, Alswaid A, Zylberberg L, Aldohayan N, et al.
(2002) Homozygosity mapping of a Weill-Marchesani syndrome locus to
chromosome 19p13.3-p13.2. Hum Genet 110: 366-370.
47. Rommel K, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M, et al.
(2002) Mutation screening of the fibrillin-1 (FBN1) gene in 76 unrelated
patients with Marfan syndrome or Marfanoid features leads to the
identification of 11 novel and three previously reported mutations. Hum
Mutat 20: 406-407.
48. Latasiewicz M, Fontecilla C, Milla E, Sanchez A (2016) Marfan syndrome:
ocular findings and novel mutations-in pursuit of genotype-phenotype
associations. Can J Ophthalmol 51: 113-118.
49. Schrijver I, Liu W, Odom R, Brenn T, Oefner P, et al. (2002) Premature
termination mutations in FBN1: distinct effects on differential allelic
expression and on protein and clinical phenotypes. Am J Hum Genet 71:
223-237.
50. Rommel K, Karck M, Haverich A, von Kodolitsch Y, Rybczynski M, et al.
(2005) Identification of 29 novel and nine recurrent fibrillin-1 (FBN1)
mutations and genotype-phenotype correlations in 76 patients with
Marfan syndrome. Hum Mutat 26: 529-539.
51. Goldblatt J, Hyatt J, Edwards C, Walpole I (2011) Further evidence for a
marfanoid syndrome with neonatal progeroid features and severe
generalized lipodystrophy due to frameshift mutations near the 3' end of
the FBN1 gene. Am J Med Genet A 155A: 717-720.
52. Jacquinet A, Verloes A, Callewaert B, Coremans C, Coucke P, et al. (2014)
Neonatal progeroid variant of Marfan syndrome with congenital
lipodystrophy results from mutations at the 3' end of FBN1 gene. Eur J
Med Genet 57: 230-234.
53. Faivre L, Gorlin RJ, Wirtz MK, Godfrey M, Dagoneau N, et al. (2003) In
frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani
syndrome. J Med Genet 40: 34-36.
54. Achelrod D, Blankart CR, Linder R, von Kodolitsch Y, Stargardt T, et al.
(2014) The economic impact of Marfan syndrome: A non-experimental,
retrospective, population-based matched cohort study. Orphanet J Rare
Dis 9: 90.
55. Dietz HC, McIntosh I, Sakai LY, Corson GM, Chalberg SC, et al. (1993)
Four novel FBN1 mutations: significance for mutant transcript level and
EGF-like domain calcium binding in the pathogenesis of Marfan
syndrome. Genomics 17: 468-475.
56. Aoyama T, Francke U, Dietz HC, Furthmayr H (1994) Quantitative
differences in biosynthesis and extracellular deposition of fibrillin in
cultured fibroblasts distinguish five groups of Marfan syndrome patients
and suggest distinct pathogenetic mechanisms. J Clin Invest 94: 130-137.
57. Ramirez F, Pereira L (1999) The fibrillins. Int J Biochem Cell Biol 31:
255-259.
58. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, et al.
(2003) Dysregulation of TGF-beta activation contributes to pathogenesis
in Marfan syndrome. Nat Genet 33: 407-411.
59. Doyle JJ, Gerber EE, Dietz HC (2012) Matrix-dependent perturbation of
TGFbeta signaling and disease. FEBS Lett 586: 2003-2015.
60. Benke K, Agg B, Szilveszter B, Tarr F, Nagy ZB, et al. (2013) The role of
transforming growth factor-beta in Marfan syndrome. Cardiol J 20:
227-234.
61. Huang F, Chen YG (2012) Regulation of TGF-beta receptor activity. Cell
Biosci 2: 9.
62. Ramachandra CJ, Mehta A, Guo KW, Wong P, Tan JL, et al. (2015)
Molecular pathogenesis of Marfan syndrome. Int J Cardiol 187: 585-591.
63. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, et al.
(1995) Life expectancy in the Marfan syndrome. Am J Cardiol 75:
157-160.
64. Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH, et al.
(1999) Phenotypic features and impact of beta blocker or calcium
antagonist therapy on aortic lumen size in the Marfan syndrome. Am J
Cardiol 83: 1364-1368.
65. Shores J, Berger KR, Murphy EA, Pyeritz RE (1994) Progression of aortic
dilatation and the benefit of long-term beta-adrenergic blockade in
Marfan's syndrome. N Engl J Med 330: 1335-1341.
66. Loewenstein A, Barequet IS, De Juan E, Jr., Maumenee IH (2000) Retinal
detachment in Marfan syndrome. Retina 20: 358-363.
67. Jones KB, Erkula G, Sponseller PD, Dormans JP (2002) Spine deformity
correction in Marfan syndrome. Spine (Phila Pa 1976) 27: 2003-2012.
68. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, et al. (2006)
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model
of Marfan syndrome. Science 312: 117-121.
69. Gao L, Chen L, Fan L, Gao D, Liang Z, et al. (2016) The effect of losartan
on progressive aortic dilatation in patients with Marfan's syndrome: A
meta-analysis of prospective randomized clinical trials. Int J Cardiol 217:
190-194.
70. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, et al. (2014)
Atenolol versus losartan in children and young adults with Marfan's
syndrome. N Engl J Med 371: 2061-2071.
71. Carmody SR, Wente SR (2009) mRNA nuclear export at a glance. J Cell
Sci 122: 1933-1937.
72. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of
alternative splicing complexity in the human transcriptome by high-
throughput sequencing. Nat Genet 40: 1413-1415.
73. Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and
mechanisms. Mol Cancer Ther 1: 347-355.
74. Muntoni F, Fletcher S, Wilton S (2017) Response to "Railroading at the
FDA". Nat Biotechnol 35: 207-209.
75. Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of
Duchenne muscular dystrophy. Drug Des Devel Ther 11: 533-545.
76. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. (2013)
Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann
Neurol 74: 637-647.
Citation: Cale JM, Fletcher S, Wilton SD (2018) A Review of the Type-1 Fibrillinopathies: Pathophysiology, Diagnosis and Novel Therapeutic
Strategies. J Genet Syndr Gene Ther 9: 323. doi:10.4172/2157-7412.1000323
Page 7 of 8
J Genet Syndr Gene Ther, an open access journal
ISSN:2157-7412
Volume 9 • Issue 1 • 1000323
77. Franken R, den Hartog AW, Radonic T, Micha D, Maugeri A, et al. (2015)
Beneficial outcome of Losartan therapy depends on type of FBN1
mutation in Marfan syndrome. Circ Cardiovasc Genet 8: 383-388.
78. Burchett ME, Ling IF, Estus S (2011) FBN1 isoform expression varies in a
tissue and development-specific fashion. Biochem Biophys Res Commun
411: 323-328.
 
Citation: Cale JM, Fletcher S, Wilton SD (2018) A Review of the Type-1 Fibrillinopathies: Pathophysiology, Diagnosis and Novel Therapeutic
Strategies. J Genet Syndr Gene Ther 9: 323. doi:10.4172/2157-7412.1000323
Page 8 of 8
J Genet Syndr Gene Ther, an open access journal
ISSN:2157-7412
Volume 9 • Issue 1 • 1000323
 International Journal of 
Molecular Sciences
Article
Proof-of-Concept: Antisense Oligonucleotide Mediated
Skipping of Fibrillin-1 Exon 52
Jessica M. Cale 1, Kane Greer 1, Sue Fletcher 1,2,3 and Steve D. Wilton 1,2,*


Citation: Cale, J.M.; Greer, K.;
Fletcher, S.; Wilton, S.D.
Proof-of-Concept: Antisense
Oligonucleotide Mediated Skipping
of Fibrillin-1 Exon 52. Int. J. Mol. Sci.
2021, 22, 3479. https://doi.org/
10.3390/ijms22073479
Academic Editors: Salvador F. Aliño
and Luis Sendra
Received: 10 February 2021
Accepted: 25 March 2021
Published: 27 March 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University,
Murdoch, WA 6150, Australia; jessica.cale@murdoch.edu.au (J.M.C.); K.Greer@murdoch.edu.au (K.G.);
S.Fletcher@murdoch.edu.au (S.F.)
2 Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational
Science, The University of Western Australia, Nedlands, WA 6009, Australia
3 PYC Therapeutics, Nedlands, WA 6009, Australia
* Correspondence: s.wilton@murdoch.edu.au; Tel.: +61-8-9360-2305
Abstract: Marfan syndrome is one of the most common dominantly inherited connective tissue
disorders, affecting 2–3 in 10,000 individuals, and is caused by one of over 2800 unique FBN1 muta-
tions. Mutations in FBN1 result in reduced fibrillin-1 expression, or the production of two different
fibrillin-1 monomers unable to interact to form functional microfibrils. Here, we describe in vitro
evaluation of antisense oligonucleotides designed to mediate exclusion of FBN1 exon 52 during pre-
mRNA splicing to restore monomer homology. Antisense oligonucleotide sequences were screened
in healthy control fibroblasts. The most effective sequence was synthesised as a phosphorodiamidate
morpholino oligomer, a chemistry shown to be safe and effective clinically. We show that exon
52 can be excluded in up to 100% of FBN1 transcripts in healthy control fibroblasts transfected with
PMO52. Immunofluorescent staining revealed the loss of fibrillin 1 fibres with ~50% skipping and
the subsequent re-appearance of fibres with >80% skipping. However, the effect of exon skipping
on the function of the induced fibrillin-1 isoform remains to be explored. Therefore, these findings
demonstrate proof-of-concept that exclusion of an exon from FBN1 pre-mRNA can result in inter-
nally truncated but identical monomers capable of forming fibres and lay a foundation for further
investigation to determine the effect of exon skipping on fibrillin-1 function.
Keywords: Marfan syndrome; fibrillin-1; antisense oligonucleotides; exon skipping; splice-switching
1. Introduction
Marfan syndrome (MFS, MIM 154700) is one of the most common dominantly inher-
ited connective tissue diseases, affecting an estimated 2–3 in 10,000 individuals [1,2], in a
family of disorders called the type-1 fibrillinopathies [3]. Marfan syndrome is characterised
by extreme height with disproportionate limb and digit length in comparison to the torso,
coupled with a myriad of other skeletal, ocular, skin and cardiovascular abnormalities [4].
However, it is the progressive growth of the aorta often eventuating into aortic dissection
and rupture that is the most common cause of death [5].
Marfan syndrome was linked in the early 1990s to mutations in the, then recently
discovered [6], fibrillin-1 gene (FBN1) [7,8]. Since then, over 2800 disease-causing mutations
have been reported [9]. Fibrillin-1 encodes a large 350 kDa glycoprotein of the same name
that is secreted from the cell and deposited into the extracellular matrix (ECM) [6]. In a
healthy individual, fibrillin-1 monomers aggregate into multimer units within the first few
hours after secretion [10]. Fibrillin-1 multimers form the backbone of microfibrils [6] that
are essential in the majority of connective tissues and to which many microfibril associated
proteins bind [11]. It is in the microfibril form that fibrillin-1 exerts its structural and regu-
latory roles, providing a backbone for microfibrils [12], maintaining the stability of elastic
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fibres [13], and regulating the bioavailability of signalling proteins such as transforming
growth factor-beta (TGF-β) [14,15].
In a Marfan syndrome patient, the disease-causing FBN1 mutation results in a lack of
functional microfibrils, in turn leading to instability of the ECM that is further compounded
by the dysregulation of TGF-β [12,16]. An increase in bioavailable TGF-β activates a
signalling cascade resulting in, among other outcomes, increased expression of matrix
metalloproteinase [15] that degrade fibrillin-1 and other matrix proteins leading to further
destabilisation of the ECM [15,17]. The initial loss of functional microfibrils is theorised
to depend on the type of mutation. In general, missense mutations, which do not affect a
conserved cysteine, as well as splicing mutations are thought to exert dominant negative
effects. Such mutations result in the production of a dominant aberrant monomer that
disrupts the assembly of the wild-type protein into microfibrils [18]. In contrast, many
nonsense and frameshifting mutations are associated with haploinsufficiency [19,20]. This
haploinsufficiency is the result of transcript instability that leads to degradation and thus
reduced fibrillin-1 expression [21]. A small subgroup of nonsense and frameshift mutations
that affect the C-terminal region can produce stable transcripts that are translated into
protein rather than being degraded [22,23]. Such mutations have been associated with
intracellular retention of fibrillin-1, the outcome of which is a similar lack of microfibrils in
the ECM [20,22].
The most common type of mutations are missense mutations that result in the dis-
ruption of a cysteine residue [9,24]. The fibrillin-1 protein has several repeated domains
including 47 epidermal growth factor (EGF)-like domains, 43 of which are involved in
calcium-binding (cbEFG-like), seven TGF-β binding protein-like (TB) domains and two
hybrid domains [25,26]. Each of these domains are cysteine-rich with six to eight conserved
cysteine residues that play a critical role in the folding and stability of the fibrillin-1 pro-
tein [25,27]. Mutations affecting a conserved cysteine have been shown to either increase
the susceptibility of fibrillin-1 to proteolysis [28,29] or disrupt the folding and secretion of
fibrillin-1 leading to intracellular retention [30]. The outcome of either scenario is a similar
decreased microfibril stability and abundance.
Following the discovery that mutations in fibrillin-1 result in TGF-β dysregulation, a
research area emerged focussing on the antagonism of TGF-β as a therapeutic strategy [31,32].
However, no breakthroughs have yet been made in the field and treatment of MFS patients
remains heavily focused on symptom management. The current standard of care includes
surgical correction of scoliosis, ectopia lentis, pectus deformities and aortic dilatation, as
well as pain management and the use of β-Blockers [33–35] or more recently angiotensin II
receptor type 1 blockers [1,31,36] to slow aortic growth. Here, we propose that personalised
medicines using antisense oligonucleotides (AO) to alter FBN1 exon selection during the
splicing process, may be an appropriate therapeutic approach for some individuals with
Marfan syndrome.
Antisense oligonucleotides (AO) are short sequences, generally between 15 and
30 bases in length, that are single-stranded analogues of nucleic acids. An AO is de-
signed to be complementary to the region of interest binding to the target RNA or DNA
through Watson-Crick base pairing. When bound to the target sequence and depending
upon the chemistry, AOs can alter transcripts through two main mechanisms; recruiting
RNase-H to cleave the target leading to degradation [37,38] or physically blocking the
binding of regulatory factors or machinery of the transcription [39], translation [40] or
splicing [41,42] processes. Several studies have outlined the potential of AOs in the treat-
ment of genetic diseases. Several notable examples—eteplirsen [43,44], nusinersen [45,46]
and more recently golodirsen [47], viltolarsen [48] and casimersen [49]—have now been
approved by the United States Food and drug authority (FDA). All four drugs are a class of
AO commonly referred to as splice switching. Splice switching AOs function by blocking
the splicing machinery or regulatory features, altering the normal splicing process.
Splicing is an essential process for all multi-exon genes; removing the non-coding
introns and re-joining the coding exons, before the transcript can be translated. The splicing
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process is, therefore, tightly regulated by several cis- and trans-acting elements. The majority
of multi-exon genes, however, also undergo a process called alternative splicing [50].
Alternative splicing allows the production of multiple transcripts, and thus proteins, from
a single gene, significantly increasing genetic complexity and diversity. To maintain the
precise removal of introns, as well as supporting alternative splicing, the regulation of
these processes is multi-layered and complex while maintaining a level of flexibility in
the definition of an exon. Utilising the inherent flexibility of exon definition AOs can be
targeted to motifs involved in exon recognition and processing, such as the acceptor and
donor splice sites, as well as hotspots for splicing enhancers either in the intron or exon.
Targeting enhancer sites can block the binding of positive splicing factors, thus decreasing
the definition and recognition of an exon sufficiently to result in its exclusion [51,52].
Contrariwise, targeting exonic splicing silencer or intronic splicing silencer sequences can
inhibit the binding of negative splicing factors, increasing exon recognition leading to
inclusion [52,53].
The affinity, specificity, efficiency, stability and tolerance of an AO can be increased by
modifying the chemical structure of the monomers and the backbone. Two widely used
chemistries were utilised in this study. First of which has 2′-O-methyl (2′OMe) ribose ring
modifications on a negatively charged phosphorothioate (PS) backbone. The resulting
2′OMe-PS compounds are robust RNase-H independent AOs that are nuclease resistant and
relatively cost-effective to synthesise. The second chemistry is the phosphorodiamidate
morpholino oligomer (PMO) that completely replaces the ribose sugar moiety with a
morpholine ring and has phosphorodiamidate linkages [54]. The PMO chemistry is RNase-
H independent, and has a neutral charge that precludes interaction with proteins, greatly
reducing the possibility of off-target effects [55,56]. While the PMO chemistry is both more
technically challenging and costly to synthesise than 2′OMe-PS AOs, PMOs are generally
recognised as both safe and effective in a clinical setting, making it a promising chemistry
for drug development [43,57].
As described previously, fibrillin-1 monomers are secreted from the cell and rapidly ag-
gregated into multimer units to form the backbone of fibrillin-1 microfibrils [10]. Mutations
in FBN1 disrupt the formation of microfibrils, ultimately leading to a disease phenotype;
either Marfan syndrome or another type-1 fibrillinopathy. Therefore, we propose that
removal of a mutation-associated exon from all FBN1 transcripts during the splicing pro-
cess could result in the production of fibrillin-1 proteins that are able to form functional
microfibrils, restoring ECM stability. To assess the viability of this hypothesis, we ad-
dressed three preliminary questions using FBN1 exon 52 as a model. (1) Can an exon
be specifically removed from FBN1 pre-mRNA using antisense oligonucleotides, (2) Can
sufficient exon skipping be achieved, and (3) can the internally truncated fibrillin-1 protein
form microfibrils.
2. Results
2.1. The FBN1 Transcript and Antisense Oligonucleotide Design
The fibrillin-1 transcript (LRG_778t1; NM_000138.4) contains 11,695 bases separated
into 66 exons, 65 of which encode the 350 kDa fibrillin-1 protein (Figure 1a). Exon 52 of
FBN1 encodes a total of 22 amino acids and makes up a portion of the sixth, of seven TB
domains. Over 20 disease-causing mutations have been reported to affect exon 52, the
majority of which result, or are predicted to result, in aberrant exon 52 splicing [9,24]. To
excise exon 52, along with the flanking introns during the splicing process, five AOs were
designed to target the acceptor, and donor splice sites as well as exonic splice enhancer
(ESE) and intronic splice enhancer (ISE) sites across exon 52, predicted using the webtool
SpliceAid [58] (Figure 1c). SpliceAid examines the exonic and intronic sequence of interest
and determines associated silencer and enhancer sites. Each site is given a score of 1 to
10 that indicates the strength of the site, with the value closest to 10 being the strongest
ESE sites.
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2.2. Evaluation of AOs to Induce Exon 52 Skipping from FBN1 Transcripts
Initial AO screening was performed using AOs composed of 2′OMe-PS molecules. An
unrelated control AO that does not anneal to any transcript was included in all transfections
as a sham treatment to observe any chemistry or delivery related effects on cell health and
transcript abundance. A complete list of AOs can be found in Table 1.
All 2′OMe-PS AOs were transfected into fibroblasts, derived from a healthy control
subject, at three concentrations (200 nM, 100 nM and 50 nM) and incubated for 24 h before
collection for RNA extraction and RT-PCR analysis to assess exon skipping efficiencies.
The 24-h transfection incubation period was chosen after a time course of 24, 48 and 72 h
revealed negligible differences in skipping efficiency over time (data not shown). However,
treated cells, in particular those treated with the higher AO concentration, showed changes
in morphology and began to die after 48 h (data not shown).
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Table 1. Antisense oligonucleotide binding coordinates and sequences.
Nomenclature
(FBN1 H . . . ) Name Sequence (5
′-3′) Chemistry
52A(+29+53)N AO52.1n AUC AGG UCC CAC GAU GAU CCC ACU UATC AGG TCC CAC GAT GAT CCC ACT T
2′OMe-PS
PMO
52A(+29+53)M AO52.1m AUC AGG UCC CAC AAU GAU CCC ACU U 2′OMe-PS
52A(−08+17) AO52.2 UAU CUG GCG GAA GGC CUC UGU GGU G 2′OMe-PS
52D(+13-12) AO52.3 CAG GCA ACU GAC CAA CUG CUG AAU C 2′OMe-PS
52A(−23+02) AO52.4 CUC UGU GGU GGA GAC ACU CAU UAA U 2′OMe-PS
52A(+03+27) AO52.5 CAU AAG GAC AUA UCU GGC GGA AGG C 2′OMe-PS
Control AO Ctrl GGA UGU CCU GAG UCU AGA CCC UCC G 2′OMe-PS
GeneTools Control GTC CCT CTT ACC TCA GTT ACA ATT TAT A PMO
Analysis of PCR amplicons revealed the presence of two products in several samples;
the expected full length (FL) product between exon 47 forward and exon 54 reverse primers,
as well as a smaller product corresponding to the expected size after skipping of exon 52
(∆52) (Figure 2a). The identity of the amplicons was confirmed by band purification and
Sanger sequencing, confirming the precise removal of all 66 bases of exon 52 (Figure 2b,c).
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The most efficient exon 52 skipping was induced by AO52.1n, with 41% of transcripts
lacking exon 52 after transfection at 200 nM (Figure 2a). However, three other sequences,
AO52.1m, AO52.3 and AO52.5 were also relatively efficient, inducing up to 40%, 37% and
22% skipping, respectively (Figure 2a). The remaining two sequences did not induce
any measurable exon 52 skipping. The sequences AO52.1n and AO52.1m differ by a
single base, with each being an exact complementary pair for the wild-type and a known
Marfan syndrome patient cell line, respectively. This AO was designed in the hopes of
understanding the mechanism behind the mutation that is known to cause mis-splicing of
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exon 52. The one base-pair mismatch did not greatly reduce the efficiency of AO52.1m in
healthy control cells.
Following initial AO screening, removal of exon 52 was deemed an appropriate option.
In an attempt to further enhance exon exclusion, two AOs targeting FBN1 exon 52 were
combined into cocktails and evaluated. This method has previously been shown to boost
skipping efficiency through synergy between the two AOs [59]. Six of the eight cocktails
tested, induced between 23% and 42% exon 52 skipping, suggestive of an additive or
baseline effect, similar to that achieved with a single AO. The combination of AO52.1n with
AO52.2 or AO52.3 was antagonistic resulting in no measurable exon skipping (Figure S2).
No synergistic cocktails were identified, therefore AO52.1n was chosen as the most promising
candidate and the sequence was synthesised as a PMO for further analysis (Table 1).
2.3. PMO52 Induces Efficient Exon 52 Skipping and an Increase in Fibrillin-1 Microfibrils
Determined by Immunofluorescent Staining
To both confirm the efficiency of the AO52.1n sequence as a PMO, and to assess the
effect of exon 52 skipping on fibrillin-1 microfibril formation, PMO52 was transfected into
healthy control fibroblasts. An electroporation-based transfection method, nucleofection,
was used to deliver PMO52 into control cells at two concentrations, 250 and 50 µM, as
calculated in a 20 µL cuvette. Transfected cells were plated either directly into 24 well plates
or onto coverslips and incubated for 72 h before cells were collected for RNA analysis and
coverslips fixed for immunofluorescent staining.
Representative results of healthy control cells treated with PMO52 are presented in
Figure 3a. These representative RT-PCR results reflect exon 52 removal from approximately
100% of transcripts, with no measurable FL product remaining. The lower AO concen-
tration was observed to induce approximately 50% skipping, with no endogenous exon
52 skipping observed in either the control or untreated samples (Figure 3a). Analysis of
RT-PCR amplicons across four replicates revealed relatively consistent dose-dependent
exon 52 skipping. On average ∆52 transcripts constituted 91% of total FBN1 transcripts
from cells transfected at the higher concentration and 55% at the lower concentration
(Figure 3b). The lowest skipping efficiency at the highest concentration was 74%; in the
same experiment, the lower concentration maintained the average 55% skipping efficiency
(Figure 3b).
Fibrillin-1 protein was detected through immunofluorescent staining using a fibrillin-
1 specific primary antibody and a fluorescently tagged secondary. Staining of the untreated
sample revealed the long-thin extracellular fibre-like formations expected of fibrillin-1
(Figure 3c iii). Notably, the morphology of fibres in the sample with more than 90%
skipping is trending toward those seen in the untreated healthy control (Figure 3c i,iii).
The abundance of fibrillin-1 staining, as well as the abundance of fibre-like formations
is, however, noticeably reduced in the 250 µM-treated samples. In contrast to the fibre
formation in both untreated and high concentration of PMO52, healthy control cells treated
with 50 µM of PMO52, present with a complete loss of fibrillin-1 fibres and an overall
reduction in fibrillin-1 staining (Figure 3c ii).
Following successful exon 52 skipping in healthy control fibroblasts, PMO52 was
further assessed in fibroblasts derived from an individual with Marfan syndrome obtained
from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical
Research. The patient fibroblasts (MFS∆52) were reported to harbour a silent c.6354C > T,
p.(Ile2118Ile) mutation in FBN1 that was found to result in the in-frame skipping of exon
52 [60]. PMO52 was nucleofected into the MFS∆52 and healthy control fibroblasts and
collected for RNA and protein analysis after 4 days. The PMO52 sequence resulted in
robust skipping in both cell lines and a strong dose response was observed. Treatment with
50 µM resulted in 64% and 41% exon 52 skipping in MFS∆52 and healthy control fibroblasts,
respectively (Figure 4a). Increasing the concentration to 250 µM resulted in 92% skipping
in both cell lines (Figure 4a).
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Immu ofl orescence once again revealed the strong fibre-like structures formed by
fibrillin-1 in the untreated, and GTC treated, healthy control fibroblasts. These fibres were
completely lost when 41% skipping was induced (Figure 4b vi). The staining pattern
mirrored that observed in the untreated MFS∆52 fib oblasts with no fibre formation and
minimal diffuse fibrillin-1 staining (Figure 4b iv). The minor increase in the proporti n of
skipped products after treatment of MFS∆52 fibroblasts with 50 µM of PMO52, did not alter
the fibrillin-1 staining pattern (Figure 4b ii). In both cell lines, treatment with 250 µM of
PMO52 resulted in the formation of fibrillin-1 fibres. In the healthy control cells, these fibres,
while of high staining intensity, were fragmented and reduced in abundance compared to
the untreated healthy control sample (Figure 4b v,viii). However, in MFS∆52 cells treated
with the 250 µM, fibrillin-1 fibres had a continuous, non-fragmented morphology trending
toward those seen in the untreated healthy control (Figure 4b i,viii). The fibres are also
relatively abundant filling the majority of the field-of-view; however, they are not as
plentiful as those seen in the untreated healthy control that form a multi-layered lattice
(Figure 4b i,viii). Similar staining patterns were seen across multiple biological replicates
representative images of one replicate are presented in Figure S4.
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3. Discussion
Although Marfan syndrome is well established as an inherited connective tissue disor-
der caused by mutations in the fibrillin-1 gene, the exact mechanism of pathogenesis has not
been fully resolved. Current understanding suggests that the pathogenesis is dependent
on the mutation type with an overarching basis that a lack of functional fibrillin-1 mi-
crofibrils leads to TGF-β dysregulation, further compounding ECM destabilisation [15,61].
Therefore, we propose that removal of a mutation-associated exon from all FBN1 transcripts
could result in the production of internally truncated fibrillin-1 proteins that retain some
function and are able to form microfibrils. We addressed this hypothesis by designing
antisense oligonucleotides to induce exon 52 exclusion from unaffected FBN1 pre-mRNA.
We suggest that many fibrillin-1 gene lesions will be amenable to the removal of the af-
fected exon for two main reasons. Firstly, fibrillin-1 is highly repetitive suggesting the
possibility of functional redundancy. Secondly, excluding exons 2, 3, 64, 65 and 66, the
majority of fibrillin-1 exons are in-frame, and therefore can be removed without disrupting
the reading frame.
Here, we describe evidence for the efficient removal of FBN1 exon 52. Of the five
2′OMe-PS AOs tested three were found to induce exon 52 skipping. Earlier dystrophin
screening studies similarly found that two out of three AOs induced some skipping, albeit
at different efficiencies [59]. The different delivery methods, concentration and length
of incubation that were used when assessing the 2′OMe-PS and PMO sequences, make
it impossible to directly compare their efficiencies. However, our data show that the
proportion of ∆52 transcripts induced is greater when using the PMO sequence, this is
likely in-part because a higher PMO concentration and longer incubation period could
be used without a large decrease in cell viability. A higher concentration is generally re-
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quired for the PMOs as the neutral charge of the chemistry hinders cellular uptake [62,63].
Immunofluorescent staining of fibrillin-1 in treated cells supports the hypothesis that
fibrillin-1∆52 proteins can interact to form multimers. We observed fibre formation, mir-
roring that of the untreated control cells, when more than 92% exon 52 skipping was
induced in either the healthy control or MFS∆52 patient fibroblasts. We also established
that inducing approximately 50% exon 52 skipping results in a complete loss of fibrillin-
1 fibre staining in healthy control fibroblasts mimicking the disease-like state caused by
splicing mutations. Together, these results demonstrate proof-of-concept that the internally
truncated fibrillin-1∆52 proteins produced through efficient exon 52 skipping are able to
form multimers.
Of particular interest, is the total loss of microfibril formation that results from the
induction of a combination of wild-type and FBN1∆52 transcripts after sub-optimal levels
of PMO-induced exon skipping. This finding demonstrates the inability of the heteroge-
nous population of ∆52 fibrillin-1 proteins to form microfibrils, supporting the dominant-
negative pathogenic mechanism [64]. We observed a similar lack of extracellular fibrillin-
1 as that reported by Liu et al. [65] resulting from the c.6354C > T mutation that leads
to 41% fibrillin-1 synthesis and only 5% deposition of fibrillin-1 in the extracellular ma-
trix. However, this finding also has relevance to mapping of amenable FBN1 exons that
could be targeted in a splice intervention therapy. The elimination of microfibrils and
subsequent formation with increased skipping efficiency could prove to be an invaluable
tool in optimisation of fibrillin-1 AO sequences as well as identification of potential tar-
get exons for therapeutic intervention. Importantly, being able to induce a disease-like
state would allow the use of healthy control cells, rather than specific patient cells, for
the identification of exons that when removed do not affect the expression or function of
fibrillin-1. Furthermore the occurrence and severity of dominant negative effects depend
on the mutation type and location [66]. For example, duplications causing a mouse model
of tight skin syndrome, result in a larger fibrillin-1 protein that has been shown to only form
microfibrils in the presence of wild-type fibrillin-1 [67]. While the co-polymerisation of
the two fibrillin-1 isoforms forms functionally deficient microfibrils, the outcome is a mild
phenotype lacking vascular involvement [67]. Identification of such naturally occurring
co-polymerisation events that lead to a mild phenotype could reveal potential therapeutic
strategies to assess in the future.
We predict that the AOs reported here can manipulate FBN1 splicing such that, at
lower skipping efficiencies disease characteristics can be induced in unaffected cells and
upon increased efficiency, sufficient skipping can be induced to reduce the key phenotype
of MFS. This prediction is based on the dominant-negative model that suggests that
in the presence of two protein isoforms, the aberrant protein disrupts the formation of
microfibrils by the wild-type protein [18]. It is unknown exactly what ratio of wild-type
to aberrant proteins would negate the dominant negative effects. However, the results
presented here suggest that this tolerable threshold may be approximately 95%. We
demonstrate that fibrillin-1 fibres can be formed when exon 52 skipping is sufficient, likely
>90% skipping, such that more than 95% of total multimers that are formed would be
of the fibrillin-1∆52-fibrillin-1∆52 structure. We also note, however, that FBN1 mutations
resulting in haploinsufficiency lead to disease. Therefore, we believe that the abundance of
microfibrils has to be maintained, as a minimum, above that observed in haploinsufficiency
patients [19,21]. It is also important to note that while this exon skipping strategy relies on
excluding the target exon from both the mutation-harbouring and healthy FBN1 transcripts,
the exon skipping is at the mRNA level, and therefore not permanent as would be the case
for other techniques such as gene therapy.
While we demonstrated efficient and consistent exon skipping using PMO52, the
concentrations used are relatively high, when compared to similar studies targeting other
genes [59,68]. One of the possible explanations for the high concentration required is
the abundance of fibrillin-1 transcripts. Fibrillin-1 RNA is expressed in the vast majority
of cell types and is maintained at relatively high levels throughout the body [69]. We
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noted the efficient PCR amplification of FBN1 transcripts; requiring 20 or fewer rounds of
amplification coupled with the need for very low template concentrations (25 ng). While
the in vitro PMO transfection concentrations used seem relatively high, we noticed no
changes in morphology or health of cell cultures up to four days post-transfection with
PMO52. The PMO chemistry is generally considered to be safe with no off-target effects
nor toxicity [43,57,62]. Nevertheless, while the PMO chemistry may be safe and a higher
concentration required due to the level of fibrillin-1 expression, there are still several
ways in which the efficiency of an AO can be improved, including optimisation of AO
delivery, sequence, length and chemistry. Further optimisation could allow for the use of a
significantly lower dosage that in turn would not only reduce the possibility of off-target
effects or toxicity but also lower the cost of treatment.
The fibrillin-1 protein produced by excising exon 52 is predicted to be internally
truncated, fibrillin-1∆52, and lack the last seven amino acids of the sixth TB domain. This
isoform has only been reported in the context of exon 52 mutations, where it is known to
act in a dominant-negative manner against the wild-type protein and result in a severe
lack of functional microfibrils [60,65]. Liu et al. [65] also reported that an exon 52 splicing
mutation leads to reduced fibrillin-1 synthesis, less than 50% of that observed in healthy
controls, while the mutant mRNA levels remain unchanged, suggesting that the fibrillin-
1∆52 proteins are unstable. Liu et al. [65] suggests this instability may result from the partial
deletion of a TB domain that leads to misfolding of the fibrillin-1 protein increasing its
susceptibility to proteolysis. If this is the case then attempts to induce exon skipping of
other exons encoding partial TB domains; 10, 11, 17, 18, 38, 39, 42, 43 and 51, would likely
face the same issue. It is possible that removal of the two exons encoding the TB domain
as a pair could solve this problem. However, our findings suggest that the fibrillin1∆52
proteins produced through exon 52 skipping are able to be synthesised, secreted from the
cell and form fibre-like structures in both healthy control and MFS∆52 patient fibroblasts.
Nevertheless, the synthesis, deposition and function of fibrillin-1∆52, especially in the
absence of wild-type fibrillin-1, needs to be investigated further.
Here, we illustrate that when fibrillin-1∆52 is the predominant product it is able to
be both synthesised and secreted from the cell, with no evidence of intracellular staining.
We also demonstrate that fibrillin-1∆52 proteins can form fibres, provided that FBN1∆52
transcripts make up more than 90% of total FBN1 transcripts. These results suggest that
the fibrillin-1∆52 protein is at least partially functional, although further protein analysis is
required to assess if the fibres formed can interact with the microfibril associated proteins
with which fibrillin-1 naturally interacts. The ability of fibrillin-1∆52 proteins to sequester
TGF-β also needs to be assessed. If removal of exon 52 disrupts the regulation of TGF-
β, then regardless of the high skipping efficiency and fibre formation that is observed,
symptoms such as aortic growth would continue to progress with no benefit from this
treatment. To assess the effect of FBN1 exon skipping and the function of the induced
fibrillin-1 isoform especially the impacts on TGF-β signalling, surrogate markers such as
the phosphorylation of Smad2 can be analysed [70,71]. The level of active and total TGF-β
can similarly be assessed as a measure of functionality [61,71,72]. Such assays were outside
the scope of the current study and will be the focus of further research.
As previously noted, our results support the hypothesis that fibrillin-1∆52 can form
fibres. However, while the morphology of fibres is superficially similar to that of the
untreated, healthy control, their abundance is reduced. The reduction in abundance could
be the result of the experimental design and protocols. For example, nucleofection can
cause cell stress potentially reducing fibrillin-1 expression, or the transfection incubation
time could be insufficient to allow more efficient formation of microfibrils after treatment.
However, it is likely that, as reported by Liu et al. [65], fibrillin-1∆52 synthesis is reduced in
comparison to the wild-type. Western blotting analysis of intracellular and extracellular
fibrillin-1 was attempted, however, due to poor signal and resolution in samples from
healthy control fibroblasts we were unable to confirm any changes in fibrillin-1 abundance.
Further optimisation of the Western blot protocol to produce reliable results is required
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before the effect of FBN1 exon skipping on the abundance of fibrillin-1 can be assessed.
While restoring microfibril abundance and function to a ‘normal’ state would be ideal, this
may not be possible. We believe that any increase in functional microfibrils could provide
a therapeutic benefit by reducing disease progression and severity.
As discussed earlier, the current standard of care for individuals living with MFS
relies heavily on invasive surgical interventions and the lifelong use of medicines such
as β-adrenergic receptor blockades that slow the progression of aortic dilation [33–35].
These interventions have proven lifesaving, as well as life-extending [5,73]. However,
the burden of MFS on quality of life, and the economic stress, for both patients and their
families, remains substantial [74,75]. In more recent years major efforts have been made to
discover and develop therapeutics for MFS [31–33,76]. Research has focused on slowing
aortic growth as well as a continued improvement upon current treatment strategies for the
main symptoms of MFS. With FDA approval of AO therapeutics to restore gene function
in spinal muscular atrophy [45] and Duchenne muscular dystrophy [77–79], we suggest
that antisense oligonucleotide-mediated splice switching as described here could be an
appropriate direction for the development of therapies for Marfan syndrome.
In conclusion, this study assessed the ability of a suite of AOs to induce targeted
exon 52 skipping from full-length FBN1 mRNA transcripts expressed in healthy control
fibroblasts. The most efficient sequence, and the consequences of splice modification, was
further evaluated in both healthy control and MFS∆52 patient fibroblasts. We showed
in vitro, that AO52.1n, AO52.1m and AO52.3 as well as PMO52 induced dose-dependent
exon 52 skipping. Encouragingly the presence of more than 90% of one transcript type;
wild-type or FBN1∆52, corresponded with the formation of fibrillin-1 fibres in both cell lines.
In contrast, a mixed transcript pool resulted with the complete loss of fibrillin-1 fibres,
mimicking the disease-like state.
While this study is a preliminary, in vitro investigation, our candidate PMO consis-
tently induces efficient exon 52 exclusion while maintaining fibrillin-1∆52 fibre formation.
With increasing numbers of AO therapeutics being approved for clinical use, our results
suggest that PMO52 may be an attractive therapeutic option for the treatment of Marfan
syndrome caused by mutations in fibrillin-1 exon 52. This study provides proof-of-concept
and a foundation for the further development of antisense oligonucleotide therapies for
Marfan syndrome.
4. Materials and Methods
4.1. Design and Synthesis of Antisense Oligonucleotides
Antisense oligonucleotides were designed to target splicing regulatory motifs at the
exon-intron junctions as well as exonic splicing enhancer sequences predicted using the
SpliceAid web tool [58]. AO sequences were also analysed using NCBI nucleotide BLAST
(NCBI, Bethesda, MD, USA) [80] to identify any possible off-target annealing. Antisense
oligonucleotides with 2′OMe-PS chemistry were purchased from TriLink biotechnologies
(Maravai LifeSciences, San Diego, CA, USA), and PMOs were purchased from GeneTools
LLC (Philomath, OR, USA). The nomenclature of AOs is based on that described by
Mann et al. [42] and provides information on the gene, exon, annealing co-ordinates and
species. A full list of AOs used in this study are provided in Table 1. The FBN1 exon
nomenclature was determined with respect to the NCBI Reference Sequence NM_000138.4,
in which the translation start codon is in the second of 66 exons.
4.2. Cell Culture and Transfection
Fibroblasts were originally sourced from a dermal biopsy derived from a healthy
volunteer with informed consent. The following cell line was obtained from the NIGMS
Human Genetic Cell Repository at the Coriell Institute for Medical Research: GM21941
(Camden, NJ, USA). The use of human cells for this research was approved by the Murdoch
University Human Ethics Committee, approval numbers 2013_156 (25 October 2013) and
2017_101 (12 May 2017) and The University of Western Australia Human Research Ethics
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Committee, approval number RA/4/1/2295 (21 April 2009). Healthy control fibroblasts
were maintained in Dulbecco’s Modified Essential Medium (DMEM, Gibco; Thermo Fisher
Scientific, Melbourne, Australia) supplemented with 10% foetal bovine serum (FBS, Scien-
tifix, Melbourne, Australia). The MFS∆52 patient fibroblasts were maintained in DMEM
supplemented with 15% FBS (Scientifix, Melbourne, Australia) and 1% glutaMax (Gibco;
Thermo Fisher Scientific, Melbourne, Australia). Both cell lines were maintained at 37 ◦C
with 5% CO2.
Antisense oligonucleotides (2′OMe-PS chemistry) used for target site screening were
transfected into healthy control fibroblasts using Lipofectamine 3000 (L3K, Life Technolo-
gies, Melbourne, Australia). Transfections were prepared by incubating the AO with 3 µL
of L3K, at room temperature in 50 µL of Opti-MEM (Gibco; Thermo Fisher Scientific, Mel-
bourne, Australia), according to manufacturer’s protocol. The transfection mixture was
then diluted to the desired AO concentration in a final volume of 1 mL and applied to cells.
Transfected cells were incubated for 24 h before collection.
The PMO was delivered using the 4D-Nucleofector™ and P3 nucleofection kits (Lonza,
Melbourne, Australia). One microliter of stock PMO (5 mM), either undiluted (250 µM) or
diluted 1:4 in sterilised water (50 µM), was added into a cuvette along with 300,000 fibrob-
lasts resuspended in 19 µL of pre-warmed transfection solution. The mixture of fibroblasts
and PMO was subsequently nucleofected using the pulse code, CA 137, previously opti-
mised in our laboratory for dermal fibroblasts. Nucleofected fibroblasts were maintained
in DMEM supplemented with 5% FBS before collection after 3 or 4 days.
4.3. RNA Extraction and RT-PCR Analysis
Total RNA was extracted using MagMax™ nucleic acid isolation kits (Thermo Fisher
Scientific, Melbourne, Australia) as per the manufacturer’s protocol. Total RNA concentra-
tion and purity were determined using a Nanodrop 1000 spectrophotometer (Thermo Fisher
Scientific, Melbourne, Australia). Transcripts were amplified using one-step SuperScript®
III reverse transcriptase (Thermo Fisher Scientific, Melbourne, Australia) with 25 ng of
total RNA as a template. To assess exon 52 skipping, FBN1 transcripts were amplified
using exon 47 Forward (5′-GGTTTCATCCT-TTCTCACAAC-3′) and exon 54 Reverse (5′-
TCACATGTCATCATTGGACC-3′) primers (Integrated DNA Technologies, Sydney, Aus-
tralia). The cycling conditions were as follows; 55 ◦C for 30 min, 94 ◦C for 2 min followed
by 20 cycles of 94 ◦C for 30 s, 55 ◦C for 30 s and 68 ◦C for 1 min. The PCR amplicons
were fractionated on 2% agarose gels in Tris-Acetate-EDTA buffer. Relative exon skipping
efficiency was estimated through densitometric analysis of images using ImageJ (version
1.8.0_112) imaging software (NIH, Bethesda, MD, USA) [81] and reported as the proportion
of FL or ∆52 transcript products relative to the sum of products.
4.4. Immunofluorescence
Immediately after nucleofection, 100,000 fibroblasts were seeded into each well of
a 24-well plate lined with a 13 mm #0 round uncoated glass coverslip. Cells were incu-
bated for 72 h before being fixed in ice-cold acetone: methanol (1:1, v:v) and allowed to
air dry. Fixed cells were washed once with PBS to rehydrate before blocking with 10%
goat serum in PBS for 1 h at room temperature. The primary antibody, Anti-fibrillin-
1 antibody clone 26 (Merck Millipore, Sydney, Australia), was applied at a dilution of
1:100 in 1% goat serum-PBS and incubated overnight at 4 ◦C. Secondary antibody; Alex-
aFluor568 anti-mouse IgG (Thermo Fisher Scientific, VIC, Australia) was applied, 1:400,
for 1 h at room temperature, and co-stained with Hoechst 33,342 (Sigma-Aldrich, Sydney,
Australia) for nuclei detection (1 mg/mL diluted, 1:125). Coverslips were mounted us-
ing ProLong™ Gold antifade mountant (Thermo Fisher Scientific, Melbourne, Australia).
Fibrillin-1 was detected using a Nikon 80i microscope with NIS-Elements software (Nikon,
Adelaide, Australia). The brightness and contrast of individual channel images were altered
equally for each image, then merged. The merged image was cropped from the original
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1280 × 1024 pixel image using Adobe Photoshop CC. A 20 µm scale bar was added using
ImageJ software (NIH, Bethesda, MD, USA) [81].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ijms22073479/s1, Figure S1: Full gel images for figures listed, Figure S2: Evaluation of AO
cocktails designed to induce FBN1 exon 52 skipping, Figure S3: Full immunofluorescence staining
images for figures listed, Figure S4: Additional evaluation of PMO52.
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